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General introduction:
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Abstract
A healthy human body contains at least tenfold more bacterial cells than human cells 
and the most abundant and diverse microbial community resides in the intestinal tract. 
Intestinal health is not only maintained by the human intestine itself and dietary factors, but 
also largely supported by this resident microbial community. Conversely, however, a large 
body of evidence supports a relationship between bacteria, bacterial activities and human 
colorectal cancer. Symbiosis in this multifaceted organ is thus crucial to maintain a healthy 
balance within the host-diet-microbiota triangle and accordingly, changes in any three of 
these factors may drive a healthy situation into a state of disease. In this review, the factors 
that sustain health or drive this complex intestinal system into dysbiosis will be discussed. 
Emphasis is on the role of the intestinal microbiota and related mechanisms that can drive 
the initiation and progression of sporadic colorectal cancer (CRC). These mechanisms 
comprise the induction of pro-inlammatory and pro-carcinogenic pathways in epithelial cells 
as well as the production of (geno)toxins and the conversion of pro-carcinogenic dietary 
factors into carcinogens. A thorough understanding of these processes will provide leads for 
future research and may ultimately aid in development of new strategies for CRC diagnosis 
and prevention.
General introduction
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The gastrointestinal tract is essential for human life as it functions as an energy supplier for 
the body by digesting food compounds and selectively transporting nutrients across the 
epithelium. In this process, the commensal intestinal microbiota makes dietary nutrients 
available and serves the intestinal barrier function by stimulating cell turnover, mucus 
formation and peristalsis. Importantly, a healthy microbiota also provides colonization 
resistance for invasive pathogens. Intestinal health is thus not only maintained by the human 
intestine and dietary factors, but also largely supported by the resident microbial community. 
Conversely, a large body of evidence supports a relationship between infective agents and 
human colorectal cancer (CRC) by production of DNA damaging metabolites or toxins, and 
the induction of cell proliferation and pro-carcinogenesis pathways by a subpopulation of the 
intestinal microbiota. Symbiosis in this multifaceted organ is therefore crucial to maintain 
a healthy balance within the host-diet-microbiota triangle and accordingly, changes in any 
three of these factors may drive a healthy intestine into a state of disease. Suspiciously, the 
increased bacterial density in the large intestine (~1012 cells/ml) compared to that in the 
small intestine (~102 cells/ml), is paralleled by a massive increase in risk for cancer in these 
respective parts of the intestinal tract (Jemal et al., 2009). The latter observation is only one 
of the many reasons why studies on bacterial interference in CRC should be considered of 
major importance to fully understand the pathology of this disease (Table 1).
Table 1. Evidence for a role of the microbiota in CRC-development
Key ref.
•  The incidence of small and large intestinal cancer relates to the 
microbial density in the lumen
(Jemal et al., 2009)
•  Germ-free mice have reduced CRC-rates compared to conventional 
mice
(Dove et al., 1997, Sellon et al., 
1998, Uronis et al., 2009)
•  The use of NSAIDS reduces CRC-progression and development (Eaden et al., 2000, Labayle et al., 
1991, Thun et al., 1991)
•  Specific bacterial infections, such as S. bovis and C. septicum, occur in 
CRC-patients
(Corredoira et ai., 2005, Mermsen 
et al., 2008)
•  Microbial metabolism results in dietary derived toxins or carcinogens (Homann et al., 2000, Knasmuller 
et ai., 2001, Takada et ai., 1982)
•  Bacterial toxins increase inflammation, cell proliferation and cancer 
progression
(Cuevas-Ramos et al., 2010, Wang 
and Huycke, 2007, Wu et al., 
2009)
•  Bacterial metabolism results In the generation of oxygen radicals 
and other electrofiles that induce DNA damage and chromosomal 
instability
(Attene-Ramos et al., 2007, 
Huycke et al., 2002, Wang et al., 
2008)
•  IBD patients have increased intestinal host-microbe interactions that 
results in a 5-fold increased risk of developing CRC
(itzkowitz and Yio, 2004, 
Macfarlane et al., 2005, Rutter et 
al., 2004)
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Scope of this chapter
In this chapter, different factors that sustain health or drive the complex intestinal system 
into dysbiosis will be discussed. Emphasis will be on the possible roles of the intestinal 
microbiota in the initiation and progression of sporadic CRC. For a good understanding of the 
microbial influence on CRC, this chapter will start with an introduction into the physiology 
of the large intestine. Next, the influence of dietary factors on the intestine and microbial 
population will be discussed. In view of the complexity of intestinal immunology, this 
chapter will only highlight the immune pathways that are important for the understanding 
of bacterial interference in CRC. Finally, this chapter will portray the few bacteria of which an 
infection has been clinically linked to CRC and elaborate on all known bacterial mechanisms 
that are (potentially) involved in the development of sporadic CRC. Together, this will bridge 
intestinal microbiology with host biology to increase insight in CRC-related host-microbe 
interactions on a molecular level. Knowledge of these interrelationships will build our 
understanding of intestinal ecology and provide leads for future research that may aid in the 
development of new strategies for CRC diagnosis and prevention.
Intestinal physiology
The small intestine is responsible for the digestion of food and the uptake of nutrients. 
All undigested material will eventually reach the large intestine where it can be further 
digested by the colonic microbial population. The main function of the large intestine 
(colon) is the absorption of water and salt, which concentrates feces to a substantial 
mass. The colonic contractions mix the contents and pass it along the colonic wall with a 
progression of approximately 5 to 10 cm/hr. Although the intestines contain roughly 7 liters 
of water per day, only 50 to 150 ml of water is lost by excretion. Whereas the small intestine 
extends its surface by villi and microvilli to promote absorption of digested compounds, 
these villi are absent in the large intestine. Up to the anus the colonic wall consists of simple 
columnar epithelium and tightly packed crypts (Levy et al., 2006).
The colonic wall
The wall of the large intestine is composed of: i. a single layer of epithelial cells covered 
by a mucus layer with underlying loose connective tissue (the lamina propria) that 
contains numerous immune cells (together called the mucosa), ii. a thin layer of smooth muscle 
(the muscularis mucosa), iii. loose connective tissue (the submucosa), iv. layers of smooth 
muscle (the muscularis externa), v. and an outer layer of connective tissue (the serosa) 
(Figure 1) (Levy et al., 2006).
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Figure 1. Colonic physiology
The w all o f  the large intestine consists o f  sim ple  co lum nar epithelium  (EP) that consists o f  epithelial 
cells (ec) and goblet cells (gc). G oblet cells are specia lized  cells that produce a viscous m ucus la yer (M) 
that protects the underlying epithelium  fro m  harm ful substances in the colonic lumen. Beneath the 
epithelium , the lam ira propria  (LP) contains loose connective tissue (ct), num erous im m une cells (ic) 
that fo rm  a second line o f  defense and blood capillaries (ca) that perfuses the lam ina propria. A  thin 
la yer o f  sm ooth m uscle  (the m uscularis m ucosa) separates the m ucosa fro m  the subm ucosa.
Epithelium. The colonic epithelium is in continuous contact with the microbiota and is the 
first line of defense against enteric antigens and bacteria. In a normal healthy colon, the 
epithelial barrier regulates uptake of nutrients and limits uptake of potential toxic 
substances and infectious agents. At the boundary between the apical and the basolateral 
membrane of adjacent epithelial cells, tight junctions, adherens junctions, gap junctions 
and desmosomes seal the paracellular space (Chichlowski and Hale, 2008). Tight junctions 
are located at the apical site and form a physiologically active barrier that can change its 
permeability on the basis of the cellular environment (Forster, 2008). The tight junction 
complex consists of transmembrane proteins that are linked to the cytoskeleton and 
regulate permeability under influence of various signals like growth factors, cytokines, drugs 
and hormones. This protein complex limits transport of solutes across the epithelial layer by 
size selectivity and charge selectivity. The exact size limit has not been defined, though it is 
clear that macromolecules can pass tight junctions whereas intact bacteria are unable to do 
so (Marchiando et al., 2010, Turner, 2009).
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Immune cells. In case bacteria translocate across the epithelial layer, immune cells in the 
lamina propria form a second line of defense. During the flrst months of life, immune 
maturation is aided by the intestinal microbiota (Duerkop et al., 2009). Bacteria provide 
a source of regulatory signals that for example direct the differentiation of Th17 and Treg 
cell activity (Ivanov et al., 2008). These signals influence the maturation of the gut, the 
immune system and other organs. In the absence of bacteria, the development of mucosal 
and systemic immune systems is impaired (Bouskra et al., 2008, Mazmanian et al., 2005). 
This is illustrated by the fact that germ-free mice produce reduced amounts of IgA and have 
decreased numbers of circulating B and T cells compared to conventional mice (Duerkop et 
al., 2009, Sansonetti and Medzhitov, 2009, Smith et al., 2007). However, supplementation 
of immunomodulatory polysaccharides from B. fragilis was shown to correct mucosal 
and systemic immunity defects in germ-free mice (Mazmanian et al., 2005), which again 
underscores the importance of the microbiota for a well-functioning and healthy intestinal 
tract. See Sansonetti et al., Abreu et al. and Duerkop et al. for further reading on this topic 
(Abreu et al., 2005, Duerkop et al., 2009, Sansonetti and Medzhitov, 2009).
Mucus layer. Goblet cells are specialized epithelial cells within the mucosa that produce 
a viscous mucus layer that covers the intestinal epithelium (Heazlewood et al., 2008). The 
goblet cells generate glycoproteins in its well-developed rough endoplasmatic reticulum 
(RER) and Golgi-apparatus. These carbohydrate-rich structures are excreted into the colonic 
lumen, where they absorb water to form a viscous, elastic gel. In fact, mucus is a complex 
mixture containing large glycoproteins (mucins), water, electrolytes, sloughed epithelial 
cells, and secreted anti-bacterial compounds such as immunoglobulin A (IgA), lysozyme, 
lactoferrin and al-antitrypsin (Aksoy and Akinci, 2004, Dekker and Strous, 1990, Matsuo 
et al., 1997). The mucus functions as lubricant for the transport of intestinal mass but also 
plays an important role in protecting the underlying mucosa for harmful substances in 
the intestinal lumen. In the small intestine the mucus layer is very thin, not attached and 
soluble. Contrarily, in the large intestine the mucus layer is thick and consists of an inner 
flrmly attached mucus layer and an outer non-attached loose mucus layer (Atuma et al., 
2001). In a healthy gut, the inner of the two mucus layers excludes bacteria from direct 
contact with the underlying mucosa (Johansson et al., 2008). The most important mucin in 
the colon is Muc2 representing the major gel-forming secretory mucin (Gum et al., 1994). 
Deficiency of Muc2 in the colon leads to a reduced mucus barrier and thereby to increased 
inflammation and susceptibility for intestinal infections. The underlying mechanism for these 
increased infection rates is probably mediated by inflammation-induced overexpression 
of IL-1P, TNF and IFN-a that leads to a 2-fold increase of intestinal permeability 
(Van der Sluis et al., 2006). Furthermore Muc2 alterations, or its absence, can lead to other 
disorders like celiac disease and CRC (Boland et al., 1982, Hasnain et al., 2010). Altogether, 
these studies illustrate the importance of the mucus layer to maintain the epithelial barrier 
function and to prevent development of gastrointestinal diseases.
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Microbiota in health
Colonization of the gastrointestinal tract occurs during the first 2 years of life. After this 
period, the microbiota are rather stable and fluctuate around an average composition throughout 
adulthood (Dethlefsen et al., 2006). In elderly subjects, this composition is gradually changing, 
nevertheless it is thought that these different marked microbiota may perform similar functions, 
in-line with the functional core microbiome hypothesis (Claesson et al., , Rajilic-Stojanovic et al., 
2009, Turnbaugh et al., 2009, Zwielehner et al., 2009). Bacterial colonization differs consistently 
between individuals, but certain bacterial strains are regularly recovered from different individuals. 
Although the main bacterial composition is maintained, it is likely that the colonic microbiota 
transiently respond to dietary intake and host physiology (Thompson-Chagoyan et al., 2007). 
Digested particles, like cellulose, resistant starch, and endogenous products, such as mucins, are 
essential energy sources that support the intestinal microbiota and may allow biofilms to develop 
at the intestinal epithelial interface (Flint et al., 2007, Macfarlane and Macfarlane, 2006). It has 
been shown that mucosa-associated bacteria differ from the community recovered from feces, 
but are uniformly distributed throughout the colon (Green et al., 2006, Macfarlane et al., 2004, 
Zoetendal et al., 2002). This mucosa adherent population is less prone to physiological 
effects, such as dietary changes and hydrodynamic shear forces (Sonnenburg et al., 2004).
Microbial metabolism
The intestinal microbiome provides its host with crucial physiological functions that 
humans have not developed themselves (Candela et al., , Gill et al., 2006, Neish, 2009, O'Hara 
and Shanahan, 2006, Xu et al., 2007). Microbial metabolism increases energy yield and 
storage from diet, regulates fat storage and generates essential vitamins (Backhed et al., 
2004, Backhed et al., 2005). This is primarily due to the fermentation of indigestible dietary 
polysaccharides (Neish, 2009). In general, anaerobic carbohydrate fermentation in the intestine 
results in Short Chain Fatty Acids (SCFA) including butyrate, propionate, acetate, CO2, H2 and 
CH4. Butyrate constitutes an important energy source for the colonic epithelium (McIntyre 
et al., 1993, Neish, 2009, Pryde et al., 2002), whereas acetate and propionate impact the host 
lipid metabolism (Laparra and Sanz, 2009, Wall et al., 2009). On the other hand, proteolytic 
fermentation results in metabolites such as phenolic compounds, amines, ammonia, 
N-nitroso compounds and indoles, which can be toxic to the host (Manning and Gibson,
2004, Simmering et al., 2002). Overall, however, the intestinal microbiota favor the renewal 
and barrier function of the gastro-intestinal epithelium (Neish, 2009) and have significant 
effects on host energy, gene expression, cell differentiation and xenobiotic metabolism (Flint et 
al., 2007, Qin et al., 2010).
Colonisation resistance
Besides making dietary nutrients available to the host, the commensal microbial community 
prohibits colonization of intruding pathogens; a process called microbial interference or 
colonization resistance (Stecher and Hardt, 2008). The molecular basis of this phenomenon 
is still poorly understood, but probably involves competition with adhesion receptors 
(Bernet et al., 1994, Gill, 2003), stabilization of the gut mucosal barrier (Vollaard and
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Clasener, 1994), competition for nutrients (Hooper et al., 1999) and the production of anti­
microbial substances (Brook, 1999, Cotter et al., 2005, Lievin et al., 2000, Vollaard and 
Clasener, 1994). Disruption of colonization resistance by gut inflammation can be triggered 
by enteropathogenic pathogens like Citrobacter rodentium and Salmonella typhimurium. 
A reduction in colonization resistance by either pathogens or an antibiotic intervention 
increases the risk for gut infections by affecting gut immunity, and thereby causes shifts in the 
intestinal ecosystem (Stecher et al., 2007).
Dietary maintanance of the microbiota
Dietary factors are not only essential for human health, but also for the maintenance of the 
microbial population. Factors from dietary, microbial or host origin within the gut lumen 
can greatly influence bacterial metabolism and competition. For example, African children 
consume much more plant material and have therefore higher SCFA's in feces then European 
children, which is reflected by a more diverse microbial composition. Contrarily, enteropathogens 
are overrepresented in European children. The main determinant of those differences is 
consumption of sugar, animal fat and calorie dense foods that could limit the adaptive 
potential of the microflora and reduce the richness in species (De Filippo et al.). In line with 
this alternate consumption, pH is one of the factors thought to play an important role in 
influencing bacterial shifts and turnover (Duncan et al., 2007). pH differs as a result of fermentation 
of non-digestible carbohydrates, but may also be locally reduced by e.g. carcinogenic tissue 
(Koukourakis et al., 2006, Liu et al., 2001, Svastova et al., 2004, Tredan et al., 2007).
Polyphenols. Some dietary constituents have been investigated for their role as anti­
microbial agent. Polyphenols, like catechol, are present in green teas, black tea, coffee, wine 
and onions kale and these compounds are known for their function as iron removal agent 
of high-affinity mammalian iron-binding proteins, including transferrin and lactorferrin. 
Presence of these polyphenolic compounds in the colonic lumen can withhold iron from the 
intestinal bacterial population and thereby inhibit the growth of certain groups of bacteria. 
However, some enteropathogenic bacteria could aid from the presence of catechols under 
iron restrictive conditions by their production of siderophores. Siderophores can remove 
iron from catechols and make it available to the bacterium, to promote bacterial growth 
(Freestone et al., 2000, Freestone et al., 2007).
Prebiotics. Dietary factors have also been extensively studied for their role as prebiotics to 
stimulate the growth and/or activity of health-promoting bacteria. Inulin, which is naturally 
present in e.g. garlic, leek, asparagus and wheat, increases the amount of Bifidobacteria 
in the lumen and mucosa-associated parts of the gut (Langlands et al., 2004, Rao et al., 
2001). This is reflected by an increase in SCFA, but also benefits the integrity and functioning 
of the epithelial lining (Gibson et al., 1995, Kleessen et al., 1997, Lee et al., 2003b, Li et al.,
2008). Inulin intake was reported to result in reduced translocation of enteropathogenic 
bacteria (Lesniewska et al., 2006, Osman et al., 2006) and an increase in the intestinal 
barrier function in polyp patients (Rafter et al., 2007). In addition, inulin modulates the 
disease processes in a dextran sulfate sodium (DSS)-induced colitis model (Videla et al.,
10
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2001) and reduces the amount of aberrant crypt foci (ACF) in the colon of weanling rats 
(Verghese et al., 2002), probably through its role on the gut microbiota. Such a prebiotic 
effect has also been suggested for other dietary compounds like oligosaccharides and 
resistant starch (Kolida and Gibson, 2007, Lim et al., 2005). The break-down of simple 
carbohydrates creates opportunities for microbial competition but also for cooperation by 
metabolic cross-feeding within the intestinal microbial population (Belenguer et al., 2006, 
Falony et al., 2006). Thus, altered diet patterns are of influence on the microbial population in 
the intestine (Dethlefsen et al., 2008, Eckburg et al., 2005, Flint et al., 2007), which may have 
substantial effects on the health status of the host.
Microbiota in disease
The preceding paragraphs described that the physiology of the gut, dietary factors and 
microbial competition are of importance for a healthy intestinal ecosystem. However, 
alterations in either one of these factors might drive the balanced system into dysbioses, 
which could lead to intestinal diseases. In the following paragraphs, the effects of physiological 
and dietary alterations on the microbial composition are discussed. First, we summarize the 
reported changes in microbiota composition during intestinal diseases. This information aids 
in the understanding of the effect of disease on the intestinal microbiota and vice versa. For 
example, a reduced colonization resistance may affect the bacterial composition in the gut 
by affecting gut immunology (Stecher et al., 2007). These mechanisms are thought to play an 
important role in the pathogenesis of Inflammatory Bowel Disease (IBD) and might also be 
of importance in other diseases that are associated with distorted gut homeostasis. Several 
studies have shown that the number and composition of mucosal bacteria is altered in disease 
states as IBD and CRC (Swidsinski et al., 2005) as described below.
IBD-associated microbiota
Recent high-throughput 16S rDNA sequencing approaches on fecal samples from patients 
with Chron's disease (CD) or Ulcerative colitis (UC), together named IBD, have provided 
detailed insight into the microbial changes that occur during these inflammatory diseases. 
Overall, microbial diversity is decreased in CD and UC patients, and the presence of 
enteropathogenic bacteria, such as specific E. coli strains, are increased (Darfeuille-Michaud 
et al., 1998, Giaffer et al., 1992, Seksik et al., 2003, Sokol et al., 2008, Willing et al., 2009). 
Strikingly, due to the grave mucosal changes in IBD patients, the amount of mucosal adherent 
bacteria is much higher compared to healthy controls. This difference appears to be due 
to a loss of distinction between the mucosal microbiome and luminal bacteria (Gillevet et 
al., 2010). Willing et al. performed a study in twins to reduce genetic background influences 
on microbial composition and were able to discriminate ileal CD (ICD) and colorectal CD 
(CCD) from healthy controls based on fecal microbial composition. Even ICD and CCD were 
significantly different and showed opposite shifts in levels of several bacterial populations 
(Willing et al., 2009). For example, CCD patients tended to have more Firmicutes, whereas
11
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ICD patient had fewer Firmicutes than healthy controls. However, fecal microbiota diversity 
of UC patients was not strikingly different from healthy controls and differences were 
limited to some bacterial strains (Willing et al., 2010). The latter studies underscore the 
importance of disease localization on bacterial composition.
CRC-associated microbiota
Only few studies have investigated the composition of microbiota changes during CRC. 
Nevertheless, these studies indicated that the altered colonic environment in CRC could 
have implications for the composition of the microbiota in the lumen and on mucosal 
surfaces. Scanlan et al. investigated the diversity and presence of methanogens in healthy, 
polyp and cancer patients and found significant differences in bacterial stability over 
time. Specifically, the diversity of the Clostridium leptum and coccoides subgroups were 
increased compared to healthy controls. Importantly, metabonomic fecal water analysis 
was able to distinguish CRC and polyp groups from healthy controls (Scanlan et al., 2008), 
indicative for an altered metabolic activity of the intestinal microbiota in these patients. 
In another study it was shown that the mucosa of adenomas and carcinomas had increased 
intracellular mucosal carriage of E.coli compared to healthy controls. Whether this 
increased carriage had a causal or incidental origin is currently not known (Maddocks 
et al., 2009, Swidsinski et al., 1998). Some support for an incidental relationship comes 
from a study by Martin et al. in 2004. These investigators speculated that certain surface 
antigens on tumor cells, which display homology to surface antigens of fetal origin, may 
be responsible for the binding of E. coli. These abarrant 'oncofetal' proteins are the result 
of altered mucosal glycosylation at malignant intestinal sites (Martin et al., 2004). A similar 
relation has been described for the opportunistic pathogen Streptococcus gallolyticus. This 
bacterium is thought to selectively colonize malignant and pre-malignant colonic sites by which 
it can cause systemic infections in susceptible individuals (See section: bacterial infections 
associated with CRC and Chapter 2). More recently, several studies have reported 
altered adherent bacterial communities to healthy, adenoma and CRC tissue. Shen 
et al. compared the bacterial composition in normal tissue samples from adenoma 
patients and from individuals without colon abnormalities. The data showed increased 
levels of proteobacteria and decreased bacteroidetes species in the tissue samples 
from the adenoma patients (Shen et al., 2010). Interestingly, Sobhani et al reported 
that the abundance of Bacteroides was significantly increased in tumor and normal 
tissue of cancer patients compared to healthy controls. More importantly, the 
abundance of bacteroides was higher in tumorous tissue of cancer patients than adjacent 
normal tissue. This finding was associated with increased IL-17/CD3 immune cell infiltration 
in tumor tissue, which was found to be rarely present in healthy subjects (Sobhani et al., 
2011). Another study compared differences in healthy and cancerous tissue within cancer 
patients and found that tumor tissue was overrepresented by species of the genera 
Coriobacteridae, Roseburia, Fusobacterium and Faecalibacterium, which are generally 
regarded as gut commensals with probiotic features. On the contrary, this study found 
decreased colonisation of members of Enterobacteriaceae, such as Citrobacter, Shigella, 
Cronobacter, and Salmonella in CRC tissue from the investigated patients (Marchesi et al.,
12
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2011). Altogether, these studies indicate that CRC is associated with differences in bacterial 
composition both between subjects with and without cancer and between cancerous 
and normal tissue within patients. However, the current data do not yet show consistent 
patterns of cancer-associated bacterial populations. This is likely due to the relative small 
number of studies and included patients. Hopefully, future microbiome studies on samples 
from extended groups of patients and controls will be able to define the population of CRC- 
associated bacteria.
Colorectal cancer
The initiation and progression of CRC is accompanied by severe (local) physiological 
alterations. As shown by the above mentioned studies, these changes will affect the 
intestinal microbiota composition. Furthermore, knowledge on the individual effects of 
host genetic and dietary factors on the development of intestinal disease is important for 
the understanding of the microbial contribution to CRC. In this respect, the most important 
factors that influence the intestinal microbiota during the development of CRC will be 
discussed hereafter.
Alterations in gut m icrobiota
Î
| Environmental changes |
increased lactate (pH reduction) 
increased amino acids, 
lipids and fatty acids 
reduced glucose and pyruvate
Increased inflammation  
Increased intestinal perm eability
1
barrier function
reduced mucin production 
altered mucin glycosylation
Figure 2. Physiological changes of the colonic epithelium during CRC
The CRC m icroenvironm ent is characterized  b y severa l changes during disease progression. Due to 
increased turnover o f  m alignant cells, the tum or m icroenvironm ent contains reduced glucose and  
pyruvate levels. Conversely, the tum or cells re lease increases levels o f  lactate, secondary glucose  
m etabolites, am ino acids, lip ids and fa tty  acids. These environm ental changes m ay provoke local 
alterations in gut m icrobiota as this new  niche is likely to provide a com petitive advantage fo r  a 
selective num ber o f  in testinal bacteria. In addition to a ltered nutritional conditions, m ucus production  
is both reduced and altered in glycosylation, b y  which the protective m echanism  o f  the epithelial 
b arrier is reduced. This increased in testinal perm ea b ility  leads to continuous bacteria l-host contacts 
and m ay lead to increased in testinal in flam m ation and bacteria l infiltration.
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Physiological changes of the epithelium during CRC
To better understand CRC-associated changes of the gut microbiota, the physiological 
changes in the CRC microenvironment will be discussed in the following two paragraphs.
Cell Metabolism. The CRC microenvironment is characterized by several changes (Figure
2). First of all, recent metabolomics studies revealed that extremely altered nutritional 
conditions exist between the CRC tumor microenvironment and non-malignant mucosa. 
The most prominent and consistent findings concerned a drastic decrease in glucose and 
pyruvate and an increase in lactate (low pH) related to hyperactivity of glycolysis in tumor 
cells, and an increase in amino acid levels, lipids and fatty acids (Hirayama et al., 2009). 
pH reduction is not only a mechanism leading to tumor acidity, but also CO2 is thought 
to be an important contributor to acidity in the tumor microenvironment, mainly through 
the action of carbonic anhydrases (the influence of this altered nutritional environment on 
bacterial growth is discussed in Chapter 8) (Helmlinger et al., 2002, Svastova et al., 2004).
Epithelial Permeability. During CRC progression, the colonic epithelium shows increased 
tight junction permeability via loss of Claudin-1 expression (Resnick et al., 2005, Soler et al., 
1999). Furthermore, Oliveira et al. reported an increase of Claudin-1, -3 and -4 expression 
in human CRC that was accompanied by a significant disorganization of tight junction 
fibrils (de Oliveira et al., 2005). This reduced barrier function was also reported in another 
study (Hirohashi and Kanai, 2003) and is accompanied by changes in expression of mucin 
carbohydrates that are important for the protection of the epithelium (Blank et al., 1994, 
Hollingsworth et al., 1994, Pilbrow et al., 1992). The expression of Muc2 decreases during 
transition from adenoma to adenocarcinoma (Aksoy and Akinci, 2004, Aksoy et al., 2000, 
Byrd and Bresalier, 2004, Mizoshita et al., 2007) and is accompanied by altered glycosylation 
in carcinomas. This results in significantly reduced and fewer oligosaccharide chains per 
potential glycosylation site (Itzkowitz et al., 1992, Jenab et al., 2001). Alterations or the absence 
of these protective layers, as in the colon of Muc2~/~ mice, allow bacteria to have a direct 
contact with epithelial cells, to penetrate lower into the crypts and to invade into epithelial 
cells. It is easy to understand that such a close contact between bacteria and epithelial 
cells can trigger an inflammatory response. Importantly, chronic inflammation is known 
to be an important player in CRC development (Johansson et al., 2008). Thus, the current 
knowledge supports the idea that the altered tumor micro-environment makes the human 
body more susceptible to (opportunistic) pathogenic infections and that a more intimate 
contact between the colonic epithelium and the intestinal microbiota may contribute to the 
progression of CRC.
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Diet & CRC risk
In general, CRC is more common in the Western world than in developing countries (Sharma 
and O'Keefe, 2007). The incidence is almost equal between men and women and is 
estimated to be 52,010 for men and 54,090 for women in the USA (Jemal et al., 2009). Like 
all cancers, the development of CRC is a combination of genetic and environmental factors. 
A Western diet greatly influences CRC risk, since Japanese and Africans that migrate to the 
USA obtain increased CRC rates as compared to their native counterparts (Haenszel and 
Kurihara, 1968, Kolonel et al., 2004). This difference in CRC risk is mainly due to the very 
different diets of native Africans and African-Americans (O'Keefe et al., 1999). African- 
Americans have a diet that is rich in meat and saturated fats, whereas Africans have a diet 
that is low in meat, saturated fat and vitamins, but rich in complex carbohydrates and 
vegetables (Ahmed et al., 2000). Recently, the European prospective investigation into Cancer 
and Nutrition in >500.000 subjects showed that in particular the consumption of red meat, 
animal fat and processed meat are linked to increased risk for CRC, whereas the consumption 
of calcium, vitamin D, fish and fiber are thought to reduce the risk for CRC (Gonzalez and 
Riboli, 2010, Kim and Milner, 2007, Norat et al., 2005, Platz et al., 2000, Sandhu et al., 2001, 
Willett et al., 1990). Closely linked to these factors are (abdominal) obesity and, lack of 
exercise that underscore the effects of overfeeding on CRC risk (Alazmi et al., 2006, Basterfield and 
Mathers, 2010, Bingham et al., 2003, Pischon et al., 2006). Intriguingly, alcohol and smoking only 
have modest effects on CRC risk (Basterfield and Mathers, 2010, Ferrari et al., 2007). It is likely 
that several of these dietary factors directly affect CRC development. However, in the following 
sections we will briefly discuss how certain of these factors could affect the intestinal microbial 
composition towards a more pathogenic profile and how this may affect CRC development.
Red meat. Red and processed meat may have a particularly significant effect on CRC risk 
due to its high content of saturated fat, protein, nitrate, heme iron and production of 
heterocyclic amines during cooking processes (Chao et al., 2005, Cross et al., 2010, Sesink et 
al., 2001). A study in rats by Sesink et al. illustrated that heme in red meat irritates the colonic 
epithelium and results in significantly increased proliferation of the colonic mucosa (de 
Vogel et al., 2005, Sesink et al., 1999). Furthermore, heme has been shown to be genotoxic 
in tumor cells and increases the amount of ACF and mucin-depleted foci in rats with 
increasing heme content in the diet (Pierre et al., 2004, Pierre et al., 2003). Some pathogenic 
bacteria (e.g. Bacteroides fragilis) can use heme as an iron source to release complexed 
iron and heme-derived porphyrins (Andrews et al., 2003, Young et al., 1990). Fascinatingly, 
increase of dietary heme was shown to favor the colonization of enterobacterial pathogens 
(N. IJssennagger & R. van der Meer, personal communication), which could lead to the 
increased incidence of CRC (by causing low-grade chronic intestinal inflammation). 
Meat is also an important source of dietary sulfur that promotes the growth of sulfur 
reducing bacteria (Christl et al., 1992). In fact, the amount of total meat intake increases 
the risk for gastric cancer in combination with a Helicobacter pylori infection that has been 
defined as a Class I carcinogen for stomach cancer (Gonzalez et al., 2006). This strengthens 
the idea that certain (pathogenic) bacteria may be linked to the formation of CRC through 
high red meat intake.
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Polyphenols. Contrary to red meat, polyphenols that are for example present in red wine, 
can shift the composition of the microbiota to a more health-promoting profile by increasing 
the amount of lactic acid bacteria (Lactobacillus and Bifidobacterium) and reducing the 
amount of Clostridium and Bacteroides (Dolara et al., 2005). These polyphenolic compounds 
also reduce tumor yield in polyphenol-treated rats, probably via reducing enzyme activity 
of B-glucuronidase and nitroreductase resulting in reduced toxic intermediates of N-nitroso 
compounds and heterocyclic amines (Rowland et al., 1996). These data indicate that certain 
dietary factors may influence the composition of the intestinal microbiota, which on the 
long term may modulate the risk for CRC.
Obesity & CRC risk
Overweight and obesity do not only increase the risk of cardiovascular disease and type 
2 diabetes mellitus but also of various types of cancer, including CRC (van Kruijsdijk et al.,
2009). The impact of calorie intake on CRC risk was demonstrated by Hughes et al., who 
showed that energy restriction during early childhood (during WW2 and hunger winter) 
reduced CRC risk in later life (de Vogel et al., 2005). It is tempting to speculate that this 
low energy diets have altered the intestinal microbiota towards a more health-promoting 
profile, which has beneficial effects on the long term. In this respect, it was an interesting 
observation that obese and lean people have a different microbial composition. The 
microbiota of obese individuals was enriched with Firmicutes and Actinobacteria and had a 
low relative abundance of bacteroidetes. Furthermore, the microbiota of obese subjects was 
characterized by a decreased functional diversity (Turnbaugh and Gordon, 2009). As already 
mentioned, dietary factors can affect microbial composition, which indirectly can have 
repercussions on colonic health and also on uptake and storage of fat in the host (Backhed 
et al., 2004, Wall et al., 2009). This is further illustrated by the observation that total body 
fat of conventionally raised mice was 42% higher compared to their germ-free counterparts 
(Samuel et al., 2008, Yoon et al., 2000). Thus, genetic and diet induced obesity are associated 
with alterations in the composition and functional properties of the gut microbiota, which 
results in high bacterial fermentation rates and increased capacity to harvest energy 
(Tilg et al., 2009, Turnbaugh et al., 2008). This underscores the important role of the 
microbiota on host adiposity. As obesity is closely related to diet, this could also be of 
major impact on obesity related CRC risk. Nevertheless, it remains difficult to determine 
whether the different microbiomes in obese individuals are a contributing factor or merely a 
consequence of the obese life style.
Genetic mutations and altered protein expression in CRC development
Cancer is usually characterized by several hallmarks, including self-sufficiency in growth 
signals, angiogenesis, insensitivity to anti-growth signals, evasion of apoptosis, limitless 
replicative potential, reprogramming of energy metabolism, evading immune destruction 
and finally tissue invasion and metastasis (Hanahan and Weinberg, 2011).
Mutations in CRC development. The formation of CRC is initiated by the mutation of stem 
cells at the base of the crypt (Barker et al., 2009, Ricci-Vitiani et al., 2009). One of the first
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mutations is located in the APC gene, however, for malignant transition to occur both 
alleles must be inactivated or mutated. About 65-70% of sporadic CRC cases are typified by 
chromosomal instability (CIN). The consequence is an imbalance in chromosome number 
(aneuploidy), subchromosomal genomic amplifications, and a high frequency of loss of 
heterozygosity (LOH) (Pino and Chung, 2010). This loss of heterozygosity may lead to 
inactivation of the intact APC allele. Conversely, malignant transition may occur due to a 
mutation in both apc alleles (Barker et al., 2009, Zhu et al., 2009). About 20% of the CRC 
cases have a hereditary basis (Familial adenomatous polyposis coli (FAP) or Hereditary 
non-polyposis CRC (HNPCC)), whereas the remainder sporadic CRC cases (80%) are linked 
to environmental causes, which includes bacterial intervention, rather than heritable 
genetic factors (Rustgi, 2007). FAP patients already carry a genetic mutation in one APC 
allele, meaning that for genetic transition to occur only inactivation of the 2nd APC allele is 
necessary. This mostly happens during the first 30 years of life.
Figure 3. Progression of IBD-derived CRC compared to sporadic CRC
IBD -derived CRC is characterized b y  f la t  dysplastic precursors, w hereas sporadic CR C typically arises 
fro m  polyps. Both prim a ry lesions can lead  to the developm ent o f  CR C b y  the accum ulation o f  m utations. 
The m ost sign ificant d ifferences betw een IBD -derived CR C and sporadic CRC are re lated  to A P C  
m utations that arise e arly  in sporadic CRC, b ut late in IBD -derived CRC. Conversely, p53 m utations are 
am ong the first m utations in IBD -derived CRC, whereas these appear late in the adenom a-carcinom a  
sequence in sporadic CRC. Both in sporadic and IBD -derived CRC, COX-2 expression is a lready increased  
during the early  stages and is p ro bab ly  re lated to (chronic) infection and in flam m ation that drive the 
progression o f  CRC.
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Around 80% of the sporadic CRC cases have inactivated APC alleles, or otherwise have 
mutations in the p-catenin gene or in genes more downstream in the Wnt pathway. The 
CRC sequence as described by Fearon and Vogelstein pictures the changes from ACF to 
polyps, to adenomas and then carcinomas, including the most common mutations in tumor 
suppressor genes (APC, p-catenin, DCC, p53) and oncogenes (ras, c-myc) (Figure 3) (Fearon 
and Vogelstein, 1990, Lakatos and Lakatos, 2008, Phelps et al., 2009, Reya and Clevers, 2005, 
Sheng et al., 1998). Approximately 15% of the sporadic CRC cases carries a somatic mutation 
in one of the mismatch repair genes MLH1 or MSH2 (Arnold et al., 2003, Boland and Goel,
2010). Germline mutations in these genes determine the increased susceptibility for CRC 
in HNPCC patients and induce tumors that are most often located in the proximal colon, 
poorly differentiated and seldom contain mutations in k-ras and p53 (Lengauer et al., 1998, 
Peinado et al., 1992).
Changes linked to inflammation. Proper immune function is necessary for a healthy 
intestinal tract. Toll-like receptor (TLR) polymorphisms have been associated with 
increased risk for cancer (Boraska Jelavic et al., 2006, El-Omar et al., 2008). Similarly, 
TGFp is important for immunosurveillance in the colon and mutations in the TGFp gene 
predispose to colonic tumor development and growth (Terzic et al., 2010). Importantly, 
production of TNFa and PGE2 promote tumor formation in sporadic CRC, which signifies 
the importance of (chronic) infection in the CRC process (Castellone et al., 2005, Oguma 
et al., 2008, Wang and Dubois, 2006). In fact, cyclooxygenase-2 (COX-2) overexpression, a 
marker for chronic inflammation, is detected in 43% of adenomas and 85% of carcinomas 
(Eberhart et al., 1994, Oshima et al., 2001). Furthermore, it has been shown that Wnt 
deregulation and ras signaling, as well as hypoxia via HIF1 expression contribute to the 
upregulation of COX-2 in adenoma and carcinoma tissue (Araki et al., 2003, Boraska Jelavic 
et al., 2006, El-Omar et al., 2008, Kaidi et al., 2006). Conversely, p-catenin is increased by 
PGE2 and TNFa produced by macrophages, which illustrates the close relation between 
inflammation and Wnt signalling in CRC (Castellone et al., 2005, Oshima et al., 2009).
Inflammation and cancer predisposition
As discussed in the previous section, the genetic background of the host together with dietary 
intake influences the microbial composition in the gut. However progression of CRC also 
influences the gut barrier and micro-environment in the intestine. This dynamic interplay 
between environment, genetic and microbial influences makes it hard to define the exact 
contributionofthemicrobiotainthedevelopmentandprogressionofCRC.Inthenextparagraphs, 
the mechanisms by which microbiota contribute to inflammation-induced CRC are further 
discussed. The effects of inflammation and infection on the development of CRC are best 
illustrated by the diseases UC and CD, together housed under the name IBD. UC only affects 
the colon and rectum, whereas CD can affect any part of the gastrointestinal tract. Both 
diseases are thought to originate from an altered host response to a normal intestinal bacterial
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population (Round and Mazmanian, 2009). Importantly, patients with IBD have a high 
predisposition for CRC, induced by a state of chronic intestinal inflammation (Macfarlane 
et al., 2005).
Host factors in IBD
Genome wide association studies have given insight into the genetic factors that play an 
important role in the pathogenesis of IBD. For example, genetic variations that are involved 
in bacterial sensing (NOD-2) and T-cell mediated immunity (such as IL-23R) highlight 
the connection between commensal microorganisms and intestinal inflammation (Cho,
2008, Frank et al., 2007, Mathew, 2008). It is thought that these genetic variations are 
important for the emergence of dysbiosis in IBD patients, but it is still unknown if this 
directly causes disease. The gut of IBD patients is characterized by defects in immune 
regulatory functions and goblet cell depletion (colitis) that leads to reduced mucus 
production and thus a reduced barrier function. This altered physiology of the intestine 
is the cause of increased immune cell activation against commensals that is illustrated by 
an increased production of antibodies against intestinal bacterial antigens. Furthermore, 
more pronounced inflammation is seen in the regions of the intestine that contain high 
amounts of bacteria, i.e. the colon (Sartor, 1997). Chronic immune stimulation and distorted 
tolerance for the intestinal microbiota leads to a shift from a regulated immune response 
to one that is driven by unrestrained immune cell activation and pro-inflammatory cytokine 
production. The importance of mucus in this process has been illustrated in Muc2 knock­
out mice, which show morphological changes of the intestinal epithelium and extensive 
inflammation of the colon. More importantly, due to the loss and changed mucus 
composition these mice develop intestinal adenomas, invasive carcinomas as well as rectal 
cancer at an older age (Van der Sluis et al., 2006, Velcich et al., 2002). This points out that 
Muc2 is an essential component of the protective epithelial barrier that shield epithelial 
cells from the intestinal microbiota and that changes in the mucin composition contribute 
to the onset of experimentally-induced IBD and inflammation-induced CRC.
IBD-associated CRC compared to sporadic CRC
The increased risk for CRC in patients with IBD that can be mainly ascribed to UC, has long been 
recognized and affects people at a younger age than sporadic CRC (mean age <50 compared to 
>65). More than 20% of the IBD patients develop CRC within 30 years of disease onset. Compared 
to the normal population, IBD patients have an up to 5-times increased risk to develop CRC, 
which is linked to the site, extent and duration of disease (Itzkowitz and Yio, 2004, Rhodes and 
Campbell, 2002, Rutter et al., 2004, Xie and Itzkowitz, 2008). Over the years, it became clear that 
both genetic and acquired factors are important for the development of CRC in IBD patients. 
IBD-derived CRC, is accompanied by the same genomic alterations as sporadic CRC, however 
the order of appearance of these mutations is different (Figure 3). Sporadic CRC typically arises 
from polyps that carry APC mutations or have a dysfunctional Wnt signaling pathway. Contrarily, 
IBD-associated cancers arise from flat dysplastic mucosa in which p53 mutations are acquired 
relatively early during carcinogenesis. One of the striking similarities between IBD-associated 
and sporadic CRC is the importance of COX-2 induction and prostaglandin synthesis.
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CRC protection by NSAIDs
Many studies point towards COX-2 as one of the key players in colon carcinogenesis. 
COX-2 expression is highly elevated in colonic tumors and its expression is correlated with disease 
stage. Furthermore, COX-2 induction has been implicated in the initiation and progression of 
CRC, by the production of prostaglandins and eicosanoids that stimulate cell proliferation and 
pro-inflammatory pathways (Menter et al., 2010). Human intervention studies have clearly 
shown that the usage of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) can reduce CRC risk 
by as much as 75% (Eaden et al., 2000, Labayle et al., 1991, Thun et al., 1991). Over the years, 
new specific COX-2 inhibitors have been developed to circumvent the side effects of general 
COX-inhibition, such as liver toxicity. These specific COX-2 inhibitors have been shown to reduce 
CRC risk via inhibition of inflammatory pathways (Yan et al., 2009). The fact that COX-2 plays such 
a pivotal role in both IBD and CRC underscores that intestinal inflammation is a critical factor in 
the carcinogenic process.
COX-2 induction
As mentioned previously, COX-2 is responsible for the synthesis of PGE2 that has been implicated 
in the induction of pro-inflammatory and procarcinogenic pathways. Evidence for a bacterial 
involvement in the upregulation of COX-2 during CRC development is gained through animal and 
in vitro studies (Figure 4A). Superoxide radicals produced by Enterococcus faecalis were shown 
to upregulate the expression of COX-2 in hybrid hamster cells containing human chromosome 11 
and macrophages (Wang and Huycke, 2007). Furthermore, macrophages that were pre-treated 
with a COX-inhibitor and subsequently exposed to E. faecalis totally inhibited the induction of 
CIN in these hybrid hamster cells. These data suggest that COX-2 induction is critical for the 
induction of chromosome instability. Importantly, this study provided evidence for the concept 
that superoxide radicals from bacterial origin can contribute to COX-2 induction and CIN (Figure 
5A). An animal study published by Ellmerich et al. suggested that Streptococcus bovis biotype II 
(Streptococcus infantarius) could also play a role in the progression of CRC through induction of the 
COX pathway (Ellmerich et al., 2000b). These investigators employed a rat model in which 
pre-treatment with the carcinogen azoxymethane (AOM) induced pre-neoplastic ACF. 
Strikingly, when such rats were co-exposed to S. infantarius or wall extracted antigens (WEA) 
from this bacterium, the number of ACF increased drastically. Even some adenomas were 
found in the animals exposed to WEA, whereas these were never found in the animals treated 
with AOM alone. Similarly, the production of the pro-inflammatory cytokine IL-8 in the mucosa 
of rats exposed to S. infantarius was increased (Figure 5B). This finding is in accordance with 
in vitro studies on epithelial Caco-2 cells that release both IL-8 and PGE2 upon incubation with 
S. infantarius (Biarc et al., 2004). Moreover, Abdulamir et al. have recently shown that increased 
COX-2 and IL-8 expression was associated with the presence of S. gallolyticus (S. bovis biotype 
I) in colon tumor tissue. However, IL-8 expression was not increased in non-malignant tissue 
that contained S. gallolyticus (Abdulamir et al., 2010). Together these studies strongly suggest 
that inflammation-induced COX-2 induction is associated with both tumor development and 
exposure to bacterial stimulants.
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Inflammatory pathways in CRC development
(A) Bacteria may directly trigger Toll-like receptors 
(TLRs) on eptithelial or inflammatory cells, which 
respond through c-src, NFk B and ERK/p38 that leads to 
the upregulation of COX-2. Alternatively, inflammatory 
mediators generated by bacterial infection may signal 
via MAPKKKs and ERK/p38 to the upregulation of 
COX-2. Increased COX-2 expression results in 
prostaglandin synthesis, inflammation and increased 
6-catenin expression, which induce increased cell 
turnover and increase CRC risk. NSAIDS and specific 
COX-2 inhibitors can inhibit malignant transition 
via the inactivation o f prostaglandin production.
(B) Enterotoxigenic Bacteroides fragilis triggers 
inflammatory responses in either epithelial or dendritic cells within the gut wall. These bacteria induce 
upregulation o f STAT3, TGF8 and IL-23, which stimulate the activation o f Th17 cells that subsequently produce 
IL-17. The activation o f Th17 cells in the Apc+/min mice model has been shown to initiate and promote tumor 
development. This increased tumor formation was counteracted by blocking the IL-23-receptor (IL-23-R) or by 
anti-IL-17 therapy. (C) T-regulatory (Treg) cells are important immune regulatory cells that prevent prolonged 
immune activation via IL-10 and TGF6. Inactivating mutations in either the TGF8-receptor (TGF6-R), or SMAD2, 
-3 or -4 lead to the increased expression of the oncogene c-myc, which eventually can trigger tumor promotion. 
(D) TLR signaling is important fo r the maintenance o f intestinal health, but chronic activation may lead to tumor 
progression. Activation of TLR2 and TLR5 aids tumor suppression by the infiltration of tumor antigen specific 
T-cells and neutrofiles into the tumor. Conversely, chronic stimulation of TLRs by bacterial ligands may lead to 
overexpression o f COX-2, interleukins and urokinase type plasminogen activator (uPA) or its receptor (uPAR). 
Sustained intestinal inflammation may promote tumor progression.
I
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Mice models for IBD-derived CRC
An important question is whether changes in microbial composition can directly affect 
the development of tumors from IBD tissue. A study by Glimcher et al. provided intrigning 
evidence that bacteria can indeed transfer the increased risk for intestinal inflammation 
from colitis prone TRUC mice (Tbx21-/-;Rag2-/- Ulcerative Colitis) to wild-type mice by 
simply housing them together. In this experiment, the normally resistant mice developed 
aggressive colitis (Garrett et al., 2007, Garrett et al., 2009). The influence of the microbial 
composition on the development of colitis-associated CRC was further illustrated by a 
study of Uronis and colleagues who used AOM treated IL-10'1' mice in their experiments. In 
this model the mice develop colitis due to lack of immune suppressive IL-10. This chronic 
inflammation is accompanied by remarkably increased numbers of adenocarcinomas in 
the colon. Strikingly, however, under germ-free conditions, these mice did not suffer from 
chronic inflammation and did not develop colorectal adenomas at all (Berg et al., 1996, 
Sellon et al., 1998). These experiments clearly showed that the intestinal microbiota is an 
essential trigger for intestinal inflammation that directly correlates with tumor multiplicity 
and tumor progression. Furthermore, disruption of the MyD88 signaling pathway, a key 
integrator of multiple TLRs, was shown to prevent development of CRC in this mouse model 
(Figure 4D) (Uronis et al., 2009). Altogether, these studies nicely demonstrated that the 
microbiota respond to colitis and subsequently have an increased potential to impact the 
development of CRC through induction of inflammatory pathways. Other mouse models 
that have been developed to study IBD-associated CRC have been recently reviewed by 
Taketo and Edelmann (Taketo and Edelmann, 2009). These models can aid future studies on 
the role of the intestinal microbiota in this process.
Probiotics. Intervention studies with probiotic bacterial strains in IBD mouse models have 
shown to ameliorate the symptoms of IBD, probably via their ability to control inflammation 
by the induction of T-regulatory (Treg) cells (Ostanin et al., 2009). The importance of Treg cells 
in the regulation of intestinal homeostasis is best illustrated by the finding that these cells can 
prevent the induction of experimental colitis by naïve T-cells following transfer into diseased 
mice. This naïve T-cell transfer model shares 30 up- or down-regulated genes with human IBD, 
which underscores the importance of T-cells in the development of the latter disease (te Velde 
et al., 2007). It seems that cytokine production by Treg cells might be an important protective 
mechanism at environmentally exposed surfaces, such as the gut, that counter balances Th17 
immune responses (Eastaff-Leung et al., 2010, Himmel et al., 2008). These Th17 cells (T-helper 
subset that produces IL-17) have been implicated in the pathogenesis of human experimental 
colitis, but also in the pathogenesis of Enterotoxigenic Bacteroidesfragilis (ETBF)-induced CRC 
(Figure 4B) (Housseau and Sears, 2010, Wu et al., 2009).
Apcmin/+ mice models
The multiple intestinal neoplasia mouse model (Apcmin/+) was identified by random 
mutagenesis in a colony of mice and is one of the most employed animal models in CRC 
research. This mutant strain carries a heterozygous mutation in APC and is thereby ideal 
to study the role of additional environmental factors on the development of CRC (Moser
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et al., 1990), as only a single hit in the wild-type allele results in adenoma formation. 
However, it must be noted that these mice predominantly develop polyps and tumors in 
the small intestine, a phenomenon that is rather uncommon in humans. Apcmin/+ mice fed 
on a high fat or western style diet have accelerated tumor formation. Contrarily, restriction 
of caloric intake and increased exercise reduced the amount of polyps (Hioki et al., 1997, 
Mai et al., 2003, Mehl et al., 2005, Yang et al., 1998). Apcmin/+ mice harboring additional 
mutations in SMAD4, which is linked to TGFp signaling, have a very rapid progression of 
polyps to very invasive adenocarcinomas (Figure 4C) (Takaku et al., 1998). Furthermore, 
inactivation of the COX-2 gene in these mice dramatically decreased polyp numbers (Oshima 
et al., 1996, Oshima et al., 2001). The involvement of the intestinal microbiota in these 
processes could also be addressed with this mouse model. First, studies with germ-free 
Apcmin/+ mice revealed that the formation of adenomas was reduced by 50%, compared to 
mice bred under conventional conditions (Dove et al., 1997, Moser et al., 1990, Su et al., 
1992). More importantly, when these mice were exposed to enterotoxigenic Bacteroides 
fragilis (ETBF), tumors developed more rapidly with a predominant localization in the colon. 
On the contrary, mice colonized with non-toxigenic Bacteroides fragilis (NTBF) showed no 
increased tumor formation compared to conventional mice (Housseau and Sears, 2010). 
These data imply that certain species within the intestinal microbiota contribute more than 
average to the accumulation of mutations that lead to CRC.
TLR signaling in CRC
The basis for a healthy intestinal tract is a balanced immune stimulation to commensal and 
pathogenic bacteria. TLRs are proteins that activate immune responses towards potentially 
harmful pathogens upon sensing of pathogenic components, such as the cell wall. However, 
chronic stimulation of these responses may be detrimental by leading to the initiation and 
progression of CRC. Several roles of TLRs have been described both in inhibition of cancer 
and stimulation of tumorigenesis as described below (Figure 4D).
TLR-mediated protection against CRC. Animal models showed that TLR2 deficiency leads 
to increased tumor burden and increased tumor size in mice with DSS-induced colitis (Lowe 
et al., 2010). This effect was related to increased cytokine levels of IL-6, TGFp, TNFa and 
IL-17A, that may drive inflammation-induced CRC. In addition, TLR5/MyD88 signaling has 
been shown to reduce tumor size in a mouse xenograft model for CRC. More specifically, 
TLR5/MyD88 signaling regulated neutrophil infiltration into tumor xenografts (Rhee et al.,
2008). These studies suggested that TLR-signaling has a protective role in inflammation- 
induced CRC and is crucial to control innate immune responses against tumors. Under chronic 
colitis conditions, as induced by DSS, MyD88 deficient mice developed increased numbers 
of polyps and showed increased levels of inflammation that was mainly characterized by the 
overexpression of IL-6, IL-18 and COX-2 (Salcedo et al., 2010). Further experiments showed 
that MyD88 restoration in these tumors suppressed local tumor growth and increased 
tumor-antigen specific T-cell recruitment (Hartman et al., 2010). Thus, these experiments 
indicate that TLR2 and TLR5/MyD88 play an important role in the suppression of tumor 
formation, via the activation of specific anti-tumor immunity.
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TLR-mediated progression of CRC. TLR5/MyD88-induced pathways have also been implicated 
in the progression to CRC. Apcmin/+ mice crossed with MyD88-deficient mice developed the 
same amount of tumors as Apcmin/+ mice, however, these tumors were significantly smaller 
of size. The main mediator thought to be responsible for this phenomenon is COX-2, since its 
expression was lower in mice lacking MyD88 than in control mice. This finding may suggests 
that TLR signaling can contribute to the development of CRC (Rakoff-Nahoum and Medzhitov,
2007). Moreover, mice deficient in TLR4 were protected against the development of 
neoplasia by AOM and DSS (Fukata and Abreu, 2007). Correspondingly, the TLR4 ligand LPS 
was shown to directly promote tumor cell adhesion and invasion through the upregulation 
of urokinase plasminogen activator (u-PA) and its receptor (u-PAR) mediated by TLR4- 
dependent activation of NF-kB (Killeen et al., 2009).
A promoting role of TLRs in colon carcinogenesis was further demonstrated by Grimm 
et al., who showed that TLR7 and TLR8 levels were increased in CRC tissue compared to 
healthy mucosa (Grimm et al., 2010). High TLR7 (Hazard ratio 2.195; 95%CI 0.72-6.66) and 
TLR8 (Hazard ratio 4.997; 95%CI 1.12-22.23) expression were also found to be related to 
cancer progression and reduced survival of cancer patients. These data suggest that chronic 
activation of TLRs may sustain inflammation responses, mediate resistance to apoptosis 
and promote further tumor progression. A direct impact of bacteria on the development 
of CRC through TLR pathways was demonstrated in germ-free and gnotobiotic mice. These 
experiments showed that AOM-treated double knock-out mice (IL-10'/_ and MyD88~/~) failed 
to develop colorectal tumors when these mice were subjected to bacteria, whereas IL-10'/' 
mice developed CRC upon bacterial colonization. Together, these results implicate that TLR/ 
MyD88 signaling is a prerequisite for the development of CRC (Uronis et al., 2009).
Finally, evidence was presented for another mechanism by which TLR4 signaling can promote 
colon carcinogenesis by stimulating tumor infiltration of Th17 cells (Su et al., 2010). This 
infiltration was mediated by pro-inflammatory signals produced from stromal cells, the tumor 
itself, or may be mediated via chronic inflammation. It was shown that several bacterial TLR 
ligands increased the chemotactic activity of tumor cells in vitro (Scanlan et al., 2008). Also 
the intracellular receptor for bacterial ligands, nucleotide-binding oligomerization domain 
containing 2 (NOD-2), may play a role in the latter process. In conclusion, several studies 
show that TLR signaling plays an important role in maintaining the balance between health 
and disease. TLR signaling is important for the effective clearance of harmful pathogens 
and mediates anti-tumor cell responses. However, chronic activation of inflammation 
pathways may tip the balance to tumor-promoting activity (Rakoff-Nahoum and Medzhitov,
2009). Altogether, these studies indicate that chronic bacterial stimulation of inflammatory 
pathways at malignant sites can directly influence tumor development.
24
General introduction
1
Molecular mechanisms of bacteria-induced CRC
As clearly illustrated in the previous paragraphs, inflammation is an important mediator 
of bacteria-induced CRC. In this scenario, chronic infection leads to induction of 
pro-inflammatory cytokines, increased proliferation, cell-turnover and finally malignant 
transformation. This mechanism is underscored by the close relation of COX-2 both with 
responses to infection and CRC progression. Two other mechanisms for bacterial-induced 
carcinogenesis can be envisaged. First, bacteria can produce toxins, toxic metabolites or can 
convert dietary factors into toxic substances. These toxins can either induce inflammation 
or directly cause DNA damage when these compounds have genotoxic activity. Secondly, 
bacteria can directly induce pro-carcinogenic pathways in colon epithelial cells by which 
these cells have an increased susceptibility for the accumulation of mutations eventually 
leading to carcinogenesis. Below the scientific evidence for the different mechanisms that 
can mediate bacteria-induced CRC (Figure 5 and 6) will be further discussed.
Figure 5. Molecular 
mechanisms of bacteria 
induced CRC: toxins
(A) Bacteria l m etabolites such as 
fecapentaenes, hydrogen sulfide  
(H2S) and superoxide radicals  
all m ay produce reactive oxygen  
species that can penetrate colonic  
eptithelia l cells and induce DNA 
dam age. Besides DNA damage, 
superoxide radicals and H 2S can 
also induce COX-2 expression. 
Together this m ay lead  to 
chrom osom al instab ility  (CIN), 
d isrupted  repa ir m echanism s  
and increased inflam m ation  
that contribute to the initiation  
and prom otion o f  CRC. (B) 
bacteria l toxins m ay in itiate or 
prom ote tum or developm ent by  
the induction o f  inflam m ation  
(H. pylori, enterotoxigenic B. 
frag ilis, S. infantarius) o r DNA 
dam age (E. coli). This involves 
increased oncogene activation, 
chrom osom al instab ility  (CIN) 
and excessive proliferation o f  
tum or cells (see text fo r  details).
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Bacterial toxins
In addition to induction of inflammation, bacteria may directly induce DNA damage by 
the production of genotoxins as shown for certain Enterobacteria and Bacteroides strains 
(Figure 5B). The role of these genotoxins will be reviewed in the next two paragraphs.
Colibactin. Certain E. coli strains can induce an increased mutation rate as demonstrated by 
Cuevas-Ramos and colleagues (Cuevas-Ramos et al., 2010). Their experiments showed that 
E. coli strains harboring the pks island caused DNA damage in human epithelial cells and 
in an ex vivo mouse intestinal loop model by the induction of single strand breaks and 
activation of DNA damage signaling pathways. The pks gene cluster codes for nonribosomal 
peptide synthetases (NRPS) and polyketide synthetases (pks) that synthesize a genotoxin 
named Colibactin. The pks island is commonly present in about 34% of commensal E. coli 
isolates. Upon infection of epithelial cells with physiological concentrations of pks+ strains, 
initial DNA damage occurred and cells exhibited mitotic aberrations resulting in CIN (Cuevas- 
Ramos et al., 2010). Furthermore, it was shown that cells continued to proliferate in the 
presence of DNA damage after E. coli infection resulting in an increased mutation frequency 
and a transformed phenotype (Cuevas-Ramos et al., 2010). These studies suggest that pks+ 
strains of E. coli could be involved in the initiation and progression of CRC. However, E. coli 
is generally regarded as a normal commensal inhabitant of the gastro-intestinal tract and 
it is therefore essential to investigate the differences between E. coli strains collected from 
healthy individuals and cancer patients as done by Bronowski and co-workers (Bronowski et 
al., 2008). These authors showed that a subset of E. coli strains recovered from CRC tissue 
shared pathogenicity islands, coding for HlyA (alfa haemolysin) and Cnf (cytotoxic necrotizing 
factor) virulence genes, with uropathogenic E. coli strains. This suggests that other virulence 
characteristics may provide these E. coli strains with a competitive advantage to colonize 
adenoma and carcinoma tissue.
Bacteroides fragilis toxin. As aforementioned, Enterotoxigenic Bacteroides fragilis (ETBF) 
has been implicated in the promotion of CRC through inflammatory pathways. B. fragilis is 
a normal inhabitant of the gastrointestinal tract, but the enterotoxigenic from is present in 
approximately 20% of the healthy population (Sears, 2009). ETBF produces the B. fragilis 
toxin that degrades E-cadherin in epithelial cells. This degradation causes p-catenin to 
migrate towards the nucleus where it can activate oncogenes like c-myc, which in turn 
will lead to cell proliferation (Wu et al., 2003). Consequently, APCmin/+ mice colonized with 
ETBF have increased tumor burden compared to control mice colonized with non-toxigenic 
B. fragilis (NTBF) strains (Housseau and Sears, 2010, Wu et al., 2009). Importantly, Wu et al. 
have shown that this increased tumor burden is mediated through the increased expression 
of STAT3 that leads to a Th17 response. This increased tumor formation was blocked by 
anti-IL-17 therapy and IL-23 receptor inhibition, the effector of IL-17 (Wu et al., 2009). In 
conclusion, these experiments show that induction of a STAT3/Th17-dependent pathway for 
inflammation, leads to inflammation-induced cancer by ETBF in a mice model. Since ETBF is 
a quite common bacterium in the gastro-intestinal tract, this could have major implications 
for the development of CRC in the human population. In-line with this idea, Toprak et al.
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observed that patients with CRC have indeed increased carriage rates of ETBF compared 
to NTBF (Toprak et al., 2006). Moreover, this mechanism of tumor induction could also be 
associated with other toxigenic commensal bacterial strains in the human gut.
Toxic bacterial metabolites
In addition to the direct production of (geno)toxins, bacteria can produce harmful 
metabolites, such as fecapentaenes, hydrogen sulfite and superoxide radicals that induce 
epithelial damage. The production of these metabolites by Bacteroides and Enterococcus 
species and their effects in the colonic epithelium is discussed below.
Fecapentaenes. Fecapentaenes are potent mutagens synthesized by Bacteroides species 
(Hinzman et al., 1987). Although their relationship with cancer is not clear, these compounds 
appear in relatively high concentrations in human feces. Some evidence points towards 
a mechanism through oxygen radicals that causes oxidative damage to DNA (Figure 5A). 
Furthermore, fecapentaenes themselves are reactive electrophiles that may alkylate 
DNA to form mutagenic adducts (Hinzman et al., 1987, Povey et al., 1991, Shioya et al., 
1989). Despite the fact that fecapentaenes were shown to induce DNA damage by several 
studies, the excretion of fecapentaenes in CRC patients appeared to be reduced compared 
to controls (Schiffman et al., 1989). Since, fecapentaens are initiateors of mutations it is 
hypothesized that fecapentaene-mediated DNA damage may be more relevant in the early 
stages of CRC. Nevertheless, also no significant differences in fecapentaene production were 
found between cases and controls during the early stages of disease. Despite this lack of 
epidemiological evidence, however, fecapentaenes should be regarded as possible bacterial 
hazardous compounds with mutagenic potential (de Kok and van Maanen, 2000). For 
instance, their detrimental effects may locally contribute to the accumulation of mutations, 
which is not directly reflected by the increased levels in fecal material.
Hydrogen sulfite. Sulfate reducing bacteria are naturally present in the intestinal tract and 
use sulfate as energy source by converting it to sulfide and hydrogen sulfide (H2S) in the 
human colon. The genotoxic potential of H2S is in part mediated by oxidative free radicals 
(Figure 5A), which is shown to result in increased levels of DNA damage in in vitro cultured 
epithelial cells (Attene-Ramos et al., 2010, Attene-Ramos et al., 2007, Attene-Ramos et 
al., 2006). Furthermore, exposure to H2S may disrupt the balance between apoptosis, 
proliferation and differentiation (Cai et al., 2010, Deplancke and Gaskins, 2003). Moreover, 
COX-2 was shown to be upregulated in epithelial cells after H2S treatment at physiological 
concentrations. Attene-Ramos and colleagues proposed that the induction of COX-2 by H2S 
is mediated through the production of oxidative species mediated by the same mechanism 
as E. faecalis-derived reactive oxygen species (Attene-Ramos et al., 2010)(see subheading 
COX-2 induction). The human colonic enzymes thiol methyltransferase and rhodanase 
(RHOD) are in turn responsible for the degradation of H2S in the gastrointestinal epithelium. 
Interestingly, expression of RHOD is diminished in advanced CRC tissue, which may lead to 
reduced detoxification of H2S, and could therefore represent a contributing factor in colon 
carcinogenesis. Importantly, increased fecal H2S concentration was implicated as a risk
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factor for the development of colonic neoplasia in a clinical study (Kanazawa et al., 1996). 
Whether these increased H2S levels originates from increased activity of sulfate reducing 
bacteria and/or reduced epithelial RHOD activity remains to be investigated. Unfortunately, 
the actual levels of H2S that reach intestinal epithelial cells is hard to determine (Blachier 
et al., 2010). Future assessment of the amount and activity of sulfate-reducing bacteria in 
CRC, UC or healthy mucosa could shed new light on the pathophysiological mechanisms 
and contribution of sulfate reducing bacteria in colon carcinogenesis (Medani et al., 2010).
Superoxide radicals. Although E. faecalis has no evident clinical association with CRC, it has 
been found to induce IBD and tumor formation in IL-10 knock-out mice (Balish and Warner,
2002). These studies showed that mice monoassociated with E. faecalis developed colitis 
and tumors, whereas numerous other commensal and pathogenic bacteria failed to produce 
any intestinal pathology. E. faecalis was found to produce extracellular superoxide, which 
is the result of dysfunctional microbial respiration (Huycke et al., 2002). The production of 
hydroxyl and sulfur-centered radicals has been confirmed in colonic material of rats colonized 
with E. faecalis. These rats produced 15-25 fold increased concentrations of hydroxylated 
aromatic metabolites in urine than rats colonized with a closely-related strain (Huycke and 
Moore, 2002). Importantly, superoxide can in the gut be converted to hydrogen peroxide, 
which has the potential to diffuse into epithelial cells and cause DNA damage (Figure 5A). In 
an in vitro setup, it was shown that the formation of DNA adducts by E. faecalis can promote 
CIN through a bystander effect (Wang et al., 2008). In this case, oxygen radicals produced 
by E. faecalis activated COX-2 expression in macrophages that in turn promoted CIN in 
epithelial target cells (Wang et al., 2008, Wang and Huycke, 2007). Since COX-2 induction 
has a clear clinical association with CRC, this might suspect superoxide-producing bacteria 
to have a contributing role in disease development. This notion is further underscored by 
the finding that E. faecalis fecal carriage was increased in CRC patients, whereas butyrate 
producing bacteria were decreased (Balamurugan et al., 2008). However, the only human 
study that examined superoxide production in CRC patients failed to associate superoxide 
producing enterococci with adenomas or CRC (Winters et al., 1998). This clearly indicates 
that, although the in vitro data and animal studies strongly suggest that oxygen radicals 
produced by E. feacalis or other commensals could play an important role in CRC initiation or 
progression, the impact of these findings remains to be properly examined in well-designed 
clinical studies (Huycke and Gaskins, 2004).
Bacterial conversion of dietary compounds
Bacterial metabolism of dietary substances aids intestinal health by producing fuel for colonic 
epithelial cells, for instance butyrate, and making dietary nutrients available for uptake into 
the body. On the other hand, the genetic make-up of the host and dietary feeding pattern 
influences the microbial composition in the gut. This dynamic and complex interplay within 
the diet-host-microbiota triangle can be disturbed by changes in either one of these factors. 
Below, the bacterial conversion of food compounds into potential harmful substances that 
could play a role in colon carcinogenesis (Figure 6A) will be discussed.
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Figure 6. Molecular mechanisms of 
bacteria induced CRC: 
modulation of diet and host
(A) Bacteria l enzym e activ ity  in the gut m ay  
lead  to the activation o f  d ietary substances  
to carcinogenic com pounds. These harm ful 
substances lead  to DNA dam age, cell 
dam age, reduced m ucosal barrier function  
and im paired  DNA repa ir m echanism s. A ll 
these effects m ay aid the accum ulation  
o f  m utations in colon ep ithelia l cells that 
drive the developm ent o f  CRC. (B) E. coli 
and S. gallolyticus m ay directly be involved  
in the carcinogenic process b y  inducing  
pro-carcinogenic pathw ays. E. co li reduces 
the expression o f  m ism atch repa ir (M M R) 
genes that can lead  to an increased  
m utation rate. S. gallolyticus increases  
the expression o f  the b iotransform ation  
enzym es CYP1A1 andA LD H 1A 3, which could  
increase the form atio n  o f  carcinogens in the  
gut epithelium . Conversely, the activation  
o f  b iotransform ation pathw ays co u ld  also 
lead  to reduced levels o f  carcinogens and  
reduced m utation rates.
Nitritogenous compounds. In the gut, ingested nitrate is reduced by microbial nitrate 
reductases, present in Escherichia, Pseudomonas, Proteus, Klebsiella and Neisseria families, 
to its more reactive metabolite nitrite. Subsequently nitrite can react with nitrogenous 
compounds to form N-nitroso adducts that are DNA-alkylating agents and thus highly 
carcinogenic. These reactions may occur at acidic pH in the stomach or may be mediated by 
bacterial activity in the gut (Rowland et al., 1991). Interestingly, the levels of fecal N-nitroso 
compounds has been shown to be increased by high red meat consumption, which may link 
high-risk diets to the production of these toxic products and increased risk for CRC (Hughes 
et al., 2001). However, it has not yet been established which part of N-nitroso-compound 
production can be attributed to bacterial nitrate reductase activity (Rowland, 2009).
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Activation of carcinogens. Bacterial p-glucuronidase activity can hydrolyse conjugated 
carcinogenic compounds that are excreted via bile into the small intestine. In the liver, toxic 
products are conjugated to glucuronic acid that in general deactivates the toxic potential of 
many metabolites. However, in the gut this de-activation may be negated by bacteria with 
p-glucuronidase activity. These activities may thereby in turn alter the induction of CRC in 
the colon. In an AOM model for colon carcinogenesis, it was demonstrated that inhibition 
of bacterial p-glucuronidase activity reduced the number of AOM-induced tumors in the 
rat colon (Takada et al., 1982). In addition, fecal p-glucuronidase activity was shown to 
be increased in CRC patients compared to healthy controls (Kim and Jin, 2001). Together 
these findings strongly suggest that bacterial p-glucuronidase activity can contribute to the 
initiation and progression of CRC by re-activation of toxins that were conjugated by host 
detoxification systems and excreted in the colonic lumen. Interestingly, it has been shown 
that high risk diets for CRC increase the p-glucuronidase activity compared to low risk diets, 
indicating that diet influences bacterial composition and/or its activity that consecutively 
may affect the health status of the colon (Reddy et al., 1977).
Bioactivation of heterocyclic amines. During cooking of meat and fish, heterocyclic 
amines are generated that upon consumption can reach the colonic lumen. Most of these 
compounds are subsequently converted into more genotoxic compounds that may form 
DNA adducts. Several studies have clearly implicated heterocyclic amines as initiators of 
carcinogenesis in laboratory animals (Felton et al., 1997, Knasmuller et al., 2001). Their 
conversion into highly genotoxic intermediates can be mediated by host metabolizing 
enzymes, such as CYP1A2 and COX isomers. However, also bacteria have been directly 
implicated in the bio-activation of these heterocyclic amines. This occurrence of bacterial 
bio-activation was shown to be dependent on the presence of certain bacterial strains in 
the gut. For example, B. fragilis was shown to increases the mutagenicity in the presence 
of heterocylcic amines whereas lactobacilli showed an opposite effect (Knasmuller et al., 
2001). In addition, in vitro evidence supports a role of Eubacterium species in the conversion 
of 2-amino-3-methyl-3H-imidazo[4,5-f]quinoline (IQ) into its more reactive metabolite IQ-7- 
one (HOIQ) and thereby can increases IQ-induced DNA damage (Hambly et al., 1997, Kassie 
et al., 2001, Rumney et al., 1993). Interestingly, IQ-induced DNA damage was shown to be 
higher in rats colonized with the human fecal microbiota from meat-eaters compared to rats 
colonized with a vegetarian microbiota (Kassie et al., 2004). From these experiments it can 
be concluded that meat-rich diets affect microbial composition towards a profile with more 
effective metabolizers of heterocyclic amines, which in turn may increase the risk for CRC. 
This hypothesis is, in part, supported by recent observations that African Americans that 
have a higher risk for CRC than Caucasian Americans, ingest higher amounts of heterocyclic 
amines. However, this apparent difference was not accompanied by higher fecal water 
toxicity or increased DNA damage (Mai et al., 2009). Future research needs to determine 
the actual contribution of bacterial conversion of heterocyclic amines on the initiation or 
progression of CRC, and how this weighs to other CRC-stimulating mechanisms.
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Conversion of bile acids. Primary bile acids excreted in the small intestine are converted 
by microbial metabolism into secondary bile acids, which are predominantly deoxycholic 
acid and chenodeoxycholic acid. It is thought that these secondary bile acids can cause cell 
necrosis, hyperplasia, DNA damage and tumor promoting activities (Gill and Rowland, 2002). 
One of the mechanism by which bile acids can exert DNA damaging potential is via the 
production of oxygen radicals and reactive nitrogen species (Bernstein et al., 2005, Dvorak 
et al., 2007). Chronic exposure to secondary bile acids may therefore increase the rate of 
unrepaired DNA damage, leading to genomic instability and eventually the progression of 
CRC. In addition, bile acids have detergent- like characteristics and thereby affect the mucosal 
barrier, making the epithelial cells more accessible for food or harmful substances from 
microbial origin (Jansen, 2007, Stamp, 2002). Some observational studies on (secondary) 
bile acids have reported an association between increased bile acid concentrations and CRC 
risk (Imray et al., 1992, Owen, 1997, Stadler et al., 1988). Furthermore, an epidemiological 
studies found higher concentrations of secondary bile acids in CRC patients compared to 
healthy control subjects (Gill and Rowland, 2002). Conspiciuosly, bile acid excretion is also 
closely related to fat consumption and red meat intake that are known risk factors for CRC 
(Reddy et al., 1980). Together, these data underscore a close link between dietary intake, 
microbiota composition and production of carcinogens.
Conversion of ethanol. Chronic alcohol consumption is a risk factor for the development 
of CRC and upper gastrointestinal tract cancers. Ethanol is converted to acetaldehyde by 
aerobic and facultative anaerobic bacteria in the gut. The fact that bacteria are important 
in this process can be derived from two findings. First, small intestinal acetaldehyde levels 
are low compared to that in the colon, which also has the highest bacterial concentrations 
(Homann et al., 2000). Second, the conversion of ethanol to acetaldehyde was shown 
to be inhibited by the use of ciprofloxacin, an antibiotic that kills mainly aerobic and 
facultative anaerobic bacteria (Homann et al., 2000). In addition, genetic studies on human 
polymorphisms and mutations in the genes coding for alcohol dehydrogenase (ADH) and 
acetaldehyde dehydrogenase (ALDH) that lead to increased acetaldehyde accumulation, 
are associated with increased risk of CRC (Seitz et al., 1990, Seitz and Stickel, 2009). 
Acetaldehyde is a known carcinogen that exerts its carcinogenic effect by binding to DNA, 
thereby forming carcinogenic adducts (Anonymous, 1985). Furthermore, acetaldehyde may 
indirectly increase the risk for CRC by reducing folate levels in the colon (Shaw et al., 1989), 
which can lead to a general hypomethylation of DNA and impaired DNA excision repair as 
shown for the rat colon (Choi et al., 1998). Importantly, epidemiologic evidence indicates 
that low folate diets are indeed correlated with increased risk for CRC (Giovannucci et al., 
1995). Together, these studies indicate that the consumption of alcohol in concert with 
microbial ADH activity in the gut, together with low folate diets may increase the risk for 
CRC, especially in subjects with a "high risk" genetic profile.
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Induction of pro-carcinogenic pathways in host cells
Besides the induction of pro-inflammatory pathways, there is evidence that bacteria can also 
induce host epithelial pathways that may make cells more susceptible to the accumulation 
of mutations, which is characteristic for the adenoma-carcinoma sequence (Figure 6B). 
Evidence for such a causal relationship between E. coli and CRC is obtained from in vitro 
research. Maddocks et al. have shown that enteropathogenic E. coli down-regulate 
mismatch repair genes in colon epithelial cells (Maddocks et al., 2009). It can be envisaged 
that this impaired expression of mismatch repair genes can lead to a net increased mutation 
rate and could therefore drive the initiation of carcinogenesis by promoting somatic 
mutations. In Chapter 9 a mechanism by which a diffusible factor from S. gallolyticus can 
alter the biotransformation capacity of colon epithelial cells is discussed. S. gallolyticus 
increases the expression of CYP1A1 and ALDH1A3 enzymes that are involved in metabolism 
of heterocyclic amines and alcohol. Bacterial induction of these host biotransformation 
pathways in vivo could either lead to accelerated detoxification or increased production of 
reactive metabolites (also called bio-activation), depending on the substrate. The impact 
of these modulating activities on CRC risk is currently unknown and should be further 
investigated. However, these studies accentuate the bacterial potential to directly affect 
epithelial mismatch repair and biotransformation pathways, which in turn may under 
certain conditions lead to an increased accumulation of mutations and carcinogenesis.
Bacterial infections associated with CRC
Relatively few bacteria have been clinically associated with CRC. These bacteria are 
opportunistic enteric pathogens that are thought to benefit from the tumor and use it as 
a portal of entry to establish systemic infections. The most appreciated CRC-associated 
bacterium is Streptococcus bovis, the infections of which are long recognized as signs 
for occult carcinomas of the colon. In addition, such relationships may be present for 
Clostridium septicum and H. pylori, although these are less evident. In the next paragraphs, 
the current knowledge on the association of these specific bacterial infections with CRC will 
be reviewed, with emphasis on the underlying mechanisms that link S. bovis infections to 
intestinal carcinogenesis.
Clostridium septicum
Clostridium septicum is one of the bacteria that has been clinically associated with sporadic 
CRC (Chew and Lubowski, 2001, Mirza et al., 2009). C. septicum is not considered to be 
part of the normal intestinal microbiota and is a rare cause of bacteremia, responsible for 
approximately 1% of all cases. Recently, Hermsen et al. reviewed 320 cases of C. septicum 
infections, 42% of which had a gastrointestinal origin (Hermsen et al., 2008). Malignant 
disease was present in 30-50% of these cases. The underlying mechanism of this association 
is not known, but it has been speculated that the hypoxic and acidic environment of the 
tumor specifically favor germination of C. septicum spores that enter the gastrointestinal 
tract via contaminated food (Dylewski and Luterman). A direct involvement of C. septicum
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in the development of CRC has thusfar not been investigated, but it is hypothesized that C. 
septicum infection is primarily an incidental cause of CRC itself. Also Clostridium perfringens 
and Clostridium butyricum have been described in relation with CRC (Cabrera et al., 1965, 
Rathbun, 1968). However, these strains are much less virulent than C. septicum and the 
association with CRC is less prominently present. Although infections with C. septicum 
are rare, underlying malignancy should be suspected and also in these cases full bowel 
examination could eventually save the patients life.
Helicobacter pylori
In 1994, the International Agency for Research on Cancer (IARC) classified Helicobacter pylori 
as a carcinogen, or cancer-causing agent of the gastrointestinal tract. Most H. pylori strains 
are non-invasive organism and exist in a nonadherent extracellular mucous environment. 
A small number of strains adheres to gastric epithelial cells, this is a complicated process 
which most likely involves a number of surface receptors (Lewis-b, Lewis-X, Trefoil factor 
1, Muc5A) (Wilkinson et al., 1998). The presence of the pathogenicity island CagA, coding 
for a cytotoxin, is an important virulence determinant in these strains. It is thought that 
long-term exposure to this toxin induces gastric inflammation that can eventually lead to 
gastric carcinomas (Higashi et al., 2002). In time, over 26 novel Helicobacter species have 
been identified and assigned to the Helicobacter genus (more than 90% similarity) of which 
only some have been directly associated with gastrointestinal cancers (Fox, 2002). A meta­
analysis conducted in 2006 by Zumkeller et al. evaluated all studies on H.pylori and CRC 
published between 1991 and 2002. The combined relative risk for CRC was estimated at 
1.4, which indicates a slightly increased risk for CRC in individuals with a H. pylori infection 
(Zumkeller et al., 2006). Contradictory results on the association of H. pylori with CRC may 
have occurred due to differences in H. pylori strains and their specific virulence factors.
H. pylori virulence factors. The presence of the pathogenicity island expressing CagA and 
VacA is variable among H. pylori isolates and a much higher Odds ratio for gastric cancer 
was associated with H. pylori/Cag+ infection (Ekstrom et al., 2001, Huang et al., 2003). 
While VacA primarily causes cell damage and interferes with proliferation of T-cells (Gebert 
et al., 2003), CagA positive strains are capable of inducing IL-8 expression and are linked to 
increased gastritis and gastric cancer (Crabtree et al., 1994, Kuipers et al., 1995). Also genetic 
polymorphisms in host IL-16 and IL-1-RN genes seem to play a role in the susceptibility to 
gastric cancers (El-Omar et al., 2000, El-Omar et al., 2003). CagA is also thought to play a role 
in CRC, since positive strains are more likely to induce inflammation and malignancy than CagA 
negative strains (Figure 5B). One study among hospitalized patients compared CagA status 
between colorectal adenocarcinoma patients with H. pylori seropositivity and 24 controls that 
were also seropositive for H. pylori. This study showed that CagA status was associated with 
a significantly increased risk of CRC (Odds ratio 10.6) (Shmuely et al., 2001). This study again 
underscores the importance of proper classification and characterization of cancer-associated 
infectious agents, since not all Helicobacter strains are strongly associated with CRC. Lack of 
proper distinction between H. pylori subspecies could have biased or even underestimated a 
possible association of this bacterium with CRC (Erdman et al., 2003a, Erdman et al., 2003b).
33
1
Chapter 1 - Bacterial interference in colorectal cancer
Streptococcus bovis
McCoy and Mason first reported a case of enterococcal endocarditis associated with CRC in 
1951 (McCoy and Mason, 1951). In the 1970's this association was re-discovered by Hoppes 
and Lerner, who reported that 64% of the 14 S. bovis endocarditis cases had gastrointestinal 
disease (Hoppes and Lerner, 1974). A few years later, Klein et al. reported an increased 
incidence of CRC in patients with S. bovis endocarditis. Of the 18 patients with available 
records, 2 had villous adenoma and 6 had carcinoma of the colon. Importantly, most of 
these patients had no clinical signs or symptoms referable to gastrointestinal cancer (Klein 
et al., 1979). Klein et al. additionally discovered that fecal carriage of S. bovis in CRC patients 
was increased about 5-fold (56%) compared to healthy controls (10%) (Klein et al., 1977). 
These findings led to the recommendation to perform colonic evaluation in patients that 
presented with an S. bovis infection.
Clinical association of S. bovis infection with CRC. Over the years, many studies have 
confirmed the association between S. bovis infection and CRC. In these studies, the 
prevalence of S. bovis infection with underlying CRC ranged from 6 -  88 % for all cases and 
from 33 -  100% when only patients that underwent colonic evaluation were taken into 
account (systematic review and meta-analysis of the literature in Chapter 2).
S. bovis biotypes. Based on phenotypic diversity, S. bovis can be divided in the three biotypes
I, II/1 and II/2. Of these biotypes, biotype I is most often associated with endocarditis, while 
biotype II is mostly found in cases of bacteremia or liver disease. Strikingly, the association 
between S. bovis biotype I infection and CRC is much higher (21- 90%) then that of S. bovis 
biotype II (11-30%) as discussed in Chapter 2 (Corredoira et al., 2008, Corredoira et al.,
2005, Giannitsioti et al., 2007, Herrero et al., 2002, Jean et al., 2004, Lee et al., 2003a, 
Ruoff et al., 1989, Vaska and Faoagali, 2009). In fact, the reported incidences of carcinomas 
and adenomas in S. bovis biotype II-infected patients are within the range for the normal 
asymptomatic population (0.3% for carcinomas / 10-25% for adenomas), whereas the rates 
for S. bovis biotype I were significantly increased (Lieberman and Smith, 1991, Lieberman 
et al., 2000, Spier et al., 2010). The distinct association of these different S. bovis biotypes 
with CRC may have accounted for the wide range of association percentages that have 
been reported over the years in literature. More importantly, because most studies have 
not discriminated between S. bovis biotypes the association between S. bovis biotype I and 
CRC may have structurally been underestimated. It is important to mention that in 2003, 
Schlegel et al. suggested to rename S. bovis biotype I into S. gallolyticus subsp. gallolyticus, 
S. bovis biotype II/1 into S. infantarius subsp. coli or S. infantarius subsp. infantarius and 
to rename S. bovis biotype II/2 into S. gallolyticus subsp. pasteurianus (Table 2). This new 
nomenclature may aid in a better discrimination between the different S. bovis subspecies 
of which S. gallolyticus is the only species with an unambiguous association with CRC. As the 
distinction between these subspecies has not been made in most of the published papers, 
we refer to these strains as S. bovis in the remainder of this review, unless subspecies 
classification has been clearly documented by the authors of the original papers.
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Table 2. S. bovis Nomenclature 
New name Former phenotypic desigation Synonym
S. gallolyticus subsp. gallolyticus S. bovis biotype I S. gallolyticus
S. infantarius subsp. infantarius S. bovis biotype ll/1 S. infantarius
S. infantarius subsp. coli S. bovis biotype ll/1 S. lutiensis
S. gallolyticus subsp. pasteurianus S. bovis biotype ll/2 S. pasteurianus
Age-dependency of S. bovis infection. Enterococcal and S. bovis endocarditis are correlated 
with age and are more frequently found in the elderly population, in contrast to for instance 
Staphylococcus aureus that is also one of the major infective agents of this disease (Durante- 
Mangoni et al., 2008, Lopez et al., 2010, Parker and Ball, 1976). This correlation was already 
reported in 1976 by Parker et al, and recently confirmed in a very large study by Durante- 
Mangoni and co-workers. The latter study included a total of 2759 infective endocarditis 
cases, of which 163 concerned S. bovis endocarditis (5.9%). Notably, only S. bovis and 
Enterococcal endocarditis were significantly correlated with age. More specifically, only 
2.1% of patients under 50 had S. bovis endocarditis in contrast to 8.9% of patients over 
70. Conspicuously, the presence of polyps, adenomas and carcinomas has a similar age- 
dependency. Thus, these findings fit with a model in which S. bovis uses colonic lesions to 
enter the human body.
Fecal carriage of S. bovis. Since the study by Klein et al. who showed a 5-fold increased fecal 
carriage of S. bovis in CRC patients compared to healthy controls, some contradicting results 
have been reported on this issue (Klein et al., 1977). Two small studies reported similar 
carriage rates between healthy controls and CRC patients of around 10 - 16% (Dubrow et al., 
1991, Potter et al., 1998). A large study in 255 patients by Burns et al in 1985 investigated 
the fecal carriage rate of polyps and adenomas. This study documented a 3-fold increased 
fecal carriage rate in patients with polyps with carcinogenic potential, i.e., villous and 
tubulovillous adenoma and adenocarcinoma (Burns et al., 1985). It should be realized that 
all these studies used fecal culturing to detect S. bovis. The discrepancy between these 
studies could therefore be caused by differences in specimen collection, processing and 
culturing techniques.
S. bovis in polyps and carcinoma tissue. It is known that fecal communities differ from 
mucosal communities (Zoetendal et al., 2002) and therefore the mucosal detection of 
S. bovis may be a better tool to assess its presence in CRC patients. Some contradicting 
results on actual S. bovis colonization of tumor tissue have been reported. Norfleet et 
al. used conventional culturing techniques to determine the carriage rate of S. bovis in 
adenoma, carcinoma and healthy biopsies (Norfleet and Mitchell, 1993). S. bovis could be 
cultured from 1 out of 33 adenoma biopsies and 1 out of 40 biopsies from pathological 
normal tissue that was taken from sites adjacent to malignant tissue. However, none of the
SS
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colonic tumor specimens contained viable S. bovis. These data provided no evidence for the 
selective colonization of adenoma's or carcinomas by S. bovis (Norfleet and Mitchell, 1993). 
The same was concluded by Potter et al. in 1998, who could only culture S. bovis from 2 
out of 19 malignant tissue samples from CRC patients (Potter et al., 1998). More recently, 
however, Abdulamir et al. showed the presence of S. gallolyticus DNA in CRC and adenoma 
tissue via polymerase chain reaction (PCR)-based techniques, which are more sensitive 
than conventional culturing techniques. In 39 CRC patients with co-incidental S. gallolyticus 
infection, DNA from S. gallolyticus was detected in 49% of the tumor biopsies and in 36% 
of non-tumor tissue samples from the same patients. These numbers were lower in 52 
CRC-patients that did not have clinical signs of S. gallolyticus infection, being respectively 
33% and 23%. Strikingly, from the 50 healthy control patients, only 2 colon tissue samples 
were positive for S. gallolyticus DNA (Abdulamir et al., 2010). Altogether, the evidence for 
the actual presence of S. bovis in CRC tissue still remains inconclusive. However, recent 
molecular data clearly point towards an increased mucosal colonization of S. gallolyticus in 
CRC patients with an increased preference for malignant tissue.
Virulence features of Streptococcus gallolyticus. Recently, we and other research groups 
have discovered some striking differences between S. bovis biotypes that could explain their 
different association rates with CRC as discussed in Chapter 7. First of all, S. gallolyticus seems 
to contain distinguished mechanisms to adherence to extracellular matrix (ECM) structures 
like collagen and fibrinogen (Ellmerich et al., 2000a, Sillanpaa et al., 2009, Sillanpaa et al.,
2008). Interestingly, (pre-)malignant colonic sites are characterized by displaced collagen 
of the lamina propria (Galbavy et al., 2002, Yantiss et al., 2001), through which specifically 
S. gallolyticus could colonize and invade these sites. Besides the ECM components, also other 
structures at the epithelial surface may play a role in the initial adhesion to enterocytes. 
For example, Henry-Stanley et al. reported binding of S. bovis strains to heparan sulfate 
proteoglycans (Chapter 6) (Henry-Stanley et al., 2003). After initial adherence to the epithelial 
surface, invasion and translocation of the epithelial barrier is the next step to infection. In 
an in vitro trans-well model containing a differentiated intestinal monolayer, translocation 
efficiency of S. gallolyticus was shown to be significantly higher than that of other S. bovis 
biotypes. The data also suggested that S. gallolyticus uses a paracellular route to pass the 
monolayer, which could mean that this bacterium has an advantage over other S. bovis 
subspecies to cross an intestinal epithelium, possibly at (pre-)malignant sites with reduced 
barrier function (Chapter 7). Underneath the intestinal epithelium, immune cells guard the 
fences for intruding pathogens. Recent data suggested that S. gallolyticus does not induce a 
pro-inflammatory IL-8 response in epithelial cells in contrast to other S. bovis strains, which 
may be a possibly mechanism S. gallolyticus to stay rather invisible for macrophages in the 
lamina propria (Chapter 7). Furthermore, Hirota et al. discovered that S. gallolyticus isolates 
from endocarditis patients, express human sialyl Lewisx antigens on their cell surface unlike 
fecal isolates. Mimicking human sialyl antigens, which are naturally present on monocytes 
and granulocytes, could therefore be a second mechanism of S. gallolyticus to remain 
unnoticed by the human immune system. Moreover, sialyl Lewisx antigens could make these 
bacteria more efficient in binding to endothelial cells and invasion into the circulatory system
36
General introduction
1
(Hirota et al., 1995, Hirota et al., 1996). Finally, recent data showed that S. gallolyticus can, 
in contrast to other S. bovis strains, efficiently form biofilms on collagen I and IV surfaces 
(Chapter 7) (Sillanpaa et al., 2008). The latter finding could explain the increased incidence 
of S. gallolyticus as causative agent in infective endocarditis. In conclusion, based on the 
current available data we hypothesize that S. gallolyticus has a specific ability to colonize 
(pre)-malignant sites and cross the intestinal epithelium, is relatively invisible to the 
epithelial immune system and is uniquely able to form biofilms on sites with high collagen 
exposure, such as damaged heart valves . Together, these molecular studies provide new 
clues on the specific association between S. gallolyticus infections and CRC.
S. bovis-based immunodiagnostics. The above pictured model for S. bovis infection in 
CRC patients implies that these infections can occur without symptoms and that clinically 
infections primarily occur in otherwise compromised patients. This notion has been the 
incentive to investigate whether a humoral immune response to sub-clinical S. bovis 
infections could aid in the early detection of CRC. These studies showed that serum IgG levels 
against S. bovis antigens could discriminate CRC cases from healthy controls as described in 
Chapter 3 and Chapter 4 (Abdulamir et al., 2009, Darjee and Gibb, 1993, Tjalsma et al., 
2006). Interestingly, the humoral immune response to ribosomal protein (Rp) L7/L12 from 
S. gallolyticus was found to be higher in early CRC stages compared to late CRC stages, 
whereas this was not paralleled by increased antibody production to endotoxin, an intrinsic 
cell wall component of the majority of intestinal bacteria . This finding implies that the 
immune response to RpL7/L12 is not a general phenomenon induced by the loss of colonic 
barrier function (Chapter 3). Furthermore, this observation could point to a temporal 
relationship between S. gallolyticus and CRC, by suggesting that late stage tumors may 
change in such a way that bacterial survival in the tumor microenvironment is diminished. 
The possibility that disease progression may drive bacteria out of the cancerous tissue is 
similar to what has been reported for H. pylori during gastric cancer progression (Corfield et 
al., 2000, Kang et al., 2006). The relationship of S. bovis with early CRC stages is underscored 
by a vast amount of case studies showing that CRC was present in S. bovis-infected patients 
or even "healthy" blood donors (Haimowitz et al., 2005) without any further signs of gastro­
intestinal malignancy. These CRC cases would have remained undiscovered if these patients 
did not present with an active S. bovis infection (Tjalsma, 2010, Tjalsma et al., 2008, Tjalsma 
et al., 2006).
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Aim and outline of this thesis
The aim of this thesis was to further elucidate the association of Streptococcus gallolyticus 
infections with colorectal cancer on a clinical (Part I) and molecular (Part II) level. Finally, the 
data from the two experimental Parts of this thesis are summarized and integrated into an 
up-to-date model that sheds new light on this intriguing coincidence.
Part I - Clinical Association of Streptococcus gallolyticus 
with Colorectal Cancer
Chapter 2 documents a meta-analysis on the clinical association of different S. bovis 
subtypes with colorectal cancer, which shows that only Streptococcus bovis biotype I 
(S. gallolyticus) infections have an unambiguous association with this disease. As 
S. gallolyticus can also cause subclinical infections in colorectal cancer patients that do not 
have any signs or symptoms of gastro-intestinal disease, it was investigated to which extent 
an humoral immune response against the S. gallolyticus antigen RpL7/L12 (Chapter 3) and 
four pilus proteins (Chapter 4) could discriminate colorectal cancer patients from healthy 
controls. These latter two chapters point towards the use of S. gallolyticus antigens as novel 
tools for the early detection of colorectal cancer.
Part II -  Molecular Explorations at the Host-Pathogen Interface
The second part of this thesis focuses on the molecular mechanisms that could be responsible 
for the clinical association of S. gallolyticus and colorectal cancer. Figure 7, illustrates the 
three hypothetical mechanisms for this association, which are not necessarily mutually 
exclusive, that were further investigated: (i) S. gallolyticus can specifically adhere to (pre-) 
malignant colonic sites for instance via binding to tumor cell specific adherence factors; 
(ii) S. gallolyticus has a competitive growth advantage in the tumor microenvironment for 
instance by fouraging on tumor cell metabolites; (iii) S. gallolyticus stimulates progression 
of colorectal cancer by inducing inflammation or pro-carcinogenic pathways in tumour cells.
To address the first hypothesis (i), a host-affinity profiling technique was used to find novel 
tumour cell receptors with affinity for the S. gallolyticus cell surface (Chapter 5). In addition, 
the role of bacterial HlpA as adhesion factor was investigated (Chapter 6). Besides defining 
specific adhesin-receptor pairs, the infection route of S. gallolyticus was mimicked by in vitro 
cell culture and biofilm formation models (Chapter 7), showing that the collagen-binding 
ability of S. gallolyticus may be an important mediator of its association with CRC.
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Figure 7. Association of Streptococcus 
gallolyticus with CRC
Schem atic representation o f  three possible  
underlying m echanism s that cou ld  explain the 
specific association o f  S. gallo lyticus with CRC. 
These three m odels are n o t m utually  exclusive. 
First, specific adherence factors, such as collagen  
exposure in the tum or m icroenvironm ent, m ay  
lead to increased S. gallolyticus colonization o f  
tum or sites. Second, due to the a ltered nutritional 
status o f  the tum or m icro-environm ent, S. 
gallolyticus m ay gain a com petitive growth  
advantage at these sites. Finally, S. gallolyticus 
m ay upon colonization o f  (pre-)m alignant 
tissue induce in flam m atory o r pro-carcinogenic  
pathw ays that increase the progression o f  CRC. 
colorecta l cancer b y  inducing in flam m ation o r pro- 
carcinogenic pathw ays in tum our cells.
In order to test whether the tumor-microenvironment can give S. gallolyticus a competitive 
growth advantage at these intestinal sites (ii), the influence of tumour cell metabolites on 
the growth and adaptive response of S. gallolyticus was investigated by two-dimensional 
protein analysis (2D-PAGE) and HNMR-spectroscopy (Chapter 8). This showed that 
S. gallolyticus increases its glycolytic activity in the CRC-cell environment, which is most 
likely the result of the increased presence of glucose derivates and amino acids from 
CRC-cell activity. In Chapter 9, the direct influence of S. gallolyticus on pro-carcinogenic and 
inflammatory pathways of colorectal cancer cells (iii) was profiled by micro-array analysis. 
These investigations showed the distinguished induction of cellular phase I biotransformation 
enzymes, which was paralleled by an increased carcinogenic potential of polycyclic aromatic 
hydrocarbons upon co-exposure with a diffusible S. gallolyticus factor (SGF-X).
Chapter 10 summarizes the Chapters 2-9 of this thesis and integrates the gained insights 
with the current state of the literature, resulting in an up-to-date model that helps to explain 
the specific relationship between S. gallolyticus and colorectal cancer. This working model 
provides new testable hypothesis for future research.
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Abstract
Background:
Streptococcus bovis has long been associated with colorectal cancer (CRC). However, not all 
genospecies are as closely related to CRC. With this systematic review we aim to increase 
the awareness on the association between S. bovis biotype I (S. gallolyticus) and CRC, and 
plead for uniform molecular microbiological classification.
Methods:
In January 2011, the PubMed database was searched for all studies that investigated the 
association between S. bovis, infective endocarditis (IE) and CRC. A total of 191 studies 
were screened for eligibility. This yielded 52 case reports and 31 case series, of which 11 
were used for meta-analysis on the association between S. bovis biotype, IE and adenomas/ 
carcinomas (colorectal neoplasia (CRN)).
Results:
Among the S. bovis-infected patients that underwent colonic evaluation, the median 
percentage of patients that had concomitant adenomas/carcinomas was 60% (Inter 
Quartile Range (IQR) 22%), which largely exceeds the disease rate reported in the general 
asymptomatic population. Meta-analysis showed that patients with S. bovis biotype I 
infections had a strongly increased risk of having CRN (pooled OR 7.26 (95% CI 3.94-13.36)) 
and IE (pooled OR 16.61 (95% CI 8.85-31.16)) compared with S. bovis biotype II-infected 
patients. Notably, CRN occurred more often among S. bovis IE patients than among patients 
with S. bovis infections at other sites (pooled OR 3.72 (95% CI 2.03-6.81)).
Conclusions:
Our meta-analysis clearly points out that S. bovis should no longer be regarded as a single 
species in clinical practice, since especially S. gallolyticus (S. bovis biotype I) infections have 
an unambiguous association with CRN.
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Introduction
The association between streptococcal endocarditis and colorectal cancer (CRC) was first 
reported in 1951 by McCoy and Mason (McCoy and Mason, 1951). In the 1970's this association 
was rediscovered by Hoppes and Lerner who reported that among 14 Streptococcus bovis 
endocarditis cases, 9 (64%) had gastro-intestinal disease (Hoppes and Lerner, 1974). This 
was supported by the finding that the fecal carriage rate was approximately 5 times higher in 
CRC patients compared to healthy controls (Klein et al., 1977). Importantly, several of these 
patients with villous adenoma or carcinoma had no clinical signs or symptoms referable to 
gastrointestinal cancer (Klein et al., 1977). Consequently, cancer was solely discovered based 
on S. bovis infections in these cases. Since the publication of these remarkable associations, 
a vast amount of case studies on S. bovis infections with underlying occult CRC have been 
published. However, restrictions of the phenotypic microbiological typing techniques used 
in many of these studies (Facklam et al., 1984) has hampered distinction between the 
three known S. bovis biotypes I, II/1 and II/2. In an attempt to modernize and harmonize 
molecular classification of S. bovis subspecies, Schlegel et al. proposed in 2003 (Schlegel 
et al., 2003) to rename these biotypes into Streptococcus gallolyticus subsp. gallolyticus, 
Streptococcus infantarius subsp. infantarius and Streptococcus infantarius subsp. coli 
(both II/1), and Streptococcus gallolyticus subsp. pasteurianus (II/2) based on molecular 
characteristics (Table 1) (Beck et al., 2008, Schlegel et al., 2000, Schlegel et al., 2004). The 
latter nomenclature has been embraced by some, but not by the majority of studies that 
appeared in literature since then. This lack of uniform microbiological classification in 
scientific literature has led to an underestimation of the relation between S. bovis and CRC, 
since not all genospecies seem to be as closely related to colonic malignancies. With this 
systematic review we aim to increase the awareness of the specific association between 
S. gallolyticus subsp. gallolyticus (biotype I) and CRC. Furthermore, we plead for proper 
classification of S. bovis-related strains to increase the understanding of disease pathology 
which could have major implications for the early detection of CRC and patient's health.
Table 1. Nomenclature of the principal human species of the S. bovis/equinus complex
New name Former phenotypic desigation Synonym
S. gallolyticus subsp. gallolyticus S. bovis biotype I S. gallolyticus
S. infantarius subsp. infantarius S. bovis biotype ll/1 S. infantarius
S. infantarius subsp. coli S. bovis biotype ll/1 S. lutiensis
S. gallolyticus subsp. pasteurianus S. bovis biotype ll/2 S. pasteurianus
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* studies selected through narative review articles
Figure 1. Prisma flow-diagram
Methods
Data sources and study selection
In January 2011, a total of four independent searches via PubMed (www.ncbi.nlm.nih.gov/ 
pubmed) were performed using the following search terms: "Streptococcus bovis AND 
Colorectal Cancer [Mesh Terms]", "Streptococcus gallolyticus AND Colorectal Cancer [Mesh
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Terms]", "Streptococcus infantarius AND Colorectal Cancer [Mesh Terms]", "Streptococcus 
pasteurianus AND Colorectal Cancer [Mesh Terms]", "Streptococcus bovis AND Malignancy" 
and "Endocarditis AND Colorectal Cancer [Mesh Terms]. After elimination of duplicates, this 
yielded a total of 191 records. Studies that reported infections with S. bovis or one of its 
subspecies were selected for individual evaluation. Case series from 1970 to 2010 with a clear 
description of CRC-rates among S. bovis-infected patients with an age above 20 were selected 
for further evaluation. All narrative literature reviews, studies that were not published in the 
English language, or comprised in vitro research were excluded. This resulted in a total of 52 case 
reports and 31 case series that were included in this review. Of the 31 case series, 11 provided 
detailed information (see below) suitable for inclusion in the meta-analysis (Figure 1).
Data extraction
The 52 case reports were screened for the following information: type of infection, S. bovis 
biotypes involved, stage of (pre)-malignant lesions and other underlying diseases besides 
CRC. The 31 case series were screened to extract the following information: number of 
patients, mean age of patients, number of gastro-intestinal (GI) evaluations, number of 
infective endocarditis (IE) cases, biotypes reported, number of adenomas and carcinomas 
and presence of other infections or GI disorders. Adenomas includes neoplastic polyps 
(adenomatous polyps, villous adenomas, tubular adenomas and adenomas), but excludes 
non-neoplastic polyps. Since most articles did not use the genotypic designation of the S. 
bovis/equines complex (Table 1) (Schlegel et al., 2003), we used the former phenotypic 
designation and assumed that species that were characterized as S. bovis biotype I belonged 
to the genospecies S. gallolyticus subsp. gallolyticus. The synonyms for the different 
genotypes (Table 1) were used throughout this review and the S. bovis biotype II strains were 
grouped together, because 6 studies did not specify the number of species belonging to 
biotype II/1 and II/2. When no further classification was reported, the general term S. bovis 
was used. From these data the colorectal neoplasia (CRN) occurrence among all S. bovis 
cases and among colonic evaluated subjects was calculated. Unless stated otherwise, the 
term "CRN" relates both to carcinomas and adenomas. CRN occurrence was subcategorized 
by S. bovis biotype when possible. The median prevalence with corresponding Inter-quartile 
range (defined as Q3 -  Q1) (IQR) was calculated for a combined overview of the case series. 
The methods used to determine the rate of CRN, the S. bovis biotype involved and the 
presence of IE are presented in Figure 2.
Meta-analysis
For quantitative meta-analysis, 11 of the 31 case series were selected that discriminated 
between S. bovis biotypes, or between IE and other infection sites. The aim of this meta­
analysis was to assess the risk for having CRN or IE among S. bovis biotypes. Furthermore, 
the risk for having CRN among S. bovis IE or infections at other sites was assessed. Data 
were extracted independently by two reviewers, and discrepancies in data extraction were 
resolved by repeated manuscript review to reach consensus. We reported only subjects 
that underwent GI evaluation when possible. We calculated odds ratios (ORs) with 95% 
confidence intervals (CIs) for all studies with sufficient data on the previously specified 
associations. Pooled ORs were calculated as the weighted average of the ORs for the
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associations of interest. Weights were assigned according to the inverse of the variance. 
Heterogeneity was tested using chi-square tests and quantified with the I2 statistic (Higgins 
et al., 2003). As all values of the I2 statistic were smaller than 50%, fixed-effects models were 
used. Statistical analyses were performed using RevMan version 5.0.25 for Windows (The 
Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen).
Figure 2. Flow-diagram of methods used to assess biotype, infective endocarditis and CRC
This flow -d iagram  show s the m ethods used fo r  the determ ination o f  S. bovis biotypes, d iagnosis o f  
IE  and assessm ent o f  co lonic disease in 31 case series. The num ber o f  stud ies that used the indicated  
m ethod are show n in brackets. In 21 o f these case series colonic evaluations were carried out. Colorectal 
cancer (CRC); trans-thoracic echocardiography (TTE); trans-esophageal echocard iography (T E E ).
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Table 2. Case reports
Results 
Case reports
A total of 52 case reports from 1951 to 
2010 were reviewed (Table 2) (Ackerman 
et al., 1995, Aizawa et al., 2006, Apsingi 
et al., 2007, Barcelos et al., 2010,
Beadsworth et al., 2005, Belinkie et al.,
1983, Ben-Haim et al., 1988, Bleibel et 
al., 2007, Copeland and Malster, 1993,
Dowd and Loftus, 1985, Dunham et al.,
1980, Emerton et al., 1995, Ferrari et 
al., 2008, Florescu et al., 2009, Friedman 
et al., 1986, Garcia-Porrua et al., 2000,
Genta et al., 1998, Goumas et al., 1997,
Haimowitz et al., 2005, Harley et al., 1992,
Herrington et al., 1980, Hossenbux et al.,
1983, Kahveci et al., 2010, Kewal et al.,
1983, Kim et al., 2010, Klein et al., 1977,
Kok et al., 2007, Ma et al., 1992, Mann 
et al., 1997, McCoy and Mason, 1951,
McMahon et al., 1991, Montalto et al.,
2004, Muhlemann et al., 1999, Noble et 
al., 1978, Robbins and Klein, 1983, Roses 
et al., 1974, Seglenieks and Black, 1998,
Seifert, 2009, Silver, 1984, Smith et al.,
1978, Spadafora et al., 1996, Srivastava et
al., 2010, Steinberg and Naggar, 1977, Tabibian and Clarridge, 1989, Thota et al., 2002, Trajber 
et al., 1984, Vince et al., 2003, Waisberg et al., 2002, Watanakunakorn, 1988, Weitberg et al.,
1981, Weng et al., 2005, Wentling et al., 2006). From these reports, data from 74 patients were 
extracted that collectively had 84 CRCs. Most cases involved carcinomas (n = 55 (65%)); the 
remaining colonic lesions were reported as villous adenoma or polyps. Other underlying diseases, 
such as gastric carcinoma and diverticulitis, were described in five cases. S. bovis predominantly 
caused IE (n = 42 (72%)), but also abscesses and infections of knee replacements were reported. 
Unfortunately, however, the S. bovis biotype was only documented in seven of the case reports. 
These concerned four biotype I strains that caused IE (two times), endopthalmitis, and an 
unspecified infection. S. bovis biotype II was reported as causative agent in three cases including 
IE, peritonitis, and an unspecified infection. Thus, evaluation of these case reports showed that 
S. bovis infective endocarditis (IE) might be associated with CRC. However, evaluation of case 
reports may introduce selection bias, which could lead to an overestimation of the observed 
association. Therefore, 31 case series of patients with S. bovis bacteremia were investigated to 
examine the relation between S. bovis biotypes, IE, and CRC in an evidence-based manner.
N
case reports 52
patients 74
biotype reported 7
biotype I 4
biotype II 3
colorectal cancer 84
polyps 15
vilous adenoma 14
carcinom a 55
reported infections* 58
endocarditis (IE) 42
knee arthroplasty 3
endophthalmitis 1
osteomyelitis 2
spo ndylo d iscits 1
se ptc arthritis 2
abscess 5
peritonitis 1
meningitis 1
other underlying diseases 5
gastric carcinom a 2
d iv e rtc u lits 2
* excludes 16 unspecified infections
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Table 3. case series on S. bovis and CRN
ref- author (year) Mean age Totaltt + 
biotype
ft CE ft IE
2 Hoppes (1974) 61 14
10 Murray (1978) 61 36 26
11 Levy(1978) 74 3 2 3
12 Klein (1979) 70 29 15 13
13 Wilson (1981) 59 21 21
14 Reynolds (1983) 72 19 10 14
15 Beeching (1985) 66 12 9 10
16 Leport (1987) NR 34 23 34
17 Pigrau (1988) 48 16 5
18 Ruoff (1989) 67 38 
1(17) 
l l/ l (12) 
11/2(9)
12
12
19
16
1
2
19 Zarkin (1990) 57 92 43 26
20 Hoena(1994) 61 32
64
32
64
21 Ballet (1995) 61 53 43 53
22 Kupferwasser (1998) 67 22 21 22
23 Gonzalez-Quintela (2001) 61 20 13 10
24 Duval (2001) 62 20 16 20
25 Pergola (2001) 64 40 40 40
26 Herrero (2002) 65 14
l ( U ) 
11/2(1)
9
9
14
27 Gonzalez-Juanatey (2003) 63 20 13 20
28 Lee (2003) 61 37 
1(2) 
H/1 (3) 
H/2 (32)
4b
29 Tripodi (2004) 59 30 
1(28) 
11(2)
28
27
1
30°
28
2
N>
# adenomas # carcinomas % C R N / % CRN / CE % adenomas % carcinomas
Total #_______________________ /CE___________ /CE
2 14 
2 2 11
2 67 100
4 8 41 73 27 53
4 1 24
4 2 32 50 40 10
5 3 67 89 56 33 
9 6 44 65 39 26
1 6
15 39
12 71 100
1 8
2 22
9 7 17 37 21 16
15 3 56 56 47 9
15 2 27 27 23 3
16 9 47 58 37 21 
4 2 27 29 19 10
3 3 30 46 23 23 
8 3 55 69 50 19
4 10 10 10
1 2 21 33 11 22
1 40 62 54
4 11
13 1 47 50 46
13 1 47 52
0
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ong 
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patients
30 Gold (2004) 74 41 17 12 13 3 39 94 76 18
31 Jean(2004) 61 60 19 15 l l d 18 47
1(10) 8 5 50
11(37) 4 6 16
32 Corredoira (2005) 67 64 34 27 44
1(42) 31 24 57
11(22) 3 3 14
33 Alazmi (2006) 56 38 10 1 3 3 16 60 30 30
34 Giannitsioti (2007) 63 142" 92 142 55 5 42 65 60 5
1(71) 46 24 3 38 59 52 7
H/1 (5)
11/2(3)
35 Corredoira (2008a) NR 133s 54 41
1(90) 51 57
ll/l (28) 3 11
11/2(15)
36 Corredoira (2008b) 66 107® 71 55 25 4 39 59 49 10
1(69) 52
11(38) 3
8 Beck(2008) 70 46s 15 13 8 3 24 73 53 20
1(21) 9 5 2 33
ll/ l (14)" 4 3 1 29
11/2(11)
37 Vaska (2009) 68 20 14 8 5 5 50 71 36 36
1(10) 9 6 2 5 70 78 22 56
11(10) 5 2 3 30 60 60
38 Fernandez-Ruiz (2010) 71 59 33 16 15 6 36 64 45 18
1(12)
11(10)
3 32 cases and 64 controls; Risk Ratio for developing endocarditis was 3.6 (95% Cl 1.4-9.4) for tumors; 3.4 (95% Cl 1.2-9.2) for adenomas and 5.7 (95% Cl 0.9-48.5) for adenocarcinoma's 
b 14 cases of cholangitis; 17 out of 30 had concomittant liver disease; 4 patients had both liver disease and colonic neoplasia; 2 patients had CRC prior to SB infection (without 
colonoscopy);e subspecies defined in nomenclature by Schlegel et al. see Table 1; 'includes 63 unspecified blotypes;8 endocarditis cases;h Infantarius subsp. coll
NR = not reported, CE = colonic evaluation, IE = infective endocarditis, adenomas are defined as adenomatous polyps, villous adenoma and advanced adenomas, CRC = colorectal cancer and 
defined as adenomas + carcinomas
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2 Case seriesOf the 31 included case series, 24 retrospectively and 7 prospectively included S. bovis- infected patients (Alazmi et al., 2006, Ballet et al., 1995, Beck et al., 2008, Beeching et al., 1985, 
Corredoira et al., 2008a, Corredoira et al., 2008b, Corredoira et al., 2005, Duval et al., 2001, 
Fernandez-Ruiz et al., 2010, Giannitsioti et al., 2007, Gold et al., 2004, Gonzalez-Juanatey et al., 
2003, Gonzalez-Quintela et al., 2001, Herrero et al., 2002, Hoen et al., 1994, Hoppes and Lerner, 
1974, Jean et al., 2004, Klein et al., 1979, Kupferwasser et al., 1998, Lee et al., 2003, Leport 
et al., 1987, Levy and Brooks, 1978, Murray and Roberts, 1978, Pergola et al., 2001, Pigrau 
et al., 1988, Reynolds et al., 1983, Ruoff et al., 1989, Tripodi et al., 2004, Vaska and Faoagali,
2009, Wilson et al., 1981, Zarkin et al., 1990). The age of patients was reported in 29 studies 
and ranged from 48-74 years with an average of 64 years. From these data the proportion of 
S. bovis-infected patients that had concomitant CRN (both adenomas and carcinomas) was 
calculated (Table 3). The median prevalence of CRN among S. bov/'s-infected patients was 39% 
(IQR of 24%) (Figure 3). However, not all subjects underwent colonic evaluation and therefore 
lesions could have easily been missed, resulting in underestimation of the actual prevalence 
of CRN among S. bovis-infected patients. When only the colonic evaluated patients were taken 
into account the median prevalence of CRN in S. bov/s-infected patients markedly increased to 
60% (IQR of 22%). In 20 of these case series a distinction was made between adenomas and 
carcinomas. Strikingly, the median prevalence of carcinomas was 18% (IQR 13%), whereas that 
of adenomas was 43% (IQR 22%). This could suggest that S. bovis infections are predominantly 
associated with pre-malignant colonic lesions. Unfortunately, only the study by Hoen et al. 
(Hoen et al., 1994) investigated the proportion of CRC in an age-matched control population. 
They reported adenomas and carcinomas in 27% of healthy controls compared to 56% in 
S. bovis-infected subjects (Table 3). The general elderly population between 60 and 70 years 
of age has a rate of 0.3% for carcinomas and 10-25% for adenomas (dotted lines in Figure 3) 
(Arminski and McLean, 1964, Lieberman and Smith, 1991, Lieberman et al., 2000, Regula et 
al., 2006, Spier et al., 2010). Together, these data make it presumable that S. bovis-infected 
individuals have increased rates of both adenomas and carcinomas.
Figure 3. Box-whisker plots of case series
Graphical representation o f the occurrence o f CRN (in 
%) among all 31 case series (CRN /  Total) and among 
a selection o f 21 case series that reported the number 
o f gastro-intestinal (GI) evaluations (CRN /  CE). The 
combined cases o f the latter 21 case series were 
further subdivided in adenomas (adenomas /  CE) and 
carcinomas (carcinomas/CE). Box-whisker plots show the 
lowest, first quartile, median, third quartile and highest 
values o f the percentages reported in Table 2. Dotted 
lines represent the respective 25% and 0.3% incidences 
fo r adenomas and carcinomas in the asymptomatic 
age-matched population. CE  =  colonic evaluation, 
CRW = colorectal neoplasia (adenomas and carcinomas).
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2Biotypes and CRNA total of 12 case series provided detailed information on S. bovis biotypes. Of these 
studies, three provided the number of S. bovis biotype I and II infections, but did not report 
the number of CRN cases stratified by biotype (Corredoira et al., 2008a, Fernandez-Ruiz
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Figure 4. Forest plots on the relation between biotype, infective endocarditis and CRC
Forest p lots were generated to provide a m ore detailed v iew  on the relation betw een S. bovis biotype, 
IE  and CRN. Pooled ORs were ca lculated as the w eighted average o f  the ORs fo r  the associations o f  
interest. The occurrence o f  (A) CRN  and (B) IE  am ong S. bovis biotype I-infected patients com pared to 
that am ong S. bovis biotype II-infected patients, and (C) CRN  in patients with S. bovis IE  com pared to 
patients with S. bovis infections at other sites.
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et al., 2010, Lee et al., 2003). Another three studies comprised almost exclusively S. bovis 
biotype I-infected patients, with reported CRN prevalence's of 33%, 52% and 59% (Table
3) (Giannitsioti et al., 2007, Herrero et al., 2002, Tripodi et al., 2004). The remaining six 
studies were included in the meta-analyses (Beck et al., 2008, Corredoira et al., 2008b, 
Corredoira et al., 2005, Jean et al., 2004, Ruoff et al., 1989, Vaska and Faoagali, 2009) 
and showed that patients with a S. bovis biotype I infection had a statistically significantly 
increased risk of having CRN compared to S. bovis biotype II-infected individuals (pooled 
OR 7.26 (95% CI 3.94-13.36)) (Figure 4A). However, it should be noted that the inconsistent 
naming of S. bovis due to characterization via phenotypic and genotypic methods could 
have biased the results of this analysis. Nonetheless, from these studies it is evident that 
infection with S. bovis biotype I, currently known as S. gallolyticus, is strongly associated 
with CRN (range 33-71%) that markedly exceeds the normal range of CRN (10-25%) in the 
general population.
Biotypes and infective endocarditis
It has previously been reported that S. bovis biotype I infections are more often associated 
with IE than S. bovis biotype II infections (Parker and Ball, 1976). To investigate this further, 
seven case series that stratified the number of IE cases by biotype were selected for statistical 
analysis (Beck et al., 2008, Corredoira et al., 2008a, Corredoira et al., 2005, Fernandez-Ruiz 
et al., 2010, Jean et al., 2004, Ruoff et al., 1989, Vaska and Faoagali, 2009). This showed that 
43-100 % of the S. bovis biotype I-infected cases presented with IE, whereas IE was markedly 
less common (8-29%) among S. bovis biotype II-infected patients (pooled OR 16.61 (95% 
CI 8.85-31.16)) (Figure 4B). This finding strongly suggests that S. bovis biotype I is a more 
potent causative agent for IE than S. bovis biotype II.
Infective endocarditis in relation to CRN
As especially S. bovis biotype I is strongly associated with both CRN and IE, it can be 
envisaged that CRN occurs more often among S. bovis endocarditis cases than among 
cases with S. bovis infections at other locations. Therefore, six case series that stratified 
the number of CRN cases by infection site were included in this analysis (Corredoira et al., 
2008a, Fernandez-Ruiz et al., 2010, Gonzalez-Quintela et al., 2001, Murray and Roberts, 
1978, Vaska and Faoagali, 2009, Zarkin et al., 1990). As indicated in Figure 4C, the percentage 
of CRN among patients with IE ranged between 12 and 93%, whereas this was lower among 
patients with S. bovis infections at other locations (10 to 50%), yielding a pooled OR of 3.72 
(95% CI 2.03-6.81). Omitting the study of Corredoira et al., which contributed almost half of 
the CRN cases, did not alter the pooled OR substantially (3.49 (95% CI 1.22-9.95). This finding 
confirms that S. bovis IE is more likely to relate to an underlying occult colon malignancy than 
S. bovis infections at other sites. Taken together, these data make it tempting to speculate that 
S. bovis biotype I I  S. gallolyticus, that is highly associated with both CRN and IE, contains 
specific virulence factors that links its potency to establish IE with colonic lesions.
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Discussion 
Summary of evidence
This is the first meta-analysis on S. bovis infections that evaluated the relation between different 
subtypes of this bacterium, infection sites, and adenomatous and carcinomatous colonic lesions. 
These analyses clearly showed that adenomas or carcinomas (CRN) were significantly more 
prevalent in patients with an S. bovis biotype I infection than in patients diagnosed with an S. bovis 
biotype II infection. In fact, the incidence of CRN in S. bovis biotype II-infected patients may not 
even exceed that of the general asymptomatic population (Arminski and McLean, 1964, Lieberman 
and Smith, 1991, Lieberman et al., 2000, Regula et al., 2006, Spier et al., 2010). These different 
associations may have accounted for the wide range of CRN prevalence's that have been reported 
over the years (Figure 3). Importantly, because most studies did not discriminate between S. bovis 
biotypes, the association of S. bovis biotype I and CRC has systematically been underestimated. 
With our current meta-analysis, we emphasize that S. bovis biotype I is the whistle-blower for 
occult CRN. Conspicuously, both S. bovis IE and CRC are more frequently diagnosed in the elderly 
population (Durante-Mangoni et al., 2008, Hoen et al., 2005, Lopez et al., 2010, Parker and Ball, 
1976). In this respect it is important to know that S. bovis biotype I has been recently renamed 
S. gallolyticus. We and others have shown that collagen I/IV-binding is one of the distinguished 
features of S. gallolyticus strains (Boleij et al., 2011, Rusniok et al., 2010, Sillanpaa et al., 2008). 
Superior binding to collagen I on heart valves could be responsible for the increased occurrence of 
S. gallolyticus IE compared to that caused by other S. bovis biotypes. Intriguingly, polyps and early 
colorectal tumors are surrounded by a continuous and increased expression of collagen IV, which 
is distinct from healthy tissues (Galbavy et al., 2002, Skovbjerg et al., 2009, Yantiss et al., 2001). 
Thus, S. gallolyticus strains may also have a competitive advantage to colonize collagen-rich (pre-) 
malignant sites in the intestine. Together, this could explain why S. gallolyticus (S. bovis biotype I) 
is strongly associated with both IE and CRN. Recently, S. gallolyticus DNA was detected in 49% of 
CRC tissue samples whereas only 8% of healthy colonic samples were found positive (Abdulamir 
et al., 2010), which correlates with increased fecal carriage of S. bovis in CRC patients (Burns 
et al., 1985, Klein et al., 1977). Previous research showed that the antibody response against S. 
gallolyticus antigens was significantly increased in patients with early stages of CRC compared 
to asymptomatic controls (Boleij et al., 2010, Tjalsma et al., 2006). Moreover, S. bovis has been 
cultured from blood of asymptomatic individuals with occult CRC (Haimowitz et al., 2005, Lin et 
al., 2011). Together, these finding shows that these infections can occur at subclinical level, which 
accentuates the potency of S. gallolyticus as diagnostic tool for CRC.
Limitations
During the course of this meta-analysis, some difficulties emerged during data extraction 
and evaluation that could have introduced bias. The first and most important limitation that 
could have led to information bias was the inconsistent naming of S. bovis subspecies among 
studies. Evolving insights and microbiological techniques have extended the knowledge 
on its genotypic and phenotypic characteristics (Schlegel et al., 2003). However, this new 
nomenclature has only slowly been adopted by the clinic and is still not consistently used 
throughout studies and case reports. Secondly, due to several reasons not all included patients 
were screened by colonoscopy, which could have underestimated the association between
Part 1 - Clinical association of S. gallolyticus with colorectal cancer
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S. bovis and CRC. Conversely, some studies did not specify whether polyps were adenomas 
or belonged to non-neoplastic polyps, which could have overestimated the association. 
Furthermore, most studies included cases based on retrospective chart evaluation, which may 
have introduced selection bias. For example, if only patients that already were suspected for 
having GI-disease were screened, the observed association would have been overestimated. 
Lastly, the diagnosis of IE according to (modified) Duke's criteria is a subjective procedure 
that is based on the opinion of the individual physician and could therefore differ substantially 
between hospitals. This could have introduced detection bias across studies (Durack et al., 
1994, Li et al., 2000).
Conclusions and recommendations
The most important conclusion of this meta-analysis is that S. bovis biotypes should no longer 
be regarded as a single species, since especially S. gallolyticus (S. bovis biotype I) has an 
unambiguous association with CRN. In this respect, we would like to increase the awareness 
of the new nomenclature of different S. bovis subspecies among physicians (Clarridge 
et al., 2001, van't Wout and Bijlmer, 2005) and recommend that clinical microbiologists, 
researchers and physicians use the classification as proposed by Schlegel et al. (Schlegel et 
al., 2003), both in clinical practice and scientific publications (Table 1). The latter implies 
that in all cases molecular genetic techniques should be used for the classification of S. 
bovis group bacteria. Secondly, we would like to stimulate researchers to conduct properly 
designed case-control studies, including colonoscopic evaluation of all included subjects, 
to further unravel the association between S. gallolyticus infections and different stages of 
CRC. Finally, we want to encourage research that aims at the elucidation of those virulence 
features, for example collagen binding properties, that are responsible for the specific 
association between S. gallolyticus IE and CRC. We believe that microbiological classification 
tools based on such features will allow further improvement of the guidelines to screen for 
underlying occult malignancy in case of bacterial infection. Furthermore, this may provide 
tools for the early detection of subclinical infections that are associated with CRC in a larger 
part of the population. The annual incidence of this disease is about one million cases in 
Western societies. Unfortunately, about 40% of the cases is detected during an advanced 
stage resulting in a sharp decline in prognosis. Therefore, the early detection of CRC is one 
of the great challenges in the battle against this disease. Ultimately, S. gallolyticus-related 
diagnostic tools may aid CRC screening programs and thereby contribute to a decrease in 
morbidity and mortality of this disease.
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Chapter 3 - Bacterial antigen exposure in early stage CRC
Abstract
Background:
Intestinal bacteria have been implicated in colorectal cancer pathology for a long time and 
a large number of reports point to a close linkage between Streptococcus bovis biotype I 
(recently renamed Streptococcus gallolyticus) infections and tumors of the human colon. 
This work aims to investigate the humoral immune response to this bacterium during 
different stages of colorectal cancer.
Method:
The presence of serum antibodies against S. gallolyticus antigen RpL7/L12, previously 
assigned as a potential diagnostic antigen, was evaluated in Dutch (n=209) and American 
(n=112) populations using a newly developed ELISA assay.
Results:
The analyses consistently showed that an immune response against this bacterial antigen 
was increased in polyp patients and stage I/II colorectal cancer patients as compared to 
asymptomatic individuals. This was not paralleled by increased antibody production 
to endotoxin, an intrinsic cell wall component of the majority of intestinal bacteria, 
which implicates that the humoral immune response against RpL7/L12 is not a general 
phenomenon induced by the loss of colonic barrier function. Notably, increased anti-RpL7/ 
L12 levels were not or only mildly detected in late stage colorectal cancer patients having 
lymph node or distant metastasis.
Conclusion:
These findings are indicative for an increased exposure to antigen RpL7/L12 during early 
stages of colon carcinogenesis and suggest that intestinal bacteria, such as S. gallolyticus, 
constitute a risk factor for the progression of pre-malignant lesions into early stage 
carcinomas. Clearly, the current findings emphasize the necessity for further studies on the 
possible etiologic relationship between intestinal bacteria and human colorectal cancer.
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Introduction
The human gastrointestinal tract is the habitat for a large and dynamic bacterial community, 
which is essential for digestion of food and the control of intestinal epithelial homeostasis 
and human health. Gut flora may, however, also be a critical factor in gastrointestinal 
diseases such as colorectal cancer (CRC) (Guarner and Malagelada, 2003). Although 
hundreds of microbial species reside in the human intestinal tract, only a systemic infection 
with the Gram-positive gut bacterium Streptococcus bovis (biotype I), recently renamed 
Streptococcus gallolyticus, has a well-known clinical association with CRC (Boleij et al., 2009b, 
Burnett-Hartman et al., 2008, Corredoira et al., 2008, Klein et al., 1977, zur Hausen, 2006). 
This opportunistic pathogen is normally detected in the gastrointestinal tract of about 10% of 
the human population (Schlegel et al., 2000). Due to its relative low virulence, S. gallolyticus 
can only establish a systemic infection in immunocompromised hosts (bacteremia) and/or 
individuals with damaged heart valves (endocarditis) together resulting in a ~1% incidence 
of pathological S. gallolyticus infections in CRC patients. Interestingly, fecal carriage of 
S. bovis was shown to be increased about 5-fold in patients with CRC (Klein et al., 1977), 
and a colon tumor was detected up to 60% of patients with an S. bovis endocarditis or 
bacteremia (zur Hausen, 2006). Despite these observations, clear implications of this 
infection have not yet been established. There are several possible interpretations that are 
not necessarily mutually exclusive. First, it has been hypothesized that colorectal neoplastic 
sites provide a specific niche for S. gallolyticus resulting in sustained colonization, survival, 
and the establishment of a local tumor-associated (clinically silent) infection. Second, 
S. bovis itself may promote colorectal carcinogenesis, which has been supported by 
experimental studies (Ellmerich et al., 2000a, Ellmerich et al., 2000b).
A previous pilot study showed that S. gallolyticus infection profiles generated by mass 
spectrometry, which consisted of antigens that were specifically bound by patient serum 
IgG, could be observed in CRC patients. The most abundant antigen peaks in these profiles 
belonged to a cluster of proteolytic fragments from ribosomal protein (Rp)L7/L12 (Tjalsma 
et al., 2006, Tjalsma et al., 2007). The aim of the current study was to determining the 
relative serum anti-RpL7/L12 (IgG) levels during different stages of CRC using a newly 
developed quantitative ELISA assay. Cases and control samples from both Dutch and American 
institutes were used to determine geographical influence. Importantly, these analyses 
consistently showed an increased humoral immune response against RpL7/L12 in polyp and 
early CRC patients as compared to healthy controls. In contrast, no increased anti-RpL7/ 
L12 levels were found in late stage CRC patients having lymph node or distant metastasis. 
Together, this provides the first clinical support for a temporal association between 
S. gallolyticus and human colon tumors during CRC progression.
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Materials and methods 
Patient material
Serum samples from 82 CRC and polyp patients and 10 patients with a systemic bacterial 
infection who had been admitted to the Radboud University Nijmegen Medical Centre 
(Nijmegen, The Netherlands) were used in this study. Patients suffering from infection 
with S. gallolyticus (Gram-positive) or E. coli (Gram-negative) strains were recognized by 
a positive blood culture and routine microbial typing. Anonymized serum samples from 
100 healthy volunteers (age 18-25 years), which were collected as part of the Nijmegen 
Biomedical Study (Hoogendoorn et al., 2006, Wetzels et al., 2007) and 27 healthy blood 
donors (>50 years) were used as controls. In addition, plasma samples from 64 CRC/polyp 
patients and 48 healthy controls who participated in a population-based case-control study 
in Metropolitan Detroit (USA), were included as a second independent study population; 
Detroit cancer cases included 7 with stage unknown. The use of the samples was approved 
by the local medical ethical committees and informed consent was obtained when required. 
Serum and plasma samples were stored at -80 °C until use.
RpL7/L12 overproduction and purification
To construct the RpL7/L12-His production vector pET11-RpL7/L12-His, chromosomal DNA 
from S. gallolyticus subsp. gallolyticus strain UCN34 (previously classified as S. bovis biotype I), 
was used as a template to amplify the rpL7/L12 gene. First a fragment comprising the complete 
open reading frame of the rpL7/L12 gene was amplified by PCR using the primers RpL7-u 
(5'-TCGACATATGGCATTGAACATTGAAAACATTATTGC-3') containing an NdeI cleavage site and 
RpL7-d (5'-TCGAGGATCCTTAATGGTGATGGTGATGGTGTTTAAGAGTAACTGAAGCTCCAGC-3') 
that inserts a hexahistidine (6xHis) tag upstream of the rpL7/L12 gene stop codon and 
contains a SomHI cleavage site. Next, the amplified fragment was cleaved with NdeI and 
SomHI and ligated into the corresponding sites of pET11a (Novagen) and used to transform 
Escherichia coli DH5a (Invitrogen) after which plasmid containing cells were selected on 
50 ^g/ml ampicillin (Sambrook, 1989). Intact pET11-RpL7/L12-His was transferred to E. 
coli BL21 (DE3; Novagen) and cells were grown aerobically at 37°C in liquid Luria Broth 
(LB) medium containing Bacto-tryptone (1%), Bacto-yeast extract (0.5%), NaCl (1%) and 
50 ^g/ml ampicillin. RpL7/L12-His production was induced in exponentially growing cells 
by 500 nM isopropyl-D-thiogalacto-pyranoside (IPTG). Cells were harvested after 4 hours 
and lysed by two freeze-thaw cycles after which native His-tagged RpL7/L12 was purified 
(>95%) by Nickel-affinity chromatography using the Ni-NTA mini spin kit from Qiagen (Boleij 
et al., 2009a). Cell lysates and isolated protein fractions were analyzed by Tricine SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE) (Schagger, 2006). The identity purified RpL7/ 
L12-His was confirmed by in-gel tryptic digestion followed by tandem mass spectrometry 
(Barclay, 1995).
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ELISA measurements
To measure anti-RpL7/L12 IgG levels, ELISA microtiter plates (Maxisorp Nunc) were first 
coated with purified RpL7/L12-His (0.3 ^g/ml) in 50 mM NaHCO3 (pH9.5) during a 48 hour 
incubation at 4°C. Next, wells were washed 3 times with 50 mM KH2PO4 / 130 mM NaCl buffer 
(pH7) containing 0.01% Tween-20 (wash/incubation buffer) after which the immobilized 
antigen was incubated with 100-fold diluted serum samples for 18 hours at 4°C. Wells 
were washed (3 times) after which incubation was prolonged for 90 min in the presence 
of Horseradish peroxidase (HRP)-labeled goat anti-human IgG (1:15.000; Jackson Immuno 
Research) at room temperature. After washing, 100 mM citric phosphate buffer containing 
O-phenylenediamine dihydrochloride substrate (DAKO) and 0.0125% H2O2 was added. The 
subsequent coloration reaction was terminated by the addition of 11% sulfuric acid when 
appropriate. The optical density of HRP-mediated substrate conversion was quantified at a 
wavelength of 492 nm in a spectrophotometer. Titers were expressed in arbitrary optical 
density (OD) units. The correlation of the anti-RpL7/L12 ELISA and the previously used 
RpL7/L12 immunocapture MS assay (peak m/z 7888) on 24 samples from CRC patients 
and controls was 0.42 (Pearson; p=0.018) (Tjalsma et al., 2006). The average coefficient of 
variation of the ELISA assay was determined to be 2.5% by repeated measurements of 48 
samples included within this study. Anti-endotoxin IgG levels in serum were determined 
by the EndoCab ELISA assay (Hycult Biotechnology) according to the manufacturer's 
instructions. Titers were expressed as median units (MU)/ml (Barclay, 1995). For the latter 
analysis, 180 samples, including 120 polyp and CRC samples and 60 controls, were randomly 
selected from the Nijmegen and Detroit populations.
Statistical analyses
Routine statistical analysis was performed by SPSS version 16. Obtained data sets were 
normally distributed. Detailed analyses by SAS version 9.1 revealed that age was correlated 
with anti-RpL7/L12 IgG titer levels in each population at marginal levels (p=0.09 for Nijmegen 
and p=0.07 for Detroit), while gender did not show any associations. Therefore also age- 
adjusted analyses were performed. Age was imputed for 6 polyp cases in the Nijmegen group 
using the overall mean of known values in this disease group. For all tumors combined and 
their subgroups, age-adjusted means and standard errors (SE) of the titers were calculated 
using a one-way analysis of covariance (Littell et al., 2002). Age-adjusted odds ratios (OR) 
associated with the above-median titer level, which was determined separately for the 
Nijmegen and Detroit populations, were calculated by unconditional logistic regression 
model (Breslow and Day, 1980).
59
Chapter 3 - Bacterial antigen exposure in early stage CRC
Figure 1
Humoral immune response against bacterial antigen RpL7/L12. Median serum anti-RpL7/L12 
IgG levels in healthy individuals older than 50 years of age (>50y), colon polyp patients, and CRC patients 
with stage (st) I/II, stage III and stage IV tumors in the Nijmegen (A) and Detroit (B) populations. The 
Nijmegen population contains an additional healthy control group of individuals between 18 and 
25 years (18-25y) of age. Relative anti-RpL7/L12 IgG levels were expressed as optical density units 
measured at 492 nm (OD 492 nm); standard deviations are indicated. The Nijmegen (C) and Detroit 
(D) populations were divided into "healthy", "early stage CRC" (polyp and local stage I/II tumors) and 
"advanced CRC" (tumors with regional and distant metastases) for statistical analysis. Median levels, 
second and third quartile (boxes), ranges (lines) and numbers (n) of included subjects are indicated; 
significant differences of p<0.05 are indicated with "*".
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Results
Measurement of anti-RpL7/L12 serum levels in Dutch patients and controls
To evaluate whether serum anti-RpL7/L12 levels were positively associated with CRC as 
found in our previous experiments (Tjalsma et al., 2006, Tjalsma et al., 2007), the anti-RpL7/ 
L12 IgG levels were determined in 12 polyp patients, 36 stage I/II, 18 stage III and 16 stage 
IV CRC patients using a new ELISA assay (see Material and Methods Section). These levels 
were compared to the anti-RpL7/L12 IgG levels of 27 healthy blood donors (>50 years) and 
100 healthy youthful blood donors between 18-25 years of age to investigate the effect of 
age on the serum anti-RpL7/L12 levels.
At first sight, no noticeable differences in the median RpL7/L12 levels were observed when 
all cases were combined and compared with healthy controls. However, detailed analysis 
revealed a positive correlation of anti-RpL7/L12 levels with age and the presence of colon 
polyps (Fig. 1A), thus showing a positive association with increased risk for CRC. In contrast, 
a negative association of anti-RpL7/L12 levels was observed between patients with early 
stage (I/II) tumors and those with advanced stage (III and IV) disease. Both polyp patients 
and stage I/II CRC patients (here together defined as early stage CRC; Fig. 1C) contained 
the highest anti-RpL7/L12 titers, which were significantly different from those of healthy 
individuals (p=0.013) and advanced stage CRC patients (p=0.025). The age-adjusted odds 
ratios (ORs) for colorectal tumors associated with above-median RpL7/L12 titers ranged 
from 0.7 for stage III/IV tumors to 4.04 for polyps (Table 1). It should be noted that although 
the relative anti-RpL7/L12 levels between polyp and early stage CRC patients and healthy 
individuals are significantly different (Fig. 1C); this significance is lost with respect to ORs as 
these are calculated in an age-adjusted manner (see Materials & Methods section). 
Nevertheless, these data show that an increased humoral immune response to bacterial 
antigen RpL7/L12 is associated with increased risk for CRC in a Dutch population, whereas 
the immune response against this antigen in advanced stage CRC patients is similar to that 
of healthy controls.
Measurement of anti-RpL7/L12 serum levels in patients and controls 
from the U.S.A.
To confirm the apparent temporal association of the humoral immune response against 
RpL7/L12 and CRC progression as observed in the Nijmegen population, a similar but completely 
independent set of samples from CRC patients and controls from Detroit (Michigan, USA) was 
included in this study. These comprised 12 polyp patients, and 23 stage I/II, 9 stage III, and 13 
stage IV CRC patients. The serum anti-RpL7/L12 levels were compared to those of 48 healthy 
control subjects. This showed the same overall trend as observed for the Nijmegen samples 
(compare Figs. 1A and B). Compared to controls, early stage CRC patients contained significantly 
increased serum anti-RpL7/L12 levels (p=0.021; Fig. 1D). However in this population the anti- 
RpL7/L12 levels were not significantly lower in patients with stage III and IV compared to early 
stage CRC patients. The age-adjusted OR for colorectal tumors associated with above-median 
titers was the highest for early stage CRC (2.75), but also for all CRC cases the OR of 2.58 was 
significantly increased compared to the population controls (Table 1).
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Thus, these data show that increased anti-RpL7/L12 levels in patients from the U.S.A. are 
significantly associated with an increased risk for CRC and that increased anti-RpL7/L12 
levels are associated with early stage CRC irrespective of geographical location.
Table 1. Age-adjusted mean anti-RpL7/12 titer levels and age-adjusted odds ratios (ORs) 
for colorectal tumors associated with above-median titers
Population Disease status N Mean SE P-values ORa 95% CI
Nijmegen Controls 127 1.06 0.07 - 1.00 -
Colorectal tumors 82 1.05 0.10 0.993 1.90 0.49 - 2.84
Polyps 12 1.28 0.20 0.309 4.04 0.45-36.45
Cancer 70 1.02 0.10 0.836 1.07 0.44 - 2.61
Early stage 36 1.15 0.13 0.518 1.50 0.48 - 4.62
Advanced stage 34 0.90 0.12 0.352 0.70 0.25 - 1.98
Detroit Controls 48 0.95 0.10 - 1.00 -
Colorectal tumors 64 1.29 0.08 0.011 2.30 1.06 - 5.00
Polypsb 12 1.20 0.20 0.245 1.53 0.43 - 5.49
Cancerc 52 1.30 0.09 0.011 2.58 1.14 - 5.83
Early stage 23 1.31 0.14 0.042 2.75 0.96 - 7.88
Advanced stage 22 1.22 0.15 0.130 1.90 0.68 - 5.35
SE: Standard errors; P-values: in comparison with controls; CI: Confidence intervals 
o Median cutoff points were 0.93 for the Nijmegen (n=209) and 1.00 for the Detroit (n=112) populations 
(all groups combined); above-median titers (> median cutoff) for each disease group were used to 
calculate OR's.
b Detroit polyp cases were self-reported 
c Detroit cancer cases include 7 cases with stage unknown
Comparison of anti-endotoxin and anti-RpL7/L12 serum levels in CRC patients
To investigate whether the increased humoral immune response against RpL7/L12 is related 
to the fact that colon tumors make the intestinal tract more prone to bacterial infiltration 
in general, the humoral immune response to endotoxin was determined in 120 polyp and 
CRC patients and 60 healthy controls, randomly selected from the Nijmegen and Detroit 
populations, by an ELISA assay. Endotoxin is an intrinsic component of the cell wall from 
the majority of Gram-negative intestinal bacteria, and increased humoral immune response 
against endotoxin is known to be associated with decreased colonic barrier function 
(Gardiner et al., 1995a, Gardiner et al., 1995b). As shown in Figure 2A, the anti-endotoxin 
levels displayed a similar tendency as the anti-RpL7/L12 levels.
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However, in contrast to anti-RpL7/L12, the relative endotoxin antibody expression in patients with 
stage I/II tumors was markedly lower than in polyp patient. Moreover, no significant differences 
were observed in anti-endotoxin IgG levels between healthy, early stage CRC and advanced CRC 
(Figure 2B). This suggests that increased anti-RpL7/L12 levels in early CRC patients cannot be fully 
attributed to a general loss of intestinal barrier function. To further evaluate specificity of the 
observed increased anti-RpL7/L12 levels in CRC patients, these levels were also determined in 5 
patients with a systemic S. gallolyticus infection and 5 patients with an E. coli (Gram-negative) 
infection. As shown in Figure 3, anti-RpL7/L12 levels in S. gallolyticus-infected patients displayed 
a higher tendency than those in E. co/i-infected individuals. In fact, these levels matched to those 
of CRC patient with high anti-RpL7/L12 levels. On the other hand, RpL7/L12 antibody levels in 
E. coft-infected patients were higher than those of individuals with low anti-RpL7/L12 titers, 
which is indicative for a certain extent of cross reactivity between antibodies elicited by ribosomal 
proteins of E. coli and the RpL7/L12 antigen of S. gallolyticus. Taken together, the increased 
anti-RpL7/L12 levels observed in early stage CRC patients strongly point towards a selective 
interaction of S. gallolyticus and colonic tumors, however, it cannot be excluded that this is also 
the case for related bacterial species with highly homologous RpL7/L12 proteins.
Figure 2
Humoral immune response against endotoxin. (A) 
Median serum anti-endotoxin IgG levels in healthy 
individuals older than 50 years of age (>50y), colon 
polyp patients, and CRC patients with stage (st) I/II, 
stage III and stage IV tumors in samples that were 
randomly selected from the Nijmegen and Detroit 
populations. Relative anti-endotoxin IgG levels were 
expressed as Median Units (MU/ml) according to 
calibration standards of the EndoCab assay (open 
circles). The levels were compared with the anti- 
RpL7/L12 IgG levels of the same set of serum samples 
(filled circles); relative anti-RpL7/L12 IgG levels were 
expressed as optical density units measured at 492 
nm (OD 492 nm); standard deviations are indicated. 
No significant overall correlation between anti- 
RpL7/L12 and anti-endotoxin levels was observed 
(Pearson = 0.10). (B) The study population was 
divided into "healthy", "early stage CRC" (polyp and 
local stage I/II tumors) and "advanced CRC" (tumors 
with regional and distant metastases) for statistical 
analysis. Median anti-endotoxin levels and ranges 
(open bars), were compared with anti-RpL7/L12 IgG 
levels and ranges (filled bars); lines represent upper 
and lower quartiles. Numbers (n) of included subjects 
are indicated; significant differences of p<0.05 are 
indicated with "*".
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Figure 3
RpL7/L12 antibody levels in S. bovis and E. 
coli infected patients. Anti-RpL7/L12 IgG 
levels in serum samples from patients with 
proven systemic E. coli or S. bovis infections 
were compared with those in serum of a 
representative set of CRC patients. Relative anti- 
RpL7/L12 IgG levels were expressed as optical 
density units measured at 492 nm (OD 492 nm); 
median and numbers (n) of included subjects are 
indicated and significant differences of p<0.05 
are indicated with "*".
Discussion
Inspired by the results of our previous pilot study showing an enhanced immune response 
against RpL7/L12 in CRC patients (Tjalsma et al., 2006), we developed an ELISA-based 
quantitative serological assay for S. gallolyticus. The application of this anti-RpL7/L12 (IgG) 
ELISA on two independent sample collections demonstrates that anti-RpL7/L12 response 
is the most pronounced in patients with early stage colonic tumors, which cannot be fully 
attributable to impaired colonic barrier function. To our knowledge the present data show 
for the first time that specific intestinal bacteria constitute a risk factor during the early stages 
of colon carcinogenesis and may actively contribute to the progression of pre-malignant 
lesions into early stage carcinomas. However, due to the observed cross reactivity of the 
anti-RpL7/L12 ELISA, we can currently not yet pinpoint the increased humoral immune 
response to specific intestinal pathogens. It should be noted that an increased humoral 
immune response does not linearly reflect increased exposure on the individual level as 
there are many host factors that determine the strength of an immune response. However, 
RpL7/L12 antibody expression is preceded by exposure to this antigen, and we therefore 
feel that it is justified to regard the increased RpL7/L12 serum antibody levels as a marker 
for increased antigen exposure at the population level. As our observations are indicative 
for increased exposure to S. gallolyticus and possibly a subset of related intestinal bacteria, 
our current data will be discussed in view of what is known about the clinical association 
between S. gallolyticus and CRC. We hypothesize the following events to take place during 
CRC development, although we want to emphasize that most questions still remain to be 
answered. Furthermore, it should be realized that although S. bovis biotype I (most strongly 
associated with CRC) was recently renamed S. gallolyticus, we use S. bovis in this study 
where it was unclear whether the bacterial strains in the cited reference were classified 
as S. bovis biotype I or biotype II (renamed Streptococcus infantarius) (Boleij et al., 2009b,
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Corredoira et al., 2008). In healthy individuals, S. bovis incidentally enters the large intestinal 
tract where the protective mucus layer prevents direct interaction of these bacteria with 
colon epithelial cells (Johansson et al., 2008), whereas the established intestinal flora may 
prevent S. bovis to be a general inhabitant of the human gastrointestinal tract (detectable 
in ~10% of the healthy population) (Schlegel et al., 2000). Increased anti-RpL7/L12 antibody 
prevalence in older subjects compared with younger subjects observed in our control group 
may be explained by cohort effect or by impaired local immunity to clear bacteria from the 
gastrointestinal tract associated with aging. It should also be worth noting that about 20% 
of the population over age 50 years carries asymptomatic colon polyps (Bond, 2005), and 
thereby this group may acquire higher anti-RpL7/L12 titers as described below. 
Pre-malignant lesions can be initiated and progressed by carcinogenic (dietary) factors that 
diffuse through the colonic mucus layer and induce mutations within the APC or B-catenin 
genes (Cho and Vogelstein, 1992). These thereby immortalized epithelial cells are prone to 
the accumulation of other mutations and as a side effect, the aberrant epithelial physiology 
disturbs the mucus layer covering the epithelial cells (Corfield et al., 2000) and makes it 
susceptible to bacterial infiltration (Fig. 4). Pre-malignant epithelial sites may also provide a 
selective bacterial microenvironment, for instance by the excretion of specific metabolites, 
recruitment of immune cells and/or production of selective anti-microbial substances. 
Bacteria, such as S. bovis, which are unable to effectively colonize the healthy colon may 
have a competitive advantage in this microenvironment and survive for prolonged periods 
of time. These pre-malignant lesions may also provide a portal of entry for S. gallolyticus, 
which explains the increased anti-RpL7/L12 antibody and the increased occurrence of 
S. bovis endocarditis in colon adenoma patients (Boleij et al., 2009b). Late stage tumors 
entering the metastatic phase seem to change in such a way that bacterial survival on the 
tumor surface is diminished or antibody expression due to bacterial interaction is reduced. 
The possibility that tumor progression may drive bacteria out of the cancerous tissue is 
similar to what has been reported for H. pylori during gastric cancer progression (Brenner et 
al., 2007, Kang et al., 2006). If true, this phenomenon may partly account for a wide range 
(10-60%) of the prevalence of S. bovis reported for CRC patients that is comprised of various 
stages of the disease. The current data suggest that the exposure to bacterial antigen 
RpL7/L12 is accompanied by an increased risk factor for CRC during the early stages of tumor 
development. This may be explained by the fact that the interaction between bacteria and 
colorectal epithelial cells can induce inflammatory pathways (Biarc et al., 2004, Wu et al., 
2009) or carcinogenic pathways that stimulate progression of adenomas into carcinomas. 
Increased mutation rate may for instance be achieved by the bacterial conversion of dietary 
constituents into carcinogens or the toxic effects of specific bacterial metabolites (Huycke et 
al., 2002, Rescigno, 2008). On the other hand, increased bacterial interaction by for instance 
probiotic bacteria may also have a negative effect on tumor cell development (Capurso 
et al., 2006). Thus, bacterial interference may positively and negatively affect tumor cell 
progression, which may be balanced by the composition of the gut flora and dietary 
intake. The present observations, however, point towards a net increased risk for colon 
tumor development upon increased humoral immune response against bacterial antigen 
RpL7/L12. Although this risk seems low, a small increase may be relevant for the progression 
of colon adenomas to carcinomas (accumulation of mutations), a process which can take
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over a decade to take place. In this respect, it is interesting to note that the calculated ORs of 
1.50 and 2.75 for early stage CRC are within the range of those calculated for the serological 
response to a panel of Helicobacter pylori antigens in patients with early stage gastric cancer 
(ORs ranging from 1.0 - 8.9) (Gao et al., 2009).
A drawback of the current approach is the fact that the RpL7/L12 antigen is conserved within 
the bacterial community, resulting in a certain extent of cross reactivity of our serological 
assay. Furthermore, the strength of the humoral immune response to a specific antigen is 
both dependent on the immune status of the host and may vary between different infective 
strains. Finally, no data are yet available that correlate bacterial colonization of tumor tissue 
with the humoral immune response to bacterial antigens. Accordingly, our future plans 
include the identification of new S. gallolyticus-specific antigens and the development of a 
panel of preferably less conserved antigens for the detection of S. gallolyticus exposure in 
CRC patients, which will be correlated with S. gallolyticus carriage in the intestinal tract. We 
anticipate that a broader approach will yield a more specific assay that may be applied on 
an individual level. Finally, and most important, cross-sectional and retrospective studies, 
including the current study and others, are not able to address the temporal relationship 
between an exposure and a disease outcome directly. Thus, prospective studies are essential 
to elucidate the etiological roles of S. gallolyticus and other intestinal bacteria in colorectal 
carcinogenesis. These, altogether, would provide a more detailed insight in the relation 
between intestinal bacteria and the development and progression of CRC.
Exposure RpL7/L12
Figure 4
Temporal association between bacterial infection and CRC progression. The development of colorectal 
tumors is schematically depicted from left (healthy) to right (invasive and metastasizing carcinomas). 
Hallmarks are a first mutation, mostly in the APC gene, resulting in immortal adenomas and a following 
mutation that transforms adenomas into carcinomas, often in the P53 gene. We hypothesize that 
adenomas and early carcinomas provide a preferred niche for S. bovis, which leads to an increased 
exposure to RpL7/L12 as monitored by increased serum antibodies against this bacterial antigen. 
By this, S. bovis and possibly related intestinal bacteria may specifically interfere with early colon 
carcinogenesis, whereas tumor progression may drive these bacteria out of advanced cancerous tissue 
(see text for details).
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Chapter 4 - CRC-associated IgG response to bacterial pilins
Abstract
Streptococcus gallolyticus subsp. gallolyticus (previously called Streptococcus bovis biotype
I) infections have long been associated with colorectal cancer (CRC). This work aimed to 
investigate the CRC-associated humoral immune response to four pilus proteins of this 
bacterium by newly developed ELISA assays. Pilus proteins are interesting diagnostic targets 
as they are the building blocks of pilin-like structures that mediate bacterial virulence and 
are readily exposed to the host immune system upon infection. The presence of serum 
antibodies against these pilus proteins was evaluated in Dutch and American populations. 
These analyses showed that an immune response to these antigens was specific for 
clinical S. gallolyticus subsp. gallolyticus infections, but that increased serum antibody 
titers to multiple pilus proteins in single individuals were rarely observed. However, a 
multiplex approach based on antibody titers against any of these four antigens resulted 
in assay sensitivities between 16-43% for the detection of early stage CRC. Together these 
findings underscore the potential of a multi-antigen approach to complement diagnosis of 
S. gallolyticus subsp. gallolyticus-associated CRC.
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Introduction
The human gastrointestinal tract is the habitat for a large and dynamic bacterial community, 
which is essential for digestion of food and the control of intestinal epithelial homeostasis 
(Guarner and Malagelada, 2003, Qin et al., 2010). Remarkably, although hundreds of 
bacterial species reside in the human intestinal tract, only the opportunistic pathogen 
Streptococcus gallolyticus subsp. gallolyticus (S. bovis biotype I), seems to benefit from the 
presence of (pre-) malignant colonic lesions to invade the human body (Burnett-Hartman 
et al., 2008, Corredoira et al., 2008, Guarner and Malagelada, 2003, Klein et al., 1979, Klein 
et al., 1977, zur Hausen, 2006). In this respect, S. gallolyticus subsp. gallolyticus can be 
regarded as a whistleblower for CRC as multiple studies showed that a (precursor of) CRC 
is detected in 33-100% of the individuals that undergo full bowel examination following 
diagnosis of this infection. Notably, our recent meta-analysis showed that this percentage 
is far above the prevalence of this disease in the asymptomatic age-matched population 
(Boleij et al., 2011b). S. gallolyticus subsp. gallolyticus is a known causative agent for 
infective endocarditis (IE), however, due to its mild virulence characteristics this bacterium 
can only establish a clinical infection in patients with pre-existing heart valve abnormalities. 
Molecular studies suggested that S. gallolyticus subsp. gallolyticus is relatively invisible for 
the innate immune system due to its inert surface structure (Boleij et al., 2011a, Hirota et al., 
1996), (our unpublished observations), which implies that S. gallolyticus subsp. gallolyticus 
may cause subclinical infections in a substantial part of CRC patients (Haimowitz et al.,
2005). The latter idea was supported by our previous finding that the humoral immune 
response against the ribosomal protein (Rp) L7/L12 from S. gallolyticus subsp. gallolyticus 
was significantly increased in early stage CRC patients (Boleij et al., 2010, Tjalsma et al., 
2007, Tjalsma et al., 2006), which is indicative for an increased exposure to this bacterium. 
However, a drawback of this approach was the fact that the high conservation of this antigen 
in the bacterial kingdom was associated with a considerable amount of cross-reactivity in 
the immunoassay (Boleij et al., 2010).
The current study aimed at the development of new ELISAs exploiting antigens that are 
specific for S. gallolyticus subsp. gallolyticus strains. These candidate antigens concerned 
four cell wall peptidoglycan-anchored proteins that form pilin-like structures on the S. 
gallolyticus subsp. gallolyticus cell surface (Telford et al., 2006). Two of these proteins, 
annotated Gallo2178 (major pilin) and Gallo2179 (collagen-binding adhesin) are encoded 
by the pill locus that also encodes a sortase (Gallo2177) which is specifically responsible 
for the polymerization of these two LPxTG into a pilus structure. The pill locus is present in 
the majority of clinical S. gallolyticus subsp. gallolyticus IE isolates and involved in binding to 
collagen type I, biofilm formation and virulence in a rat model of experimental endocarditis 
(to be published elsewhere). Interestingly, collagen I-binding capacity has also been 
proposed as a distinguished virulence feature of S. gallolyticus subsp. gallolyticus strains 
to facilitate its adherence to (pre-)malignant colonic sites (Boleij et al., 2011a). Collagen- 
binding is likely to be mediated by Gallo2179, which contains a collagen-binding domain. 
The other two candidate antigens, Gallo1569 and Gallo2039, are major pilins related to 
Gallo2178, but encoded by the pil2 and pil3 operons, respectively (Rusniok et al., 2010).
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The pil2 operon has a low conservation among S. gallolyticus subsp. gallolyticus strains, 
whereas homologous pil3 operons can also be found in Streptococcus infantarius subsp. 
infantarius strains. Our current data showed that ELISAs with these four antigens were 
indeed specific for S. gallolyticus subsp. gallolyticus infections. Furthermore, our data 
showed a highly selective humoral immune response to these antigens in CRC patients. 
However, a multimarker approach could identify a substantial number of these patients. 
This finding argues in favor of developing extended multiplex assays based on specific 
antigens from CRC-associated bacteria as screening tool for CRC.
Materials and methods 
Patient material
Blood samples were derived from the same collections as used before in our studies (Boleij 
et al., 2010). However, here we primarily focused on the early stages of CRC (i.e. colorectal 
adenomas and local stage of colorectal cancer). Serum samples from 37 CRC, 12 polyp 
patients (6 adenomas, 2 villous adenomas and 4 undefined polyps) and 15 patients with a 
clinical bacterial infection (E. coli (3), K. pneumonia (3), S. typhimurium (3) S. pneumonia (3) 
or S. gallolyticus subsp. gallolyticus (3; CRC diagnosed in 1 patient) who had been admitted 
to the Radboud University Nijmegen Medical Centre (Nijmegen, The Netherlands) were 
used. Patients suffering from bacterial infections were recognized as such by a positive 
blood culture and routine microbial typing. As control samples, serum from 27 healthy 
blood donors (>50 years), who not underwent colonic evaluation, was used. In addition, 
plasma samples from 33 CRC, 11 polyp patients and 47 healthy controls who participated 
in a population-based case-control study in Metropolitan Detroit (USA), were included as a 
second independent study population. CRC samples concerned localized disease (stage I or
II), with the exception of 7 Detroit cases with unknown stage. All cases in both the Nijmegen 
and Detroit population underwent colonic evaluation. The use of the samples was approved 
by the Medical Ethical Committee of Nijmegen/Arnhem (#2006/078) and Wayne State 
University Human Investigation Committee (#0409000504); informed consent was obtained 
when required. Serum and plasma samples were stored at -80 °C until use.
Antigen overproduction and purification
DNA fragments internal to gallo2179, gallo2178, gallo2039 and gallo1569 were produced 
by PCR using genomic DNA of UCN34 strain as template and the primers described in Table 
1. These DNA fragments were digested with the appropriate enzymes (Nhe\/Nde\ and 
SamH1) and cloned into pET28-a(+) (Novagen). The resulting plasmids were introduced 
into E. coli strain DH5a for sequence analysis or BL21(ADE3) for protein expression. 
For overproduction, cells were grown aerobically at 37°C until OD600nm=0.4 after which 
recombinant gene expression was induced by 1 mM isopropyl-D-thiogalacto-pyranoside 
(IPTG). Recombinant His-tagged antigens were purified (>95%) under native conditions by 
affinity chromatography using the Nickel-NTA columns according to the manufacturers'
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recommendations (Novagen). Cell lysates and isolated protein fractions were analyzed by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and accurate protein concentrations 
were determined with the BCA system (Pierce) prior to use in ELISA assays.
Table 1. Primers used to construct expression plasmids for recombinant protein production
4
Name Sequences 5'® 3'1 Size Amplified fragment
gallo2178-MeI AG CT GCTAGCTAT GATATTACTGTTGAGAACGGT 1293 bp
gallo2178-SarnH1 GTTCCGGATCCTCAAGTTGAAGGAAGTGTTGC 1293 bp
gallo2179-MeI GAAGTAGCTAGCGCT GATGTTAGTAAT CGT GTA 1807 bp
gallo2179-SarnH1 TAATGGATCCTCAACCTGTATTAGGGAATAG 1807 bp
gallo1569-MeI AAAGCCGCTAGCGATGAGT CAACTTATACG 1370 bp
gallo1569-SarnH1 GTTCCGGATCCTCAAGTTGAAGGAAGTTTTGAACC 1370 bp
gallo2039-WdeI GCAGTACATATGCAAACAGTTGACTCAGGT 1283 bp
gallo2039-SarnH1 CCAAAGGATCCT CATGAAGGCAATT CTGCACC 1283 bp
1 restriction sites used for cloning are in bold
ELISA measurements
ELISAs were build and performed as described before (Boleij et al., 2010). A few improvements 
were made as we observed that background levels due to non-specific binding of serum 
immunoglobulins to the ELISA plate could vary significantly between samples. First, after 
antigen (AG) coating for at least 18 hours at 4°C, the well was extensively blocked by 1% 
bovine serum albumin (BSA) in PBS-Tween20 (0.1%) for 2 hours at 37°C. In addition, for 
each antigen-coated well, a duplicate well on the same plate was incubated in coating 
buffer without antigens and subsequently blocked with 1% BSA (blank). Finally, 1% BSA was 
added to all incubation buffers that were used during the ELISA measurements. The optical 
density of HRP-converted TMB-substrate was quantified at a wavelength of 450 nm in a 
spectrophotometer. Samples were measured in duplicate and titers of a specific sample 
were calculated as the mean 0D450AG - 0D450bfank and expressed as arbitrary S. gallolyticus 
units (SGU) based on a reference sample from a S. gallolyticus-infected patient that was 
measured in every plate. Titers were set to zero in case of negative values.
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Results
Specific humoral immune response to S. gallolyticus pilus proteins
The current study aimed at the development of new ELISA-based assays exploiting 
antigens that are specific for S. gallolyticus subsp. gallolyticus strains (further designated as 
S. gallolyticus) (Boleij et al., 2011b). To this purpose, purified pilus proteins Gallo1569, -2039, 
-2178 and -2179 from S. gallolyticus were used as IgG-capturing antigens in an ELISA setup. 
To evaluate whether an antibody response to these antigens was specific for S. gallolyticus 
infections, the corresponding serum IgG levels were determined in serum from patients 
exhibiting various clinical bacterial infections. As shown in Figure 1, the anti-Gallo2178 and 
-2179 IgG levels in serum from two out of three S. gallolyticus infected patients were several 
order of magnitude higher than those in control patients infected with Escherichia coli, 
Klebsiella pneumoniae, Salmonella typhimurium or Streptococcus pneumonia infections. 
For the Gallo2039 antigen, this was only observed in one patient. The anti-Gallo1569 IgG 
levels were mildly increased in serum from all three S. gallolyticus-infected individuals, but 
they showed superior discrimination between S. gallolyticus and the other clinical bacterial 
infections. These data clearly illustrate that an antibody response to these antigens could 
be a useful clinical marker of S. gallolyticus infection. However, it also clearly points out that 
this humoral immune response has a high inter-individual variation.
Figure 1. Pilin antibody levels in patients with systemic bacterial infections
Anti-Gallo1569, -Gallo2039, -Gallo2178 and -Gallo2179 IgG levels were measured in serum samples 
from patients with clinical infections with E. coli (Eco; n=3), K. pneumonia (Kpn; n=3), S. typhimurium 
(Sty; n=3) S. pneumonia (Spn; n=3) or S. gallolyticus (Sga; n=3). Anti-pilin IgG levels were expressed as 
arbitrary S. gallolyticus units (SGU). The data from S. gallolyticus-infected patients are differentially 
marked to allow assessment of the intra-individual differences in the responses to these four antigens.
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Figure 2. Pilin antibody levels in patients with CRC and asymptomatic controls
Anti-Gallo1569, -Gallo2039, -Gallo2178 and -Gallo2179 IgG levels were measured in serum (Nijmegen 
population) and plasma samples (Detroit population) from polyp and CRC patients and in samples from  
asymptomatic age-matched controls. Anti-Pilin IgG levels were expressed as arbitrary S. gallolyticus 
units (SGU); median levels are indicated. Nijmegen population: controls (n=27); polyp patients (n=12); 
CRC patients (n=37); Detroit population: controls (n=47); polyp patients (n=11); CRC patients (n=33). 
Cutoff values used to calculate assay specificity as indicated in Table 2 are indicated as dashed lines; 
upper line reflects 100% specificity (no positive controls); lower line reflects 78% specificity (i.e. the 
95 percentile in each control group) which adjusts for a 22%-incidence of polyps in the control group.
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Selective humoral immune response to S. gallolyticus pilus proteins in 
CRC patients
To investigate whether subclinical infections with S. gallolyticus can be monitored in CRC 
patients by the developed pilus ELISAs, serum/plasma from polyp and early stage CRC 
patients and asymptomatic age-matched individuals from the Nijmegen (serum) and Detroit 
(plasma) populations (Boleij et al., 2010) were measured. As shown in Figure 2, the IgG titers 
in serum/plasma of CRC patients did never reached those observed in patients with a clinical 
S. gallolyticus infection. In addition, no significant differences were observed between the 
polyp, CRC and control groups. However, with a few exceptions, the highest IgG titers were 
observed in serum/plasma from CRC patients.
Table 2. Sensitivity and specificity of S. gallolyticus pilin-based ELISA assays for the 
detection of CRC1
Nijmegen (49 cases and 27 non-cases) Detroit (44 cases and 47 non-cases)
Antigen
Positive cases 
Cutoffs /non-cases2 Sens Spec
Positive cases 
Cutoffs /non-cases2 Sens Spec
A
Gallol569
Gallo2039
Gallo2178
Gallo2179
6.6 3/0 6% 100% 
6.9 2/0 4% 100%
4.6 2/0 4% 100% 
19.2 2/0 4% 100%
7.7 2/0 5% 100% 
9.5 3/0 7% 100% 
5.1 4/0 9% 100% 
34.0 0/0 0% 100%
Any of the above 8/0 16% 100% 7/0 16% 100%
B
Gallol569
Gallo2039
Gallo2178
Gallo2179
4.9 5/2 10% 93%
4.9 2/2 4% 93% 
3.7 3/2 6% 93% 
9.2 5/2 10% 93%
4.6 6/4 14% 92%
6.7 8/4 18% 92% 
2.0 7/4 16% 92% 
12.4 3/4 7% 92%
Any of the above 10/6 20% 78% 19/10 43% 78%
‘CRC includes both polyps and tumor cases; the lower cutoff value in B represents the 95 percentile in each 
control group
2Number of cases and non-cases above the specified ELISA cut-off
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The potential of S. gallolyticus pilus antigens for CRC diagnostics
To assess to which extent an antibody response to S. gallolyticus pilus proteins can be 
instrumental in the diagnosis of CRC, a simple strategy was employed in which the highest 
IgG level in the control group was used as cutoff value for the diseased groups. This implicates 
that the assay has a 100% specificity as all controls are classified as not diseased. Table 
2A shows that no single antigen has clear superior diagnostic value over another and the 
sensitivity for polyps or CRC is only marginally when assessed for single pilin antigens. The 
highest sensitivity for CRC (4 positive identifications; 9%) was obtained for IgG titers against 
Gallo2178 in the Detroit population. When a combined approach was used in which antibody 
titers against any one of the 4 pilus antigens was considered to be diagnostic for polyps or 
tumours, the sensitivity for both the Nijmegen and Detroit populations was increased to 
16%. As about 22% of the asymptomatic elderly population carries polyps (Lieberman et 
al., 2000), which may form a portal of entry for S. gallolyticus, the sensitivity of the ELISAs 
for CRC was calculated using lower cutoff levels (i.e. 95 percentile in each control group), 
that correspond to an overall specificity of about 78%. As shown in Table 2B, this yielded an 
increased sensitivity of 20% in the Nijmegen population and 43% in the Detroit population. 
Figure 3 shows that most of these positive cases were diagnosed by increased IgG titers 
against only one of the four antigens. An immune response to two, three or four antigens 
was only detected in respectively, 15%, 4% and 2% of the cases. These data exemplify the 
added value of a multi-marker approach for the detection of CRC based on bacterial antigens.
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Figure 3. Distribution of anti-Pilin IgG levels.
From the cases that were positively diagnosed at a specificity level of ~78% (Table 2B), the number of 
antigens to which IgGs were detected, were plotted against percentage of cases.
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Discussion
Inspired by the results of our previous studies that were indicative of an increased exposure 
to S. gallolyticus antigens in early stage CRC patients (Boleij et al., 2010), we here aimed at 
the development of ELISAs for the specific detection of human infections with this bacte­
rium and the assessment of their utility for CRC diagnosis.
Four pilus proteins from S. gallolyticus were purified and used to develop ELISAs to measure 
the corresponding serum IgG levels. Pilus proteins are surface-exposed and perform key 
functions during infection and are quite specific for S. gallolyticus. This is for instance reflected 
by the unique collagen-binding capacity of this bacterium mediated by Gallo2179, which is 
absent in the closely related bacteria S. infantarius subsp. infantarius and Streptococcus 
gallolyticus subsp. macedonicus (Boleij et al., 2011a). Notably, homologues of Gallo2039 
are also found in related species, which implies that an antibody response against this 
antigen could be associated with a decreased specificity for S. gallolyticus subsp. gallolyticus 
infections. Interestingly, the ELISAs based on Gallo2039 did indeed yield the highest average 
IgG levels, which was most prominently observed in the Detroit population (Figure 2). 
For the other three antigens, the corresponding IgG levels were in most individuals not 
significantly increased compared to the background (blank) level, which underscores the 
specificity of the strong response that was observed in a minority of CRC cases.
The responses in patients with known clinical S. gallolyticus infections show a variable IgG 
response (Figure 1), which could be due to the individual status if the immune system and/ 
or strain-specific differences in pilus expression (to be published elsewhere). It should be 
realized that bacterial pilin expression and the corresponding immune response are likely to 
be different during local infiltration of the bowel wall (subclinical infection) in CRC patients. 
However, based on the three S. gallolyticus-infected patients, we may estimate that no 
more than 66% of infected patients can be distinguished as such based on increased IgG 
levels to any of the four pilus antigens tested. The maximum sensitivity for the diagnosis of 
CRC is further decreased by the fact that the presence of S. gallolyticus in the large bowel 
of CRC patients may not exceed 50% , while the presence of genomic DNA of this bacterium 
in tumour tissue samples was reported to be around 35% (Abdulamir et al., 2010, Klein et 
al., 1977). Based on these findings, the estimated limit of the current four S. gallolyticus 
pilus antigen-based approach for CRC detection would lay between 35-50%. Promisingly, 
our current data are indicative of an assay sensitivity between 20-43%, assuming that it 
is also diagnostic for adenomatous polyps with a prevalence of about 22% in the general 
elderly population (see Table 2).
Evidently, the above assumptions need to be validated with a properly designed study 
using serum samples from colonoscopy-controlled samples from healthy individuals, CRC 
patients as well as from patients with inflammatory bowel disease (IBD), who have reported 
bowel colonization rates in between healthy controls and CRCpatients (Klein et al., 1977). 
Furthermore, the re-assessment of bowel colonization of S. gallolyticus and its association
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with IBD, CRC and adenoma tissues are both subjects of our ongoing investigations. To 
further increase the detection of CRC with this antigen approach, additional S. gallolyticus- 
specific antigens should be added to the here presented panel of four antigens, together 
with antigens from other CRC-associated bacteria and/or CRC tumor antigens (Tjalsma, 2011, 
Tjalsma, 2010). Finally, the specificity of this multi-antigen approach should be validated in 
serum from patients having clinical infections with related Gram-positive pathogens (e.g. 
enterococcal infections), which is also among the subjects of our ongoing investigations. 
Nevertheless, our current proof-of-concept study clearly shows that S. gallolyticus pilus 
proteins are promising antigens to aid in the immunodiagnosis of S. gallolyticus-associated 
CRC.
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Abstract
Proteolytic treatment of intact bacterial cells has proven to be a convenient approach for the 
identification of surface-exposed proteins. This class of proteins directly interacts with the 
outside world, for instance during adherence to human epithelial cells. Here we aimed to 
identify host receptor proteins by introducing a pre-incubation step in which bacterial cells 
were first allowed to capture human proteins from epithelial cell lysates. Using Streptococcus 
gallolyticus as model bacterium, LC-MS/MS analysis of proteolytically released peptides 
yielded the identification of a selective number of human epithelial proteins that were 
retained by the bacterial surface. Of these potential receptors for bacterial interference, 
(cyto)keratin-8 (CK8) was verified as most significant hit and its surface localization was 
investigated by subcellular fractionation and confocal microscopy. Interestingly, bacterial 
enolase could be assigned as an interaction partner of CK8 by MS/MS analysis of cross-linked 
protein complexes and complementary immunoblottng experiments. As surface-exposed 
enolase has a proposed role in epithelial adherence of several gram-positive pathogens, 
its interaction with CK8 seems to point towards a more general virulence mechanism. In 
conclusion, our study shows that surface-affinity profiling is a valuable tool to identify novel 
adhesin-receptor pairs which advocates its application in other hybrid biological systems.
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Introduction
The key to bacterial infection of host tissue is the establishment of a dependable connection 
between the bacterium and host surface structures. This is essential to withstand 
mechanical cleansing processes and to compete with other bacterial strains for microbial 
succession (Gill, 2003). After initial adherence, several pathogens can invade host cells 
using intracellular structures, e.g. the cytoskeleton, to sustain growth and prolong their 
survival time (Bonazzi and Cossart, 2006, Cossart and Sansonetti, 2004). Ultimately, both 
adhesion and internalization of pathogenic bacteria will directly, or indirectly via induction 
of host responses, cause damage to the infected tissue. It is therefore important to fully 
understand the mechanisms underlying pathogenic interference, so that new methods 
to prevent pathogenic bacteria from initiating an infectious process can be developed. In 
addition, knowledge on pathogen-specific interactions and subsequent responses may aid 
in the diagnosis of corresponding diseases.
Current advances in proteomic technologies provide opportunities to compare the protein 
content from different biologic systems making it possible to characterize host-pathogen 
interactions in a global view. Therefore, the aim of this study was to explore the use of a 
proteolytic shaving approach coupled to liquid chromatography tandem mass spectrometry 
(LC-MS/MS) to identify potential host proteins for bacterial interference. To this purpose, 
intact bacterial cells were first allowed to selectively bind host proteins from epithelial cell 
lysates after which their surface was proteolytically shaved to generate small polypeptides 
that can be directly identified by LC-MS/MS (Tjalsma et al., 2008, Tjalsma et al., 2006). 
Importantly, peptides of host proteins can be effectively recognized and discriminated 
from the bulk of bacterial peptides by computer-assisted analysis of the identified peptide 
sequences.
To obtain proof-of-concept for this approach, the interaction between the Gram-positive 
bacterium Streptococcus gallolyticus (subsp. gallolyticus) and human colonocytes was 
used as a model system. Streptococcus gallolyticus is an inefficient colonizer of the healthy 
human large intestinal tract, but has long been associated with colorectal cancer (CRC) and 
endocarditis (Boleij et al., 2009b, Boleij et al., 2011b, zur Hausen, 2006). Our recent work has 
indicated that malignant epithelial sites may provide a route of infection for this bacterium 
via CRC-specific adhesion and translocation mechanisms (Boleij et al., 2011a, Boleij et al., 
2009a, Henry-Stanley et al., 2005). Therefore, knowledge on specific epithelial receptors for 
either invasion or adhesion of S. gallolyticus could provide novel insight into the association 
of S. gallolyticus with colonic malignancy.
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Materials and methods 
Bacterial strains and media
The strains used in this study were Streptococcus gallolyticus subsp. gallolyticus UCN34 
(further entitled as S. gallolyticus) that was previously isolated from a CRC patient with a co­
incidental endocarditis (Rusniok et al., 2010), and the intestinal strain Enterococcus faecalis 
(ATCC19433). Strains were cultured in Brain Heart Infusion Broth (BHI; Difco laboratories) 
supplemented with 1% glucose at 37°C/5% CO2.
Cell lines
Adherent monolayers of HT-29, Caco-2 and HCT116 colon adenocarcinoma cells were grown 
in Dubecco's Modified Eagle's Medium (DMEM, lonza) supplemented with 10% FCS, 20 mM 
HEPES, 100 nM non-essential amino acids and 2 mM L-Glutamine (Gibco) at 37°C/5% CO2. 
Cells were maintained at logaritmic growth by subculturing them every 3-5 days.
Cell affinity profiling
For cell affinity profiling, HT-29 cells were washed three times with phospate buffered sa­
line (PBS; pH 7.4) and lysed by a 5 min incubation in 2.5 ml M-PER lysis reagent (Pierce) at 
room temperature. Soluble colonocyte proteins in the supernatant were harvested (P2), 
whereas insoluble proteins present in the pellet after centrifugation were solubilised by PBS 
containing 2% Triton X-100 (P1). Both protein fractions were aliquoted and stored at -80°C 
until use. S. gallolyticus bacteria were grown overnight, resuspended 1:20 in fresh medium 
and grown for another 5 hours. Next,109 intact bacterial cells were washed with sterile PBS 
and incubated with above described HT-29-derived protein fractions, diluted to 100 ^g/ 
ml in sterile PBS containing 0.1% Triton X-100 (soluble protein fraction, P2) or 2% Triton 
X-100 (insoluble proteins, P1), for 1 hour at room temperature. As control experiments, the 
same procedure was performed with the soluble (C2) and insoluble (C1) fractions incubated 
without bacteria, while S. gallolyticus cells were also incubated in the absence of HT-29 
proteins (C3). Since our main goal was to screen if this assay could be used to identify host 
proteins with affininty for bacterial surface components we only used one biological repli­
cate per condition, which was compensated by a thorough biochemical valididation of a 
selected candidate. After incubation, bacteria were collected by centrifugation and washed 
twice with the corresponding incubation buffers containing 0.1% or 2% Triton-X100 and 3 
times with PBS without detergent. Bacterial cells were resuspended in PBS containing 10 
units trypsin (sequencing grade; Sigma-Aldrich) and incubated for another hour at 37°C un­
der gentle shaking. Next, cells were pelleted by centrifugation, after which the supernatant 
containing released peptides and protein fragments were treated with 1 mM dithiothreitol 
(DTT) and 1 mM iodoacetamide in two successive steps of 30 min at room temperature. 
Fresh trypsin was added and tryptic cleavage was continued for 18 hours at 37°C.
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LC-MS/MS
Prior to nanoLC-MS/MS analysis, all peptide samples were purified and desalted using C18 
spin columns (Pierce) and Triton-X100 was removed using anti-Triton beads (Calbiochem). 
NanoLC-MS/MS analysis was performed on an Agilent nanoflow 1100 liquid chromato­
graph coupled on-line to a 7T linear quadrupole ion trap Fourier transform ion cyclotron 
resonance mass spectrometer (LTQ-FT, Thermo Fisher, Bremen, Germany). Peptides were 
loaded directly onto the analytical column using buffer A and eluted using buffer B (see Ad­
dendum 1) at a flow-rate of 300 nl/min. Peptides eluting from the column tip were injected 
into the mass spectrometer via a nano-spray ion source using a spray voltage of 2.1 kV. The 
mass spectrometer was operated in positive ion mode using data-dependent fragmentation 
to analyze the top 4 most abundant ions from each precursor scan. For detailed information 
on NanoLC-MS/MS analysis and MS settings see Addendum 1.
Fragmentation and precursor data were parsed from the RAW files by ExtractMSn (Thermo 
Fisher) and converted into a Mascot generic peaklist. Peptides and proteins were identified 
using the Mascot algorithm (Mascot 2.2; Matrix Science) to search a local copy of human 
RefSeq database (release 33) combined with the S. gallolyticus protein database (provided 
by P. Glaser) (see Addendum 1 for data analysis settings). The following modifications were 
allowed in the search: carbamidomethylation of cysteines (fixed), oxidation of methionine 
(variable) and deamidation of asparagine and glutamine (variable). After searching, the 
peptides matching to human proteins were validated using the criteria that are summarized 
in Addendum 1.
CK8 binding assay, SDS-PAGE and Western Blot analysis
To monitor affinity of cytokeratin-8 (CK8), intact bacteria (S. gallolyticus and E. faecalis) were 
incubated with colonocyte fractions as indicated before. After washing 3 times with PBS, 
bacterial cells were directly incubated in SDS-sample buffer (50 mM Tris-HCl pH 6.0, 2% SDS, 
5% p-mercaptoethanol and 10% glycerol) and incubated for 15 min at 95°C prior to 10% 
glycine SDS-polyacrylamide gel electrophoresis (SDS-PAGE)(Towbin et al., 1979).
To determine subcellular localization of CK8, the colon adenocarcinoma cell lines were 
fragmented into four fractions: cytosolic (FI), membrane and organelle (FII), nucleic (FIII) and 
cytoskeleton (FIV) protein fractions using the S-PEK kit (Calbiochem, Subcellular proteome 
extraction kit). Subcellular protein fractions (20 ^g) were separated by SDS-PAGE. For 
detection of CK8, proteins were transferred to polyvinylidene fluoride (PVDF) membranes 
(Amersham) by Western blotting (Towbin et al., 1979). Blots were incubated with monoclonal 
rabbit-anti-keratin 8 antibodies (Abcam) diluted 1:25000, or polyclonal rabbit-anti-CYP1A1 
antibody diluted 1:5.000 (Millipore). CYP1A1, a typical membrane protein with an amino- 
terminal membrane anchor that resides in the endoplasmic reticulum, was used to 
determine the effectiveness of subcellular proteome fractionation. Bound antibodies were 
visualized with the ECL detection system (Amersham) using anti-rabbit IgG HRP conjugates 
diluted 1:25000 (Jackson ImmunoResearch).
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In Cell Western (ICW) analysis
96-wells plates were coated with intact S. gallolyticus or E. faecalis cells (1x10A9/ml) that 
were harvested during the exponential growth phase (OD 0.6) to investigate the binding 
of CK8. Briefly, bacteria were incubated with 10 ^g protein fraction FII of HT-29, HCT116 
and Caco-2 cells in PBS at room temperature for 1 hour while gently mixing. Next, bacteria 
were pelleted and resuspended in PBS and allowed to attach to a poly-L-lysine coated 96- 
well plate at 4°C overnight. The coated plates were washed with PBS and fixed with 3.7% 
formaldehyde before blocking with 5% BSA. CK8 bound to bacterial cells was detected with 
monoclonal rabbit-anti-CK8 antibody and visualized with the Odyssey (Li-COR biosciences) 
using a secondary anti-rabbit antibody conjugated with Alexa Fluor 800 (Molecular Probes). 
The DNA stain DRAQ5 (invitrogen) was used as reference to control for the amount of cells.
Confocal microscopy
HT-29, Caco-2 and HCT116 cells were seeded onto coverslips in 6-well plates for 24 hours 
at 37°C. Then cells were fixed with 3.7% formaldehyde and either left intact or made 
permeable by 4 washes with PBS 0.3% triton. Next, cells were blocked with 5% BSA in PBS 
and subsequently incubated with rabbit-anti-cytokeratin-8 antibodies (1:500) overnight 
at 4°C. Cells were washed 3 times with PBS/0.3% triton and stained with goat-anti-rabbit 
antibodies conjugated with alexa fluor 488. The DNA stain DRAQ5 was used to stain the 
nucleus. CK8 was visualized with laser scanning confocal microscopy (Olympus FV1000).
Cross-linking of recombinant CK8 to bacterial surface proteins
S. gallolyticus and E. faecalis were grown overnight, diluted 1:10 in fresh culture medium 
and incubated for 4 hours at 37°C 5% CO2. After centrifugation at 4000g for 10 minutes, the 
bacterial pellet was washed three times with PBS to remove loosly bound proteins. The cells 
were resuspended in 500 ^l PBS containing 8 ^g of recombinant CK8 (PROGEN Biotechnik) 
for 1 hour at RT while gently shaken. Next, bacterial cells were washed three times with 
incubation buffer to remove loosely bound proteins. Bound recombinant CK8 protein was 
cross-linked to the bacterial cell wall with 2 mM DTSSP (Pierce), washed three times with 
incubation buffer and subsequently boiled in SDS-sample buffer with or without DTT to 
either disrupt or conserve the cross-linked protein complexes. Cross-linked recombinant 
CK8 was visualized with SDS-PAGE and Westernblotting.
Immunoprecipitation of cross-linked protein complexes containing CK8
For the immunopreciptation of CK8 containing cross-linked protein complexes, bacteria 
were lysed in 10 mM Tris-buffer containing 2 mM MgCl2, 3 mg/ml lysozyme (Fluka) and 100 
^g/ml mutanolysin (Sigma-aldrich) for 60 minutes at 37°C. Then 1% Triton and protease 
inhibitors were added to the lysate and samples were sonicated on ice with intervals of 
0.3 sec for 20 sec (2 runs; 2x 30 pulses). To remove bacterial DNA, samples were incubated 
with benzonase for 30 minutes on ice and subsequently spun at max speed for 30 minutes 
at 4°C. Supernatants were incubated with anti-rabbit CK8 antibody (1/100) overnight at 
4°C while shaking. Next, antibodies were precipitated with Prot G Magna beads (Thermo 
Scientific) for 2 hours at RT. Beads were washed 3 times with PBS/0.1% Triton after which
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immunoprecipitated cross-linked protein complexes were boiled in electroforeses buffer 
at 100°C for 5 minutes and analysed on a 7.5% SDS-PAGE after staining with blue-silver 
coomassie (Candiano et al., 2004). Alternatively, proteins were blotted on PVDF membrane 
to control the cross-linking with monoclonal rabbit-anti-keratin 8 antibodies (Abcam) diluted 
1:25000, or polyclonal rabbit-anti-enolase antibodies (generously provided by V. Pancholi) 
diluted 1:10.000. Antibodies were visualized using the ECL detection system as described 
previously.
Analysis of protein complexes by vMALDI-LTQ MS/MS
Cross-linked protein complexes were excised from SDS-PAA gels for in-gel trypsin-digestion 
as described previously (Ettwig et al., 2010). After digestion, peptides were extracted by 
sonication in a water bath for 15-20 seconds, concentrated using a centrifugal evaporator, 
and diluted 1:1 with 2% trifluoroacetic acid (TFA). Next, samples were spotted on a stainless 
steel MALDI plate. Sample analysis was performed on a a linear ion trap fitted with an 
intermediate pressure matrix-assisted laser-desorption ionization source (vMALDI-LTQ; 
Thermo Fisher Scientific) (Guillard et al., 2009). In total, 5 full MS runs were analysed, each 
resulting in a selection of the 10 highest peaks that were further analysed by collision- 
induced dissociation fragmentation analysis. Generated RAW-data files, were analysed with 
SEQUEST (Ver. 28 Rev. 12) and identifications were considered significant with a peptide 
probability > 1e-002, and a protein probability > 1e-003. For further details on MALDI-MS 
analysis, data analysis settings and validation criteria see Addendum 2.
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Results
Profiling eukaryotic proteins with affinity for the bacterial cell surface
The main aim of this study was to provide proof-of-concept for the use of a surface-shaving 
LC-MS/MS approach to identify host proteins with affinity for intact bacterial cells. To 
this purpose, eukaryotic proteins from HT-29 intestinal epithelial cells were first allowed 
to interact with intact S. gallolyticus cells, after which firmly attached host proteins were 
released by tryptic digestion of surface-exposed proteins and protein complexes (Figure 1).
A
Figure 1. Schematic representation of the 
bacterial surface affinity profiling approach by 
proteolytical shaving coupled to LC-MS/MS
S. gallolyticus cells were incubated with host proteins 
fractions P1/P2 or without eukaryotic host proteins.
Control conditions concerned the incubation of the 
respective host protein fractions without S. gallolyticus 
cells (C1/C2) to check for protein precipitates, and 
a control for "contaminating" proteins that are not 
derived from the added host protein pool (C3). After 
washing, the bacterial surface was shaved with 
trypsin to release peptides from accessible proteins.
Protein fragments in the supernatants were further 
cleaved with trypsin for 18h and purified for LC-MS/
MS analysis (A). Subsequent database searches 
resulted in the identification of 27 proteins of which
11 proteins were assigned as candidate receptors for 
bacterial interference (see Table 1).
As expected, shotgun MS/MS analysis of the released peptides resulted in the identification of 
both bacterial and eukaryotic proteins. Candidate targets for bacterial interference (samples 
P1 and P2) were discriminated from protein precipitates originating from eukaryotic cell lysates 
that could co-fractionate with intact bacterial cells during centrifugation (samples C1 and C2) 
and "contaminating" proteins (sample C3); see Methods section "Cell affinity profiling" for 
details on these samples. A total of 27 eukaryotic proteins fulfilled the protein identification
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criteria (see supplementary Addendum 1 and 2). Proteins were ranked according to delta 
emPAI values that were generated by substracting the emPAI value of the control samples C1 
or C2 from the corresponding experimental samples P1 or P2 (Table 1). Next, proteins that 
were identified by at least 2 peptides in samples P1 or P2, but not in sample C3, were assigned 
as potential bacterial interference factors. These stringent identification criteria narrowed the 
results to a total of 8 identified proteins from the soluble fraction (P2) and 3 proteins in the 
insoluble fraction (P1; Table 1). Among these proteins were several cytoskeleton as well as 
ribonucleoproteins. Interestingly, cytokeratin 8 (CK8) and CK18 received the most significant 
emPAI values and peptide hits. Importantly, literature supports a role for CK8 as potential 
bacterial adherence factor (Gires et al., 2005, Hembrough et al., 1995), but also indicates that 
it is expressed at increased levels by colon tumour cells (Alfonso et al., 2005), which could be 
relevant for the increased incidence of infection of S. gallolyticus in CRC patients (Boleij et 
al., 2011b). For these reasons CK8 was selected as target for further evaluation in this study.
Table 1. Eukaryotic proteins identified by LC-MS/MS1
High detergent concentration (insoluble proteins) emPAI peptides
Reference Protein
Delta
P l/C l
Delta
P l/C l
gi 11483523291 ref | NP_001011553.21 cell division cycle 10 isoform 2 0.233 2
gi 11574122701 ref| NPJL12480.21 heterogeneous nuclear ribonucleoprotein M isoform b 0.160 2
gi 145066751 ref| NP_002941.11 ribophorin 1 precursor 0.150 2
Low detergent concentration (soluble proteins) emPAI
Delta
peptides
Delta
Reference Protein P2/C2 P2/C2
g 145578881 ref | NP_000215.11 cytokeratin 18 1.228 7
g 145049191 ref| NP_002264.11 cytokeratin 8 1.212 9
g 1143893091 ref | N PJL16093.11 tubulin alpha 6 0.369 3
g 1570132761 ref| NP_006073.21 tubulin, alpha, ubiquitous 0.369 3
g 1157186871 ref| NP_000996.21 ribosomal protein S3 0.359 2
g 1242346991 ref | NP_002267.21 cytokeratin 19 0.318 3
g 145018851 ref | NP_001092.11 beta actin 0.274 2
g 11162843941 ref | NP_079005.31 myosin, heavy chain 14 isoform 2 0.097 4
1Eukaryotic proteins identified by LC-MS/MS with corresponding reference number, emPAI values and 
the amount of peptide hits per fraction (see Table S2 for peak lists and peptide sequences). Proteins that 
were identified in fraction P1 and P2, but not in the control fraction C3 were evaluated based on delta 
emPAI values above 0 and a delta peptide number of at least 2 with the respective control fractions 
C1 and C2. The 11 proteins matching these criteria are marked as potential candidate target proteins 
for bacterial interference, P1, S. gallolyticus + HT-29 insoluble fraction; P2, S. gallolyticus + HT-29 
soluble fraction; C1, HT-29 insoluble fraction without S. gallolyticus; C2, HT-29 soluble fraction without 
S. gallolyticus; C3, S. gallolyticus without HT-29 proteins.
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Presence of CK8 at the eukaryotic cell surface
In general, keratins are intracellular cytoskeleton proteins. To validate a possible role of CK8 
as adherence receptor for S. gallolyticus, it was important to know whether this protein is 
also present at the cell surface of human epithelial cells. To investigate this, HT-29 cells were 
fractionated and evaluated by Western blotting. As expected, these experiments showed 
that CK8 is most abundant in the cytoskeleton fraction, however, this protein was also 
detectably present in the cytosolic, membrane and nucleus fractions (Figure 2A). Antibodies 
against the membrane protein CYP1A1 were used to control for correct fractionation, 
which confirmed that this protein was only detected in the membrane fraction (Figure 2B). 
However, as this fraction also includes intracellular membranes, confocal microscopy was 
used to further investigate the cell surface expression of CK8 (Figure 2C). This revealed a 
speckle-like membrane staining of CK8 in non-permeablized epithelial cells. Contrarily, cell 
permeablization results in a more equal staining that mainly presents the contours of the 
cell. Overall, these experiments indicate that CK8 is primarily an intracellular protein that 
also has an exposed component at the epithelial cell surface of colorectal cancer cells.
A
keratin-8 >
B
HT-29 cell fraction
I II III IV
HT-29 cell fraction
I II III IV
CYP1A1 >
C  Total Membrane
Caco-2
HT-29
Figure 2.
Localisation of CK8 in epithelial cells
The presence of CK8 (A) and CYP1A1 (B) in HT-29 
cell fractions (cytosol (FI), membrane (FII), nucleus 
(FIII) and cytoskeleton (FIV)) was evaluated by 
immunoblotting. (C) Subcellular localization of CK8 
was visualized in permeable cells and cells that 
were non-permeablized by confocal microscopy, 
showing a speckle-like membrane staining in non- 
permeablized Caco-2 and HT-29 cells (Membrane), 
whereas a more equal staining along the cell 
contours is observed in permeable cells (Total).
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CK8 binding to the bacterial cell surface
After showing that CK8 has besides an intracellular component also a possible surface 
exposed component, the binding of CK8 to the bacterial cell surface was confirmed by 
Western blotting and ICW-analysis. After incubation with the epithelial membrane fraction, S. 
gallolyticus cells were washed and boiled in SDS-PAGE sample buffer to release extracellular 
bound proteins. Western blot analysis confirmed that CK8 from HT-29 and Caco-2 cells was 
detectably retained by the bacterial cell surface under the applied conditions (Figure 3A). 
To evaluate, whether this feature is restricted to S. gallolyticus, the same procedure was 
performed with E. faecalis cells. As shown in the lower panel of Figure 3B, E. faecalis cells 
retain CK8 to a much higher extent than observed for S. gallolyticus. The latter observation 
was confirmed with ICW-analysis (Figure 3B), together suggesting that bacterial binding to 
CK8 is a rather general phenomenon.
Figure 3. CK8 binding to the bacterial surface
(A) S. gallolyticus and E. faecalis cells were incubated with HT-29 and Caco-2 cell lysates (membrane 
fraction) to allow binding of CK8, which was evaluated by SDS-PAGE and immunoblotting. (B) ICW- 
analysis was used to monitor binding of CK8 to immobilized bacteria in 96-well plates, which was 
expressed as fluorescent counts/mm2 relative to the amount of bacterial cells as measured by DNA- 
staining with DRAQ5 (see Methods section "In cell Western analysis").
CK8 interacts with bacterial enolase
Evaluation of the bacterial cell surface confirmed that CK8 binds to the S. gallolyticus 
and E. faecalis cell surface. To reveal which bacterial adhesin is involved in CK8 binding, 
recombinant CK8 was incubated with intact bacterial cells and subsequently cross-linked 
to the bacterial cell surface using the membrane impermeable agent DTSSP. Next, protein 
complexes containing CK8 were isolated through immunocapture experiments after which 
potential adhesion-receptor pairs were visualized by SDS-PAGE (Figure 4A).
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Figure 4. Identification of bacterial interaction partners of CK8.
(A) Cross-linked adhesin-receptor pairs were immunoprecipitated with anti-CK8 antibodies and 
visualized by SDS-PAGE. The position of native CK8 at approximately 58 kDa is indicated. After in-gel 
tryptic digestion and MS/MS analysis, bacterial enolase could be identified in the protein complex at 
155 kDa. The other protein products at 120,110, 85 and 75 kDa were all idenified as bacterial proteins 
with matching protein sizes indicating that these proteins are not part of a complex (Table S3). (B) 
Immunoprecipitated proteins were analyzed by Western blotting either in cross-linked (CL;) or reduced 
form (RCL;); recombinant CK8 was loaded in lane 1. The position of recombinant CK8 at 58 kDa (native) 
and cross-linked products between 110 and 160 kDa are indicated. (C) Protein sequence and peptides 
of S. gallolyticus enolase that was identified by MS/MS in the ~155 kD complex. (D) Visualization of 
enolase by Western blot analysis for which the same samples were loaded as in panel B, besides the 
enolase control (lane 1). The position of enolase at 50 kDa (native) and an enolase-containing cross­
linked complex at ~155 kDa are indicated. Importantly, this complex had the same mobility in the 
SDS-PAA gel as the CK8-containing product with the highest molecular weight as indicated in lane 2 of 
panel B. Note that the cross-linked product containing CK8 and enolase (CL) can be disrupted by DTT 
(RCL) indicating that it concerns a genuine DTSSP-induced complex.
The cross-linked adhesion-receptor pairs that were either left intact or disrupted with DTT 
were evaluated with Westernblotting for their containment of CK8. In figure 4B is clearly 
shown that the cross-linked complex (CL) is retained at approximately 155 -  160 kDa. 
Disrupting the cross-linked proteins with DTT reduced CK8 to its non-cross-linked form at 
58 kDa (RCL). In-gel trypsin digestion and subsequent vMALDI-LTQ MS/MS analysis of 6 
possible complexes resulted in the identification of bacterial enolase (47 kDa) in relatively 
faint bands with estimated sizes of 155 (2 peptides) and 160 kDa (1 peptide) (Figure 4C). 
LC-MS/MS-analysis of this peptide sample confirmed the identification of enolase in this 
155 kDa protein band (data not shown). The position of other identified bacterial proteins 
on SDS-PAGE was in accordance with their theoretical native molecular weight and these 
proteins were therefore considered not to be in complex with CK8.
To further investigate the interaction between enolase and CK8, cross-linked complexes 
were analysed by Western blotting. As already shown in Figure 4B, CK8 is present in multiple 
protein complexes, of which the ~155 kDa complex also reacts with anti-enolase antibodies 
(Figure 4D). Importantly, the enolase-CK8 complex is only detected in the cross-linked 
non-reduced sample (CL), and not in the reduced sample in which cross-links have been 
disrupted (RCL). Taken together, these experiments reveal that epithelial CK8 and bacterial 
enolase have the potential to form an adhesin-receptor pair, which may contribute to the 
interaction between bacteria and host epithelial cells.
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Discussion
Advances in proteomic tools provide the opportunity to explore interactions between 
pathogens and the host in a broad manner. The fact that bacterial shaving has previously 
been proven to be a succesfull method to identify bacterial proteins at the cell surface of 
Gram-positive bacteria (Dreisbach et al., 2010, Rodriguez-Ortega et al., 2006, Severin et 
al., 2007, Solis et al., 2010, Tjalsma et al., 2008, Wolff et al., 2008), inspired us to explore 
the ability to use a modified approach to profile potential host-pathogen interactions. Here 
we report that it is indeed possible to identify host factors that are candidate receptors for 
bacterial cells by proteolytically shaving of the bacterial surface after pre-incubation with 
complex mixtures of eukaryotic proteins. Surprisingly, the most significant hits were limited 
to soluble proteins, whereas no classical membrane proteins were identified. However, 
besides difficulties to solubilize transmembrane proteins, the identification of this class 
of membrane proteins is more challenging. Transmembrane proteins naturally contain 
fewer cleavage sites, which results in larger peptides upon proteolytic cleavage. Despite 
these apparent limitations, we have shown that this approach allows the identification of 
cytoskeletal proteins, such as CK8 and 18, that may be important mediators of bacterial 
infection by either functioning as surface receptor or as "highjacking" protein during 
invasion of epithelial cells.
Keratins are part of the cytoskeleton of eukaryotic cells that is composed of three different 
types of morphologically distinct filamentous structures; microfilaments, intermediate 
filaments and microtubules (Barak et al., 2004). This cytoskeletal network is responsible for 
the mechanical integrity of the cell. CK8 and 18 are the major constituents of intermediate 
filaments of simple epithelia, such as those of the intestine. In addition, both keratin 18 
and 19 can form heterodimers with CK8. Interestingly, CK8 and 18 have a continous and 
increased expression in tumor cells, while the expression of other cytokeratins is lost (Alfonso 
et al., 2005, Pankov et al., 1994). CK8, 18 and 19 are the most abundant intermediate 
filaments expressed in malignancy and can be detected in a number of body fluids of 
cancer patients, while the level of cytokeratins in the circulation of healthy individuals is 
low (Moll et al., 1982). Our experiments suggest that CK8 has a surface-exposed component 
in colon adenocarcinoma cells that allows its interaction with intestinal pathogens. This 
theory is supported by several reports on CK8/18 membrane localization in colon tumor 
cells (Casanova et al., 2004, Ditzel et al., 2002, Gires et al., 2005, Hembrough et al., 1995, 
Matthias et al., 2008). Furthermore, Pankov et al. found that this surface localization was 
only present in tumor cells but not in healthy tissue (Pankov et al., 1994). Since our results 
have identified CK8 and 18 as possible receptors for S. gallolyticus adherence, this might 
reflect the association between CRC and infections with this bacterium. However, our data 
also suggest that binding to these keratins is not a very specific feature of S. gallolyticus, 
which is in-line with our recent finding that this association is more likely to be dominated by 
the specific ability of S. gallolyticus to adhere to (intestinal) collagens (Boleij et al., 2011a). 
Cytosolic proteins and in particular cytoskeleton proteins have been described to be 
important for adhesion, invasion and transcytosis of several bacteria, e.g. Clostridium 
dificile, Neisseria gonorrhoe and Staphylococcus aureus (O'Brien et al., 2002, Schwan et al.,
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2009, Wang et al., 2008). Interestingly, our study is not the first to provide evidence for the 
role of CK8 as a mediator of bacterial adherence. Previously, Tamura et al. (Tamura and 
Nittayajarn, 2000) showed a role of CK8 as adherence factor for different serotypes of Group 
B streptococcus (GBS) and concluded that this represents a shared mechanism among these 
strains. Our results underscore a more general role for CK8 as bacterial interference factor, 
since S. gallolyticus as well as E. faecalis cells were able to interact with CK8. Also, the 
observation that other bacteria like Streptococcus macedonicus, Lactobacillus plantarum 
(our unpublished observations), Staphylococcus aureus and Streptococcus pyogenes (Tamura 
and Nittayajarn, 2000) were able to interact with CK8 strengthens the notion that CK8 is a 
more general adherence mediator for Gram-positive bacteria. Notably, the observed high 
CK8 binding capacity of E. faecalis cells compared to that of S. gallolyticus is consistent with 
their relative adherence characteristics to HT-29 monolayers (Boleij et al., 2011a).
The previous observation of Tamura et al. (Tamura and Nittayajarn, 2000), who showed that 
proteolytic treatment of the GBS surface abolished its interaction with CK8, is of particular 
importance for our findings as this bacterial proteinaceous compound remained previously 
unidentified. Our current investigations on CK8 interaction show for the first time that 
bacterial enolase is a bacterial counterpart of this eukaryotic protein. Notably, S. gallolyticus 
enolase was among the abundant bacterial proteins released upon the proteolytical shaving 
procedure (our unpublished data). These findings fit with a common mechanism for 
bacterial adherence to CK8 as enolase is a conserved bacterial protein with great sequence 
conservation between different bacterial species (Karbassi et al., 2010). Furthermore, 
enolase has already been shown to be expressed at the bacterial cell surface and to be 
of importance for the binding of e.g. S. pneumonia to airway epithelial cells (Adrian et al., 
2004, Bergmann et al., 2003, Cork et al., 2009, Pancholi and Fischetti, 1998, Pancholi et al., 
2003). Our current data suggest that surface-exposed bacterial enolase can in addition to 
plasminogen activator (Pancholi and Fischetti, 1998) also bind to epithelial CK8. It should be 
kept in mind, however, that our data suggest that besides enolase, CK8 could also interact 
with other presently unidentified bacterial adhesins. In addition, our profiling approach also 
resolved other candidate eukaryotic receptors for bacterial adherence, like CK18, the role 
of which needs further investigations. In conclusion, our study shows that surface-affinity 
profiling is a promising approach to discover eukaryotic mediators of bacterial interference. 
However, further refinement of this approach is necessary to also apply this procedure 
to eukaryotic membrane proteins. Furthermore, bacterial adherence to host tissue might 
also involve human or bacterial proteins, such as fimbriae, that are not cleaved by trypsin 
(Handley et al., 1984). Thus, it is cannot be excluded that some important host-bacterial 
interactions are being missed by this procedure. In future investigations, the number of 
detected interactions might be enhanced by using complementary proteases that cleave 
surface proteins at other sites (Solis et al., 2010).
It goes without saying that future follow-up experiments should further confirm the 
biological relevance of the CK8-Eno interaction for bacterial infection. Such experiments 
could comprise, but are not limited to, examining the influence of CK8 down-regulation on 
adherence to epithelial cells, and examining the virulence characteristics of an S. gallolyticus 
enolase knock-out in vitro and in vivo. Our first experiments to reduce the expression of CK8
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by okadaic acid treatment (Long et al., 2006), appeared not to be compatible with bacterial 
adherence assays due to a general loss of cell attachment (our unpublished observations). 
It may be anticipated that a RNA-silencing approach may turn out to be more successful in 
this matter. Cork et al have previously shown that enolase mutants of group A streptococci 
display a lower adhering capacity than cells of the wild-type strain, stressing the importance 
of enolase for bacterial adherence. Unfortunately, however, it was until now not possible 
to generate an S. gallolyticus enolase mutant strain to perform similar experiments in our 
model systems. Nevertheless, our present data clearly illustrate that a straightforward 
surface-affinity profiling procedure can provide leads for the identification of novel adhesin- 
receptor pairs. Thereby this approach demonstrates its potential to aid to the understanding 
of host-pathogen interactions at human epithelial surfaces.
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Abstract
Streptococcus gallolyticus (formerly known as Streptococcus bovis biotype I) is a low grade 
opportunistic pathogen which is considered to be associated with colon cancer. It is thought 
that colon polyps or tumors are the main portal of entry for this bacterium and that heparan 
sulfate proteoglycans (HSPG) at the colon tumor cell surface are involved in bacterial 
adherence during the first stages of infection. In this study, we have shown that the histone- 
like protein A (HlpA) of S. gallolyticus is a genuine anchorless bacterial surface protein that 
binds to lipoteichoic acid (LTA) of the gram-positive cell wall in a growth phase dependent- 
manner. In addition, HlpA was shown to be one of the major heparin-binding proteins of S. 
gallolyticus able to bind to the HSPG expressing colon tumor cell lines HCT116 and HT-29. 
Strikingly, although wild-type levels of HlpA appeared to contribute to adherence, coating 
of additional HlpA at the bacterial surface resulted in a reduced binding to colon tumor 
cells. This may be explained by the fact that heparan sulfate and LTA compete for the same 
binding site in HlpA. Altogether, this study implicates that HlpA serves as a fine-tuning factor 
for bacterial adherence.
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Introduction
The human gastrointestinal tract is the habitat for a large and dynamic bacterial community, 
which is essential for intestinal epithelial homeostasis and human health. In contrast, gut 
flora may also be of critical importance in gastrointestinal diseases such as colon cancer 
(Guarner and Malagelada, 2003). Although hundreds of microbial species reside in the 
human intestinal tract, only a systemic infection with the gram-positive gut bacterium 
Streptococcus gallolyticus (formerly known as Streptococcus bovis biotype I) has a well- 
known association with colon cancer (Herrero et al., 2002, Klein et al., 1977, zur Hausen,
2006). This bacterium, which can normally be detected in the gastrointestinal tract of 
about 10% of the human population (Schlegel et al., 2000), is considered to be a low-grade 
opportunistic pathogen that can only establish infections in individuals with damaged heart 
valves (endocarditis) or a compromised immune system (bacteraemia). Interestingly, fecal 
carriage of S. bovis1 was shown to be increased about 5-fold in patients with colon cancer 
indicating that colon tumors constitute a preferential colonization niche for this bacterium 
(Klein et al., 1977). In addition, multiple studies have shown that in up to 60% of patients 
with an S. bovis endocarditis or bacteraemia a colon tumor was detected upon full bowel 
examination (zur Hausen, 2006). This strongly suggests that a colon polyp or tumor is the 
main portal of entry for S. gallolyticus, which is underscored by the fact that patients with 
S. bovis endocarditis are significantly older than those with endocarditis due to other 
Streptococci (Hoen et al., 2005). Noticeably, this could mirror the increased frequency of 
tumors in the elderly population.
A first requirement to establish a bacterial infection is a dependable connection between 
bacterial adhesins and host surface structures to withstand microbial competition and 
mechanical cleansing processes within the intestinal tract. It has been suggested that 
heparan sulphate proteoglycans (HSPGs) present on intestinal epithelial cells are a target 
for S. bovis adherence and internalization, thereby participating in bacterial translocation 
across the intestinal epithelial barrier (Henry-Stanley et al., 2005). Interestingly, the heparin- 
binding histone-like protein A (HlpA) from S. bovis was recently shown to be present in 
cell wall extracts and was a target of the humoral immune response in patients with colon 
cancer (Tjalsma et al., 2006b). Several other studies confirmed that this conserved bacterial 
protein from Streptococcus pyogenes, which is for 95,6% identical to S. gallolyticus HlpA, 
had affinity for lipoteichoic acid (LTA), an intrinsic component of the gram-positive cell wall 
(Liu et al., 2008, Stinson et al., 1998, Zhang et al., 1999). Furthermore, proteomic analysis of 
the bacterial surface of S. pyogenes revealed that HlpA is a surface-linked protein (Severin 
et al., 2007). Taken together, these observations suggested that HlpA from S. gallolyticus is a 
so-called anchorless surface protein, which is a target of the humoral immune system upon 
infection and may mediate bacterial adherence to colon tumor cells by linking bacterial LTA 
to HSPG on colon epithelial cells. Anchorless proteins comprise typical cytoplasmic proteins
Streptococcus gallolyticus (Streptococcus bovis biotype I) has the highest association with 
colorectal cancer of all S. bovis biotypes. Unfortunately, not all studies distinguished S. bovis 
biotypes. Therefore we use the name S. bovis when the specific biotype is not known and 
S. gallolyticus only when it is certain that the authors refer to S. bovis biotype I.
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that are released by unknown mechanisms and re-associate with components of the bacterial 
cell wall or proteins at the bacterial surface (Pancholi and Chhatwal, 2003, Tjalsma et al., 
2008). To several of these anchorless surface proteins a secondary extracytoplasmic function 
has been assigned. For instance, alpha-enolase and glyceraldehyde 3-phosphate of group 
A streptococci have the ability to bind to plasminogen and fibronectin on pharyngeal epithelial 
cells (Boel et al., 2005, Pancholi and Fischetti, 1998, Pancholi and Fischetti, 1992, Pancholi 
et al., 2003). Similarly, these surface-exposed proteins from Streptococcus pneumoniae bind 
to and activate plasminogen and are important for tissue invasion and virulence (Chhatwal,
2002). Therefore, the main aim of this study was to investigate the ability of S. gallolyticus 
HlpA to mediate bacterial adherence to colon tumor cells. Our experiments showed 
that purified HlpA did bind to both intact bacteria and colon tumor cells. Furthermore, 
antibody-mediated blockage of HlpA reduced the adhering properties of S. gallolyticus, whereas 
loading S. gallolyticus cells with purified HlpA had no promoting effect on bacterial adherence.
Materials and methods 
Bacterial Strains and Media
The strain used in this study was Streptococcus gallolyticus subsp. gallolyticus UCN34 
(further entitled as S. gallolyticus) that was previously isolated from a colon cancer 
patient with a co-incidental endocarditis (P. Glaser, unpublished data). This strain relates 
to S. bovis biotype I, which has the highest association with colon cancer (Corredoira et 
al., 2008). S. gallolyticus cells were cultured at 37°C/5% CO2 in brain-heart infusion broth 
(Difco Laboratories) supplemented with 1% glucose. S. gallolyticus lysates were obtained 
by mechanical disruption of frozen bacterial cell pellets at 2000 rpm in N2 (l). Lysed bacteria 
were dissolved in PBS and stored at -20°C. The Escherichia coli strains DH5a (Invitrogen) 
used for recombinant DNA procedures and BL21 (DE3; Novagen) used as overproduction 
host were grown aerobically at 37°C in Luria Broth (LB) medium. When required, medium 
for E. coli was supplemented with 50 ^g/ml ampicillin.
Colon Adenocarcionoma Cell Lines and Media
The colon adenocarcinoma cell lines Caco-2, HCT116 and HT-29 (obtained from the American 
Type Culture Collection) were grown in Dulbecco's Modified Eagle's Medium (DMEM, Lonza) 
supplemented with 10% FCS, 20 mM HEPES, 100 nM non-essential amino acids and 2 mM 
L-Glutamine (Gibco). HT-29 and HCT116 cells were subcultured every 3 days and Caco-2 cells 
every 7 days. Co-culture experiments were performed in 6-well plates in complete DMEM 
containing 1% FCS.
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DNA Techniques
Procedures for polymerase chain reaction (PCR), DNA purification, restriction, ligation, 
agarose gel electrophoresis, and calcium chloride transformation of E. coli were carried out as 
described by Sambrook et al. (Sambrook, 1989). Enzymes were obtained from New England 
Biolabs and Applied Biosystems. To construct pET11-HlpA-His, first a fragment comprising 
the complete open reading frame of the hlpA gene of S. gallolyticus was amplified by PCR 
using the primers HlpA-u (5'-ACGTCATATGGCTAACAAACAAGATTT AATCGC-3') containing an 
NdeI cleavage site and HlpA-r (5'-CGTAGGATCCTTAATGGTGATGGTGATGGTGTTTTACAGCGT 
CTTTAAGTGCTTTACC-3') that inserts a hexahistidine (6xHis) tag upstream of the hlpA stop 
codon and contains a SamHI cleavage site. Next, the amplified fragment was cleaved with 
Ndel and SamHI and ligated into the corresponding sites of pET11a (Novagen).
Protein Purification
To overproduce HlpA-His, 500 ^M isopropyl-D-thiogalacto-pyranoside (IPTG) was added 
to exponentially growing E. coli BL21 that were first introduced with pET11-HlpA-His. Cells 
were harvested after 4 hours and lysed by three freeze-thaw cycles. Native His-tagged HlpA 
was purified by Nickel-affinity chromatography using the Ni-NTA mini spin kit from Qiagen.
SDS-PAGE and Western blotting
To monitor affinity of HlpA-His for intact S. gallolyticus cells, bacteria were incubated with 
purified HlpA-His (~30 ^M) for 1 hour at 37 °C. Next, bacteria were washed three times 
with sterile PBS and directly incubated in Tricine SDS-sample buffer (Schagger, 2006) for 15 
minutes. Bacteria and isolated protein fractions were analyzed by Tricine SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) (Schagger, 2006). To detect HlpA, or HlpA-His, proteins were 
transferred to polyvinylidene fluoride (PVDF) membranes (Amersham) by Western blotting 
(Towbin et al., 1979). Blots were incubated with monoclonal anti-hexahistidine antibodies 
(Qiagen) or highly cross-reactive anti-S. pyogenes HlpA antibodies that were raised against 
recombinant SP-HLP an purified as described previously (Jin and Pancholi, 2006). Bound 
antibodies were visualized with the ECL detection system (Amersham) using anti-rabbit or 
anti-mouse IgG HRP conjugates (Jackson ImmunoResearch).
In Cell Western Analysis
To investigate the binding of HlpA-His to intact S. gallolyticus or adenocarcinoma cells, 
96-wells plates were coated with either adenocarcinoma cells (50.000 cells/well) or bacteria 
(1x10A9/ml). Briefly, bacteria were cultured to exponential (OD 0.6) or stationary growth 
phase (OD 1.0) and subsequently incubated with purified HlpA (~30^M) at 37°C/5%CO2 
for 1 hour. Next, bacteria were allowed to attach to a polysine coated 96-well plate at 4°C 
overnight. To determine the net binding of endogenous and recombinant HlpA, coated 
bacteria were stripped with trypsin-EDTA (20 units/ml). The HT-29, Caco-2 and HCT116 
cells were cultured in 96-wells plates for 3 days at 37°C to create a confluent monolayer. 
Purified HlpA-His (~30 ^M) was dissolved in specified growth medium and allowed to 
bind to confluent monolayers for 1 hour. Excess protein was removed by washing three 
times with PBS. Then, cells were fixed with 3.7% formaldehyde and left intact to determine
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extracellularly adhered HlpA. After fixation, plates were washed with PBS and blocked with 
Li-COR Odyssey blocking buffer (Li-COR biosciences). HlpA was detected with polyclonal 
HlpA antibody and visualized with the Odyssey (Li-COR biosciences) using a secondary 
anti-rabbit antibody conjugated with Alexa Fluor 680 (Molecular Probes).
LTA and Heparin Binding Assays
Streptococcal LTA (Sigma; 1 ng/^l) was immobilized on IDM beads (Ciphergen) by incubation 
in 100 mM ammonium acetate (pH5). Beads were washed extensively with PBS after blocking 
unoccupied binding sites by 50 mM Tris-HCl pH8. Immobilized LTA or Heparin (Heparin 
sepharose; Pierce) was incubated with soluble bacterial proteins for 1 hour in PBS, followed 
by centrifugation after which the supernatant (unbound fraction) was collected. Next, LTA 
or heparin beads were washed 3 times with PBS and retained proteins were eluted in 100 
mM ammonium acetate (pH6) containing 0.1% SDS at 95°C for 10 minutes. Protein profiles 
of bound and unbound low molecular weight proteins were generated by surface-enhanced 
laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) as described 
previously. Alternatively, eluted proteins were boiled in SDS sample buffer for SDS-PAGE 
and Western blot analysis. Protein identification was performed by in-gel tryptic digestion 
followed by peptide sequencing by tandem mass spectrometry as described previously 
(Tjalsma et al., 2006a).
Bacterial Adherence Assay
The influence of HlpA on adherence of S. gallolyticus to adenocarcinoma cells (HCT116 and 
HT-29) was studied with an adherence assay as described previously (Bootsma et al., 2007). 
First, S. gallolyticus cells were treated with recombinant HlpA-His (~30^M), HlpA antibodies 
(1:1000) or HlpA-antibodies pre-blocked with HlpA-His in PBS. Non-treated S. gallolyticus 
cells were used to determine normal adherence levels. After pre-treatment of the bacteria, 
they were added at a multiplicity of infection of 20:1 (bacteria/cells) to sub-confluent 
monolayers and incubated for 2 hours. To determine the number of adhered bacteria, 
the monolayers were washed three times with PBS and lysed with ice-cold PBS containing
0.025% Triton X-100. Serial dilutions of cell lysates were plated on blood-agar plates and 
incubated at 37°C/5% CO2 to count the colony forming units (CFU).
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Results
HlpA of S. gallolyticus is an anchorless bacterial surface protein 
with affinity for colon tumor cells
To act as adherence factors, anchorless proteins should have affinity for components of 
both bacterial and colon tumor cells. To evaluate this for HlpA from S. gallolyticus, the hlpA 
gene was first cloned in such a way that a hexahistidine extension (His tag) was added to the 
carboxyl-terminus of HlpA. The resulting HlpA-His protein was overproduced and purified 
from E. coli cells to determine affinity for the surface of intact S. gallolyticus cells (Figure 1).
+  -  +
«HlpA «His
Figure 1. Binding of HlpA to intact bacteria
Western blot analysis of S. gallolyticus cells that were incubated with (+) or without (-) purified HlpA-His. In 
the left panel the recombinant and endogenous HlpA-molecules were visualized with anti-HlpA antibodies. 
The upper band in the + lane corresponds to the recombinant HlpA-His molecule that is also detected by the 
anti-His antibody (right panel)
To investigate whether the surface expression of HlpA from S. gallolyticus is also growth 
phase dependent, S. gallolyticus cells were harvested during the exponential and stationary 
growth phase and immobilized in microtiter plates for In Cell Western analysis using HlpA 
antibodies. To reveal the endogenous expression of HlpA at the bacterial surface, bacterial 
cells were stripped with trypsin-EDTA to remove extracellular proteins. This showed that 
endogenous expression of surface HlpA was indeed more abundant during the stationary 
growth phase (p=0.0095) than in exponential phase (ns) (Figure 2), but it should be noted 
that some low level of autolysis could have contributed to the amount of endogenous surface 
HlpA. Interestingly, the extracellular addition of HlpA-His to intact bacteria showed that the 
cell wall of S. gallolyticus cells from the stationary growth phase was not saturated with 
HlpA (p=0.0331), whereas no additional binding of HlpA-His was observed to exponentially 
growing cells. These data show that endogenous HlpA is expressed at the cell surface of 
S. gallolyticus and that this phenomenon seems most prominently present during the 
stationary growth phase.
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Exponential Stationary
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Figure 2. Affinity of HlpA for S. gallolyticus in exponential and stationary growth phase
In Cell Western analysis on S. gallolyticus bacteria in exponential and stationary growth phase exposed to 
HlpA-His. Approximately 1 x 109 exponential or stationary grown bacteria were coated to a 96-wells plate. 
Detection of HlpA and HlpA-His was established by rabbit-anti-HlpA antibodies and secondary alexa-fluor 
680 labeled anti-rabbit antibody. The bars represent the fluorescence intensity of extracytoplasmic re­
combinant HlpA-His and endogenous HlpA of bacteria. Note that non-stripped bacteria have in addition 
to HlpA-His also endogenous HlpA at their surface whereas trypsin stripped bacteria have reduced endog­
enous levels of HlpA on their bacterial cell wall. Exponential or stationary bacteria were either incubated 
with (+) or without (-) HlpA-His. Fluorescence intensity was corrected for background measurement of the 
incubation medium. Error bars indicate standard error of two replicate experiments. * = p < 0.05 and ** 
= p <0.01(students t-test).
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Figure 3. Binding of HlpA to intact adenocarcinoma cells
In Cell Western analysis on HT-29 and HCT116 colorectal cancer cells incubated with purified HlpA-His 
from S. gallolyticus. Detection of HlpA-His was established by incubation with rabbit anti-HlpA antibody, 
with alexa-fluor 680 labeled secondary anti-rabbit antibody. The bars represent the fluorescence 
intensity of HlpA-His on adenocarcinoma cells. Fluorescence intensity of HlpA was corrected for the 
basal fluorescence level (non-specific fluorescence) of the indicated cell line. The blank measurement is 
obtained by subtracting the fluorescence intensity of a blank well incubated with DMEM from DMEM 
with HlpA (background measurement). Error bars indicate standard error of two replicate experiments.
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To identify whether HlpA can play a role in S. gallolyticus adherence, the binding of HlpA- 
His to the adenocarcinoma cell lines HT-29, HCT116 and Caco-2 was quantified by In Cell 
Western analysis. The fluorescence intensity of HlpA was highest in HT-29 and than in 
HCT116 cells compared to the blank measurement (Figure 3). In contrast, the fluorescence 
intensity of Caco-2 adenocarcinoma cells remained similar after incubation with HlpA-His, 
which may reflect the low level of HSPGs in these cells (data not shown; (Henry-Stanley et 
al., 2003)). Taken together, these data show that extracellular added HlpA can bind to the 
bacterial surface and also has affinity for HT-29 and HCT116 colon tumor cells and thus, in 
principle, should be able to act as a mediator for bacterial adherence.
HlpA from S. gallolyticus is a heparin- and LTA-binding protein
To gain evidence for the components on the colon tumor and bacterial cell surface that are 
responsible for the retention of HlpA, in vitro binding assays were performed. Previous studies 
showed that HlpA from S. bovis biotype II is a heparin-binding protein (Tjalsma et al., 2006a) 
and indicated that HSPGs on epithelial cells may have a role in the binding and invasion of 
these bacteria (Henry-Stanley et al., 2005). To confirm heparin affinity of endogenous HlpA 
from the S. gallolyticus strain used in this study and that of its recombinant analogue HlpA- 
His, cell lysates and purified HlpA-His were incubated with immobilized heparin. As shown 
in Figure 4A, both endogenous and recombinant HlpA(-His) had a high affinity for heparin. 
Furthermore, mass spectrometry analysis of the low molecular weight (LMW) proteins 
showed that heparin-affinity is selective for HlpA (Figure 4B,C), which appeared to be the 
major LMW heparin-binding protein of S. gallolyticus. To investigate whether S. gallolyticus 
contains additional heparin-binding proteins >15 kDa, S. gallolyticus total cell lysates were 
incubated with immobilized heparin after which retained proteins were analyzed by SDS- 
PAGE. These analyses confirmed that HlpA is one of the major heparin-binding proteins 
from S. gallolyticus, however, at least 7 additional heparin-binding proteins were observed 
(Figure 5A) of which protein *2 could be identified as a putative alpha/beta hydrolase of 44 
kDa (Figure 5B). Nevertheless, these additional proteins were not or scarcely present in S. 
gallolyticus cell wall extracts (our unpublished observations). Thus, HlpA appears to be the 
major surface-exposed heparin-binding protein from S. gallolyticus.
To show LTA affinity of endogenous and recombinant HlpA(-His) from S. gallolyticus, cell 
lysates and purified HlpA-His were incubated with immobilized LTA and retained proteins 
were analyzed by mass spectrometry. As shown in Figure 4B and C, endogenous and 
recombinant HlpA(-His) both had affinity for LTA. This suggests that HlpA is retained by LTA 
in the bacterial cell wall and can mediate bacterial adherence by linking HSPG's of epithelial 
cells to LTA of the bacterial cell wall. Importantly, these analysis also indicated that the 
native features of HlpA have been preserved in recombinant HlpA-His, which thus can be 
used as an experimental substitute for endogenous HlpA.
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Figure 4. Heparin and LTA 
affinity of HlpA
(A) Western blot analysis of a 
total S. gallolyticus cell lysate (CL) 
and purified (P) HlpA-His, and the 
respective fractions that remain 
unbound (U) after incubation with 
immobilized heparin, and have 
heparin-affinity (H). Blots were 
decorated with anti-HlpA (aHlpA) 
or anti-6xHis (aHis) antibodies. 
Positions of endogenous HlpA 
and recombinant HlpA-His are 
indicated. (B) Low molecular 
weight (LMW) protein profiles 
of a total S. gallolyticus cell 
extract (upper panel), and the 
respective proteins that remain 
unbound after incubation with 
immobilized heparin (second 
panel) or LTA (fourth panel) and 
proteins that have heparin- 
affinity (third panel) or LTA- 
affinity (lower panel). Note that 
a second (unknown) protein 
with both heparin and LTA 
affinity is indicated with "*". 
(C) LMW spectrum of purified 
HlpA-His from S. gallolyticus 
(upper panel), the fraction 
that remains unbound after 
incubation with immobilized 
heparin (second panel) or LTA 
(fourth panel) and proteins that 
have heparin-affinity (third 
panel) or LTA-affinity (lower 
panel). The 9707 and 10530 
Da peaks, corresponding to 
respectively endogenous HlpA 
and recombinant HlpA-His, are 
indicated. Peak intensity is given 
in arbitrary units; m/z, mass /  
charge.
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Surface HlpA affects S. gallolyticus adherence to colon tumor cells
To investigate whether surface HlpA indeed mediates the adherence of S. gallolyticus to 
colorectal cancer cells, bacterial adherence assays were performed. First, endogenous HlpA 
on the surface of S. gallolyticus was blocked by anti-HlpA IgG that was also used for In Cell 
Western analysis (Figures 2 and 3). As shown in Figure 6A, this resulted in approximately 
20% (n.s.) and 60% (p = 0.0158) reduced adherence of S. gallolyticus to HCT116 and 
HT-29 cells respectively, compared to untreated S. gallolyticus cells (100% adhesion). This 
latter inhibition was partially restored (n.s.) by antibodies pre-blocked with HlpA-His that 
were used to confirm a specific interaction between HlpA and the anti-HlpA antibody. To 
investigate whether additional surface HlpA could further increase bacterial adherence, 
S. gallolyticus cells were coated with HlpA-His prior to their use in an adherence assay. 
Unexpectedly, adhesion of HlpA-His coated bacteria did not result in an increase, but 
decreased the adherence to HT-29 (n.s.) and HCT116 (p = 0.0242) to about 65% compared 
to untreated S. gallolyticus cells (Fig. 6B). This implicates that excess of surface HlpA has an 
inhibitory effect.
Heparin and LTA compete for the same binding sites in HlpA
The above apparent contradictory data suggest that HlpA adds to bacterial adherence, but 
point to a more complex process than simply linking HSPGs and LTA. One of the influencing 
factors could be that HSPGs and LTA, both strong negative structures, compete for the same 
positively charged binding sites in HlpA (Rostand and Esko, 1991, Stinson et al., 1998). Therefore, 
the interference of LTA to heparin binding of HlpA was investigated by mass spectrometry. 
As shown in Figure 1, pre-incubation of HlpA with soluble LTA inhibited the binding of both HlpA 
and HlpA-His to immobilized heparin in a concentration-dependent manner. In contrast, post­
incubation with LTA after binding to immobilized heparin had no significant inhibitory effect on 
the binding of HlpA and HlpA-His to heparin. The fact that these effects were more pronounced 
with HlpA-His is possibly due to the scavenging of LTA by other S. gallolyticus proteins with 
affinity for LTA (and possibly heparin) in the total cell extracts (see Fig. 4B). Thus, these data 
suggest that HlpA cannot efficiently bind to both HSPG and LTA in a simultaneous manner.
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Figure 5.
(A) SDS-PAGE analysis of a total S. gallolyticus cell lysate (CL) and the respective proteins that remain 
unbound (U) after incubation with immobilized heparin or have heparin-affinity (H). The position of 
endogenous HlpA is indicated. Unknown Heparin-binding proteins 1-7 are indicated with "*". (B) 
Identification of protein band 2 as a putative alpha/beta hydrolase of S. gallolyticus. Band 2, a putative 
heparin-binding protein, indicated in panel A of this Figure was excised from the gel and digested with 
trypsin to allow tandem mass spectrometry and peptide mass fingerprinting. The MS/MS spectrum of 
peptide "QKYLINSILKW" m/z 1405.82 is shown. Theoretical series of b ions produced from cleavage 
of the amide bond and y ions produced by cleavage of the amide bond are indicated with the actual 
identified ions printed in bold. The theoretical molecular weight of the corresponding putative alpha/ 
beta hydrolase is 43.7 kDa, which is in-line with its mobility by SDS-PAGE (see panel A of this Figure).
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Figure 6. Surface HlpA modulates 
bacterial adherence
(A) S. gallolyticus cells were incubat­
ed with (+) or without (-) anti-HlpA 
antibodies (a-HlpA). Antibodies pre­
incubated with (+) HlpA-His (HlpA-a- 
HlpA) served as control. Adherence of 
S. gallolyticus to HCT116 and HT-29 
cells was monitored by CFU serial dilu­
tion counting. The adherence of S. gal­
lolyticus for the specified cell line was 
set at 100%. Error bars indicate stan­
dard error of three replicate experi­
ments. * = p < 0.05 (students t-test).
(B) Adherence of S. gallolyticus cells 
coated with (+) or without (-) recom­
binant HlpA-His was monitored by CFU 
serial dilution counting. Adherence of 
S. gallolyticus to the specified cell lines 
was set at 100%. Error bars indicate 
standard error of three replicate exper­
iments. * = p < 0.05 (students t-test).
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Figure 7. LTA inhibition on heparin binding of HlpA
Low molecular weight profiles of heparin-binding proteins from a total S. gallolyticus cell extract or 
that of purified HlpA-His were generated by mass spectrometry. Bars represent the peak intensity 
of HlpA (m/z 9707) and HlpA-His (m/z 10530) that were retained by immobilized heparin after 
pre-incubation or post-incubation with 25 and/or 50 ng/^l soluble LTA. Error bars indicate standard 
error of three replicate experiments.
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Discussion
Heparan sulfate proteoglycans are proposed to give bacteria the opportunity to adhere 
to and invade the epithelium, but whether bacteria can use these eukaryotic structures is 
depending on bacterial heparin-binding proteins at the bacterial surface. Several studies 
stated that histone-like proteins are detected in the culture supernatant or at the bacterial 
cell surface of Helicobacter pylori, Streptococcus pyogenes and Streptococcus intermedius 
(Kim et al., 2002, Lei et al., 2000, Severin et al., 2007). Furthermore, it was previously shown 
that HlpA from S. pyogenes can be complexed to LTA (Severin et al., 2007, Stinson et al.,
1998). Therefore, we hypothesized that the histone-like protein HlpA of S. gallolyticus was a 
likely candidate to mediate adherence via these structures. Our studies clearly showed that 
endogenous and recombinant HlpA(-His) have affinity for both heparin and LTA. Our data 
demonstrate that endogenous HlpA is preferentially expressed at the bacterial surface in 
the stationary growth phase, which is in line with the study of Katsube et al. who reported 
that the histone-like protein MDP1 of Mycobacterium smegmatis accumulates in cell wall 
fractions in the stationary phase (Katsube et al., 2007). Furthermore, our findings correlate 
with previous studies reporting release of HlpA during the stationary growth phase (Liu et 
al., 2008, Stinson et al., 1998). In the exponential phase HlpA is required intracellularly to 
execute its physiological role in nucleoid formation (Ali Azam et al., 1999), but even though 
endogenous HlpA is maintained intracellularly, recombinant HlpA-His was not able to bind 
to the bacterial surface. Thus, HlpA relocation at the bacterial surface is growth phase 
dependent in vitro, which could mirror the in vivo bacterial steady state situation in, for 
instance, the gastro-intestinal tract.
A previous study of Henry-Stanley et al. showed that the colon adenocarcinoma cell line HT-29 
expresses heparan sulfate proteoglycans and more specific the heparan sulfate syndecan-1, 
whereas Caco-2 cells have only low levels of these proteoglycans (Henry-Stanley et al., 2003). 
Furthermore, Stinson et al. reported that bacterial HlpA of S. pyogenes binds to heparan 
sulfate in the extracellular matrix of human epithelial Hep-2 cells (Stinson et al., 1998). We 
observed that recombinant HlpA-His could bind to HT-29 and HCT116 adenocarcinoma cells, 
but not to Caco-2 cells, which coincides with the amount of HSPGs and syndecan-1 and with 
the previous reported conclusion that S. bovis may use heparan sulfates to invade eukaryotic 
cells (Henry-Stanley et al., 2005). Furthermore, we found that S. gallolyticus adherence to 
both HCT116 and HT-29 cells was reduced by anti-HlpA antibodies, although the effects in 
the independent experiments did not reach statistical significance. Nevertheless, the same 
trend was observed for both cell lines, which is in line with the fact that heparin inhibited 
S. bovis internalization to a similar extent in HT-29 cells (Henry-Stanley et al., 2005). 
Unexpectedly, however, when S. gallolyticus was coated with additional recombinant HlpA- 
His adherence was decreased. This implies that excess of surface HlpA blocks adherence. A 
possible explanation for these apparent contradictory effects may be given by the fact that 
LTA competes with heparin for the binding of endogenous and recombinant HlpA, indicating 
that HSPGs and LTA use the same binding site(s) in this molecule (Figure 7). The Escherichia 
coli DNA binding protein HU, which is homologous to HlpA, has been extensively studied in 
its interaction with DNA. Homotypic dimers of E. coli HU interact with DNA via its binding
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arms, which resemble the amino acid sequence of S. gallolyticus HlpA (Ramstein et al.,
2003). These binding arms display an amino acid sequence that contains a typical positively 
charged heparin-binding site as proposed by Cardin and Weintraub (Cardin and Weintraub, 
1989, Gandhi and Mancera, 2008), which interacts with negatively charged sulphate or 
carboxyl groups on heparin chains, but may also interact with the negatively charged LTA 
(Winters et al., 1993).
Thus, although we showed that HlpA is a major heparin-binding protein at the bacterial 
surface, the exact contribution of HlpA and HSPGs in the adherence of S. gallolyticus to colon 
tumor cells is not fully resolved yet. In this respect it was interesting to note that Sillanpaa 
and co-workers showed that S. gallolyticus can bind to several eukaryotic extracellular 
matrix proteins (Sillanpaa et al., 2008). Others demonstrated that LTA itself is important 
for bacterial adherence and invasion (Courtney et al., 1992, Kapczynski et al., 2000, Sela 
et al., 2000), which was confirmed for S. gallolyticus in a study by Hunolstein et al. who 
showed that adherence to buccal epithelial cells was affected by anti-LTA antibodies and 
epithelial LTA-treatment (Von Hunolstein et al., 1993). In view of our current observations, 
increasing the amount of HlpA at the bacterial surface could therefore decrease the amount 
of interacting LTA molecules, when attachment of our clinical isolate is mainly LTA-driven. 
Furthermore, our results could implicate that excess surface HlpA hinders the interaction of 
other important adhesion molecules on S. gallolyticus.
For opportunistic pathogens, such as S. gallolyticus, a temporal regulation of interactions 
with host cells may be of critical importance. Although a firm connection with host 
epithelial (tumor) cells is key during the first phase of infection, an interaction with tissue 
macrophages that form the second line of defense against invading pathogens should be 
avoided. In this respect, surface HlpA may for instance shield LTA from interacting with toll­
like receptors on macrophages (Draing et al., 2008). Our current data show that surface 
HlpA may be one of the modulators of these bacterial interactions with host cells. However, 
HlpA from Streptococcus mitis has by itself shown to activate an immune response in murine 
macrophages in vitro, which is mediated by the induction of IL-1 and TNF-a (Zhang et al., 
1999). Similarly, Liu et al. showed that HlpA of S. intermedius can induce cytokine production 
in human macrophages (Liu et al., 2008). However, none of these studies has determined 
the net effect of the HlpA-mediated shielding of LTA from intact bacteria on the interaction 
with, and activation of, macrophages and this will be a subject of our future investigations. 
Taken together, our current data underscore that bacterial adherence is a highly balanced 
process involving multiple interactions on the host-pathogen interface. Importantly, this 
study presents the first evidence that surface HlpA may provide opportunistic pathogens, 
such as S. gallolyticus, with the ability to adjust their host-pathogen interactions during 
different stages of infection.
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Chapter 7 - S. gallolyticus association with CRC
Abstract
Background:
The prevalence of Streptococcus gallolyticus subsp. gallolyticus (S. bovis Biotype I) 
endocarditis is in general low but very often linked to colorectal cancer (CRC). Therefore, 
this study aimed to reveal the virulence characterisitics of Streptococcus gallolyticus that 
distinguishes this opportunistic pathogen from a panel of (closely related) intestinal bacteria.
Methods:
The route of infection was reconstructed in vitro with adhesion, invasion and translocation 
assays on differentiated Caco-2 cells. Furthermore, cellular immune responses upon 
infection and bacterial biofilm formation were analyzed in a comparative manner.
Results:
Streptococcus gallolyticus strains had a relative low adhesiveness and could not internalize 
epithelial cells. However, Streptococcus gallolyticus was uniquely able to paracellularly cross 
a differentiated epithelium without inducing epithelial IL-8 or IL-ip responses. Importantly, 
Streptococcus gallolyticus had an outstanding ability to form biofilms on collagen-rich 
surfaces, which in vivo are found at damaged heart valves and (pre)cancerous sites with a 
displaced epithelium.
Conclusions:
Together, these data show that Streptococcus gallolyticus has a unique repertoire of virulence 
factors that facilitates infection through (pre-)malignant colonic lesions and subsequently 
can provide Streptococcus gallolyticus with a competitive advantage to i) evade the innate 
immune system and ii) form resistant vegetations at collagen-rich sites in susceptible CRC 
patients.
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Introduction
The human intestinal tract is the habitat for several hundred different bacterial species 
with an increasing bacterial concentration and variability towards the distal colon. The 
commensal bacterial population aids human health by making dietary nutrients available 
to the host, but also prevents attachment and subsequent invasion of pathogenic bacteria 
(Hooper and Gordon, 2001). Strikingly, however, the part of the intestine with the highest 
bacterial colonization, the colon, is also most affected by cancer, with 146,970 annual cases 
in the USA (Jemal et al., 2009). This, together with the fact that germ-free mice have lower 
rates of colon carcinogenesis (Taketo and Edelmann, 2009), implies that intestinal bacteria 
play an important role in the development of colorectal cancer (CRC).
The Gram-positive, opportunistic pathogen Streptococcus bovis (SB) is one of the few 
intestinal bacteria that has been consistently linked to CRC (Boleij et al., 2009, Corredoira 
et al., 2008, Ruoff et al., 1989). A first case report which suggested an association between 
SB endocarditis and carcinoma of the sigmoid was already published in 1951 (McCoy and 
Mason, 1951). Since then, multiple studies have shown that a colon tumor or polyp was 
detected upon full bowel examination in up to 90% (Vaska and Faoagali, 2009) of patients 
with a SB infection (Corredoira et al., 2005, Ruoff et al., 1989). Furthermore, fecal carriage 
of SB in the healthy population is low, but increases about 5-fold in patients with CRC (Klein 
et al., 1977). After Schlegel et al. introduced the new nomenclature of SB strains (Schlegel et 
al., 2003) it became clear that Streptococcus gallolyticus subsp. gallolyticus (SG;SB biotype
I, Table 1), which is a major cause of infective endocarditis, has the highest association with 
CRC (Corredoira et al., 2008, Vaska and Faoagali, 2009).
Table 1. nomenclature of S. bovis strains
New name Old name Strains in this study
5. gallolyticus subsp. gallolyticus S. bovis Biotype 1 SG1,SG2,SG3
S. infantarius subsp. infantarius S. bovis Biotype II.1 SI
S. infantarius subsp. coli 5. bovis Biotype II.1 None
S. gallolyticus subsp. pasteurianus 5. bovis Blotype 11.2 None
S. gallolyticus subsp. macedonicus S. macedonicus SM
Note: SG = Streptococcus gallolyticus subsp gallolyticus, S I= Streptococcus infantarius subsp. infantarius, 
SM = Streptococcus gallolyticus subsp. macedonicus. Historically S. bovis strains were delineated into 
two biotypes according to their ability (biotype I) or inability (biotype II) to ferment mannitol (Schlegel 
et al., 2003). The former S. bovis biotype I, S. bovis biotype II.2 and S. macedonicus are now designated 
into a single DNA cluster including three subspecies: S. gallolyticus subsp. gallolyticus, S. gallolyticus 
subsp. pasteurianus and S. gallolyticus subsp. macedonicus. S. gallolyticus subsp. gallolyticus is most 
often linked with endocarditis-associated colonic cancer.
11S
Chapter 7 - S. gallolyticus association with CRC
Although some studies have shown that SB strains can directly promote carcinogenesis in 
a rat model for CRC (Biarc et al., 2004, Ellmerich et al., 2000), an incidental relationship 
provides an alternative explanation for the association of SG with CRC. In a normal healthy 
colonic environment the host has several defense mechanisms to shield itself from bacterial 
infection. Goblet cells within the polarized epithelium secrete a continuous layer of mucus 
that protects the epithelium and promotes transit of bowel contents (Johansson et al., 
2008), whereas enterocytes secrete anti-microbial peptides, cytokines and IgA as preventive 
agents. However, CRC is characterized by several changes in this physical barrier including 
increased tight junction permeability (Soler et al., 1999) and altered mucus production and 
composition (Aksoy and Akinci, 2004). This distorted physical protection could make CRC 
patients prone to rare opportunistic bacterial infections.
However, it is still unclear why SG infections have such a high association with colon 
malignancies, whereas this is not the case for other (related) opportunistic pathogens that 
inhabit the human gastrointestinal tract. Therefore, the main aim of this study was to reveal 
the virulence characteristics that distinguish SG from other bacteria to gain insight in how 
these features could specifically cause infections in CRC patients. To this purpose, several 
host-pathogen interactions that are involved in this infective process were mimicked in vitro. 
These studies indicated that SG avails of a unique repertoire of virulence characteristics that 
gives it an advantage over related SB strains and other intestinal bacterial species, to cross 
an epithelial layer, evade the immune system and form biofilms on collagen-rich surfaces.
7
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Materials and methods 
Cell culture and bacterial strains
Colorectal adenocarcinoma cell lines HT-29 and Caco-2 (www.atcc.org) were cultured in 
Dulbecco's Modified Eagle's Medium (DMEM, Lonza) supplemented with 10% Fetal Calf 
Serum (FCS), 20 mM HEPES, 2mM L-Glutamine and 1x non-essential amino acids (Gibco) 
at 37°C/5% CO2. The human monocytic cell line THP-1 was cultured in RPMI-1640 medium 
supplemented with 10% FCS, 2mM L-glutamine, 1^M pyruvate and 5^g/ml gentamicin 
(Gibco). These media and culture conditions were used in experiments unless stated 
otherwise.
The following bacterial SB strains were used, S. gallolyticus subsp. gallolyticus UCN34 (SG1; 
(Rusniok et al., 2010)), S. gallolyticus subsp. gallolyticus NTB1 (SG3; Radboud collection), 
S. gallolyticus subsp. gallolyticus 1293 (SG2) provided by Dr. R. Zarrilli (Tripodi et al., 2005), 
S. infantarius subsp. infantarius NCTC8133 (SI; (Biarc et al., 2004)) and S. gallolyticus subsp. 
macedonicus CIP105685T(SM) (Pasteur collection). In Table 1 the new and old designations 
for SB strains is depicted.
Reference strains were: Enterococcus faecalis 19433 (EF; www.atcc.org), Escherichia coli 
NTB5 (EC) and Salmonella typhimurium NTB6 (ST) from the Radboud collection, Lactobacillus 
plantarum WCFS1 (LP;(Kleerebezem et al., 2003)) and Bacillus subtilis 168 (BS;(Kunst et 
al., 1997)). All strains were grown on Columbia blood agar or in Brain Heart Infusion (BHI) 
broth (Difco) supplemented with 1% glucose at 37°C/5% CO2. LP was grown in MRS-broth at 
37°C/5% CO2 and EC was grown at 200 rpm.
Adherence and internalization assay
Caco-2 and HT-29 cells were cultured in 24-wells plates (Corning, NY) to approximately 1x106 
cells/well and infected with a multiplicity of infection (MOI) of 20. After 2 hours of incubation, 
monolayers were washed 3x with PBS to remove non-adherent bacteria and subsequently 
lysed in trypsin/PBS containing 0.025% triton-X100. Alternatively, extracellular adherent 
bacteria were killed with 200^g/ml gentamicin and 50^g/ml ampicillin for another hour 
to measure the amount of internalized bacteria. The amount of adherent or internalized 
bacteria was determined by Colony-forming unit (CFU) counting. Adherence was expressed 
as percentage of the inoculum and internalization as percentage of adherence.
Translocation assay
Caco-2 cells were cultured on transwell permeable supports with a polycarbonate membrane 
(3 ^m pore size, Corning). Trans-epithelial electrical resistance (TEER) measurements 
confirmed the formation of a polarized monolayer by a flattening of the TEER value (250­
350 Q*cm2) at 21 days (Milipore ERS)(Behrens et al., 2004). Bacteria were added to the 
apical compartment (M0I=50) and after incubation the number of viable bacteria in the 
apical and basolateral compartment was determined by CFU counting. At every time point 
medium in the lower compartment was replaced to prevent growth of translocated bacteria. 
Translocation was expressed as percentage of the inoculum.
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Confocal microscopy
1x109 bacteria were washed in PBS and labeled for 30 minutes at RT in PBS containing 0.5 
mg/ml Fluorescein isothiocyanate (FITC; Sigma). Next, bacteria were extensively washed 
to remove non-bound FITC before infection (M0I=50) of polarized Caco-2 monolayers on 
transwell permeable supports. After 4 hours of incubation in the dark, monolayers were 
washed, fixed in 3.7% formaldehyde and permeabilized in ice-cold methanol. Non-specific 
binding sites were blocked with 5%-BSA in PBS-0,3% triton (PBS-T) for 1 hour. Mouse-anti- 
actin antibody (Sigma) and rabbit-anti-Zonula-Occludentes-1 (ZO-1) antibody (Invitrogen) 
were diluted 1:1000 in PBS-T and incubated at 4°C overnight. After washing, secondary 
antibodies labeled with texas-red or alexa-fluor 647 were used to visualize actin and ZO-1. 
After staining, the transwell membranes were excised and mounted on slides using coverslips. 
The slides were analyzed with laser scanning confocal microscopy with an objective of 60x
O NA 1:35 (Olympus FV1000). Z-stacks were generated by scanning from the apical to the 
basolateral side. YZ and XZ planes were created with ImageJ using the orthogonal view tool.
Phagocytosis assay
Human monocytic THP-1 cells were seeded in 24-well plates at 50.000 cells/well in RPMI1640 
containing 1% FCS and were differentiated to macrophages by 50 ng/ml Phorbol 12-myristate 
13-acetate (PMA) 24 hours prior to phagocytosis assay. Next, bacteria were added (M0I=50), 
spun at 400g for 5 minutes and incubated for 30 minutes to allow phagocytosis. Extracellular 
bacteria were killed with 200^g/ml gentamicin and 50^g/ml ampicillin and after incubation 
viable intracellular bacteria (CFU) were determined by macrophage lysis with 1% saponin. 
Killing was expressed as percentage of phagocytosed bacteria at t=0.
7 Real-time PCRCaco-2, HT-29 and THP-1 cells were washed and lysed in RLT-lysis-buffer (QIAGEN, Rneasy mini kit) and RNA extraction was performed according to QIAGEN protocol. The RNA 
concentration and purity was evaluated with the Nano-drop (Nano-drop technologies). 
Next, Iscript RT-PCR (Bio-rad) was performed to synthesize 1^g of cDNA under the 
following conditions: 5' at 25°C, 30' at 42°C and 5' at 85°C. Expression of IL-8 and IL-16 
(gene expression assays Hs00174103_m1 and Hs00174097_m1, Applied biosystems) was 
compared to expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 4310884E 
gene expression assay) using the following Real-time PCR protocol: 2' at 50°C, 10' at 95°C 
and 40 cycles of 15'' at 95°C and 60'' at 60°C (7900 HT, Applied biosystems). Data were 
analyzed via the Delta-Delta-Ct method using SDS 2.2.1 software.
Biofilm formation
Biofilm formations assays were essentially performed as described before with some 
minor modifications (Heikens et al., 2007). Bacteria were cultured overnight in Tryptone- 
Soya-Broth containing 0.25% glucose, diluted to 107 bacteria per ml and dispensed in 
polystyrene 96-well plates that were either coated with collagen type I, collagen type IV, or 
non-coated. Plates were incubated for 24 hours at 37°C on a 3D-plate rotator (30 rpm). The 
cell suspension was removed, and biofilms were washed 3 times with PBS. Then plates were
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dried for 1 hour at room temperature and biofilms were stained with crystal violet solution. 
After 15 minutes excess crystal violet was removed, plates were washed 3 times with PBS, 
and crystal violet was dissolved in ethanol-acetone (80:20 v/v). The absorbance, which is 
representative for the amount of biofilm formed, was measured at 595nm (A595).
Electron microscopy
Bacteria were grown in Todd-Hewitt medium and collected after overnight growth 
(stationary phase). EM pictures were made as described previously (Vanrobaeys et al.,
1999). Briefly, Bacteria were collected and washed once with PBS. Then they were fixed for
2 h in cacodylate buffer containing 5% glutaraldehyde. Fixed bacteria were incubated with
1 mg/ ml polycationic ferritin in cacodylate buffer for 30 min. Bacterial cells were washed 
three times in cacodylate buffer and subsequently immobilized in 4% agar. Immobilized 
bacteria were washed five times in 0,1M cacodylate buffer and postfixed with 1 % osmium 
tetroxide in cacodylate buffer for 2 h. After washing three times in 0,1M cacodylate buffer, 
samples were dehydrated with a graded series of acetone washes. Samples were then 
washed on propylene oxide for 15 min and embedded in Epon resin. Ultrathin sections 
(70nm) were cut with a Leica Ultracut S microtome, stained with uranyl acetate and 
lead citrate and examined at 80kV accelerating voltage using a JEOL JEM 1010 Electron 
Microscope with Keenview camera using analySIS Image Processing software.
Results
S. gallolyticus strains display a relative low adherence to colon epithelial cells
The first important step to establish a gut-borne infection is adherence of bacterial cells 
to colonic tissue. Therefore, the binding capacity of SG clinical isolates to colonocytes was 
compared to that of the pathogen ST, the opportunistic pathogen EF and non-pathogenic 
EC and LP strains (Figure 1A and B). These experiments showed that EF is by far the most 
efficient adhering bacterium to both HT-29 and Caco-2 cells, reaching an adherence of about 
80% and 98% of the inocula, respectively. The non-pathogenic strains EC, SM and LP adhered 
moderately well (20-50%) to the monolayers. Adherence of the SG strains was similar to that 
of the pathogen ST, all with adherence percentages below 15%. Thus, the adhesive properties 
of SG are more resembling those of the pathogen ST than commensal-like bacteria. This may 
reflect one of the reasons that SG cannot efficiently colonize a healthy human intestinal tract.
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A .  Caco-2
HT -29
Figure 1. Bacterial adherence and 
invasion of epithelial cells
Adherence of indicated intestinal bacteria to 
Caco-2 (A) and HT-29 (B) colorectal cancer 
cells was analyzed after 2 hours of bacterial 
exposure. (C) Bacterial internalization after 2 
hours in Caco-2 cells. Adherence is presented 
as percentage of the bacterial inocula 
and subsequent bacterial internalization 
as percentage of adherent bacteria. SG 
= S. gallolyticus subsp. gallolyticus, SI = 
S. infantarius subsp. infantarius, SM = S. 
gallolyticus subsp. macedonicus, EF = E. 
faecalis, EC = E. coli, LP = L. plantarum, 
ST = S. typhimurium.
Caco-2
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Figure 2. Bacterial translocation 
across an epithelial monolayer
(A) Translocation of the indicated 
bacteria across differentiated and 
polarized Caco-2 cells was measured 
after 2, 4 and 6 hours. Significant 
increase in time is indicated by * or 
** for p<0.05 and p<0.01 (One-Way 
ANOVA), respectively. (B) Confocal 
microscopy of FITC-labeled bacteria 
(green) after translocation (t=6h). The 
cytoskeleton was stained with anti­
actin antibodies (red); top, lateral 
side; bottom, basolateral side of the 
epithelial monolayer; (C) ZO-1 staining 
(red) of the epithelial monolayer 
showing tight junction complexes in 
the differentiated monolayer. Although 
LP displayed some discrepant results 
between translocation and confocal 
microscopy, it may be assumed that 
this bacterium cannot efficiently 
cross epithelial cells (Stevenson et 
al., 1986). SG = S. gallolyticus subsp. 
gallolyticus, SI = S. infantarius subsp. 
infantarius, SM = S. gallolyticus 
subsp. macedonicus, EF = E. faecalis, 
EC = E. coli, LP = L. plantarum, ST = 
S. typhimurium.
7
S. gallolyticus subsp. gallolyticus translocates a colonic epithelial 
monolayer by a paracellular mechanism
After adhesion to colonic tissue, several invading mechanisms can be used by (opportunistic) 
pathogens. For example, Salmonellae are efficient in transcellular crossing of intestinal 
epithelium (Ibarra and Steele-Mortimer, 2009), whereas paracellular crossing is described 
for Group B streptococci (Pezzicoli et al., 2008).
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To get insight into the translocation capacity of SB strains, their internalization and 
translocation efficiencies were analyzed in Caco-2 transwell cultures. As shown in Figure 2C, 
none of the SB strains were invasive (max. 0.2% of adherent bacteria), but 6-19% of adhered 
SG and SI cells could translocate across the polarized and differentiated Caco-2 monolayer at 
similar efficiencies as the opportunistic pathogen EF (Figure 2A). In contrast, SM was unable 
to cross the differentiated monolayer (<2% of adhered bacteria), which clearly differentiates 
this strain from SG and SI. However, the data also showed that the only internalizing strain 
ST displayed by far the highest translocation percentage (81%) of adhered bacteria. Z-stacks 
made with confocal microscopy from the apical to the basolateral site confirmed that SG1- 
3, SI, EF and ST cells were indeed present at the basolateral side of the monolayer, while 
SM could only be detected at the apical side (Figure 2B). ZO-1 visualization (Figure 2C) 
(Stevenson et al., 1986) and TEER-measurements confirmed polarization and integrity of 
the monolayer during experiments, except for ST, which induced a dramatic reduction in 
TEER after 6 hours (data not shown) (Bertelsen et al., 2004). Therefore these data implicate 
that translocation of SG, SI and EF cannot be attributed to passive leakage through a non­
polarized monolayer, but instead constitutes an active process. Together, these data imply 
that SG and SI, but not SM, can translocate across a polarized epithelial monolayer via a 
paracellular mechanism.
S. gallolyticus subsp. gallolyticus is relatively invisible for the epithelial 
innate immune system
When pathogens cross the intestinal barrier, the intestinal epithelium attracts macrophages 
by the production of alarm signals. To evaluate to which extent SB strains induce an epithelial 
innate immune response, the expression of IL-8 and IL-16 in Caco-2 cells was measured 
with real-time PCR upon bacterial infection. As shown in Figure 3A and B, both IL-8 and 
IL-16 were strongly increased 2 and 4 hours after infection with ST (max IL-8 52-fold; IL-16 
4-fold) and EC (max IL-8 79-fold; IL-16 7-fold). The Gram-positive strains SI, SM and EF also 
significantly increased IL-8 mRNA levels after 4 hours of infection, but to a lesser extent than 
Gram-negative strains (max. 6-fold induction). Surprisingly, however, all three SG strains 
did not elicit a significant IL-8 or IL-16 response (Figure 3A and B), similar to the probiotic 
bacterium LP.
To investigate to which extent SG can withstand phagocytosis, SG1 cells were exposed 
to THP-1 derived macrophages. This experiment showed that about 14% of the SG cells 
were still viable after 24 hours (Figure 3C) in contrast to LP and BS cells (0%) that were 
used as positive controls for bacterial killing (Ceragioli et al., 2009, O'Brien and Melville,
2000), while the pathogen ST killed and escaped from macrophages within 5 hours after 
infection (data not shown) (Hensel et al., 1998). However, no macrophage killing was 
observed by SG and bacterial cells remained confined within the macrophage. Accordingly, 
macrophages responded adequately to SG infection by a 4-fold upregulation of IL-8 and a 
3-fold upregulation of IL-16 on the mRNA level after 4 hours, similar to ST. Together, these 
findings indicate that SG strains are relatively invisible for epithelial innate immunity upon 
infection, which could prolong their survival by the delayed recruitment of macrophages in 
the lamina propria.
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Figure 3. Bacterial interactions with 
the innate immune system
Epithelial IL-8 (A) and IL-16 (B) immune 
response in Caco-2 cells elicited by the 
indicated bacterial strains after 2 and 4 
hours of incubation. Data are presented 
as log 2 values of fold changes. Significant 
inductions are marked with * for p<0.05 
and ** for p<0.01 (Two-way ANOVA with 
Bonferroni post tests) (C) Bacterial killing 
by PMA-stimulated THP-1 macrophages 
was analyzed after 5 and 24 hours by CFU 
counting of viable bacteria. Significant 
reductions in time are indicated with ** for 
p<0.01 (Two-way ANOVA with Bonferroni 
post tests). SG = S. gallolyticus subsp. 
gallolyticus, SI = S. infantarius subsp. 
infantarius, SM = S. gallolyticus subsp. 
macedonicus, EF = E. faecalis, EC = E. coli, 
LP = L. plantarum, ST = S. typhimurium, BS 
= B. subtilis.
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S. gallolyticus subsp. gallolyticus forms biofilms at collagen-coated surfaces
After entry into the human body and escape from the immune system, SG has the 
opportunity to establish endocarditis in susceptible patients. For endocarditis, it is known 
that bacterial binding to extracellular matrix proteins and biofilm formation are important 
characteristics to facilitate survival of bacterial vegetations on damaged or prosthetic heart 
valves (Sillanpaa et al., 2009, Vollmer et al., 2010). As shown in Figure 4, all SG strains were 
indeed efficient in forming biofilms on collagen I or IV coated surfaces (A595 0.4 - 1.4), while 
this was clearly not the case for uncoated polystyrene surfaces (A595 <0.15). In contrast, 
SM, SI and EF could form a biofilm on polystyrene surfaces (A595 0.2 -  0.4) irrespective of 
the presence of collagens. In contrast, the pro-biotic bacterium LP did not form a biofilm 
under any of the tested conditions. These data demonstrate that SG strains have exclusive 
features that enable them to form biofilms on collagen-rich surfaces.
Figure 4. Bacterial biofllm formation
Biofilm formation of gram-positive bacteria on polystyrene and collagen type I and IV coated surfaces. 
Significant differences are indicated with * for p<0.05 and ** for p<0.01 (Two-way ANOVA with 
Bonferroni post tests). SG = S. gallolyticus subsp. gallolyticus, SI = S. infantarius subsp. infantarius, SM 
= S. gallolyticus subsp. macedonicus, EF = E. faecalis, LP = L. plantarum..
7
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Discussion
In the present study we reconstructed the route of gut-borne bacterial infections in CRC 
patients. Basically there are 4 key events in establishing endocarditis starting from the 
intestinal tract: i) fixing a dependable connection with the enterocyte or its extracellular 
matrix ii) translocation of the epithelial barrier iii) evasion of immune cells in the lamina 
propria and iv) survival in the blood stream and ability to establish a secondary infection. 
By comparative bacterial virulence analysis, we provided new clues on the underlying 
mechanism that specifically causes the increased incidence of clinical SG infections in CRC 
patients. Focusing on the initial step of gut-borne infections, adhesion of SG to epithelial 
cells can be categorized as low compared to related SB strains and other intestinal bacteria. 
Genome exploration of SG revealed that SG contains a capsular operon that shows high 
similarity in its organization with S. pneumonia serotype 23F (Rusniok et al., 2010), whereas 
SM contains a different capsule operon (P. Glaser, unpublished data). The diverse surface 
structures that are likely to determine the distinct adhesive properties of SG and SM to 
epithelial cells are clearly visualized by electron microscopy (Figure 5).
Figure 5. Distinct surface structure of S. bovis strains
Electron micrograph picture of representative cells from the bacterial SG1 (A) and SM (B) strains which 
illustrates the different surface structure of these closely related SB strains. SG = S. gallolyticus subsp. 
gallolyticus, SM = S. gallolyticus subsp. macedonicus.
In general, capsular polysaccharides are known to negatively affect bacterial adhesion to 
host cells, but may also shield the bacterial cell from the immune system and thereby be 
an important virulence factor (Stollerman and Dale, 2008, Thurlow et al., 2009, Vanrobaeys 
et al., 1999). In fact, encapsulation of SG strains has already been shown to contribute to 
virulence in pigeons (Vanrobaeys et al., 1999).
Our data clearly showed that SG is able to translocate across an intestinal epithelial layer, 
while it was unable to invade epithelial cells like pathogenic bacteria such as Salmonellae 
(Ibarra and Steele-Mortimer, 2009). Genome exploration of SG revealed that this bacterium 
contains three pilus operons (Rusniok et al., 2010) with homology to the pilus backbone of 
group B streptococci that are known mediators of paracellular translocation (Pezzicoli et
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al., 2008, Soriani et al., 2006). Strikingly, none of these operons are present in the genome 
of SM (P. Glaser, unpublished data) for which no translocation was observed. These data 
suggest that pillus-like surface structures of SG are important determinants to enter the 
human body. The third crucial step to establish an infection is the escape from the host 
immune system. Upon passage of the intestinal wall by a pathogen, immune cells in the 
lamina propria are normally alerted by the production of e.g. IL-8 and IL-16 originating from 
epithelial cells (Acheson and Luccioli, 2004, Stadnyk, 1994).
Figure 6. Model for the specific association of SG-endocarditis with CRC
Based on the data of ourselves and others we postulate that SG is an inefficient colonizer of a healthy intestinal 
tract and that it benefits from adenomatous epithelial tissue with displaced collagen type IV expression to 
translocate the epithelium via a paracellular mechanism. In comparison, the closely related strain SM is very 
effective in adhesion, but unable to cross an epithelial layer. Upon infection, SG is relatively invisible for the 
epithelial immune system causing a delayed recruitment of tissue macrophages, which increases its chances 
to reach the blood stream. In contrast, other invading bacteria, such as ST and EF, induce a (strong) epithelial 
immune response upon which these infections are readily cleared by attracted macrophages. Its important 
to note that SG infections remain subclinical in the majority of individuals due to its low virulence in humans. 
However, in a very small fraction of CRC patients with co-incidental collagen depositions at for example 
damaged heart valves, SG infections can become clinically manifest by the effective formation of resistant 
bacterial vegetations, which present themselves as endocarditis. SG = S. gallolyticus subsp. gallolyticus, SM = 
S. gallolyticus subsp. macedonicus, EF = E. faecalis, ST = S. typhimurium.
7
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In this study, we showed that epithelial cells were relatively unresponsive to SG compared to 
other intestinal bacteria, which will delay IL-8 and IL-16 expression upon its infection. Notably, 
a functional TLR-2 pathway is present in Caco-2 cells (Chen et al., 2007, Melmed et al., 
2003), which is underscored by IL-8 and IL-16 induction after exposure to EF. This implicates 
that the unresponsiveness to SG is not due to lack of TLR2-mediated recognition of Gram­
positive bacteria. In contrast, SG-infected macrophages yielded immune responses similar 
to other bacterial strains, and phagocytosed SG were unable to escape from macrophages. 
Together, these findings suggests that the increased incidence of SG infections in CRC 
patients relates (in part) to a reduced epithelial immune response to SG and subsequent 
delayed recruitment of tissue macrophages, but not to resistance to macrophage-mediated 
killing itself, which increases its chances to reach the circulation upon translocation of the 
bowel wall.
The final phase in the infective process towards bacterial endocarditis is survival in the 
bloodstream and infection of the heart endothelium. In general, Gram-positive bacteria 
are relatively resistant to complement killing (Hyams et al., 2010). The fact that silent SG 
infections can occur is nicely illustrated by the fact that this bacterium was found in the blood 
of a "healthy" blood donor who appeared to have a colon malignancy upon endoscopic 
examination (Haimowitz et al., 2005). Furthermore, we have previously shown that early 
stage CRC patients can have increased antibody titers against SG antigens without clinical 
signs of infection (Boleij et al., 2010, Tjalsma et al., 2006). Our observation that SG has an 
advantage over other Gram-positive intestinal bacteria to form biofilms on collagen types
I and IV may be crucial to explain the pathology of SG endocarditis. The aforementioned 
pilus structures may, in addition to paracellular transport, also play an important role in the 
binding of SG to ECM proteins (Mandlik et al., 2008, Sillanpaa et al., 2008, Vollmer et al., 
2010), which is especially evident from the fact that one of the SG pilus operons encodes a 
collagen-binding protein (Rusniok et al., 2010, Sillanpaa et al., 2009). Thus, a prerequisite for 
SG to establish a clinical infection in CRC patients seems to be the co-incidental presence of 
collagens at the secondary infection site, including damaged heart valves, hepatic cirrhosis 
and total knee replacements (McGee and Fallon, 1978), which could explain the low co­
occurrence of SG infections in CRC patients (estimated < 0.1%). Although SI has a similar 
translocation efficiency, it lacks the improved ability to form biofilms on collagen, which is 
in-line with the fact that SI is less often found in endocarditis, but is more often the cause of 
bacteremia in CRC patients (Jean et al., 2004).
Based on our current comparative virulence analysis, the most outstanding characteristic of 
SG is its ability to form biofilms on collagen-rich surfaces. This finding inspired us to mine 
the scientific literature for additional links between SG, collagens and CRC. Intriguingly, 
this yielded previous histological observations that polyps and early colorectal tumors are 
characterized by a continuous expression of collagen type IV in basement membranes that 
surrounds the crypts in the mucosa of hyperplastic polyps (Yantiss et al., 2001). Accordingly, 
the collagen type IV containing basement membrane showed saw-like protrusions into 
the basal parts of the adenomatous epithelium (Galbavy et al., 2002). In this situation, 
opportunistic pathogens, like SG that have low adhesive properties to epithelial cells, could 
gain a competitive advantage to colonize these (pre-)malignant sites. This may very well
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explain why SG colonizes only 10% of the normal population, whereas it colonizes over 
55% of CRC patients (Johansson et al., 2008). Furthermore, recent molecular analyses have 
indeed pointed towards increased colonization of CRC tissue by SG strains ((Abdulamir et al., 
2010);our unpublished observations).
Summarizing the above, we hypothesize that two surface features of SG are the main 
determinants for its specific association with endocarditis and CRC. First, SG contains a 
polysaccharide capsule that lowers its adhesive capabilities to epithelial cells, however this 
same capsule allows SG to stay invisible for the host immune system for a prolonged period 
of time. Second, SG contains pilus-like structures that facilitates colonization of polyps 
and adenomatous epithelium, paracellular translocation and the formation of resistant 
vegetations on collagen-rich sites. A model that summarizes these distinguished virulence 
features of SG is depicted in Figure 6. It goes without saying that our experiments did not 
fully mimic the complex ecosystem of the gut or the human immune system and that future 
studies should concentrate on the actual role of the here highlighted virulence factors 
(i.e. capsular polysaccharides and pili) in invasion, immune evasion or biofilm formation. 
Preferably this would be done by evaluating mutant SG strains in live infection models. 
Nevertheless, our in vitro approach gave us the opportunity to gain new insights into the 
infective mechanisms utilized by SG in CRC patients, which provides clear leads for these 
future explorations. Finally, our study underscores the importance of proper microbiological 
classification of SB subspecies. As only SG seems to contain virulence characteristics that 
clearly associate endocarditis with underlying colon malignancies, the specific diagnosis of 
SG infection might become a valuable tool for the early detection of CRC.
7
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Chapter 8 - S. gallolyticus forages on tumor cell metabolites
Abstract
One of the few bacteria that has been consistently linked to colorectal cancer (CRC) is 
the opportunistic pathogen Streptococcus gallolyticus, an infection of which is generally 
regarded as indicator for colonic malignancy. However, in a healthy situation this bacterium 
is outcompeted by the complex microbiota in the relatively nutrient poor ecosystem of the 
large intestine. To investigate whether colon tumors can favor the survival of S. gallolyticus, 
the altered metabolic conditions in the CRC microenvironment were simulated by bacterial 
growth in spent medium of malignant colonocytes. Under these conditions, bacterial 
responses were protiled by proteome analysis and metabolic shifts were analyzed by 
lH-NMR-spectroscopy. In silico pathway analysis and further in vitro simulations indicated 
that fructose-6-phosphate and alanine provided S. gallolyticus with a significant growth 
advantage, which was not observed for other intestinal bacteria. Together, these data 
suggest that tumor cell metabolites that accumulate at the CRC interface may facilitate the 
colonic survival of S. gallolyticus and favor its local outgrowth, which eventually may lead to 
tumor-borne systemic infections.
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Introduction
The human intestine is the habitat for several hundred different bacterial species with an 
increasing bacterial concentration and variability towards the distal colon (Eckburg et al., 
2005). The resident gut microbiota is essential for human health by making dietary nutrients 
available to the host and prevents the invasion of pathogens by providing colonization 
resistance and nutrient competition (Hooper et al., 2002, Vollaard and Clasener, 1994). 
Strikingly, the part of the intestine with the highest bacterial colonization, the colon, is 
also most affected by cancer, with 146,970 annual cases in the USA (Jemal et al., 2009). 
In a healthy colonic environment, the host has several defense mechanisms to shield 
itself from bacterial infection, such as the viscous mucus layer overlaying the epithelium. 
However, colorectal cancer (CRC) is characterized by several changes such as reduced mucus 
production (Johansson et al., 2008) and increased epithelial permeability (Soler et al., 1999). 
These physiological changes can drive the intestinal ecosystem, which is relatively stable 
during adult life, into dysbiosis (Green et al., 2006, Marchesi et al., 2011). As a consequence, 
the host is more susceptible to opportunistic bacterial infections under those conditions 
(Aksoy and Akinci, 2004, Stecher and Hardt, 2008).
One of the few bacteria that has been consistently linked to CRC is the opportunistic 
pathogen Streptococcus gallolyticus (previously known as S. bovis biotype I). In the healthy 
population, this bacterium seems a prominent inhabitant of the small intestine (Booijink et 
al., 2010), but it seems to be outcompeted by the more complex microbiota upon entrance 
of the large intestine. However, in CRC patients the fecal carriage rate of this bacterium 
is increased from 10 to about 50% (Klein et al., 1977), which suggests that this disease 
facilitates the colonic survival of S. gallolyticus. Importantly, 33 to 100% of patients that 
present with S. gallolyticus endocarditis have concomitant CRC (both adenomas and 
carcinomas; our unpublished systematic review and meta-analysis) (Corredoira et al., 2005), 
which largely exceeds the rates reported in the general population (~25%) (Lieberman et 
al., 2000). Notably, these patients had no gastro-intestinal signs or clinical symptoms of 
malignancy and CRC was only detected because this bacterial infection guided the physician 
to perform a colonoscopy.
Several mechanisms for this apparent association between S. gallolyticus and CRC can 
be envisaged. Recently, we postulated a model in which the collagen binding ability of S. 
gallolyticus contributes to the specific colonization of malignant colonic sites (Boleij et 
al., 2011). However, also the altered microenvironment of the tumor itself may provide 
conditions that favor survival and outgrowth of S. gallolyticus in this newly formed intestinal 
niche. For example, Hirayama et al. have shown that glucose concentrations in CRC tissue are 
significantly lower than in normal tissue. Conversely, glucose-1-phosphate and fructose-1- 
phophate levels as well as amino acid concentrations were shown to be increased (Hirayama 
et al., 2009). To investigate if these altered nutrient conditions in the CRC microenvironment 
could facilitate the survival of S. gallolyticus, we simulated the influence of colon tumor 
cell metabolites on S. gallolyticus growth by incubating this bacterium in spent medium 
of malignant cells and subsequently profiled bacterial responses by two-dimensional 
proteome analysis, and metabolic shifts in the culture medium by JH-NMR-spectroscopy. In
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silico pathway analysis and further in vitro simulations showed that, unlike other intestinal 
bacteria, S. gallolyticus had a growth advantage when cultured on fructose-6-phosphate 
and alanine. These results provide the first molecular evidence that tumor metabolites that 
accumulate at the CRC interface may result in the recruitment and outgrowth of a local 
tumor-specific bacterial population.
Materials and methods 
Cell culture and bacterial strains
Colorectal adenocarcinoma cell lines HT-29, SW480, HCT116 and Caco-2 (www.atcc.org) 
were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Lonza) supplemented with 
10% Fetal Calf Serum (FCS), 20 mM HEPES, 2mM L-Glutamine and lx  non-essential amino 
acids (Gibco) (further indicated as standard medium) at 37°C/5% CO2. These culturing 
conditions were used unless stated otherwise.
The following bacterial strains were used; Enterococcus faecalis 19433 (www.atcc.org), 
Lactobacillus plantarum WCFS1(Kleerebezem et al., 2003) and E. coli Nissle 1917 (obtained 
from Julian Marchesi). S. gallolyticus subsp. gallolyticus UCN34 (further designated as 
S. gallolyticus) and the genetically resembling non-pathogenic strain S. gallolyticus subsp. 
macedonicus CIP105685T (further designated as S. macedonicus) from the Pasteur collection 
(Rusniok et al., 2010, Schlegel et al., 2003). Escherichia coli NTB5, Salmonella typhimurium 
NTB6(Boleij et al., 2011), Staphylococcus lugdunensis NTB8, Enterobacter cloacae NTB9 and 
Klebsiella pneumonia NTB10 from the Radboud strain collection. All strains were grown on 
Columbia blood agar or in Brain Heart Infusion (BHI) broth (Difco) supplemented with 1% 
glucose at 37°C/5% CO2. L. plantarum was grown in de Man, Rogosa and Sharpe (MRS)-broth 
and E. coli and E. coli Nissle were grown in BHI at 200 rpm at 37°C/5% CO2.
Bacterial growth experiments
To determine bacterial growth characteristics in the presence of tumor cell metabolites, CRC 
cell lines were first cultured for three days in standard DMEM growth medium. Next, the 
culture supernatants were collected (designated as spent medium) and bacterial growth in 
this spent medium was compared to the growth in standard medium (control condition). 
Every 20 minutes bacterial density was measured by determining the 0D600 in a microplate 
reader (Ascent).
To determine bacterial growth rates in simulation experiments, standard DMEM medium 
was supplemented with the amino acids L-alanine (2 mM) or phenylalanine (2 mM). Besides 
these amino acids, this medium was supplemented with fructose 6-phosphate (F6P) or 
3-phosphate glyceric acid (3PG), both at a concentration of 1 or 2 mM. Combinations of 
F6P (1mM) and 3PG (1mM) with the amino acids L-alanine (2 mM) and phenylalanine (2 
mM) were made to assess the combined effect of these substances on S. gallolyticus and 
E. coli growth. Media were inoculated with ~1x107 S. gallolyticus or E. coli and 0D600 was 
measured every 20 minutes. Bacterial growth rates were determined from 3 independent
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experiments at the linear part of the bacterial growth curves and plotted using Graphpad
4.0. Slope differences were determined in Graphpad 4.0 using linear regression models and 
considered significant at p < 0.05.
Protein sample collection
For 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) analysis, S. gallolyticus 
was grown to mid-log phase (0D600 of 0.4) in spent medium of Caco-2 or HCT116 cells. 
Alternatively, S. gallolyticus was grown in spent medium of Caco-2 cells in the presence of 
viable Caco-2 cells. As control condition S. gallolyticus was grown to mid-log phase in standard 
medium (0D600 of 0.2). All incubations were performed in triplicate. At the appropriate 
OD600, bacteria were collected (4000 g, 10 minutes) and washed 2 times with PBS (8000 
g, 3 minutes). Next, bacteria were suspended in lysis solution (2mM MgCl2) containing 3 
mg/ml lysozyme (Biochemica) and 100 ^g/ml mutanolysin (Sigma Aldrich) and incubated at 
37°C for 60 minutes. After incubation, 1% SDS was added together with a protease inhibitor 
cocktail (Roche). Samples were sonicated 3 times on ice at 30% with 0.3 sec intervals 
for 20 seconds on a DIGITAL Sonifier® UNITS Models S-250D (Branson). After sonication, 
benzonase (Novagen) treatment (0.625 U/^l) for 30 minutes on ice was performed to 
degrade remaining DNA. Insoluble material was removed by spinning the samples at 4°C for 
30 minutes at 14000g. The supernatants were solubilized 1:1 in solubilization solution (7M 
Urea, 2M Thiourea, 10% CHAPS, 50 mM DTT and 0.2% carrier ampholytes (pH 3-10)) and 
stored at -80°C until further analysis. Protein concentration in the samples was measured 
with the Bradford protein assay (BioRad) according to the manufacturers' instruction.
2D-PAGE
After thawing, 350 ^g protein per sample was diluted in rehydration solution (final 
concentration: 5 mM Tris-HCl pH 8.8, 7M Urea, 3M Thiourea, 75 mM DTT, 2% carrier 
ampholytes (pH 3-10)). Samples were spun at 14000g for 10 minutes and the supernatant 
was brought onto a 17 cm IPG-strip (pH 4-7; Biorad). Strips were rehydrated overnight (o/n) 
with active rehydration at 50 V and 20°C. After applying moist electrode wicks, iso-electric 
focusing (IEF) was performed on a Biorad Protean IEF Cell using the following protocol: 1 
hour at 200 V, 1 hour at 500 V, 1 hour at 1000 V, linear to 8000 V during 30 minutes, 8000V 
to 20.000 Vhours. Next, IPG-strips were equilibrated with equilibration solution 1 (0.375 M 
Tris-HCl (pH 8.8), 6 M urea, 2% SDS, 20 % glycerol, 2% DTT) for 10 minutes and subsequently 
with equilibration solution 2 (0.375 M Tris-HCl (pH 8.8), 6 M urea, 2% SDS, 20 % glycerol, 
4% iodoacetamide) for 10 minutes. The second dimension was run on Protean II Ready gels 
(12% Tris-HCl; Bio-rad) in 1 xTris-Glycine electrophoresis buffer (Biorad) at 24 mA/gel during
5 -  6 hours using a continuous cooling system. Next, gels were fixed for 1 hour in 10% acetic 
acid and 50 % methanol in ddH2O. Proteins were visualized with Blue silver staining (0.12% 
Coommassie G-250, 10% (NH4)2-SO4, 10% H3PO4, 20% methanol). After protein staining, gels 
were scanned on an Odyssey gel system at 700 nm (focus offset 0.5 mm and scan intensity 
4.0).
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Delta-2D analysis
High-resolution TIFF files of the protein gels were loaded into Delta-2D (Decodon) and 
warped following the group warping strategy as outlined in the Delta-2D manual. Due to 
imperfect IEF, 1 gel from the condition in which S. gallolyticus was grown in spent medium 
from Caco-2 cells in the presence of viable Caco-2 cells was excluded from analysis. After 
warping, a fusion image was generated for spot detection using one of the "control" gels 
as master image. Spots were automatically detected by the software and visually evaluated 
to remove "noise" spots. Spot intensities were generated using overall normalization. For 
a first evaluation of the samples, scatter plots were generated. Furthermore, sample and 
protein expression clustering were evaluated by principal component analyses (PCA) and 
hierarchical clustering using complete linkage with Euclidian distance. Statistical analysis 
was carried out using ANOVA for overall comparison of the groups and student's t-test 
(based on permutations) was used for individual comparisons of the experimental groups 
to the control group. Expression differences were considered significant at a p-value below 
0.01. The False Disovery Rate (FDR) was set at 10 proteins or less. Spots were selected for 
spot identification based on statistical tests, a fold-change of at least 2 and a normalized 
expression value of at least 0.05.
Global metabolic pathway analysis
To obtain a global picture of the affected metabolic pathways of S. gallolyticus, significantly 
changed proteins in all three spent media conditions , as identified by Delta-2D analysis, 
were mapped to the KEGG global map of metabolic pathways (Kanehisa et al., 2008) via 
orthologous groups (COGs) using the Signature web server (Dutilh et al., 2008). These 
pathways were visualized on the global metabolic map using iPath (Letunic et al., 2008), 
where the width of the line represents the number of protein spots, and the color represents 
the average fold-change in expression of all proteins mapped to a specific pathway (see 
Addendum 3). For a general overview of the affected metabolic pathways, mean fold 
changes for these pathways were calculated based on the average fold change in all three 
media conditions (Table 2). A more detailed outline of the affected cellular functions was 
obtained by using the annotations provided by the RAST server (Aziz et al., 2008), which 
assigns each function to a subpathway.
vMaldi-MS/MS protein identification
Preparative 2D-PAA gels were prepared as described above. Protein spots were excised with 
a clean scalpel in a laminar flow hood to reduce keratin pollution and stored in a microtiter 
plate. Spots were dehydrated with acetonitrile and stored in -80 until further analysis. Next, 
gel-pieces were thawed and subjected to in-gel-trypsin digesting as described previously 
(Ettwig et al., 2010). After digestion, peptides were extracted by sonication in a water bath 
for 15-20 seconds, concentrated using a centrifugal evaporator, and diluted 1:1 with 2% 
trifluoroacetic acid (TFA). Next, samples were spotted on a stainless steel MALDI plate. 
Sample analysis was performed on a linear ion trap fitted with an intermediate pressure 
matrix-assisted laser-desorption ionization source (vMALDI-LTQ; Thermo Fisher Scientific) 
(Guillard et al., 2009). In total, 5 full MS runs were analyzed, each resulting in a selection
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of the 10 highest peaks that were further analyzed by collision-induced dissociation 
fragmentation analysis. Generated RAW-data files, were analyzed with SEQUEST (Ver. 28 
Rev.12) and identifications were considered significant with a peptide probability > 1e- 
002, and a protein probability > 1e-003. The following modifications were allowed in the 
search: carbamidomethylation of cysteines (fixed), oxidation of methionine (variable) and 
deamidation of asparagine and glutamine (variable). See Addendum 2 for further details on 
vMALDI-MS/MS protein identification, data analysis settings and validation criteria.
1H-NMR-spectroscopy
Standard medium and spent medium samples were deproteinized using Sartorius Centrisart
I filters (cut-off 10 kDa; Sartorius AG, Goettingen, Germany). Before use, the filter was 
washed twice by centrifugation of water to remove glycerol. A small volume (20 ^L) of 
20.2mM trimethylsilyl-2,2,3,3-tetradeuteropropionic acid (TSP, sodium salt; Aldrich) in D2O 
was added to 700 ^L of the ultrafiltrate, providing a chemical shift reference (0.00 ppm) 
and a deuterium lock signal. Finally, 650 ^L of the sample was placed in a 5mm NMR tube 
(Wilmad Royal Imperial; Wilmad LabGlass, USA).
Single pulse JH-NMR spectra (500 MHz) were obtained on a Bruker DMX-500 spectrometer 
as described by Engelke et al. (Engelke et al., 2006). Phase and baseline were corrected 
manually.
All spectra were scaled to TSP and metabolite signals were fitted semi-automatically with 
a Lorentzian line shape. Metabolite concentrations in the spent media were calculated 
relative to the known concentration in the standard medium and correspondingly expressed 
as mM or mg/ml. The concentration of lactate in the standard medium was calculated by 
comparing the area of lactate with the area of the valine doublet at 1.04 ppm.
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Results
Growth advantage of S. gallolyticus in spent medium of colorectal cancer cells
To investigate the influence of CRC metabolites on the growth of S. gallolyticus and other 
intestinal bacterial strains, bacteria were inoculated in spent medium from Caco-2 cells. As 
indicated in Figure 1, the bacterial growth rate of S. gallolyticus and S. macedoncius in this 
medium was significantly increased compared to the growth rate in control medium with 
factor 3.1 and 13.9 respectively (p < 0.001).
Figure 1. Growth of S. gallolyticus and other intestinal bacteria in spent medium from 
Caco-2 cells
Bacterial growth rates were determined by linear regression analysis of the linear part of the growth 
curves as shown for S. gallolyticus (A), S. macedonicus (B), L. plantarum (C), E. coli (D), S. lugdunensis 
(E), and S. typhimurium (F). Growth rates were significantly increased in spent medium from Caco-2 as 
compared to standard medium (control) for S. gallolyticus and S. macedonicus (p < 0.001). Conversely, 
the growth rates of S. lugdunensis, L. plantarum and E. coli were significantly higher in standard 
medium as compared to spent medium from Caco-2 cells (p < 0.01), whereas no different growth rates 
were observed for S. typhimurium. These results suggest that S. gallolyticus and S. macedonicus can 
forage on excreted Caco-2 cell metabolites, whereas this is not the case for other intestinal bacteria.
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Conversely, the growth rates of L. plantarum, E. coli, S. lugdunensis (p < 0.01), and 
S. typhimurium (non-significant) were reduced in spent medium of Caco-2 cells. Similar 
effects on growth were observed when these bacteria were grown in spent medium from 
other CRC cell lines (HT-29, SW480 and HCT116; Addendum 3). Together, these results suggest 
that cancer cell metabolites can specifically provide S. gallolyticus and the closely related 
bacterium S. macedonicus with a competitive growth advantage. Since S. macedonicus lacks 
the virulence factors to become a human pathogen (Boleij et al., 2011), further experiments 
focused on S. gallolyticus.
Proteome profiling of S. gallolyticus cells grown in spent medium from 
tumor cells
To further investigate which metabolic pathways were involved in this growth advantage, 
the changes in the S. gallolyticus proteome were explored by 2D-PAGE analysis. To this 
purpose, S. gallolyticus responses upon incubation in spent medium from HCT116 cells, 
and in spent medium from Caco-2 cells in the absence or presence of viable Caco-2 cells, 
were compared to the control condition in which S. gallolyticus was grown in standard 
medium. The condition with viable Caco-2 cells was included to allow cross-talk within 
this hybrid co-culture system. Figure 2A and B show that the proteomes of the replicate 
conditions cluster together both in hierarchical clustering and in PCA. These data indicate 
that the biological replicates yielded highly similar and reproducible expression profiles, 
but that distinct responses were induced under the different experimental conditions. The 
expression profiles of S. gallolyticus grown in spent medium of Caco-2 cells were similar 
to the condition where also viable Caco-2 cells were present, which implies that the 
components that had already accumulated in the spent medium dominated the altered 
expression of S. gallolyticus proteins. The protein expression profile of S. gallolyticus grown 
in spent medium of HCT116 cells shows a somewhat different pattern than the two Caco-2 
conditions (Figure 2A). Overall comparison with ANOVA (data not shown) and the individual 
comparison with students t-test of the experimental conditions with the control resulted in 
a total of 99 differentially expressed protein spots (p<0.01). The corresponding clusters with 
identified proteins are depicted in Figure 2C.
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Figure 2. Protein expression clustering and principal component analysis (page 136-137) 
Protein expression levels o f S. gallolyticus grown in standard medium (A), spent medium o f Caco-2 
cells (B) or HCT116 cells (C), or in spent medium o f Caco-2 cells in the presence o f viable Caco-2 
cells (D) were visualized using hierarchical clustering analysis (panel A) and principal component 
analysis (panel B); numbers refer to the biological replicas o f each experimental condition. Both 
these analyses showed that the replicate experiments o f each condition clustered together. 
Furthermore, the two independent Caco-2 conditions, with and without viable cells, (B and D) had 
similar expression patterns. In panel C, proteins that were found to be expressed at significantly 
(p<0.01) different levels from  the control condition (A) are shown in clusters for each o f the three 
experimental conditions.
Protein identification
A total of 176 protein spots from the master gel (Figure 3) were selected for protein 
identification based on the selection criteria as described in the materials and methods 
section. vMALDI-MS/MS and subsequent SEQUEST searches resulted in the identification 
of 120 proteins (68%) (Table 1). Functional classification of these proteins shows that 50 
proteins have a function in metabolism, especially in carbohydrate metabolism, amino acid 
metabolism and metabolism of nucleotides (Table 1). Other identified proteins are involved 
in protein synthesis, cell wall synthesis and cellular processes. Unfortunately, to a total of 
21 hypothetical proteins, no function could be assigned . In general, protein expression 
differences of S. gallolyticus grown in the three spent media conditions pointed in the same 
direction (up- or down-regulated relative to control condition). However, the expression of 
some proteins, such as ribosomal proteins S15 and L19, was only altered in one of these 
experimental conditions. Selected differences and similarities in S. gallolyticus protein 
expression levels under the applied conditions are illustrated in Figure 3.
Figure 3. 2D-PAGE analysis of S. gallolyticus cell lysates (page 139)
S. gallolyticus proteins that were differentially expressed when grown in standard medium (A, red), 
spent medium of Caco-2 cells (B, green) or HCT116 cells (C, yellow), or in spent medium of Caco-2 cells 
in the presence of viable Caco-2 cells (D, blue) are indicated with the indicated color on the protein 
gel. A selection of differentially expressed proteins is illustrated by bar charts. For example, lactate 
dehydrogenase expression was reduced under all experimental conditions (B-D) compared to growth 
in standard medium (condition A), whereas the expression of ribosomal protein L19 was only increased 
when S. gallolyticus was grown in spent medium of HCT116 cells (condition C).
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Table 1. Identified proteins with significant changes
functional
spot nr GALLO-code protein
catergory1
Cell envelope and cellular processes
1.7 GALLO_0608 cell division initiation Droteln DivlVA
1.7 GALLO_0608 cell division initiation Droteln DivlVA
1.2 GALLO_2047 maneanese ABC transDorter. substrate-blndine IlDrotein and adhesin
1.4 GALLO_0211 NADPH-deDendent FMN reductase
1.2 GALLO_1412 ABC transDorter. substrate-binding protein
6 1.2 GALLO_1412 ABC transDorter. substrate-binding protein
7 1.1 GALLO_0830 dTDP 4-keto 6-deoxvelucose 3.5-eDlmerase
Intermediary metabolism
8 2.3 GALLO_0028 DhosDhoribosvlaminolmldazole synthetase
9 2.1 GALLOJL129 lactate dehydrogenase
10 2.3 GAI±0_0028 DhosDhoribosvlaminolmldazole synthetase
11 2.3 GALLO_2088 Deoxv UTP DvroDhosDhatase (dUTPase)
12 2.3 GALLO_0025 DhosDhoribosvlaminolmldazole succlnocarboxamide svnthetase
13 2.1 GALLO 1458 enolase
14 2.1 GALLO_1137 deoxvrlbose-DhosDhate aldolase
15 2.1 GALLO_0255 fructose-bisDhosDhate aldolase
16 2.3 GALLO_0028 DhosDhoribosvlaminolmldazole svnthetase
17 2.1 GALLO_1996 slvceraldehvde-3-DhosDhatedehvdroaenase
18 2.3 GALLO_0028 DhosDhoribosvlaminolmldazole synthetase
19 2.1 GALLO_1996 elvceraldehvde-3-DhosDhatedehvdroRenase
20 2.1 GALLO_0255 fructose-bisDhosDhate aldolase
21 2.4 GALLOJ337 dioxveenases related to 2-nitroDroDane dioxveenase
22 2.1 GALLO_0255 fructose-bisphosphate aldolase
23 2.1 GALLOJL995 DhosDhoelycerate kinase
24 2.2 GALLOJL744 DhosDhoelvcerate dehydrogenase
25 2.2 GALLO_1293 glutamate dehydrogenase
26 2.1 GALLO 1458 enolase
27 2.3 GALLO_1766 uracil Dhosohoribosvltransferase
28 2.1 GALLO_0990 Pyruvate klnsase
FC Control 
vs Caco-2
-4.79
-3.60
-2.52
1.03
1.16
1.45 
1.59
-8.08
-5.41
-3.54
-3.25
-3.05
-2.97
-2.63
-2.06
-2.06
-1.75
-1.27
-1.17
1.46 
1.55 
1.58 
1.79 
2.24 
2.37 
2.77
5.05
5.05
FC Control 
vs HCT116
-1.05
-1.06
-4.11
1.82
2.48
3.35
1.28
-2.44
-6.09
-3.66
-8.30
-1.23
-2.38
-1.35
1.11
-2.37
-3.47
-2 .6 6
-2.87
2.21
1.72
1.84
6.24
2.68
2.27
2.11
1.53
2.88
FC Control 
vs v-Caco-2
-4.49
-2.74
-1.54
2.11
- 1.01
1.19
1.35
-4.07
-5.18
-3.52
-4.92
-2.97
-2.50
-2.24
-1.77
-1.93
-2.84
-4.74
1.15
1.36 
1.53 
1.60
1.30
1.31 
2.55 
2.52 
4.97 
2.94
p-value 
Control vs 
Caco-2
0.00
0.00
0.02
0.87
0.05
0.01
0.01
0.00
0.02
0.00
0.02
0.00
0.00
0.00
0.00
0.00
0.10
0.39
0.56
0.18
0.01
0.03
0.39
0.00
0.00
0.03
0.00
0.34
p-value 
Control vs 
HCT116
0.32
0.58
0.01
0.04
0.00
0.00
0.00
0.00
0.02
0.00
0.00
0.03
0.00
0.00
0.05
0.00
0.02
0.03
0.04
0.00
0.00
0.04
0.04
0.00
0.00
0.04
0.01
0.09
p-value 
Control vs 
v-Caco-22
0.00
0.00
0.22
0.01
0.92
0.16
0.00
0.00
0.07
0.01
0.00
0.00
0.00
0.00
0.01
0.01
0.07
0.05
0.63
0.11
0.01
0.01
0.52
0.10
0.06
0.00
0.00
0.01
29 2.3 GALLO_0968 orotidine 5'-DhosDhate decarboxylase 6.20 5.29 7.42 0.00 0.00 0.00
30 2.1 GALLOJL996 elvceraldehvde-3-DhosDhatedehvdroeenase 7.33 2.77 6.93 0.02 0.12 0.00
31 2.4 GALLO_0023 Dutative fattv acid/DhosDhoimid svnthesis Drotein PIsX 12.23 2.24 4.19 0.04 0.11 0.22
Information pathways
32 3.7 GALLO 1912 ribosomal protein S6 -4.75 -1.84 -3.31 0.00 0.01 0.01
33 3.7 GALLO 1140 ribosomal Drotein subunit S20 -3.79 -1.99 -3.88 0.00 0.01 0.01
34 3.7 GALLO 1511 translation elongation factor Tu -3.29 -2.32 -2.60 0.00 0.00 0.00
35 3.7 GALLO 0064 ribosomal protein S8 -2.59 -2.10 -9.48 0.06 0.01 0.01
36 3.7 GALLO 1912 ribosomal protein S6 -2.44 -1.63 -3.28 0.00 0.00 0.00
37 3.7 GALLO 1511 translation eloneation factor Tu -2.06 -1.53 -1.64 0.00 0.00 0.00
38 3.5 GALLO 0646 transcriDtional regulator -1.87 -1.02 -2.23 0.00 0.78 0.00
39 3.7 GALLO 1479 ribosomal protein L19 -1.59 3.67 -1.81 0.00 0.00 0.01
40 3.7 GALLO 0219 ribosomal protein S15 -1.19 -1.07 2.30 0.02 0.18 0.00
41 3.7 GALLO 1640 ribosome recycling factor -1.14 -5.38 -1.32 0.30 0.00 0.10
42 3.7 GALLO 1479 ribosomal protein L19 1.18 2.18 2.04 0.19 0.00 0.01
43 3.5 GALLOJL815 transcriDtion elongation factor 1.68 1.47 2.01 0.00 0.00 0.00
44 3.7 GALLO 1998 ribosomal protein S7 3.12 1.85 2.22 0.01 0.02 0.00
45 3.7 GALLO 1479 ribosomal protein L19 4.12 -2.93 -1.23 0.01 0.04 0.55
46 3.5 GALLOJL319 transcriDtional regulator. DeoR family 6.53 3.51 4.98 0.00 0.01 0.13
47 3.7 GALLO 1511 translation eloneation factor Tu 7.65 5.49 1.01 0.00 0.02 0.99
48 3.7 GALLO 1511 translation eloneation factor Tu 32.53 2.50 9.97 0.00 0.16 0.00
49 3.7 GALLO 1511 translation eloneation factor Tu 55.87 8.56 5.65 0.01 0.16 0.07
Other functions
50 4.2 GALLO_0592 Deroxide resistance protein Dpr -6.60 -2.61 -5.05 0.00 0.00 0.00
51 4.3 GALLO 0432 hvDothetical protein 9.62 -1.77 8.75 0.00 0.15 0.00
Similar to unknown proteins
52 5.2 GALLOJL879 hvDothetical protein -10.44 -1.97 -9.15 0.00 0.01 0.01
53 5.2 GALLO_2228 hvDothetical protein -9.21 -4.38 -10.96 0.00 0.00 0.00
54 5.2 GALLO_2228 hvDothetical protein -8.90 -4.52 -6.30 0.00 0.01 0.02
55 5.2 GALLOJL955 hvDothetical protein -5.99 -2.33 -3.60 0.00 0.01 0.01
56 5.2 GALLOJL879 hvDothetical protein -5.39 -1.01 -5.66 0.00 0.85 0.00
57 5.3 GALLOJL714 hvDothetical protein -1.24 -1.25 -7.14 0.19 0.50 0.01
58 5.2 GALLOJL295 hvDothetical protein 1.79 1.75 2.06 0.00 0.00 0.00
59 5.2 GALLOJL879 hvDothetical protein 2.40 4.69 1.65 0.03 0.00 0.25
60 5.2 GALLOJL295 hvDothetical protein 6.96 1.29 5.01 0.01 0.45 0.00
61 5.2 GALLO_1805 hvDothetical protein 13.44 2.66 39.90 0.00 0.06 0.00
62 5.2 GALLO_1805 hvDothetical protein 17.34 -1.03 5.47 0.00 0.98 0.10
63 5.2 GALLO 1879 hvDothetical Drotein 18.91 2.81 7.38 0.02 0.05 0.04
1 functional categories: 1.1 Cell Wall; 1.2 Transport/binding proteins and lipoproteins; 1.4 Membrane bioenergetics; 1.7 Cell division;
2.1 Metabolism of carbohydrates and related molecules; 2.2 Metabolism of amino acids and related molecules; 2.3 Metabolism of nucleotides and nucleic acids; 2.4 Metabolism 
of lipids; 3.5 RNA synthesis; 3.7 Protein synthesis; 4.2 detoxification; 4.3 antibiotic production; 5.2 From other organisms; 5.3 from Streptococcus 
2v-Caco-2 = 5. gallolyticus grown in medium of Caco-2 cells in the presence of viable Caco-2 cells
Table 1. Identified proteins with significant changes
spot nr
functional
catergory1
GALLO-code protein
Cell envelope and cellular processes
64 1.2 GALLO 1555 amino acid ABC transDorter. ATP-binding orotein
65 1.1 GALLO_0829 Glucose-l-DhosDhatethymidvlvltransferase
66 1.4 GALLO_0791 F0F1 ATP svnthase aloha chain
67 1.4 GALLO 0211 NADPH-deDendent FMN reductase
Intermediary metabolism
68 2.3 GALL0 0970 orotate DhosDhoribosvitransferase
69 2.1 GALLO 0990 Pyruvate kinsase
70 2,3 GALLO_0034 nhosDhoribosvlaminoimidazole carboxvlase 1
71 2.3 GALLO_0032 D ho sD h o ribo sv lB lvc in am id e  svnthetase
72 2.3 GALLO_0037 adenylosuccinate lyase
73 2.1 GALLO 0698 oxidoreductase. aldo/keto reductase familv
74 2.1 GALLO_1996 elvceraldehvde-3-DhosDhatedehvdroeenase
75 2.2 GALLO_1038 serine hvdroxvmethvltransferase
76 2.3 GALLO 1766 uracil DhosDhoribosvitransferase
77 2.3 GALLO_2134 adenylosuccinate synthase
78 2.1 GALLO_1996 elvceraldehvde-3-DhosDhate dehvdroaenase
79 2.1 GALLO 0990 Pyruvate kinsase
80 2.3 GALLO_1025 guanosine 5'-monoDhosDhate oxidoreductase
81 2.2 GALLO_0151 glutamvl aminopeptidase
82 2.3 GALLO_0639 dihvdroorotate dehvdroeenase (catalvtic subunit)
83 2.2 GALLO 0307 alDha-keto-beta-hvdroxvlaciireductoisomerase
84 2.1 GALLO 1318 fructose 1-phosphate kinase
85 2.3 GALLO 0705 ribonudeoside-diohosDhate reductase (maior subunit)
86 2.1 GALLO_1996 glvceraidehvde-3-Dhosphatedehvdrogenase
87 2.1 GALLO_2098 elucose-6-DhosDhate isomerase
88 2.1 GALLO_0990 Pyruvate kinsase
89 2.1 GALLO 1458 enolase
90 2.4 GALLO 0333 enovl-CoA hydratase
91 2.1 GALLO_0746 NadD Deoendent Aldehvde Dehvdrogenase
92 2.2 GALLO_1353 Chorismate synthase
93 2.2 GALLO 0931 Xaa-His diDeptidase
FC Control FC Control FC Control 
vs Caco-2 vs HCT116 vs v-Caco-2
-1.67 -2.36 -1.57
1.09 -2.14 1.17
1.29 1.65 -3.15
1.48 1.40 2.08
-2.81 -1.78 -2.04
-2.80 -2.62 -2.71
-2.35 -2.26 -1.91
-2.29 -1.77 -2.83
-2.19 -2.67 -1.47
-2.05 -2.26 -2.21
-2.03 -1.30 -2.70
-1.72 1.02 -3.38
-1.62 1.15 -2.31
-1.36 -1.90 -2.18
-1.28 -2.26 -1.21
-1.22 2.01 -1.55
-1.22 1.86 -2.05
-1.16 -1.27 -2.56
-1.07 2.01 -1.28
1.22 2.17 1.13
1.22 1.07 2.15
1.47 -1.96 3.28
1.56 1.26 2.03
1.67 2.26 1.84
2.10 1.32 1.11
2.16 1.07 -1.62
2.24 1.34 1.66
2.25 1.15 2.21
2.29 1.52 1.11
2.53 1.56 2.55
p-value p-value p-value 
Control vs Control vs Control vs 
Caco-2 HCT116 v-Caco-22
0.02 0.01 0.07
0.48 0.01 0.33
0.06 0.16 0.00
0.01 0.07 0.00
0.00 0.01 0.03
0.01 0.00 0.02
0.02 0.02 0.08
0.03 0.01 0.01
0.03 0.03 0.23
0.00 0.01 0.00
0.01 0.29 0.01
0.01 0.89 0.01
0.01 0.20 0.02
0.05 0.00 0.02
0.07 0.00 0.23
0.16 0.00 0.24
0.02 0.01 0.01
0.38 0.24 0.05
0.82 0.00 0.30
0.35 0.00 0.56
0.18 0.80 0.01
0.34 0.27 0.02
0.09 0.39 0.05
0.01 0.00 0.18
0.05 0.40 0.82
0.02 0.86 0.27
0.01 0.13 0.13
0.02 0.29 0.13
0.01 0.04 0.62
0.03 0.06 0.02
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94 3.7 GALLO_1997 translation elongation factor G -2.22 -1.54 1.34 0.03 0.11 0.51
95 3.7 GALLO 1997 translation eloneation factor G -1.05 -2.60 -3.11 0.79 0.02 0.03
96 3.7 GALLO 1912 ribosomal protein S6 1.07 -2.02 1.14 0.46 0.00 0.21
97 3.7 GALLO 1511 translation eloneation factor Tu 1.58 2.01 5.12 0.25 0.02 0.01
98 3.7 GALLO 0491 methionvl-tRNA formvltransferase 1.79 1.32 3.76 0.36 0.62 0.03
99 3.7 GALLO 1511 translation eloneation factor Tu 1.82 1.46 4.22 0.26 0.42 0.01
100 3.7 GALLO 0981 30S ribosomal Drotein S I homolog 1.85 2.08 1.78 0.01 0.00 0.11
101 3.7 GALLO 1511 translation eloneation factor Tu 2.02 1.74 2.12 0.01 0.00 0.11
102 3.7 GALLO 0082 tvrosvl-tRNA synthetase 2.13 1.38 2.83 0.02 0.36 0.22
103 3.9 GALLO 1511 translation elongation factor Tu 2.19 1.89 2.20 0.02 0.19 0.03
104 3.7 GALLO_0251 trieeer factor (prolyl isomerase) 2.31 -2.51 1.55 0.02 0.01 0.11
105 3.7 GALLO 1511 translation eloneation factor Tu 4.20 2.56 3.08 0.04 0.04 0.05
106 3.7 GALLO 1511 translation eloneation factor Tu 7.11 2.38 6.46 0.01 0.01 0.02
Other functions
107 4.1 GALL02161 heat shock Drotein. chaoeronin. 33 kDa -2.71 -1.27 -3.78 0.02 0.59 0.03
108 4.2 GALLO 0662 suDeroxide dismutase -2.04 -1.18 -1.56 0.00 0.04 0.01
109 4.1 GALLO 0243 heat shock Drotein 70. chaDerone Drotein DnaK -1.68 -2.12 -1.30 0.00 0.00 0.03
110 4.1 GALLO 0243 heat shock Drotein 70. chaDerone Drotein DnaK -1.44 -1,55 -1.11 0.03 0.00 0.02
111 4.1 GALLO 0243 heat shock Drotein 70. chaDerone Drotein DnaK 2.07 1.91 2.13 0.04 0.01 0.02
112 4.2 GALLO 0418 thioredoxin reductase 3.58 1.19 5.50 0.00 0.68 0.02
Similar to unknown proteins
113 5.2 GALLO 1879 hvDothetical protein -2.69 -1.69 -2.12 0.01 0.03 0.04
114 5.2 GALLO__0605 hypothetical protein -2.53 -1.21 -1.92 0.00 0.03 0.01
115 5.2 GALLO_2223 hvDothetical protein -2.30 -1.39 -1.31 0.00 0.10 0.17
116 5.2 GALL02108 hvDothetical protein -2.29 -1.62 -1.77 0.00 0.01 0.02
117 5.2 GALLO_2188 hvDothetical protein -1.53 -2.18 -1.21 0.04 0.00 0.11
118 5.2 GALL00604 hvoothetical protein 1.08 3.14 2.30 0.74 0.00 0.03
119 5.2 GALLO_1788 hvDothetical protein 2.45 1.16 2.69 0.02 0.61 0.02
120 5.2 GALLO 1879 hypothetical protein 8.85 2.20 6.88 0.01 0.25 0.02
'functional categories: 1.1 Cell Wall; 1.2 Transport/binding proteins and lipoproteins; 1.4 Membrane bioenergetics; 1.7 Cell division;
2.1 Metabolism of carbohydrates and related molecules; 2.2 Metabolism of amino acids and related molecules; 2.3 Metabolism of nucleotides and nucleic acids; 2.4
Metabolism of lipids;
3.5 RNA synthesis; 3.7 Protein synthesis; 3.9 protein folding; 4.1 Adaptation to atypical functions; 4.2 detoxification; 4.3 antibiotic production; 
5.2 From other organisms; 5.3 from Streptococcus
2v-Caco-2 = S. gallolyticus grown in medium of Caco-2 cells in the presence of viable Caco-2 cells
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Pathway analysis reveals up-regulation of glycolysis
To further characterize the observed differences in protein expression, the list of identified 
proteins with corresponding fold changes was subjected to pathway analysis. The metabolic 
pathway maps generated with the iPath tool (Addendum 4) indicated similar changes in all 
three spent medium conditions that occurred mainly in the glycolytic, amino acid and nucleic 
acid pathways (Table 2). Alterations in the glycerolipid and glycolyse pathways suggest that 
the increased generation of pyruvate is a central event in S. gallolyticus cells grown in spent 
medium of tumor cells. More specifically, the glycolysis pathway was up-regulated from a-D 
glucose 6-phophate (G6P) through fructose-6-phosphate (F6P) to glycerate-3-phosphate 
(3PG) and finally pyruvate (Figure 4A). The iPath analysis further suggests that pyruvate 
is (partly) used to generate valine and iso-leucine for protein synthesis, which was shown 
by an up-regulation of 4 proteins in this pathway (Figure 4B). These findings suggest that 
S. gallolyticus preferentially forages on break-down products of glucose, and that these 
secondary glucose metabolites of tumor cells provide S. gallolyticus with improved growth 
characteristics. It should be noted that the observed changes in metabolic pathways are not 
necessarily the result of the increased growth rate of S. gallolyticus, as shown by the down- 
regulation of purine metabolism under the spent medium conditions (Table 2).
Table 2. Generally altered KEGG pathways in spent medium of CRC cells
KEGG pathway
proteins up proteins down average FC 
(average FC) (average FC)
A lan in e, aspartate  and g lu ta m a te  m etabolism 2 (2.14) 2 .1 4
G lyce ro lip id  m etabolism 2 (4.05) 1 -2 .1 7 ) 1.98
G lyco lysis/g lu co n eo g en e sis 12 (2.26) 8 -1 .8 9 ) 0 .6 0
P u rin e  m etabolism 2 (2.57) 12 -2 .3 1 ) -1 .6 1
P yrim id in e  m etabolism 3 (3.98) 3 -2 .6 0 ) 0 .6 9
Starch  and su cro se  m etabolism 1 -1 .6 6 ) -1 .6 6
V aline, leucine and iso leu cin e  b iosynthesis 4 (1 .56) 1.56
V itam in  B6 m etabolism 3 (3.12) 4 -1 .8 1 ) 0 .3 0
Bile acid b iosynthesis 3 (1 .72) 1 -2 .1 7 ) 0 .7 5
B u tyrate m etabolism 4 (1.73) 1 -2 .0 7 ) 0 .9 7
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Figure 4. Proteomic changes in the glycolysis and valine metabolic pathways
Differentially expressed proteins were mapped to the KEGG global map of metabolic pathways via 
orthologous groups (COGs). The zoom-ins of the KEGG map show the most significantly altered 
metabolic pathways, which concerned the glycolytic pathway (panel A) and valine, leucine and 
isoleucine biosynthesis pathway (panel B). The glycolytic pathway was increased from glucose 
6-phophate, through fructose 6-phosphate to 3-phophate glyceric acid, leading to increased pyruvate 
generation (A). These analyses indicate that pyruvate is subsequently (in part) used for valine, leucine 
and isoleucine biosynthesis to facilitate increased protein synthesis as reflected by the strong induction 
of translation elongation factor Tu (see Table I) (B). Increased paths (red), reduced paths (green), non­
altered paths (grey). Global maps are available in Addendum 4.
8
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Metabolome analysis confirms up-regulation of glycolysis
To further investigate which tumor cell metabolites in spent medium could be responsible 
for the growth advantage of S. gallolyticus, the metabolites in standard medium (control) 
and spent medium from Caco-2 cells were analyzed by 1H-NMR-spectroscopy before and 
after incubation with S. gallolyticus (Figure 5). These analyses showed that Caco-2 cells 
have a high glucose metabolism as indicated by the reduction of glucose and pyruvate and 
increase in lactate levels in Caco-2 spent medium compared to standard medium (Table 3). 
In addition, these data suggested that S. gallolyticus had an increased ability to metabolize 
glucose in Caco-2 spent medium, which was shown by a glucose level of 0.2 mg/L after 
growth compared to a modest decreased glucose level (4.0 mg/L) after growth in standard 
medium. It must be noted, however, that glucose, glucose-6-phophate and glucose-1- 
phosphate could not be discriminated by 1H-NMR spectroscopy. Therefore, the increased 
utilization of glucose in Caco-2 spent medium could as well be due to G6P or other glucose 
metabolites as indicated by pathway analysis of the significantly expressed S. gallolyticus 
proteins. Furthermore, alanine and phenylalanine were found to have relative increased 
levels in spent medium of Caco-2 cells, whereas the alanine levels decreased after growth of 
S. gallolyticus in these media (Table 3). Taken together, pathway and 1H-NMR-analysis both 
indicate that the glycolytic activity of S. gallolyticus is increased in spent medium from tumor 
cells, which could very well be the result of the increased presence of secondary glycolytic 
metabolites, such as G6P, F6P and 3PG, and the amino acids alanine and phenylalanine that 
are shed by metabolically active tumor cells.
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Figure 5. lH-NMR-profiles of Caco-2 and S. gallolyticus metabolites
500 MHz 1H-NMR spectra (10 -  0.5 ppm) of standard medium before (A) and after (B) growth of 
S. gallolyticus and spent medium of Caco-2-cells before (C) and after (D) growth of S. gallolyticus. 
Spectra E-H show an expanded scale for the 0.8 -  2.55 ppm region of the respective A-D spectra. The 
corresponding concentrations of several of these metabolites are indicated in Table III. Assigned peaks: 
Lactic acid (LA), glucose (GLC), valine (VAL), leucine (LEU), isoleucine (ILEU), ethanol (E), acetoine (AT), 
alanine (ALA), lysine (LYS), acetic acid (A), pyruvic acid (P) and succinic acid (S).
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Table 3. Metabolic profiles of standard growth medium and spent medium of Caco-2 cells 
before and after incubation with S. gallolyticus
METABOLITES
Threo­ Valine* Ala­ Tyro­ Phenyl­ Glucose” Pyruvate” Lactate* Acetoin*
nine* nine* sine* alanine*
Chemical shift (ppm) 4.26 1.04 1.48 6.90 7.34 5.24 2.38 1.33 1.38
Standard medium 0.80 0.80 0.10 0.4 0.4 4.5 110 1.28 0
Standard medium after 
growth of S. gallolyticus
0.85 0.81 0.13 1.9 1.6 4.0 124 7.26 +
Caco-2 spent medium 0.75 0.63 0.23 0.4 1.5 2.9 57 15.9 0
Caco-2 spent medium after 
growth of S. gallolyticus 
*mM; **mg/L
0.48 0.53 0.20 1.6 1.2 0.2 72 36.2 +
Figure 6. Effect of fructose 6-phosphate, 
glycerate 3-phosphate, 
alanine and phenylalanine on the 
growth of S. gallolyticus and E. coli
(A) The growth rates of S. gallolyticus and 
E. coli in standard medium (control), were 
compared to those in standard medium 
supplemented with fructose 6-phosphate 
(F6P) and glycerate 3-phosphate (3PG). 
The effect of alanine (green) or phenylalanine 
supplementation on the growth rates of E. coli 
and S. gallolyticus in standard medium with or 
without F6P or 3PG is shown in panels B and
C, respectively. Calculation of the growth rates 
was based on 3 independent experiments. Bars 
represent the ratio between the growth rate 
in supplemented medium to that in standard 
medium. Evaluation with linear regression 
analysis was used to define if the growth rates 
were significantly different from each other. 
Significant differences (p < 0.05) are indicated 
with an asterisk (*).
B
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S. gallolyticus forages on alanine, F6P and 3PG
To simulate the proposed growth advantage of bacteria in the CRC microenvironment, 
the growth of S. gallolyticus (advantage) and E. coli (disadvantage) in standard medium 
was compared to that in the same medium supplemented with the metabolites alanine, 
phenylalanine, F6P and/or 3PG. As shown in Figure 6A, the growth rates of both S. gallolyticus 
and E. coli were significantly increased with factors 1.7 and 1.4, respectively, in medium 
supplemented with F6P. However, when 3PG was supplemented, only S. gallolyticus had 
a significant growth advantage (factor 1.6). The addition of alanine or phenylalanine alone 
to standard medium had no effect on the growth rate of S. gallolyticus (Figure 6C; control). 
However, in combination with F6P or 3PG, the addition of alanine increased the growth 
rate of S. gallolyticus with a factor of about 1.4, whereas this was not observed for E. coli 
(Figure 6B and C). Taken together, these simulation experiments show that S. gallolyticus 
can utilize the secondary glucose metabolites F6P and 3PG, and the amino acid alanine to 
increase its growth rate, which is in-line with the proteomic and metabolomic findings of 
this study. Furthermore, these data provide proof-of-concept for a model in which tumor 
cell metabolites provide a competitive advantage to a subset of the intestinal bacterial 
population.
Discussion
The association between S. gallolyticus and malignancy of the intestinal tract has long 
been recognized, however, the underlying mechanisms still need to be resolved. Here we 
show for the first time that CRC cell metabolites specifically provide this bacterium with 
a growth advantage. Proteome and metabolome analyses point towards the increased 
utilization of the glucose metabolites G6P, F6P and 3PG, and the amino acid alanine by 
S. gallolyticus, suggesting that these CRC metabolites are of particular importance for this 
growth advantage. Although several pathways were up-regulated in spent medium of CRC 
cells, the observed decrease in purine metabolism supports the idea that these differences 
cannot simply be attributed to increased growth itself, but instead are directly caused by 
the different metabolic composition of the culture media. It can be envisaged that this 
phenomenon may be one of the molecular mechanisms that supports the high incidence of 
S. gallolyticus infections in CRC patients (Boleij et al., 2011, Boleij et al., 2010), as discussed 
below.
The colonic lumen is a highly competitive environment, in which a balanced microbial 
composition is maintained at a rather stable level. The current state-of-the-literature suggest 
that S. gallolyticus is a bad colonizer of the colon in which a poor nutritional status exists. 
Instead, it has been recently shown that about 47% of the distal small intestinal (ileum) 
microbiota consists of Streptococci, of which about one third seems to belong to S. bovis 
species. In the ileum, where high levels of carbohydrates and dietary nutrients are available 
(Booijink et al., 2010, van den Bogert et al., 2011), carbohydrate fermentation by Streptococci
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leads to the formation of lactate, which can be further fermented by Veillonella species, 
which are also abundantly present in the ileum, to acetate and propionate. Adaptation to 
this carbohydrate-rich environment is reflected by the enrichment of genes for proteins 
with functions in substrate transport and carbohydrate metabolism in the S. gallolyticus 
genome (Rusniok et al., 2010). In-line with this observation, S. bovis strains were shown to 
be among the most efficient glucose fermenting bacteria in an experimental human in vitro 
gut fermentation model (TIM-2; (Egert et al., 2007)).
It seems plausible that S. gallolyticus cells that are shed from the ileum and enter the 
colonic lumen are gradually outcompeted by the colonic microbiota and disappear from this 
ecosystem, which is reflected by the relative low fecal carriage of about 10%, and colonic 
mucosal colonization of 2% in the healthy human population (Abdulamir et al., 2010, 
Klein et al., 1977). Suspiciously, however, the CRC microenvironment has some interesting 
similarities with the nutritional status of the ileum. Recent metabolome studies have shown 
that CRC tissues were associated with increased levels of lactate, glucose derivates, amino 
acids, lipids and fatty acids (Bi et al., 2006, Chan et al., 2009, Hirayama et al., 2009, Righi et 
al., 2009). Our current in vitro metabolome analysis of CRC cell supernatants were in-line 
with these in vivo data and strongly suggest that the metabolic changes at the interface of 
developing tumors create a new colonic niche that resembles the conditions in the small 
intestine and recruits a subset of intestinal bacteria. Importantly, our current data show 
that this environment favors the growth of S. gallolyticus. It is tempting to speculate that 
in this way, colonic tumors "capture" S. gallolyticus cells that are shed from the ileum to 
allow their colonic outgrowth. This could explain the fact that both fecal carriage and colonic 
mucosal colonization in CRC patients was found to be strongly increased, to respectively 
50% and 48% (Abdulamir et al., 2010, Klein et al., 1977). Eventually, these events can lead 
to tumor-borne systemic infections, when S. gallolyticus breaches through the colonic wall 
and evades the innate immune system.
A recent study by Marchesi et al. showed that colonic malignancies did indeed strongly 
affect the local composition of mucosa-associated microbiota. Deep pyrosequencing of 
16S rRNA amplicons derived from CRC tissue biopsies and adjacent non-malignant mucosa 
from the same patients showed significant shifts towards increased abundance of butyrate 
producing species, such as Roseburia, Fusobacterium and Faecalibacterium (Marchesi et 
al., 2011). Interestingly, our current proteome analysis indicates that butyrate metabolism 
is also increased when S. gallolyticus is grown in the presence of CRC metabolites, which 
thereby corroborates the clinical findings on differential microbial colonization of CRC tissue.
We have recently postulated a model in which the distinguished collagen-binding capacity 
of S. gallolyticus may contribute to the initial colonization of malignant colonic sites through 
the binding of displaced collagen IV from the basal lamina (Boleij et al., 2011). Here we 
show that tumor cell metabolites that accumulate at the CRC interface may further favor the 
survival and outgrowth of S. gallolyticus at these sites. This finding provides another piece of 
the puzzle of the specific clinical association between S. gallolyticus and CRC. However, the
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full impact of these CRC-associated metabolic changes on the colonic microbome should 
be further investigated by in vitro gut systems or in vivo models that include the ecological 
complexity of the gastro-intestinal tract. Ultimately, this knowledge may provide leads for 
novel microbiome-related tools for early detection of CRC, which is one of the major issues 
in human health care. Furthermore, understanding the cross-talk between CRC tumors and 
the intestinal microbiota may provide leads towards novel therapies of strategies to reduce 
the risk of developing this disease.
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Chapter 9 - S. gallolyticus-induced CYP1 expression
Abstract
The opportunistic pathogen Streptococcus gallolyticus is one of the few intestinal bacteria 
that has been consistently linked to colorectal cancer (CRC). This study aimed to identify 
S. gallolyticus-induced pathways that could on the long-term add to CRC progression. 
Transcription profiling of S. gallolyticus-exposed CRC cells revealed the persistent induction 
of enzymes involved in biotransformation pathways. Specifically, a diffusible factor of S. 
gallolyticus (SGF-X) was shown to interact with the aryl hydrocarbon receptor, thereby 
inducing CYP1 enzymes that catalyze the bioactivation of polycyclic aromatic hydrocarbons 
(PAHs) into toxic intermediates. Importantly, priming CRC cells with SGF-X containing 
medium increased the DNA-damaging effect of the PAH 3-methylcholanthrene, which was 
not observed with supernatants from other intestinal bacteria. In conclusion, this study 
shows for the first time that bacteria can modulate the biotransformation capacity of CRC 
cells, which offers a novel theory on the contribution of S. gallolyticus in the etiology of 
sporadic CRC.
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Introduction
The resident gut microbiota is essential for human intestinal health and prevents the invasion 
of pathogens by providing colonization resistance and nutrient competition (Hooper et al.,
2002, Vollaard and Clasener, 1994). The human epithelium itself wards of infections by the 
excretion of a continuous protective mucus layer and antimicrobials, and by tightly sealing 
the paracellular space between adjacent cells (Chichlowski and Hale, 2008, Matsuo et al., 
1997). However, in case of intestinal diseases such as Inflammatory Bowel Disease (IBD) and 
Colorectal Cancer (CRC), these protective mechanisms are impaired and the bowel wall 
becomes prone to bacterial infiltration rendering the host more susceptible to opportunistic 
bacterial infections (Aksoy and Akinci, 2004, Stecher and Hardt, 2008).
One of the intestinal bacteria that has been consistently linked to human CRC is the 
opportunistic pathogen Streptococcus gallolyticus (previously known as S. bovis biotype I). 
Multiple studies have documented that 33 to 100% of S. gallolyticus-infected patients have 
concomitant CRC (our unpublished meta-analysis)(Corredoira et al., 2005), which largely 
exceeds the CRC rates reported in the general population (Lieberman et al., 2000). Notably, 
nearly all of these patients did not present with gastro-intestinal signs or symptoms and CRC 
was thus solely detected based on the infection with S. gallolyticus.
Recently, we presented experimental data that fits with an infection model in which the 
collagen-binding ability of S. gallolyticus contributes to the specific colonization of malignant 
colonic sites (Boleij et al., 2011). Displacement of the epithelium during the early phases of 
colon carcinogenesis exposes collagen from the basement membrane, which is shielded by 
the epithelium in a healthy colon (Yantiss et al. 2001, Skovbjerg et al. 2009). This is likely to 
provide S. gallolyticus with a local colonization and invasion advantage, which is reflected by 
i) the increased presence of its DNA in CRC tissue samples, ii) its increased fecal carriage in 
CRC patients, and iii) systemic infections of this bacterium in CRC patients (Abdulamir et al., 
2010, Klein et al., 1977)(our unpublished meta-analysis).
Although an incidental relationship between S. gallolyticus and CRC seems plausible, it still 
remains to be determined to which extent S. gallolyticus may also play a contributory role in 
the carcinogenesis process itself. In fact, it was already shown that S. bovis biotype II (now 
called Streptococcus infantarius) increased the amount of aberrant crypt foci and adenomas 
in an azoxymethane (AOM) induced rat model (Ellmerich et al., 2000b). However, our recent 
meta-analysis indicated that only S. gallolyticus (biotype I) has an unambiguous association 
with CRC, whereas the occurrence of CRC among patients infected with other S. bovis 
biotypes seems not to be different from the asymptomatic population (our unpublished 
meta-analysis). Therefore, the aim of the current research was to identify S. gallolyticus- 
induced epithelial pathways that can on the long-term contribute to carcinogenesis. 
To accomplish this, microarray analysis was performed to profile tumor cell responses 
upon exposure to S. gallolyticus. These experiments confirmed our previous finding that 
S. gallolyticus had relatively little effect on epithelial innate immunity (Boleij et al., 2011). 
Strikingly, however, these studies revealed that cytochrome P450 (CYP)1 and COX-2 were 
persistently induced through the aryl hydrocarbon receptor (AhR) in colon adenocarcinoma 
cells by a diffusible factor (SGF-X) of S. galloltyicus. More importantly, this soluble factor was
153
Chapter 9 - S. gallolyticus-induced CYP1 expression
shown to increase the DNA damaging effect of the polycyclic aromatic hydrocarbon (PAH) 
3-methylcholanthrene. Together, the current data show for the first time that S. gallolyticus 
can interfere with AhR-mediated gene regulation and thereby can modulate important 
processes, such as inflammation, cell proliferation and DNA-adduct formation by PAHs.
Materials and methods 
Cell culture and bacterial strains
The colorectal adenocarcinoma cell lines (CRC-cells) HT-29, SW480, HCT 116 and Caco-2 
(www.atcc.org) were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Lonza) 
supplemented with 10% Fetal Calf Serum (FCS), 20 mM HEPES, 2mM L-Glutamine and 
1x non-essential amino acids (Gibco) at 37°C/5% CO2. For gene-expression analysis, cells 
were serum starved to 1% FCS for 24 hours before co-culturing with bacterial cells. These 
culturing conditions were used unless stated otherwise.
The following bacterial strains were used; S. gallolyticus subsp. gallolyticus UCN34 (Rusniok 
et al., 2010), Enterococcus faecalis 19433 (www.atcc.org) and Escherichia coli NTB5 
(Boleij et al., 2011). All strains were grown on Columbia blood agar or in Brain Heart Infusion 
(BHI) broth (Difco) supplemented with 1% glucose at 37°C/5% CO2. E. coli was grown at 200 
rounds per minute (rpm).
Microarray analysis
HT-29 cells were grown to confluence in T75 flasks and subsequently incubated with or 
without S. gallolyticus (Multiplicity of Infection (MOI) of 20) in two duplicate experiments. 
After 2 hours, the culture medium was refreshed and incubation was prolonged for another
2 hours. Next, HT-29 monolayers were washed 3 times with pre-warmed PBS after which 
RNA was isolated according to the Qiagen protocol (Qiagen RNeasy kit) with on-column 
DNA-digestion. RNA-quantity was measured with nano-drop (Thermo-Scientific, USA) and 
RNA quality was checked with the Bio-analyzer 2000 (Agilent Technologies, USA). Samples 
with RNA integrity scores > 9.0 were approved for microarray analysis.
Gene expression profiling was performed using Affymetrix GeneChip Human Gene 1.0 ST 
arrays, representing all known human genes (Affymetrix Inc., Santa Clara, CA, USA). The 
Affymetrix GeneChip Whole Transcript Sense Target Labeling Assay was used to generate 
amplified and biotinylated sense-strands DNA targets from the entire expressed genome 
(1.0 ^g of total RNA). The manufacturer's manual was followed for the hybridization, 
washing, and scanning steps (version 4, P/N 701880 Rev. 4). Arrays were hybridized by 
rotating them at 60 rpm in the Affymetrix GeneChip hybridization oven at 45 °C for 17 hours. 
After hybridization, the arrays were washed in the Affymetrix GeneChip Fluidics station FS 
450. Arrays were scanned using the Affymetrix GeneChip scanner 3000 7G system.
The Affymetrix cel files were first imported into Affymetrix Expression Console version 
1.1 where control probes were extracted using the default RMA algorithm in order to
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perform quality analysis checks. The Area Under the Curve (AUC) of the Receiver Operator 
Characteristic was calculated using the positive and negative control probes. All arrays had 
an AUC score above the empirically defined threshold of 0.85 indicating a good separation 
of the positive controls from the negative controls.
Subsequently the cel-files were imported into Partek® (Partek® Genomic Suite software, 
version 6.4 Copyright © 2008 Partek Inc., St. Louis, MO, USA) where only core exons were 
extracted and normalized using the RMA algorithm with GC background correction. Core 
transcript summaries were calculated using the mean intensities of the corresponding 
probesets. The correspondence of the replicate samples was confirmed using Principle 
Component Analysis (PCA) and Pearson correlation analysis. After grouping the samples 
by cel type an Anova was performed on the log2 intensities and contrast p-values were 
calculated for all pair wise comparisons between the sample groups. Genes with a fold 
change of at least 1.5 and a p-value below 0.05 were selected for further evaluation. Raw 
data files are available at https://www.ncbi.nlm.nih.gov/geo/ under accession number 
GSE29295.
Quantitative real-time PCR (Q-PCR)
For determination of CYP1A1, ALDH1A3 and COX-2 gene expression in time-series 
experiments, the CRC cell lines were incubated with S. gallolyticus (M0I20) for the indicated 
time periods. To determine concentration-dependence and additive effects of 1 and 10 nM 
3-Methylcholanthrene (3MC; Sigma) on CYP gene expression, cells were incubated for 4 hours 
with the indicated bacterial MOIs. To determine AhR-dependent CYP gene expression, CRC 
cells were incubated in the presence of the AhR-antagonist CH-223191 (3^M; Calbiochem) 
for 1 hour and subsequently incubated with S. gallolyticus with a MOI20 and/or 1 nM 3MC. 
To investigate intertwinement of COX-2 and CYP pathways, HT-29 cells were pre-incubated 
with the AhR-antagonist and/or the COX-2 inhibitor celecoxib (10^M; BioVision) for 1 hour 
prior to incubation with S. gallolyticus (MOI20) and/or 3MC (10 nM) for another 4 hours. To 
determine the effect of bacterial factors on CYP gene expression, S. gallolyticus, E. faecalis 
or E. coli were co-cultured with Caco-2 cells for 6 hours. Then the supernatants were spun 
for 10 min at 4000g and subsequently passed through a 0.2 ^m filter. Next, fresh serum- 
starved Caco-2 cells (24 h) were incubated with the supernatants for the indicated time 
periods. The above described interventions were all performed in at least two replicate 
experiments. CRC cells were disrupted in RLT-lysis buffer and RNA was extracted according 
to the Qiagen protocol (RNeasy mini-kit). Next, Iscript Reverse transcriptase-PCR (Bio-rad) 
was performed to synthesize 1^g of cDNA under the following conditions: 5 min at 25°C, 30 
min at 42°C and 5 min at 85°C. Expression of the genes listed in Table 1 was compared to the 
expression of the household gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(4310884E gene expression assay; Applied biosystems) using the following Q-PCR protocol:
2 min at 50°C, 10 min at 95°C and 40 cycles of 15 sec at 95°C and 60 sec at 60°C (7900 
HT, Applied biosystems). All genes measured with custom primers (Biolegio) were analyzed 
with SYBR green Mastermix (Applied Biosystems) and all gene-expression assays (Applied 
biosysstems) were analyzed with Universal Mastermix (Applied Biosystems). Log 2 Relative
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Quantity (RQ) values were calculated via the AACt-method using SDS 2.2.1 software. For all 
data with 2 grouping variables, two-way ANOVAs were performed and for data with one 
grouping variable, one-way ANOVA or student's t-test were performed in Graph-Pad Prim
4.00. Differences were considered significant below p-value of 0.05.
Table 1. Primer pairs and gene expression assays
Gene Forward primer Reverse primer Gene-expression assay
ClOorflO Hs00199735 m l
DUSP1 cgaggccattgacttcataga ctggcagtggacaaacacc
ZNF561 agtgcggtttcgcctttat agggttatttgcggtccac
POR aggtgtacatgggggagatg gaacggattcttggcatcaa
ZSCAN20 gttgtgaagtgggtgtctcg acggtgagtccttcaagagg
NONO ctggacagatgcagtgaagg cacagtcacaggacgaggaa
ULBP3 aggaagaagaggctggaacc ctatggctttgggttgagcta
RAET1L catcccagctttgcttctgt gcaaagagagtgagggtcgt
C3orfl9 cgacgatgaggaaaaccttc ccaaagagtccacgtaatcca
TRUB1 agctgctgaatcggttgaag ttcctcttggtccattctgg
LYPLA2 caagtacatctgtccccatgc gactcagccccatcaggtc
COX5A caaagtgtaaaccgcatgga tccaggtaactgttcacactcaa
ADH1A cacca gtctcctggtctgc cagctgctttgcatttgatt
FTH1 gaagctgcagaaccaacga cacactccattgcattcagc
MAP2K1 cattgctgtaataaaaggcctga tgttggagggcttgacatc
NPPC Hs00360930_gl
ALDH1A3 tctcgacaaagccctgaagt ggcgttgtagcagttgatcc
CYP1A1 Hs00153120 m l
CYP1A2 HSÛ1070374 m l
CYP1B1 HS00164383 m l
PTGS2 (COX-2) Hs00153133 m l
Western blotting
Expression of CYP1A1 was evaluated at the protein level in Caco-2 cells. Confluent monolayers 
were co-cultured with 1 |iM 3MC or with S. gallolyticus (MOI 50). After 6h of incubation, cells 
were refreshed with medium containing 10|ig/ml chloramphenicol to block further bacterial 
growth. After 6, 9 and 12 hours, cells were dislocated in PBS-EDTA and disrupted in lysis buffer 
(50 mM HEPES, 0.5 M NaCl, 1.5 mM MgCl2, 1 mM EDTA, 10% glycerol and 1% Trition-X100) 
(Anwar-Mohamed and El-Kadi, 2009). Lysates were vortexed every 10 min during incubation 
on ice for 1 hour. Next, samples were spun at 12,000 g for 10 min and stored at -20°C until 
further analysis. 50 |ig protein in SDS-sample buffer (50 mM Tris-HCl pH 6.0, 2% SDS, 5% 
P-mercaptoethanol and 10% glycerol) was incubated for 5 min at 95°C prior to 12.5% glycine 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Towbin et al., 1979). Proteins were 
transferred to polyvinylidene fluoride (PVDF) membranes (Amersham) by Western blotting. 
Next, membranes were blocked for 1 hour in 5% BSA in Tris buffered Saline supplemented with 
Tween 20 (0.1%)(TBS-T) and incubated with monoclonal mouse-anti-CYP1A1 antibodies (Santa- 
cruz) diluted 1:500 in TBS-T, or monoclonal mouse anti-P-actin antibody (Sigma A5441) diluted 
1:25,000. Bound antibodies were visualized with the ECL detection system (Amersham) using 
anti-mouse IgG HRP conjugates diluted 1:50,000 (Jackson ImmunoResearch) in 5% milk in TBS-T.
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7-ethoxyresorufin-O-deethylase (7-EROD) enzyme activity assay
After incubation under the conditions described in the previous section, cells were washed 
with ice-cold PBS and lysed in 0.1M potassium phosphate buffer (0.1M dipotassiumphosphate, 
0.1M EDTA and 20% glycerol, pH 7.4). Cells were disrupted by mechanical shearing on ice 
and stored at -80°C until use. Protein concentrations were determined with the Bradford 
protein assay following the manufacturers' description (BioRad). Crude cell lysates were 
diluted to 100^g/ml protein in assay buffer (0.1M dipotassiumphosphate and 0.1M EDTA, 
pH 7.4) and 4 ^M ethoxuresorufin (Molecular Probes) was added. Samples were pre­
warmed at 37°C before addition of 10 ^M NADPH (Sigma). Next, samples were measured 
during a 10-min time period on a Shimadzu RF-5000 spectrofluorometer at an excitation 
of 550 nm and emission of 580 nm. Known concentrations of resorufin (Molecular Probes) 
were used to create a calibration curve to calculate the amount of resorufin formed from 
ethoxyresorufin, catalyzed by the CYP1A1 enzyme (Yu et al., 2001). To compare individual 
samples, the amount of resorufin produced per min was related to the protein concentration 
in the sample (resorufin/min-mg).
COMET assay
The additional effects of bacterial products on DNA damage by 0.1 ^M 3MC were measured 
using the COMET assay (Trevigen). Spent media of S. gallolyticus, E. faecalis and E. coli were 
incubated with Caco-2 cells in quadruplicate. After priming Caco-2 cells for 6 hours with 
these spent media, 0.1 ^M 3MC was added and incubation was prolonged for 18 hours. 
H2O2 (100^M) was used as positive control for DNA damage. Cells were washed with warm 
PBS, harvested and spun at 200g for 5 min. Then, 8000 cells per condition were washed with 
Mg and Ca free ice-cold PBS, were dissolved in low-melting agarose and mounted on COMET 
slides. After 30 min at 4°C in the dark, the immobilized cells were disrupted in Trevigen lysis 
solution for 60 min at 4°C. DNA was unwinded by alkaline treatment (pH >13) for 30 min, 
followed by electrophoresis for 30 min at 25V. Next, slides were washed in 0.4M Tris-HCl 
(pH 7.5) and fixed for 10 min in absolute alcohol. DNA damage (apparent as COMET-like 
structures) was visualized by SYBRgreen staining and fluorescence microscopy (Leica). A 
total of 100 COMETs per condition were independently scored by 2 researchers that were 
uninformed about the experimental conditions, following the methodology of Collins et al. 
(Collins, 2004). DNA damage was calculated as reference to the positive H2O2 control. One­
way ANOVA in Graph-Pad Prism 4.00 was performed to determine significance of the results 
(p<0.05).
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Results
Microarray analysis uncovers induction of host oxidoreductase gene 
expression by S. gallolyticus
Transcriptome analysis was performed to pinpoint genes altered by S. gallolyticus that 
could on the long-term contribute to the progression of CRC. Previously, it was shown 
that the related bacterium S. infantarius induced COX-2 expression in colon epithelial cells 
(Ellmerich et al., 2000a), which is a marker for chronic inflammation and CRC progression in 
vivo (Wang and Dubois, 2010). However, our recent studies showed that the closely related 
bacteria S. gallolyticus and S. infantarius (previously both classified as S. bovis) have quite 
distinct virulence characteristics (Boleij et al., 2011, Schlegel et al., 2004). Therefore, our 
initial experiment aimed to investigate whether COX-2 was also induced by S. gallolyticus. 
These experiments showed a mild, but significant, induction of COX-2 expression in HT-29 
cells after 4 hours of co-culturing with S. gallolyticus (data not shown). Consequently, this 
time point was chosen to search for additional genes that were differentially expressed 
under these conditions. Microarray analysis resulted in a total of 44 significantly up- or 
downregulated genes upon S. gallolyticus exposure (Figure 1A), which was a surprisingly 
low number in comparison to about 150 differently expressed genes upon co-incubation 
with other bacteria under the same conditions (data not shown). Strikingly, as much as 9 
of these S. gallolyticus-regulated genes appeared to belong to oxidoreductase pathways 
(Figure 1A in bold), including CYP1A1, ADH1A and ALDH1A3 (Addendum 5).
u p -re g u la te d  g e n e s  
reference gene FC p-value
d o w n -re g u la te d  g e n e s  
reference gene FC p-value
NM_000499 CYP1A1 3.01 0.01 AF280797 C3orf42 0.70 0.04
NM_007363 NONO 2.68 0.03 NM_052861 GC21675 0.70 0.03
NM_016474 C3orfl9 2.31 0.01 NMJL44712 SLC23A3 0.69 0.01
NM_000667 ADH1A 2.25 0.00 NM_000437 PAFAH2 0.69 0.02
NM_007260 LYPLA2 1.99 0.04 BC090889 AHNAK2 0.69 0.03
NM_012399 PITPNB 1.82 0.03 NM_001384 DPH2 0.69 0.01
NM_000693 ALDH1A3 1.77 0.03 NM_018373 SYNJ2BP 0.68 0.01
NM_024409 NPPC 1.75 0.02 NM_002500 NEUROD1 0.66 0.02
NM_013252 CLEC5A 1.54 0.02 NM_006147 IRF6 0.65 0.04
NM_001083538 POTE2 1.54 0.01 NM_000941 POR 0.65 0.04
NM_003079 MARCE1 1.50 0.01 NM_001009955 SSBP3 0.64 0.04
NR_002308 RP11-278E11.2 1.48 0.04 NM_001930 DHPS 0.64 0.05
NM_013289 KIR3DL1 1.46 0.02 NM_005793 NME6 0.63 0.05
NM_002032 FTH1 1.45 0.05 NM_015690 STK36 0.63 0.02
NM_004891 MRPL33 1.45 0.05 NMJL52289 ZNF561 0.62 0.01
NM_002755 MAP2K1 1.44 0.02 NM_015911 ZNF691 0.62 0.04
NM J.73359 EIF4E3 1.44 0.03 NM_001005749 GBA 0.61 0.04
NM J.82488 USP12 1.43 0.04 NM_007021 ClOorflO 0.59 0.01
NM_005004 NDUFB8 1.42 0.03 NM_024518 ULBP3 0.59 0.00
NM J.78433 LCE3B 1.42 0.02 NM_004417 DUSP1 0.57 0.01
NM_004255 COX5A 1.42 0.02 NM_145238 ZSCAN20 0.53 0.03
NM_139169 TRUB1 0.48 0.03
NM_130900 RAET1L 0.43 0.04
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gene
microarray 
log 2
Real-time 
log 2
ClO orflO -0.75 -1.00
DUSP1 -0.81 -0.42
ZNF561 -0.68 -0.29
POR -0.63 -0.23
ZSCAN20 -0.92 -0.22
NONO 1.42 -0.16
ULBP3 -0.77 -0.15
RAET1L -1.23 -0.11
C3orfl9 1.21 -0.09
TRUB1 -1.06 -0.05
LYPLA2 0.99 0.00
COX5A 0.50 0.16
ADH1A 1.17 0.24
FTH1 0.54 0.32
MAP2K1 0.53 0.55
NPPC 0.80 0.93
ALDH1A3 0.82 1.02
CYP1A1 1.59 1.94
Microarray log 2
COX-2
time (h)
Figure 1. Microarray data and validation (page 158-159)
Microarray analysis was performed to profile S. gallolyticus-induced pathways that could be involved 
in CRC progression. (A) 44 genes were significantly up or down-regulated in HT-29 cells after exposure 
to S. gallolyticus; the corresponding Fold Change (FC) and p-value are listed. Genes printed in bold 
belong to the oxidoreductase pathway as depicted in Supplemental Figure 1. (B) The upregulation of 
18 selected genes was validated by quantitative real-time PCR (Q-PCR) analysis. The corresponding log 
2 values of microarray and Q-PCR are listed for each gene. The 10 genes that showed similar effects 
in microarray and Q-PCR (Pearson correlation (r = 0.94; p < 0.001)) are printed in bold (B) and marked 
by black squares (C). Gene expression changes that could not be validated by Q-PCR are printed in 
grey (B) and marked by grey triangles (C). The positions of the most significantly up-regulated genes 
CYP1A1 and ALDH1A3 are indicated (C). (D) After exposure of S. gallolyticus to HT-29 cells, COX-2 
expression was evaluated by Q-PCR at the indicated time points. COX-2 was significantly upregulated 
as determined by one-way ANOVA ("*" indicates p < 0.05).
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Validation of microarray data
For validation, the 18 (out of 44) genes with normalized expression levels >6 on the used 
Affymetrix GeneChip were selected as this level is required to detect mRNA of these 
genes by Q-PCR (C. Gilissen, personal communication). The corresponding log-2 values 
for microarray and Q-PCR of 10 of these genes showed similar levels by both methods 
as predicted by Pearson correlation (r = 0.94; p < 0.001) (Figure 1B and 1C). In-line with 
microarray results, CYP1A1 (log 2 RQ: 1.94) and ALDH1A3 (log 2 RQ: 1.02) were also found 
to be the most significant differently expressed genes by Q-PCR. Surprisingly, COX-2 that was 
initially used to determine the time point for transcriptome analysis, was not among the 
significant microarray hits. Therefore, COX-2 induction by S. gallolyticus was re-evaluated 
by Q-PCR under the conditions used for microarray analysis. Figure 1D clearly shows that 
COX-2 is persistently increased to a log 2 RQ of 1.6 after 2 and 4 hours (p = 0.017) of co- 
culturing HT-29 cells with S. gallolyticus, which confirms our initial finding. To evaluate 
whether the altered transcription profiles resulted in changes on the proteome level, HT-29 
cells that were exposed to S. gallolyticus for 6 hours were subjected to 2D-PAGE analysis. 
These experiments confirmed that colon epithelial cells are relatively unresponsive to 
S. gallolyticus (Boleij et al., 2011), as only 8 of the 520 detectable proteins had significantly 
altered expression levels (p < 0.05; FC >1.5; Addendum 6). Taken together, these data imply 
that the strong induction of CYP1A1 and ALDH1A3 by S. gallolyticus relates to specific cellular 
changes that are not part of a general stress response to bacterial infection. Interestingly, 
the corresponding enzyme activities of these genes are involved in biotransformation of 
drugs and food components and are best known for their clearing function in the liver 
(Nebert and Dalton, 2006). The expression of these genes is induced by their toxic substrates 
after which CYP1A1 and ALDH1A3 can, depending on the substrate, contribute to either 
the detoxification or bio-activation of these toxins and thereby modulate the carcinogenic 
potential of these compounds (Kim et al., 2009). As the expression of these enzymes is 
elevated during colorectal cancer progression (Ding and Kaminsky, 2003, Huang et al., 2009, 
McKay et al., 1993), and thereby could be related to colon carcinogenesis, we decided to 
focus on these genes in our further investigations.
S. gallolyticus-induced oxidoreductase expression and activity
The temporal induction of CYP1A1 and ALDH1A3 expression was examined in the cell lines 
Caco-2, SW480 and HCT116 after exposure to S. gallolyticus, and compared with the induction 
in HT-29 cells. These experiments showed that CYP1A1 was consistently upregulated (p < 
0.001) in all cell lines upon 2, 4 and 6 hours of co-culturing with S. gallolyticus (Figure 2A). 
The induction of ALDH1A3 was less evident among the different cell lines, though ALDH1A3 
was significantly increased to a log 2 RQ between 1.1 for Caco-2 and 6.9 for HT-29 after 4 
and 6 hours (p < 0.001) (Figure 2B).
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Figure 2. S. gallolyticus-induced 
CYP1A1 and ALDH1A3 expression
The expression of CYP1A1 (A) and 
ALDH1A3 (B) was evaluated by Q-PCR in 
the CRC cell lines HT-29, SW480, HCT116 
and Caco-2 upon 2, 4 and 6 hours of 
incubation with S. gallolyticus. Note 
that the expression of CYP1A1 is highly 
similar in all investigated cell lines. Two­
way ANOVA was performed to determine 
significant changes ("*" indicates p < 
0.05; "**" indicates p <0.01) (C) Protein 
expression of CYP1A1 in Caco-2 cells was 
investigated by Western blotting after 
exposure to S. gallolyticus or 3MC for 
6, 9 and 12 hours. The arrows indicate 
the position o fC Y P lA l protein. The right 
panel shows the corresponding 6-actin 
protein expression levels (D) CYP1A1 
enzyme activity was measured by the 
7-EROD assay. The bars indicate the 
amounts of pmol resorufin produced 
per min per mg protein; RQ, Relative 
Quantity; Con, control (untreated 
cells); 3MC, 3-methylcholanthrene; SG, 
S. gallolyticus.
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Based on the consistency of CYP1A1 induction in the different cell lines, we chose to 
further evaluate the bacterial induction of CYP1A1 at the protein and functional level. To 
this purpose, Western blot analysis was performed on protein extracts from Caco-2 cells 
harvested at different time points after the start of incubation with S. gallolyticus. Our 
initial experiments, and results of others, indicated that Caco-2 cells were best suited to 
detect CYP1A1 at the protein level (Meunier et al., 1995). Furthermore, it should be noted 
that bacteria had to be removed from the co-culture after 6 hours to prevent Caco-2 cell 
damage by excessive bacterial proliferation. The PAH 3MC was used as positive control 
for CYP1A1 induction (Aboutabl et al., 2009). As expected, S. gallolyticus induced cellular 
CYP1A1 levels after 6 and 9 hours compared to untreated Caco-2 cells (Figure 2C). However, 
CYP1A1 protein levels were reduced to background levels after 12 hours, which is likely to be 
attributed to loss of the bacterial stimulus. Correspondingly, the presence of 3MC continued 
to increase CYP1A1 levels up to 12 hours of stimulation. In-line with these findings, CYP1A1 
enzyme activity in Caco-2 cells exposed to S. gallolyticus (as measured by the conversion of 
ethoxyresorufin into resorufin) was only found to be increased after 6 and 9 hours, while 
3MC increased CYP1A1 activity at all three time points (Figure 2D). Altogether, these data 
show that the induction of CYP1A1 by S. gallolyticus is a general phenomenon in CRC cells, 
which is correlated to CYP1A1 protein expression and activity. These data indicate that S. 
gallolyticus can modulate the potential of colon adenocarcinoma cells to detoxify and/or 
bio-activate toxic substances.
Bacterial modulation of CYP1A1 expression
To investigate whether the induction of CYP1A1 is a specific feature of S. gallolyticus, the 
expression of this gene was investigated upon co-incubation of HT-29 cells with two other 
intestinal bacterial strains. As shown in Figure 3A, both S. gallolyticus and E. faecalis induced 
the expression of this gene at similar levels in a MOI-dependent manner (p <0.01). Contrarily, 
co-incubation of HT-29 cells with E. coli did not result in an induction of CYP1A1, and might 
even reduce the expression of this gene. Thus, these data show that different bacteria have 
different modulatory effects on the expression of this biotransformation enzyme. To assess 
whether S. gallolyticus can increase CYP1A1 expression in the presence of a CYP-inducing 
substrate, HT-29 cells were cultured with different concentrations of 3MC in the absence or 
presence of bacteria. As shown in Figure 3B, S. gallolyticus had a modest, but significant, 
additive effect on the induction of 0.001 ^M 3MC (p < 0.05), while this was not observed 
upon co-incubation with E. coli. At a 3MC concentration of 0.01 ^M, the additive effect of S. 
gallolyticus is lost, which may be attributed to saturation of induction. Together, these data 
could suggest that S. gallolyticus can increase CYP1A1 expression in the presence of low 
concentrations of 3MC that enter the colonic lumen through intake of contaminated food 
products.
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Figure 3. Bacterial induction of CYP1A1, CYP1A2 and CYP1B1
(A) The expression of CYP1A1 was evaluated by Q-PCR in HT-29 cells upon 4 hours of incubation with 
the intestinal strains E. coli (EC), S. gallolyticus (SG) and E. faecalis (EF) at increasing multiplicity of 
infection. (B) Similarly, the expression of CYP1A1 was evaluated upon incubation with E. coli (EC), or 
S. gallolyticus (SG) in the presence of increasing concentrations of the AhR-ligand 3MC. (C) Model 
for AhR-dependent gene regulation. Polycyclic aromatic hydrocarbons (PAHs) diffuse into the cell 
and bind to the intracellular Aryl hydrocarbon receptor (AhR). Next, this complex translocates into 
the nucleus and binds to a XRE-response element, as present in the CYP1A1 promoter region. After 
transcription/translation, CYP1A1 acts in the endoplasmatic reticulum as a phase I enzyme that 
converts PAHs to more toxic intermediates that can form DNA adducts. (D) The expression of CYP1A1, 
CYP1A2 and CYP1B1 upon incubation with S. gallolyticus at increasing multiplicity of infection was 
compared to non-infected control cells (Con) in the presence or absence of the AhR ligand 3MC (E). 
Note that S. gallolyticus and 3MC have an additive effect on CYP1A1, CYP1A2 and CYP1B1 induction. 
(F) The induction of CYP1A1 by 3MC or S. gallolyticus in HT-29 cells, in the presence or absence of an 
AhR-inhibitor, was investigated by Q-PCR. Statistical analysis by two-way ANOVA was performed to 
determine significant changes ("*" indicates p < 0.05; "**" indicates p < 0.01).
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Induction of CYP1 expression by S. gallolyticus is dependent on AhR
PAH substrates of CYP1 enzymes interact with the intracellular Aryl hydrocarbon receptor 
(AhR) to induce CYP1 expression. After the subsequent binding of this AhR-PAH complex 
to several co-factors, it translocates to the nucleus to activate a xenobiotic response 
element that is present in the promoter regions of the CYP1A1, CYP1A2 and CYP1B1 genes 
(McMillan and Bradfield, 2007) (Figure 3C). To examine whether S. gallolyticus also targets 
AhR, the induction of CYP1A2 and CYP1B1 was examined in a co-culture experiment. As 
shown in Figure 3D, the presence of S. gallolyticus induced the expression of these genes 
in a concentration dependent manner, similar to that of CYP1A1 (MOI 40; p < 0.001). 
Furthermore, S. gallolyticus had also a slight additive effect on 3MC stimulation for both 
CYP1A2 and CYP1B1 (Figure 3E), though this was not significant. The fact that the induction 
of CYP1A2 and CYP1B1 did not reach the level of CYP1A1 upon S. gallolyticus exposure (MOI 
20) could explain why these genes were not found in the initial microarray screen. To further 
investigate co-regulation of these genes, an AhR-antagonist that prevents the binding of 
PAHs to this receptor (Kim et al., 2006) was added to co-cultures. These experiments showed 
that pre-incubation of HT-29 cells with this AhR-inhibitor clearly blocked the upregulation of 
CYP1A1 (Figure 3F), CYP1A2 and CYP1B1 (data not shown) by both 3MC and S. gallolyticus. 
Taken together, these results show that CYP1 induction by S. gallolyticus is mediated by an 
AhR-dependent mechanism that resembles the induction of these enzymes by their natural 
PAH substrates.
Expression of CYP1A1 is intertwined with COX-2 expression
As shown in the above experiments, S. gallolyticus can induce CYP1 as well as COX-2 in CRC 
cells. Interestingly, some suggestions have been made on possible links between the COX and 
CYP regulatory pathways (Haarmann-Stemmann et al., 2009, Han et al., 2010, Nebert and 
Karp, 2008) (Figure 4A). For instance, it has been hypothesized that stimulation of the AhR can 
result in COX-2 upregulation (Gasiewicz et al., 2008). Like COX-2, CYP1 enzymes are involved 
in the metabolism of arachidonic acid to eicosanoids that in turn have been suggested to 
interact with the AhR receptor and interfere with CYP1A1 expression (Choudhary et al., 
2004, Nebert and Karp, 2008) (Figure 4A). To investigate whether S. gallolyticus affects the 
intertwinement of these pathways, the expression of CYP1A1 and COX-2 was investigated 
in the presence or absence of the AhR and COX-2 inhibiting compounds CH-223191 and 
celecoxib. These experiments showed that the AhR antagonist blocked COX-2 upregulation 
by S. gallolyticus from log 2 RQ of 0.7 to 0 after 4 hours (Figure 4B). Contrarily, the induction 
of CYP1A1 remained unaffected by addition of celecoxib under these conditions (Figure 
4C). These results suggest that the induction of COX-2 by S.gallolyticus may (in part) be a 
consequence of AhR-mediated gene regulation, but that CYP1A1 induction is independent of 
the COX pathway. Taken together, these data confirm an intertwinement between the CYP1 
and COX-2 regulatory pathways, suggesting that stimulation of the AhR by S. gallolyticus 
may induce COX-2 expression in CRC cells. Clearly, the exact regulatory mechanisms that link 
these pathways remains to be elucidated.
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Figure 4. AhR-dependent CYP1A1 induction and intertwinement with the COX pathway
(A) Schematic representation of factors that interact with the AhR. Ligand binding (indicated by large arrow) 
leads to the transcription of CYP1 enzymes via the XRE response elements, which could lead to increased genotoxic 
substances. In addition, AhR is thought to be involved in deregulation of cell-cell adhesion and regulation of Treg 
and TH17 cell differentiation (Abel and Haarmann-Stemmann, 2010, Dietrich and Kaina, 2010). The COX pathway 
could be intertwined with the AhR pathway by production of prostaglandins that can bind to the ERE promoter 
region of CYP1 genes. Also the metabolites of prostaglandin metabolism, like HETEs and EETs that are mutagenic 
themselves, may act as AhR ligands leading to increased CYP transcription (Choudhary et al., 2004, Plastaras et 
al., 2000). Conversely, AhR activation itself may also lead to increased COX-2 expression (Gasiewicz et al., 2008). 
Expression of COX-2 (B) and CYP1A1 (C) was evaluated by Q- PCR after 4 hours exposure of HT-29 cells to S. 
gallolyticus (SG) in the presence or absence of the AhR and COX-2 inhibitors CH-223191 and celecoxib. Significant 
expression changes were calculated with students t-test ("*" indicates p< 0.05; "**" indicates p< 0.01).
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A soluble released factor from S. gallolyticus (SGF-X) induces CYP1A1 
expression
A remarkable finding was the fact that the intracellular AhR is stimulated by S. gallolyticus 
cells, which lack the ability to invade CRC cells (Boleij et al., 2011). Thus, these bacteria 
should release a diffusible factor that can enter CRC cells to induce CYP1A1 expression. To 
confirm this hypothesis, spent medium from S. gallolyticus was filtered and added to fresh 
Caco-2 cells for 4, 8, and 12 hours. As shown in Figure 5A, this spent medium induced CYP1A1 
expression in Caco-2 cells after 8 and 12 hours of exposure (log 2 RQ 3.0; p < 0.01). However, 
this induction was lower than observed for incubation with viable bacterial cells (log 2 RQ 
5.0; Figure 3F). Interestingly, spent medium from E. faecalis only marginally induced CYP1A1 
expression after 12 hours (log 2 RQ 1.5; NS), whereas viable E. faecalis cells strongly induced 
expression of this gene (Figure 3A). In-line with the previous results, spent medium from 
E. coli had a slight inhibitory effect on CYP1A1 expression. These results confirm the idea that 
S. gallolyticus releases a factor that diffuses into CRC cells to induce CYP1 gene expression 
through intracellular binding to the AhR. Furthermore, the current data point towards an 
active involvement of living bacterial cells in this process, which was underscored by the 
fact that heat-killed S. gallolyticus cells were not able to induce CYP1A1 expression (data not 
shown). Notably, the release of this factor seems to be a salient feature of S. gallolyticus. 
Future studies should reveal the nature of this diffusible S. gallolyticus factor (SGF-X) that is 
responsible for AhR-mediated CYP1 induction.
SGF-X increases the DNA-damaging effect of 3MC in CRC-cells
The data presented above make it tempting to speculate that CYP1 upregulation by 
S. gallolyticus may contribute to the DNA-damaging effect of PAHs through increased 
conversion of these compounds into carcinogenic intermediates. To test this hypothesis, 
Caco-2 cells were first incubated in SGF-X containing spent medium for 6 hours to prime 
CYP1 expression, after which 3MC-induced DNA damage was compared to untreated cells 
by the COMET assay, which quantifies the level of DNA lesions on the cellular level. As 
shown in Figure 5B, the DNA damaging effect of 0.1 ^M 3MC was significantly exaggerated 
by pre-incubation of Caco-2 cells in SGF-X containing spent medium (p < 0.05). In contrast, 
priming of these cells with spent medium of E. faecalis or E. coli supernatants did both not 
increase 3MC genotoxicity. In fact, spent medium from E. faecalis had even a surprising 
significant inhibitory effect on 3MC-induced DNA damage (p < 0.05). It is presently unknown 
how this relates to the induction of CYP1 expression by whole E. faecalis cells. Figure 5C and
D, show the corresponding COMET counts and COMET categories of the summarized data 
depicted in panel B. Together, these results show that S. gallolyticus produces a diffusible 
factor (SGF-X) that can prime CRC-cells towards an increased susceptibility to 3MC-induced 
DNA damage, whereas such a factor is not produced by E. faecalis and E. coli under the 
applied experimental conditions. The current data suggest that this effect is mediated 
through the induced production of CYP1 enzymes by SGF-X, which in turn convert 3MC 
into more carcinogenic intermediates such as dihydrodiol- and 2-hydroxy 3MC that have 
higher DNA-binding efficiencies than the parent compound 3MC. These bioactivation events
166
Part 2 - Molecular explorations at the host-pathogen interface
thereby result in increasing DNA adduct formation and consequently higher mutation rates 
(Eastman and Bresnick, 1979). However, it cannot be excluded that other S. gallolyticus 
factors, which act in an AhR-independent manner, also add to the observed increase in 
DNA damage. Nonetheless, these results make it evident that intestinal bacteria should 
be regarded as modulators of intestinal biotransformation systems, which could either 
protect the host, or lead to increased DNA-damaging effects of PAHs as illustrated in our 
experiments for S. gallolyticus.
Figure 5. SGF-X induced CYP1A1 expression and exaggeration of the DNA-damaging 
effect of 3MC
(A) Expression of CYP1A1 in Caco-2 cells was examined by Q-PCR after exposure of these cells to the 
spent medium of E. coli (EC), S. gallolyticus (SG) and E. faecalis (EF). Note that only, exposure to spent 
medium from S. gallolyticus resulted in increased CYP1A1 levels after 8 and 12 hours("**" indicates 
p< 0.01); the unknown S. gallolyticus factor responsible for this effect is named SGF-X. (B) DNA damage 
under the conditions described in panel A of this figure were measured by the COMET assay. To induce 
low levels of DNA damage, incubation was prolonged for 18 hours after addition of 0.1 ^M 3MC to 
the culture medium. Reference ranges were determined by the incubation of Caco-2 cells without 3MC 
(0% damage) and with 100 ^M H202 (100% damage). Only exposure to SGF-X in spent medium from 
S. gallolyticus yielded increased levels of DNA damage compared to 3MC alone (Con). Panel C illustrates 
that the increase in DNA damage by SGF-X is mainly due to an increased number of cells with high 
levels of DNA damage (COMET scores 3 and 4). (D) Representative fluorescence microscope images 
with assigned COMET scores used for the quantification of DNA damage as shown in panel B and C of 
this figure.
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Discussion
Accumulating evidence supports a relationship between intestinal bacteria and the 
pathogenesis of CRC. Several recent publications have provided mechanistic evidence for 
the involvement of specific bacterial species in the development of CRC, which comprises 
bacterial production of DNA damaging radicals, genotoxins or toxic metabolites, and/or the 
induction of chronic inflammation and cell proliferation in epithelial cells (Attene-Ramos et 
al., 2010, Cuevas-Ramos et al., 2010, Rakoff-Nahoum and Medzhitov, 2009, Wang et al., 2008, 
Wu et al., 2009). However, until now, it was generally assumed that the well-appreciated 
clinical association of S. gallolyticus infections with CRC was a consequence of the altered 
intestinal environment that provides this bacterium with a competitive advantage for 
colonization of these malignant sites. By a microarray profiling approach, we here discovered 
that S. gallolyticus is a potent and specific inducer of epithelial biotransformation pathways. 
Particularly, S. gallolyticus excretes a diffusible factor (SGF-X) that exerts an inducing effect via 
the AhR on CYP1 enzyme production. This factor increases the DNA damaging effect of 3MC 
in CRC-cells, showing that S. gallolyticus is able to functionally alter the biotransformation 
capacity of tumor cells.
Intestinal food-derived toxins induce CYP1 enzyme production, which in turn contribute 
to the biotransformation of these toxins (Shimada et al., 1992). CYP1 enzymes oxidize or 
hydrolyze (toxic) compounds (phase I metabolism) often resulting into more reactive 
intermediates (Eastman and Bresnick, 1979), a process which is also called bio-activation. 
This is often followed by conjugation reactions catalyzed by phase II enzymes, such as 
glutathione S-transferases (GSTs) or UDP-glucuronosyltransferases (UGTs) to deactivate 
these compounds and make them more water-soluble for clearance from the body. Ironically, 
biotransformation of PAHs by CYP1 often results in chemical intermediates that are more 
genotoxic than their precursors. These intermediate carcinogens can covalently bind to 
chromosomal DNA that interferes with correct DNA replication and in turn may result in 
increased mutation rates (Eastman and Bresnick, 1979, Spink et al., 2002). Induction of CYP1 
enzymes is mediated through the AhR that can interact with a wide range of structurally 
diverse ligands (Abel and Haarmann-Stemmann, 2010, Denison and Nagy, 2003). AhR 
signaling results in the transcription of several different genes, including the phase I enzymes 
CYP and ALDH, and the phase II enzymes GSTs and UGTs (Dietrich and Kaina, 2010). Our 
microarray analysis shows that S. gallolyticus is able to induce both CYP1 and ALDH, whereas 
no genes of phase II metabolizing enzymes that detoxify CYP1 derived metabolites were 
found to be significantly changed. This disharmonic increase in phase I activity could result in 
the accumulation of toxic intermediates, which corroborates our finding that priming of CRC 
cells with SGF-X results in the accumulation of DNA-damaging intermediates.
The activation of the AhR contributes to the regulation of cell growth via a negative feed­
back mechanism mediated by the AhR repressor (AhRR) (Hahn et al., 2009). It was shown 
that AhRR expression levels are modestly decreased in pre-cancerous colonic polyps and 
more profoundly decreased in primary invasive colon carcinomas (Zudaire et al., 2008).
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This underscores the importance of AhR stimulation during malignant transformation. 
Besides this, it has been shown that CYP1 enzymes are poorly expressed in healthy colonic 
epithelium, but overexpressed in colonic adenomas and carcinomas (Ding and Kaminsky,
2003, McKay et al., 1993, Mercurio et al., 1995). The current data show for the first time 
that bacteria can interfere with the AhR-mediated induction of CYP1A1 and thereby can 
modulate important processes, ie. carcinogenesis of food-derived PAHs, inflammation and 
cell proliferation (see Figure 4C). However, it needs to be established if these effects will 
add up to an increased CRC-risk in vivo. Nevertheless, as developing colorectal tumors are 
in constant contact with numerous bacterial species, it seems very likely that bacterial 
induction of CYP1 enzymes, either directly or via diffusible bacterial factors, constitutes 
a previously unnoticed mechanism that contributes to the progression of adenomas to 
carcinomas.
Unfortunately, until now we were unable to identify the molecular structure of SGF-X. 
Candidates for this factor are shed structural components of the bacterial surface or 
excreted metabolites. Alternatively, this factor may be formed by S. gallolyticus from an 
inert precursor that is present in the growth medium. As killed S. gallolyticus did not induce 
CYP1 expression, we consider the latter two options as most likely. A possible candidate 
mechanism, could be the bacterial conversion of tryptophan into indoles (Nebert and Karp, 
2008), which are known ligands of AhR. However, our experiments did not provide evidence 
for such a mechanism (data not shown). Future research is required to reveal the structure 
of the bacterial diffusible factor that can induce CYP expression in CRC cells.
A second interesting observation was the fact that S. gallolyticus induces both the expression 
of COX-2 and CYP1A1 in CRC cells and that the regulatory pathways are intertwined. In fact, 
COX-2 overexpression in colorectal cancer tissue was shown to correlate with the presence 
of S. gallolyticus in this tissue (Abdulamir et al., 2010). Importantly, COX-2 expression 
and subsequent production of prostaglandins (PGE2/D2/H2) and other eicosanoids from 
arachidonic acid have been linked to the promotion of cell proliferation, the inhibition of 
apoptosis and increased angiogenesis (Araki et al., 2003, Castellone et al., 2005, Greenhough 
et al., 2009, Wallace, 2002). Strikingly, CYP1 pathways generate two biologically active 
classes of eicosanoids from prostaglandins, the epoxy (EETs) and hydroxy (HETEs) derivates, 
that both are pro-inflammatory mediators and have a prominent role in the progression of 
cancer (Choudhary et al., 2004, Steele et al., 1999). Furthermore, PGH2 can be converted 
by e.g. CYP1A2 into malondialdehyde that is directly involved in the formation of DNA 
damage (Plastaras et al., 2000). In addition, it has been suggested that eicosanoids are AhR 
ligands that can directly induce CYP1 enzymes (Nebert and Karp, 2008). As shown here, 
S. gallolyticus-mediated activation of AhR can also increase expression of COX-2, which 
confirms results of previous studies (Degner et al., 2009, Haarmann-Stemmann et al., 2009, 
Vogel et al., 2007). Taken together, these studies point towards AhR as a key regulator of 
pro-carcinogenic processes, which are prone to bacterial interference. Furthermore, these 
data suggest that CYP1 and COX-2 enzymes could be conspirators in microbiota-related 
progression of CRC.
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In conclusion, our data provide intriguing evidence for bacterial mingling in a crucial 
regulatory pathway that mediates cellular biotransformation capacity (CYP1) and cell 
proliferation (COX-2), which are both pivotal processes during carcinogenesis. Importantly, 
our data show that S. gallolyticus can exert its effect by a diffusible factor SGF-X, which thus 
can be regarded as remote control mechanism to manipulate the colonic epithelium. From 
an ecological point of view, it is tempting to speculate that S. gallolyticus can contribute to 
the creation of its own niche in the large bowel, as it is a poor colonizer of a healthy intestinal 
colon. However, a more straightforward model would be that S. gallolyticus first colonizes 
pre-malignant lesions, for instance by binding to displaced collagen IV (Skovbjerg et al., 
2009, Yantiss et al., 2001) and by foraging on metabolites of tumor cells (our unpublished 
data), after which it can contribute to CRC progression by interfering with the AhR regulatory 
pathway. Interestingly, AhR-signalling has been shown to also increase the expression of 
collagen type I and IV (Kung et al., 2009), and thereby S. galloltyicus might also avail of a 
self-supported mechanism to better colonize pre-malignant sites.
Our data underscore the need for a better understanding of host-microbe interactions 
during CRC, since it builds on accumulating studies that implicate bacteria in the initiation 
and progression of CRC. It is evident that intestinal bacteria and their activities are closely 
related to dietary factors, which makes it challenging to functionally dissect the microbial 
contribution to CRC. It can be envisaged that certain microbiome enterotypes as recently 
defined by Arumugam et al. (Arumugam et al., 2011), form an intrinsic risk factor for CRC due 
to increased activity of CRC promoting bacteria. Emerging molecular technologies will allow 
to define such high risk microbial populations (Marchesi et al., 2011), which ultimately should 
pave the way for novel bacteria-related diagnostic tools and therapeutic interventions.
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Summary
The commensal intestinal microbiota is important for developing and maintaining intestinal 
health. Its main function is to make dietary nutrients available to the host and to stimulate 
cell turnover, mucus formation and peristalsis that supports the intestinal barrier function. 
Conversely, however, a large body of evidence supports a relationship between bacteria, 
bacterial activities and human colorectal cancer (CRC). Furthermore, the physiological 
changes that accompany the development of CRC may result in increased bacterial 
infiltration and opportunistic bacterial infections. Streptococcus gallolyticus (Streptococcus 
bovis biotype I) is one of the few bacteria an infection of which has been consistently 
linked to the occurrence of CRC. This thesis aimed to further elucidate the relation between 
S. gallolyticus infections and CRC by investigating its clinical association (Part 1) with disease 
and by exploring the molecular interactions (Part 2) between this bacterium and CRC cells 
by in vitro approaches. This chapter summarizes the findings of this research. The factors 
that could explain the apparent incidental association, together with the mechanisms by 
which S. gallolyticus could contribute to the progression of CRC, are brought together in a 
working model to clarify the association between S. gallolyticus and colorectal tumors.
Part I - Clinical association of S. gallolyticus infections with CRC 
Part 1 of this thesis focused on the clinical association between Streptococcus gallolyticus 
infections and the occurrence of CRC. A systematic review and meta-analysis of the literature 
(Chapter 2) on 31 case series documented the number of S. bovis infections (including infective 
endocarditis (IE)), S. bovis biotypes and colorectal neoplasia (CRN) cases among these S. bovis- 
infected patients. A median of 65% of the S. bovis infected patients had concomitant CRN, 
which largely exceeded the disease rate reported in the general asymptomatic population 
(~25%). Additional meta-analysis showed that patients with S. gallolyticus infections had a 
strongly increased risk of having CRN and IE compared with S. bovis biotype II (Streptococcus 
infantarius and Streptococcus pasteurianus)-infected patients.
Importantly, these findings also indicated that only S. gallolyticus infections have an 
unambiguous association with CRC. Therefore, further experiments were focused on this 
bacterium. First, the humoral immune response against ribosomal protein (Rp)L7/L12 from 
S. gallolyticus was investigated (Chapter 3). This protein was picked-up as possible diagnostic 
antigen for CRC in a previous serological screen (Tjalsma et al., 2006). By using a newly 
developed RpL7/L12 ELISA assay on serum samples from Dutch (n = 209) and American (n 
= 112) populations, it was shown that antibody titers against this antigen were increased in 
polyp patients and early stage CRC patients as compared to asymptomatic individuals. This 
was not paralleled by an increased antibody response to endotoxin, which is an intrinsic cell 
wall component of the majority of intestinal bacteria. However, RpL7/L12 is a conserved 
protein among bacteria and therefore more specific ELISAs against pilus proteins of S. 
gallolyticus were developed to investigate their potential as diagnostic antigens (Chapter 4). 
Pilus proteins are interesting targets as they are the building blocks of pilin-like structures 
that mediate bacterial virulence and are readily exposed to the host immune system upon 
infection. The presence of serum antibodies against these pilus proteins was specific for
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S. gallolyticus infections, but increased serum antibody titers to multiple pilus proteins in 
single individuals were rarely observed. However, a multiplex approach based on antibody 
titers against any of these four antigens in Dutch (n=76) and American (n=91) populations 
resulted in assay sensitivities between 16-43% for the detection of early stage CRC. 
Together, these findings suggest that early stage CRC patients have increased exposures to 
S. gallolyticus bacterial antigens and that these antigens could serve as valuable diagnostic 
tool for the early detection of CRC via a multi-antigen approach.
Part II -  Molecular explorations at the host-microbe interface
The first part of this thesis clearly shows that S. gallolyticus has an unambiguous clinical 
association with CRC, which is corroborated by serological data that point toward an 
increased incidence of subclinical infections of this bacterium in CRC patients. In the second 
part of this thesis, this relation was further investigated by several molecular approaches. 
First, the infection route of S. gallolyticus was mimicked by in vitro cell culture techniques 
in order to define adhesion-receptor pairs and virulence characteristics that could be 
important for colonization and invasion. Second, the cross-talk between CRC cells and S. 
gallolyticus was examined by transcriptome and proteome analyses.
S. gallolyticus infection route
Surface-exposed bacterial proteins directly interact with the outside world, for instance 
during adherence and invasion of epithelial cells. Chapter 5 describes a proteomic approach 
for the identification of human proteins that interact with these surface-exposed proteins. 
LC-MS/MS analysis of proteolytically released peptides yielded the identification of (cyto) 
keratin-8 (CK8) as potential eukaryotic receptor for S. gallolyticus. Validation experiments 
indicated that bacterial surface-exposed enolase, which has a proposed role in epithelial 
adherence of several gram-positive pathogens, was an interaction partner of CK8. Chapter
6 documents that histone-like protein A (HlpA), which was previously identified as surface- 
exposed antigen of S. gallolyticus, binds to lipoteichoic acid (LTA) of the gram-positive 
cell wall. In addition, it was shown to be one of the major heparin-binding proteins of 
S. gallolyticus and able to bind to heparan sulfate proteoglycans (HSPGs) at the colon tumor 
cell surface. However, since both enolase and HlpA are conserved bacterial proteins, their 
adherence to CK8 and HSPGs on tumor cells point towards their involvement in general 
virulence mechanisms. Therefore, the virulence characteristics that distinguish S. gallolyticus 
from closely related intestinal bacteria that could be responsible for the adherence, invasion 
and translocation of CRC cells were further evaluated in Chapter 7. Mimicking this route 
of infection showed that S. gallolyticus had a relative low adhesiveness and could not 
internalize epithelial cells, but was able to paracellularly cross a differentiated epithelium. 
More importantly, the ability of S. gallolyticus to form biofilms on collagen type I and IV 
surfaces, which in vivo are found at damaged heart valves and (pre)cancerous sites with a 
displaced epithelium, could explain why especially infections with S. gallolyticus, but not of 
other S. bovis subspecies, are associated with CRC.
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Cross-talk between S. gallolyticus and colon tumor cells
The previous paragraph described that S. gallolyticus avails of several virulence features 
that could facilitate the binding and colonization at (pre-)malignant colonic sites. Chapter 
8 documents that metabolic changes in the growth medium of CRC cells, which reflect 
the changes at malignant colonic sites in vivo, resulted in an increased growth rate of 
S. gallolyticus. Strikingly, the growth of many other intestinal species was inhibited under 
these conditions. Especially the glycolytic activity of S. gallolyticus was significantly increased 
in the presence of tumor cell metabolites. Further in vitro simulations showed the ability of 
S. gallolyticus to forage on a combination of the glucose derivates fructose-6-phosphate, 
3-phosphate glyceric acid and the amino acid alanine, which are among the major excreted 
CRC metabolites. This could be one of the reasons why S. gallolyticus benefits from CRC 
sites with increased glucose derivates, whereas it is hardly ever found in healthy mucosal 
tissue. Upon colonization of these (pre-)malignant sites, S. gallolyticus could affect the 
progression of CRC via the induction of pro-inflammatory and pro-carcinogenic pathways. 
Chapter 9 documents that the interaction of a diffusible factor of S. gallolyticus (SGF-X) 
with the aryl hydrocarbon receptor, persistently induced CYP1 enzymes that are involved 
in the bio-activation of pro-carcinogens. More importantly, SGF-X thereby increased the 
DNA damaging effect of 3-methylcholanthrene, which was not observed for other intestinal 
bacteria.
Conclusions and future perspectives
This thesis provides possible explanations for an incidental relationship of S. gallolyticus 
with CRC and shows for the first time that intestinal bacteria, such as S. gallolyticus, can 
manipulate the biotransformation capacity of CRC cells. In the following paragraph a 
working model for the association between S. gallolyticus and CRC will be presented that is 
based on the observations in this thesis in view of the current state-of-the-literature on this 
subject. Furthermore, the diagnostic potential of bacterial antigens for the early detection 
of CRC and the assessment of bacterial risk profiles will be discussed.
Working model for the association between S. gallolyticus and CRC
The molecular explorations of the host-pathogen interface showed that S. gallolyticus 
avails of several characteristics that could link its infection with CRC (Figure 1). First, the 
increased presence of sugar-derivates at the CRC-interface may attract cancer-associated 
bacteria, such as S. gallolyticus (a). Normally, S. gallolyticus is an important carbohydrate 
fermenter in the ileum of the small intestinal tract (Booijink et al., 2010) This is paralleled 
by the enrichment in functions related to carbohydrate metabolism in the genome of 
S. gallolyticus (Rusniok et al., 2010). Interestingly, the CRC metabolome has several 
interesting similarities with the nutritional status of the ileum, e.g. high levels of lactate, 
carbohydrates and derivatives thereof (Hirayama et al., 2009). Based on these observations, 
it may be envisaged that S. gallolyticus cells that are shed from the ileum are out-competed 
by the resident colonic microbiota in a healthy situation and disappear from this ecosystem.
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Figure 1. Working model for the association between S. gallolyticus and CRC
a) CRC metabolites attract S. gallolyticus to tumor sites (Chapter 8); b) S. gallolyticus colonizes these 
sites by its ability to bind to displaced collagen from the basal membrane (Chapter 7); c) S. gallolyticus 
induces pro-inflammatory/carcinogenic pathways, such as COX-2 and CYP1, which can lead to 
increased mutation rates (when pre-carcinogens are present) and cancer progression (Chapter 9); d) S. 
gallolyticus can paracellulary cross the displaced epithelium (Chapter 7) leading to the induction of an 
humoral immune response (Chapter 3 and 4) and/or, in case of compromised patients, to endocarditis 
(Chapter 2).
This is reflected by the relative low fecal carriage of about 10% and colonic mucosal 
colonization of 2% in the healthy human population (Abdulamir et al., 2010, Klein et al., 
1977). However, it is tempting to speculate that the metabolic changes that go together 
with colon carcinogenesis, attract these S. gallolyticus cells and create a niche for its colonic 
survival and outgrowth. This could explain the fact that both fecal carriage and colonic 
mucosal colonization in CRC patients was found to be strongly increased, to respectively
B
50% and 48% (Abdulamir et al., 2010, Klein et al., 1977). The fact that S. gallolyticus can 
efficiently forms biofilms at collagen type I and IV explains its high association with infective 
endocarditis, but may also be a reason why S. gallolyticus is able to colonize (pre-)malignant 
sites with exposed collagen from the basal lamina (b) (Yantiss et al., 2001). This collagen- 
binding ability is most-likely the result of the pill locus in the S. gallolyticus genome 
that codes for a pilus protein with a collagen-binding domain (Danne et al., 2011) that is 
recognized by serum antibodies from patients with systemic S. gallolyticus infections.
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Interestingly, this pill locus is not present in the genomes of the closely related strains 
S. macedonicus and S. infantarius, which may explain why only S. gallolyticus infections are 
associated with underlying occult CRC. Upon colonization of (pre-)malignant colonic sites 
(incidental relationship), S. gallolyticus could also play a role in the progression of CRC via 
induction of COX-2 and the phase I metabolizing CYP1 enzymes. COX-2 is highly elevated 
in colonic tumors and its expression is correlated with disease stage. Many studies point 
towards COX-2 as one of the key players in colon carcinogenesis via the promotion of cell 
proliferation, the inhibition of apoptosis and the increase in angiogenesis (Araki et al., 2003, 
Castellone et al., 2005, Greenhough et al., 2009, Wallace, 2002). Epithelial CYP1 enzymes 
are induced by food-derived toxins, and contribute to the biotransformation these toxins 
in the intestine (Shimada et al., 1992), often resulting in the transient accumulation of 
genotoxic intermediates (Eastman and Bresnick, 1979). These carcinogens can covalently 
bind to chromosomal DNA, which interferes with correct DNA replication and in turn may 
result in increased mutation rates (Eastman and Bresnick, 1979, Spink et al., 2002). Thus, by 
inducing CYP1 enzymes in pre-malignant epithelial cells, S. gallolyticus has the potential to 
increase the carcinogenic activity of food-derived toxins and in that way indirectly promotes 
the accumulation of mutations that lead to malignancy. After the colonization of CRC sites, 
S. gallolyticus may translocate across the colonic wall via a paracellular mechanism, however, 
only in susceptible patients with damaged heart valves, this bacterium can eventually cause 
infective endocarditis (d). This is underscored by the fact that the incidence of S. gallolyticus 
endocarditis among CRC patients is less than 1%. However, as clearly illustrated by the 
serendipic identification of S. gallolyticus in the blood of "healthy" blood donors with occult 
CRC (Haimowitz et al., 2005, Lin et al., 2011), this opportunistic pathogen can also enter the 
human body without causing symptoms or disease.
Bacterial antigens as diagnostic tool for CRC
Our systematic literature review and meta-analysis clearly showed that S. gallolyticus is the 
S. bovis subspecies of choice to develop diagnostic tools for CRC. Nevertheless, it should 
be noted that large differences between clinical isolates exist, which is underscored by 
the fact that serum antibodies from S. gallolyticus-infected patients do not react with all 
four pilus proteins. The use of ELISAs based on multiple antigens was shown to advance 
the detection of early-stage CRC, however, the accuracy of this approach still remained 
below the diagnostic standards. Therefore, future studies should look further into the 
characteristics of clinical isolates to pinpoint virulence features, besides pilin-structures, 
that are responsible for the pathogenicity of S. gallolyticus in CRC patients. The fact that 
not all CRC tumors are colonized by S. gallolyticus (estimated around 50% max) and the fact 
that clinical isolates of S. gallolyticus are hetereogenous in their expression of pilus proteins, 
partly explains the modest sensitivity of the ELISAs for CRC detection. In order to increase 
this sensitivity, it may be necessary to identify additional cancer-associated bacteria and 
their immunogenic antigens. Applying , a combination of bacterial antigens from several 
different cancer-associated bacteria could yield an increase in the diagnostic potential of 
microbiota-based ELISAs for the early detection of CRC.
177
Summary and discussion
Bacterial CRC risk profiles
The fact that the intestinal microbiota plays a pivotal role in the risk for CRC is clearly shown 
by its inflammatory effect, which largely determines the increased CRC risk in patients with 
inflammatory bowel disease. Furthermore, bacterial conversion of dietary factors into 
genotoxic substances, their production of toxins and the direct influences on pro-carcinogenic 
pathways in host epithelial cells, such as the induction of CYP1A1 by S. gallolyticus, are likely 
to contribute to the accumulation of mutations that lead to carcinomas. This interesting, but 
complex, interplay between diet, microbiota and host shows how important it is that these 
factors are in balance. Alterations in either one of these factors could drive this ecological 
system into dysbalance, which could eventually have a major impact on the health status of 
the host. It is evident that the physiological changes at polyp and CRC sites affect the local 
microbial population (Hirayama et al., 2009; Marchesi et al., 2011).However, the full impact 
of CRC on the local intestinal microbiota is still not very well understood. Future research 
should therefore focus on the detailed mapping of the microbiota that is in close proximity 
with early adenomas and carcinomas. Local changes in microbiota may for instance provide 
scientific clues for the fact that only 10% of the adenomas progress into carcinomas. Besides 
this, an approach in which specific cancer-associated bacteria could home to CRC sites may 
provide leads for novel therapeutic approaches.
Life-style is another major determinant of CRC risk, and the consumption of a Western style 
diet significantly increases this risk, either direct or indirect via its effects on the microbial 
population. Therefore, it is important to increase our knowledge on bacterial profiles that 
constitute a risk-factor for CRC and how these high-risk bacterial profiles are associated with 
dietary feeding patterns. With help of dietary interventions it may be able to shift high-risk 
bacterial profiles toward a more "healthy" microbial population. A related issue concerns 
the identification of determinants that set the balance between healthy immune responses 
that guard our body against potential harmful pathogens and those that are responsible 
for the switch to chronic inflammation that leads to cancer initiation and progression. 
Understanding pathogen recognition and induction of immune responses in the large 
intestine could shed new light on the bacterial involvement in carcinogenesis.
Concluding remarks
This thesis provides several novel clues on the specific association between S. gallolyticus 
and CRC. Clearly, many aspects of this association, and the role of the intestinal microbiota 
in CRC initiation and progression in general, remain to be answered. Nevertheless, the 
current knowledge implicates that the colonic microbiota should be regarded as one of 
the key players in intestinal carcinogenesis. Increasing knowledge on the interrelationship 
between diet, host and microbiota will build our understanding of intestinal ecology and 
provide leads for future research that may aid in the development of new strategies for CRC 
diagnosis, treatment and prevention.
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Jaarlijks wordt bij ongeveer 10.000 mensen dikkedarmkanker vastgesteld waarmee het een 
van de meest voorkomende kankers in Nederland is. Dikkedarmkanker ontwikkelt zich bijna 
altijd uit een darmpoliep. Een poliep/adenoom is een uitstulping of een verdikking van het 
slijmvlies die de binnenkant van de darm bekleedt. Adenomen zijn goedaardige gezwellen, 
maar ongeveer 10% groeit uiteindelijk uit tot kwaadaardige tumoren (kanker). Dit komt 
doordat stoffen in de darm schade aan het DNA kunnen veroorzaken. Het opeenstapelen 
van schadelijke veranderingen in het DNA kan uiteindelijk leiden tot het ontwikkelen van 
een tumor uit zo'n adenoom. Bij darmkanker zijn vier stadia te onderscheiden. Eerst zit de 
tumor alleen aan de oppervlakte van de darm (adenoom), vervolgens wordt de muscularis 
mucosa doorbroken (vroeg carcinoom), het derde stadium wordt gekarakteriseerd door de 
aanwezigheid van uitzaaiingen in lokale klieren (laat carcinoom) en in het laatste stadium is 
de tumor ook uitgezaaid naar andere organen (carcinoom met metastasen) (Figuur 1). De 
genezingskans voor darmkanker is aanzienlijk hoger wanneer darmkanker in een vroeg stadium 
wordt ontdekt. Helaas wordt toch ongeveer 50% van de gevallen van darmkanker pas ontdekt 
in de latere stadia (3 en 4) waarbij de 3-jaarsoverlevingskans afneemt naar respectievelijk 65% 
en 13%. De late ontdekking van darmkanker komt vooral doordat symptomen van darmkanker 
vaak pas ontstaan gedurende de ver gevorderde stadia van de ziekte. Met een fecaal occult 
bloed test (FOBT) kunnen wel al eerder bloedsporen die de tumor achterlaat in de ontlasting 
worden aangetoond. Op basis van een pilot-onderzoek naar de effectiviteit van deze test heeft 
de Nederlandse Gezondheidsraad geconcludeerd dat er voldoende bewijs is om te beginnen 
met bevolkingsonderzoek naar darmkanker. Screening op darmkanker bij 50-74 jarigen met 
de FOBT kan het aantal slachtoffers met 15% verlagen. Toch zijn er nog verbeteringen aan te 
brengen in het opsporen van dikkedarmkanker. De bloedtest op ontlasting heeft één belangrijk 
nadeel. Vaak komen bloedsporen van tumoren pas voor in de latere stadia van darmkanker en 
daarmee zal nog steeds een deel van de mensen met vroege stadia van darmkanker worden 
gemist in het bevolkingsonderzoek. Daarom is het belangrijk om ook te blijven investeren in 
betere testen voor het opsporen van dikkedarmkanker. In dit proefschrift wordt ingegaan op 
een test naar antistoffen tegen bepaalde kenmerkende bacteriële eiwitten in het bloed van 
darmkankerpatiënten, om te onderzoeken of met behulp van deze bacteriële eiwitten een 
nieuwe diagnostische test voor darmkanker kan worden opgezet.
Bacteriën en dikkedarmkanker
Bacteriën (microbiota) in de darm zijn belangrijk voor het ontwikkelen en onderhouden van 
een goede darmgezondheid. De belangrijkste functie van de microbiota is het beschikbaar 
maken van voedingsstoffen voor de mens. Daarnaast zorgt de microbiota ervoor dat de 
cellen in de darmwand zich vernieuwen en dat er een gel (mucus) wordt gevormd die de 
darmwand beschermt tegen mogelijke ziekteverwekkers. Toch zijn er ook aanwijzingen 
dat bacteriën een rol kunnen spelen bij het ontstaan van dikkedarmkanker. Opmerkelijk is 
dat darmkanker vooral voorkomt in de dikke darm waar zich ook de grootste hoeveelheid 
bacteriën bevindt. Door het veroorzaken van infectie, het produceren van giftige stoffen en 
door directe invloeden van de bacterie op de darmwand, kunnen bacteriën bijdragen aan
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het ontstaan of bevorderen van darmkanker. Omgekeerd kunnen ook de veranderingen die 
gepaard gaan met de ontwikkeling van darmkanker ervoor zorgen dat er een verhoogde 
bacteriële infiltratie in de darmwand plaatsvindt, wat kan resulteren in een verhoogde kans 
op bacteriële infecties. Een van de bacteriën waarvan de infectie al 50 jaar consequent in 
verband wordt gebracht met dikkedarmkanker is Streptococcus gallolyticus. Het onderzoek 
dat is beschreven in dit proefschrift was erop gericht de relatie tussen S. gallolyticus infecties 
en dikkedarmkanker verder te ontrafelen door de klinische relatie tussen deze bacteriële 
infecties en dikkedarmkanker te onderzoeken (deel 1) en door de moleculaire interacties 
tussen bacteriën en darmwandcellen te onderzoeken met in vitro modellen (deel 2). 
Hieronder wordt een samenvatting van de bevindingen van dit onderzoek gepresenteerd.
Deel 1 - Klinische relatie tussen S. gallolyticus infecties 
en dikkedarmkanker
Hoofdstuk 2 documenteert een systematisch uitgevoerd literatuuronderzoek op 
31 patiëntenseries. In dit literatuuronderzoek is gekeken naar het voorkomen van 
dikkedarmkanker onder patiënten die geïnfecteerd zijn met S. gallolyticus infecties 
(voornamelijk hartklepontsteking). Dit onderzoek liet zien dat gemiddeld 65% van de 
geïnfecteerde patiënten een adenoom of carcinoom in de dikke darm had wat beduidend 
hoger is dan in een gezonde groep mensen tussen de 60 en 70 jaar (~25%). Dit duidt 
erop dat S. gallolyticus infecties een duidelijke klinische relatie met dikkedarmkanker 
hebben. In hoofdstuk 3 en 4 is onderzocht of met behulp van een afweerreactie tegen 
bacteriële eiwitten van S. gallolyticus onderscheid kon worden gemaakt tussen mensen 
met en zonder darmkanker. Al eerder was met een bloedscreening het ribosomaal 
eiwit L7/L12 (RpL7/L12) opgepikt als mogelijk diagnostisch eiwit voor darmkanker. Met 
behulp van een nieuw ontwikkelde test werden 209 Nederlandse en 112 Amerikaanse 
bloedmonsters van darmkankerpatiënten getest op de aanwezigheid van antistoffen 
tegen dit eiwit. Dit onderzoek liet zien dat mensen met vroege stadia van darmkanker 
een verhoogde afweerreactie tegen dit eiwit hadden vergeleken met gezonde controle 
proefpersonen. Naast de reactie tegen RpL7/L12 hebben we in hoofdstuk 4 ook gekeken 
naar de afweerreactie tegen 4 verschillende pilus eiwitten van S. gallolyticus. Deze eiwitten 
vormen belangrijke structuren op het oppervlak van S. gallolyticus. Tijdens een infectie 
worden deze pilus eiwitten gemakkelijk blootgesteld aan het menselijke afweersysteem. 
De aanwezigheid van antilichamen in het bloed van mensen met S. gallolyticus infecties 
toonde aan dat deze eiwitten door het menselijke afweersysteem inderdaad goed kunnen 
worden herkend. Daardoor hebben deze eiwitten potentie als diagnostische marker voor 
darmkanker. Om dit verder te testen werd het bloed van 76 Nederlandse en 91 Amerikaanse 
darmkankerpatiënten ook onderzocht op antistoffen tegen deze S. gallolyticus eiwitten. Er 
kon in 16-43% van de darmkankerpatiënten een afweerreactie tegen tenminste één van 
deze 4 pilus eiwitten worden vastgesteld. De bevindingen in hoofdstuk 3 en 4 suggereren 
dat de afweerreactie tegen bacteriële eiwitten van S. gallolyticus als waardevol diagnostisch 
hulpmiddel kunnen dienen voor de vroege opsporing van darmkanker. Echter, voor een nog 
betere gevoeligheid van de test zal moeten worden gezocht naar aanvullende bacteriële 
eiwitten die een immuunreactie opwekken in darmkankerpatiënten.
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Deel 2 - Moleculair onderzoek naar de relatie 
tussen darmtumor en bacterie
Het eerste deel van dit proefschrift toont duidelijk aan dat S. gallolyticus een eenduidige 
klinische relatie heeft met dikkedarmkanker. In het tweede deel van dit proefschrift werd 
deze relatie verder onderzocht door verschillende moleculaire benaderingen. Door de 
infectieroute van S. gallolyticus in vitro na te bootsen zijn we op zoek gegaan naar mogelijke 
aanhechtingsplekken van de bacterie op de darmkankercel. Deze aanhechtingsplekken zijn 
belangrijk voor de kolonisatie en uiteindelijke infectie van de darmwand. Daarnaast hebben 
we ook gekeken naar de ziekteverwekkende eigenschappen van de bacterie die ervoor 
kunnen zorgen dat juist deze bacterie infecties veroorzaakt in darmkankerpatiënten. Als 
laatste hebben we met behulp van DNA-analyse (transcriptoom) en eiwitanalyse (proteoom) 
de invloed van darmkankercellen op de bacterie, en vice versa, onderzocht.
Infectieroute van S. gallolyticus
Eiwitten op het oppervlak van de bacterie kunnen rechtstreeks communiceren met de 
buitenwereld, bijvoorbeeld tijdens het aanhechten en infecteren van de darmwand. 
Hoofdstuk 5 beschrijft een proteoombenadering voor het opsporen van mogelijke 
interactiepartners van de bacterie op het oppervlak van darmkankercellen. Hierbij werd 
het (cyto)keratine-8 (CK8) eiwit op darmkankercellen als mogelijke interactiepartner 
geïdentificeerd. Met behulp van validatie experimenten is aangetoond dat het bacteriële 
eiwit Enolase, dat al bekend was als aanhechtingseiwit voor andere bacteriën, een binding 
kan aangaan met dit CK8 eiwit. Hoofdstuk 6 laat zien dat het bacteriële eiwit Histone-like 
protein A (HlpA) bindt aan het oppervlak van S. gallolyticus. Daarnaast werd aangetoond 
dat HlpA ook kan binden aan heparaan sulfaat proteoglycanen (HSPGs) die aanwezig zijn 
op het oppervlak van kankercellen. Echter, aangezien zowel Enolase en HlpA bacteriële 
eiwitten zijn die ook voorkomen op de meeste andere bacteriën, lijkt de binding aan de 
menselijke eiwitten CK8 en HSPG een meer algemeen mechanisme te zijn dat niet direct 
de relatie van S. gallolyticus met darmkanker kan verklaren. Daarom is gezocht naar 
andere ziekteverwekkende eigenschappen van S. gallolyticus die niet aanwezig waren in 
nauw verwante bacteriën of andere darmbacteriën. In hoofdstuk 7 is de infectieroute van 
S. gallolyticus nagebootst. Dit onderzoek laat zien dat S. gallolyticus in tegenstelling tot 
andere darmbacteriën, minder goed in staat is om aan een in het laboratorium gekweekte 
darmwand te hechten en ook niet de darmcellen kan binnendringen. Wel toonde dit 
onderzoek aan dat S. galloltyicus goed tussen de darmcellen door kan kruipen en zodoende 
toch het lichaam kan binnendringen. Nog belangrijker was de ontdekking dat S. gallolyticus 
goed kan hechten aan collageen. Dit collageen is in de mens te vinden op hartkleppen en in 
de voering van de darm. In een gezonde darm is collageen niet bereikbaar voor de bacterie 
omdat het goed wordt afgeschermd door de darmwand. Maar zodra in dat darmweefsel 
een poliep ontstaat, komt het onderliggende collageen tevoorschijn en kan de bacterie wel 
aanhechten. Deze collageenbindende eigenschap kan dus verklaren waarom deze bacterie 
vaker infecties veroorzaakt in darmkankerpatiënten.
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Reactie tussen S. gallolyticus en darmkanker cellen
In hoofdstuk 8 is gekeken naar de eigenschappen van darmkankercellen die ervoor 
zouden kunnen zorgen dat S. gallolyticus juist naar darmtumoren toekomt. Kankercellen 
ondergaan verschillende veranderingen, die gepaard gaan met de uitscheiding van 
verscheidene afbraakproducten. Opmerkelijk is dat S. gallolyticus juist in de aanwezigheid 
van deze afbraakproducten beter kan groeien. Met name de verhoogde suikerafbraak 
van darmkankercellen resulteerde in een verhoogde groei van S. gallolyticus doordat de 
bacterie gebruik maakt van de suikerafbraakproducten. Opvallend is dat de groei van vele 
andere soorten darmbacteriën juist werd geremd onder deze omstandigheden. Dit kan 
een van de redenen zijn waarom S. gallolyticus een voordeel heeft in de nabijheid van 
darmkankerweefsel, maar nauwelijks voorkomt in een gezonde dikke darm. Tenslotte is in 
hoofdstuk 9 gekeken of S. gallolyticus ook een bijdrage zou kunnen leveren aan het ontstaan 
of verergeren van darmkanker. Door te onderzoeken welke reactie darmkankercellen 
geven op infectie met S. gallolyticus kwam aan het licht dat met name de eiwitten 
COX-2 en CYP1 verhoogd aanwezig waren na bloostelling aan de bacterie. Het eiwit COX-2 
is al vaker in verband gebracht met darmkanker. Naarmate het stadium van darmkanker 
ernstiger wordt, neemt de aanwezigheid van dit eiwit in de tumor toe. Door het gebruik 
van ontstekingsremmers, zoals aspirine, kan de hoeveelheid van dit eiwit weer worden 
teruggebracht en neemt de kans op het ontwikkelen van darmkanker af. Het CYP1 eiwit is 
belangrijk bij het verwerken van kankerverwekkende stoffen in de darmwandcellen. Soms 
zorgt dit eiwit ervoor dat kankerverwekkende stoffen, zoals koolwaterstoffen, die via de 
voeding de darm in kunnen komen, worden omgezet in nog actievere kankerverwekkende 
verbindingen. Uit het onderzoek bleek dat een uitgescheiden stofje (SGF-X) van S. gallolyticus 
de DNA-schade van kankerverwekkende koolwaterstoffen in darmcellen verhoogd. Middels 
dit mechanisme zou S. gallolyticus in bepaalde situaties kunnen bijdragen aan een verhoogd 
kankerrisico.
184
Nederlandse samenvatting
carcinoom 
met metastasen
mucosa
Figuur 1. Darmkankerstadia van adenoom tot carcinoom met metastasen 
Conclusie
Dit proefschrift geeft meerdere verklaringen voor de specifieke relatie van S. gallolyticus 
met dikkedarmkanker en laat zien dat een diagnostische test met behulp van bacteriële 
eiwitten hoopgevende resultaten geeft. Bovendien, geeft dit proefschrift aan dat de rol 
van bacteriën bij het ontstaan van dikkedarmkanker niet onderschat moet worden. In de 
toekomst kan nieuwe kennis op dit gebied bijdragen aan het voorkomen en tijdig opsporen 
van dikkedarmkanker.
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Addendum 1 NanoLC-MS/MS analyses
NanoLC settings
Instrument type: Agilent nanoflow 1100 liquid chromatograph (Agilent Technologies)
Column 15 cm fused silica emitter (New Objective, Tip: 8 +/- 1 |am, ID: 100 |am) packed with 3 |am 
Reprosil C18 beads (Dr. Maisch)
LC method: Gradient (total 67 minutes): From 3% buffer B to 10% buffer B in 5 minutes,
From 10% buffer B to 30% buffer B in 55 minutes, From 30% buffer B to 50% buffer B in 7 minutes 
Column washing and equilibration: 100% buffer B for 10 minutes, 3% buffer B for 17 minutes
Buffer A 
Buffer B 
Flowrate
MS settings
Instrument type 
Capillary temperature 
Data-dependent mode 
Mass range FT ICR MS 
Resolution FT ICR MS 
AGC target FT ICR cell 
Charge state rejection 
Dynamic exclusion 
AGC target LTQ 
LTQ CID settings
Data analysis settings
Peak list generation 
Database search program
0.5% Acetic acid
80% acetonitrile in 0.5% acetic acid
During sample loading, washing and equilibration: 600 nl min-1 
During gradient: 300 nl min-1
LTQ FT (Thermo Fisher)
100 °C
Sequencing of the four most abundant ions 
350-2,000 m/z 
100,000 
1E6
1+ and unassigned charge states
180 s
1E4
Minimum signal required for MS2 selection: 500 counts 
Normalized collision energy: 27%
Activation Q: 0.25
Activation time: 30 ms
Extract-MSn 
Mascot (version 2.2)
Database search parameters
Database
Enzymatic cleavage 
Precursor ion tolerance 
Fragment ion tolerance 
Number of 13C 
Fixed modification 
Variable modifications 
Peptide charge
human RefSeq database (release 33) combined with the S. gallolyticus 
protein database (provided by P. Glaser)
Trypsin (KR/P), 1 miscleavage allowed 
15 ppm 
0.5 Da 
1
Carbamidomethylation (C)
Oxidation (M), Acetyl (N-terminus)
2+ and 3+
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Validation criteria (in-house developed script (manuscript in preparation)
Single peptide hits Mascot peptide score > 50
Modified delta score > 10 
Expectation value < 0.01 
Maximum amount of variable modifications = 3 
Multi peptide hits Mascot peptide score > 30
(> 2 peptides) Expectation value < 0.1
Maximum amount of variable modifications = 5 
emPAI Calculation settings m/z range of instrument 350-2000
minimum charge state of ions selected for MS/MS = 2 
maximum charge state of ions selected for MS/MS = 3
The modified delta score is derived from the Mascot delta score and denotes the difference in score 
between the first-ranked peptide hit and the next peptide hit with a different sequence compared to 
the first-ranked peptide hit.
Addendum 2 MALDI-MS analyses
Instrument type 
Spotting method 
Matrix
Plate Motion
Auto Spectrum Filter (ASF) 
Laser power 
Number of sweep laser 
shots
Number of scans per step 
Number of Survey scans 
Number of microscans 
per scan
Data-dependent mode 
Mass range LTQ MS 
AGC target LTQ 
Dynamic exclusion 
Exclusion list size 
LTQ CID settings
vMALDI LTQ (Thermo Fisher)
1 uL sample (1% TFA) with 1 uL matrix 
5 mg a-cyano-4-hydroxycinnamic acid (CHCA) 
in 1 mL 50% Can and 0.5 % TFA 
Crystal Positioning System (CPS)
Off
35
5
Sequencing of the 10 most abundant ions of each survey scan
900-2,000 m/z
5E4
180 s
50
Minimum signal required for MS2 selection: 500 counts 
Normalized collision energy: 35%
Activation Q: 0.25 
Activation time: 30 ms
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Data analysis settings
Peak list generation and extract_msn ver 4.0, ©1997-2006
Database search program SEQUEST v.28 (rev. 12) in BioWorks™ Rev. 3.3
Database search parameters
Database
Enzymatic cleavage 
Precursor ion tolerance 
Fragment ion tolerance 
Maximum number of 
modifications 
Fixed modification 
Variable modifications
human RefSeq database (release 33) combined with the 
S. gallolyticus protein database (provided by P. Glaser) 
Trypsin (KR/P), 1 miscleavage allowed 
0.8 Da 
1 Da 
3
Carbamidomethylation (C)
Oxidation (M), Acetyl (N-terminus), deamidation (N/Q)
Validation criteria
Peptide probability 1E-2
Protein probability 1E-3
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Addendum 3
The growth rate at the linear part of the growth curves was determined by linear regression 
analysis as shown for S. gallolyticus, S. macedonicus, S. lugdunensis, L. plantarum, E. coli, E. faecalis, 
S. typhimurium, E. cloacae, E. coli Nissle and K. pneumoniae. Growth rates were significantly increased 
in Caco-2, HT-29, HCT116 and SW480 spent medium (green lines) as compared to complete medium 
(red lines) for S. gallolyticus, S. macedonicus and E. faecalis (only Caco-2 and HT-29). For all other strains 
the growth rate was significantly higher in complete medium as compared to Caco-2, HCT116, HT-29 
or SW480 medium. For S. typhimurium the growth rates were similar in all of the tested conditions.
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Addendum 4
C  control vs Caco-2 with viable Cells
All 120 identified proteins with significant expression volumes were mapped to the KEGG global map 
of metabolic pathways via orthologous groups (COGs, see Supplementary Table S4). Global metabolic 
maps of the S. gallolyticus proteome changes in (A) control versus Caco-2 medium, (B) control vesrus 
HCT116 medium and (C) control vs Caco-2 medium in the presence of viable Caco-2 cells were 
generated using iPath. The width of the line represents the number of spots measured on the 2D gel, 
and the color represents the average fold change in expression of all proteins mapped to that pathway.
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Addendum 5
Pathway analysis -  oxidoreductase pathway
All significantly expressed genes found with microarray analysis were subjected to pathway analysis 
(Ariadne Genomics) to search for significantly altered pathways. This revealed that 9 of the 44 
identified genes were related to the oxidoreductase pathway, including CYP1A1, ADH1A and ALDH1A3
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Addendum 6
A
label Control SG ratio p-value
1 0.19 0.02 -12.91 0.03
2 0.14 0.03 -4.52 0.00
3 0.04 0.01 -2.92 0.00
4 0.13 0.08 -1.53 0.00
5 0.05 0.15 2.83 0.00
6 0.09 0.29 3.25 0.05
7 0.02 0.10 4.61 0.00
8 0.01 0.12 10.84 0.02
B
4o
2D-PAGE analysis of HT-29 cell lysates upon S. gallolyticus exposure
After exposure of HT-29 cells to S. gallolyticus (M O I20) for 6 hours, 2D-PAGE proteome analysis was 
performed to identify significantly altered proteins. Interestingly, co-culturing only resulted in 8 sig­
nificantly altered proteins (A) that are indicated at the corresponding locations in the protein gel (B). 
These results indicate that HT-29 cells are surprisingly unresponsive to S. gallolyticus, which is under­
scored by micro-array analysis showing that only 44 genes were significantly changed in HT-29 cells 
upon exposure to S. gallolyticus.
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Dankwoord
Aan alles komt een eind, ook aan de afronding van dit proefschrift. Zonder de hulp en steun 
van, en samenwerking met vele mensen was dit proefschrift niet geworden wat het nu 
is. Daarom wil ik graag iedereen die me op welke wijze dan ook heeft bijgestaan oprecht 
bedanken, maar een aantal mensen in het bijzonder.
Allereerst wil ik mijn promotor Prof. Dorine Swinkels bedanken. Ondanks dat je wat verder 
van het onderwerp afstond wist jij met je helicopterview altijd de belangrijke "so what"- 
vraag te stellen. Mede daardoor bleef ik scherp en hebben we een aantal mooie publicaties 
verkregen. Daarnaast heeft jouw enorme gedrevenheid om elk onderzoek tot een goed 
resultaat te brengen mij laten zien dat motivatie en doorzettingsvermogen zeer belangrijke 
eigenschappen zijn tijdens een promotietraject. Bedankt voor alles!
Beste Harold, tja waar moet ik beginnen. In de lange weg naar de totstandkoming van dit 
proefschrift hebben we nauw met elkaar samengewerkt. Het was prettig dat de deur altijd 
open stond en dat ik met welk vraagstuk dan ook bij je terecht kon. Soms zag ik het licht 
aan het eind van de tunnel niet meer, maar jij wist me dan altijd te overtuigen om toch nog 
dat ene experimentje te doen. En zie hier het resultaat! Ik moet zeggen dat ik de Eureka- 
momenten toch het leukste vond, alhoewel die niet zo vaak voorkwamen. De afgelopen 
jaren heb ik naast de fijne samenwerking ook veel van je geleerd. Het belangrijkste is denk ik 
wel dat je me hebt leren schrijven. Dit zal me in mijn carrière als onderzoeker nog goed van 
pas komen. Daarvoor ben ik je erg dankbaar. Daarnaast waren de vele lunchwandelingen 
en "friends"-momenten een welkome afleiding tijdens mijn promotietraject. Bedankt voor 
alles!
Rian, zonder jouw bijdrage aan mijn proefschrift was dit boekje half zo dik geweest. Het 
was daarom niet meer dan logisch dat ik je heb gevraagd mijn paranimf te zijn. Ik denk dat 
het woord "optimalisatie" wel centraal staat in alle experimenten die we samen hebben 
gedaan. Met name 2D-proteomics vergde veel geduld, tijd en leidde soms tot frustratie, 
maar uiteindelijk is het gelukt! Mooi, want deze kennis komt goed van pas voor een aantal 
lopende projecten. In onze samenwerking vulden we elkaar goed aan. Jij wist precies welke 
praktische aspecten belangrijk waren en ik wist waar we heen wilden. Bedankt voor alle 
gezelligheid en de bergen werk die je voor me verzet hebt!
Natuurlijk wil ik ook al mijn directe collega's bedanken. Coby, jij was altijd in voor een geintje. 
De step verstoppen, ijs in mijn labjas, wormen gooien in de lunchpauze. Op een of andere 
manier is het me nooit gelukt om je een keer goed terug te pakken. Toch wil ik je bedanken 
;-). Met jouw kennis over eiwitidentificatie op de v-MALDI en je inventiviteit heb je een 
essentiële bijdrage geleverd aan mijn project. Het was een feest om met je samen te werken. 
Erwin, jij bent altijd behulpzaam ook als er 10 hepcidin-projecten op je bordje liggen. Door 
jouw hulp heb ik verschillende PCRs en Real-time PCRs tot succesvolle analyse-methodes 
weten te brengen. Je hebt natuurlijk niet voor niets de bijnaam PCR-win ©. Dank daarvoor.
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Siem, is er nog een plekje in de vriezer? Je hebt vele malen ruimte voor me moeten maken 
en stikkers voor me geprint, zelfs als je er eigenlijk geen tijd voor had. "Back to the future" 
en bedankt! Joyce, samen gestart met ons promotietraject en samen geëindigd. Het was 
fijn om onze promotieperikelen te kunnen delen. Renée, we zijn samen begonnen aan het 
S. bovis avontuur, jammer dat we het niet samen af hebben kunnen maken. Jouw bijdrage 
aan de opzet van het onderzoek was onmisbaar en heeft tot een aantal mooie publicaties 
geleid. Guus, het is nu aan jouw om het bacterie-darm-project te vervolgen. Ik vond het 
leuk om met je samen te werken en hoop over een paar jaar bij jouw promotie aanwezig te 
zijn. Succes! Daarnaast wil ik ook nog April en Erwin bedanken die het onderzoeksstokje aan 
mij hebben doorgegeven en mij in het begin wegwijs hebben gemaakt binnen en buiten de 
afdeling. Boukje, het was leuk om samen op een kamer te zitten en muziek uit te wisselen. 
Tevens heb jij ervoor gezorgd dat ik Endnote op mijn computer kreeg; een onmisbaar 
programma. Bedankt! Jos, Rieneke, Suzanne, Charlotte en Anne-Claire, we hebben niet veel 
samen gewerkt maar wel veel lunchpauzes samen doorgebracht, het was gezellig! Verder 
wil ik alle andere collega's van het AKC en LGEM bedanken die op welke wijze dan ook hun 
betrokkenheid hebben getoond.
Een aantal studenten hebben een waardevolle bijdrage geleverd aan mijn proefschrift. 
Suzanne, jij was mijn eerste student. Jouw optimalisaties hebben ervoor gezorgd dat 
mijn adherentieassay's een routine-experiment zijn geworden. Stan, bedankt voor al je 
cloneringswerk en eiwit-opzuiveringen die uiteindelijk hebben geleid tot onze eerste 
S. bovis-publicatie. Carla, jouw harde werk als student en student-assistent heeft ervoor 
gezorgd dat we een prachtige publicatie hebben in Journal of Infectious Diseases; hier 
beschreven in hoofdstuk 7. Ik vond het heel leuk om met je samen te werken en wens je 
veel succes in Canada!
Daarnaast wil ik graag alle andere coauteurs bedanken. Marleen van Gelder, bedankt voor 
het uitvoeren van de meta-analyses en je uitvoerige controle van mijn systematic review. 
Fantastisch dat we samen een publicatie hebben in Clinical Infectious Diseases. Daarnaast 
mochten onze gezellige lunchwandelingen en sportmomenten niet ontbreken. Hoop 
dat we dit in de toekomst nog voort kunnen zetten. Ikuko Kato, thank you for providing 
serum-samples for the immunodiagnostic studies on S. gallolyticus and colorectal cancer 
and performing the statistical analysis in both studies. Tanja Schülin, bedankt voor je inzet 
om alle nieuwe S. bovis infecties binnen het UMC en soms andere centra aan ons door te 
geven en de klinische stammen aan ons beschikbaar te stellen. Bas Dutilh, bedankt voor de 
pathway-analyses voor de proteome en metabolome studie beschreven in hoofdstuk 8. Het 
was leuk om met je samen te werken en hoop dat in de toekomst nog vaker te kunnen doen. 
Albert Bolhuis en Sarah Bukhari, bedankt voor de energie die jullie hebben gestoken in het 
uitvoeren van de C. elegans en biofilm experimenten. Julian Marchesi, thank you for all your 
work on the colorectal cancer microbiome. Udo Engelke, NMR-spectroscopy bleek mogelijk 
op medium-samples van tumor cellijnen. De resultaten waren een welkome toevoeging op 
de proteome data. Jolein Gloerich, de proteomics faciliteit heeft op verschillende vlakken 
bijgedragen aan mijn proefschrift. Bedankt voor al je tijd, je kennis en de analyses die je voor
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me hebt uitgevoerd. Vijay Pancholi, thank you for your cooperation and providing us the anti- 
enolase and anti-HlpA antibodies. Philippe Glaser, thank you for all the helpful discussions 
on S. bovis bacteria and sharing the S. gallolyticus genome with us. This information was 
extremely valuable for our studies and I enjoyed working with you. Furthermore, you 
and Nadège Cayet developed beautiful electron microscopy pictures of S. gallolyticus and 
S. macedonicus. Shaynoor Dramsi, thank you for providing the S. gallolyticus pili-proteins 
and your cooperation on the S. gallolyticus immunodiagnostic study. Also thanks to Camille 
Danne and Samuel Bellais. Rafaelle Zarilli, thank you for providing us several different
S. bovis strains for our studies. Juan Corredoira, it was great discussing with you the intriguing 
relation between S. gallolyticus infections and colorectal cancer.
Zonder de samenwerking met andere laboratoria in het UMC st. Radboud was dit proefschrift 
nooit tot stand gekomen. Daarom wil ik een aantal gastlabs bedanken. Beste Dr. Wilbert 
Peters (Maag, darm en leverziekten), fijn dat ik al die jaren bij jullie heb mogen celkweken. 
Daarnaast was je bereid om kritisch naar mijn publicaties te kijken. Hartelijk dank daarvoor. 
Ook dank aan Hennie Schaap-Roelofs en Rene te Morsche aan wie ik alles kon vragen. 
Beste Prof. Peter Hermans (Laboratorium kindergeneeskunde en infectieziekten), heel erg 
bedankt dat ik van jullie ML-II faciliteit gebruik mocht maken. Soms was ik vaker in jullie 
lab dan dat van onze groep. Daarnaast heb ik de "Monday-meetings" altijd als zeer nuttig 
ervaren. Alle LKI-collega's bedankt voor de nuttige tips en gezelligheid op het lab. Daarnaast 
wil ik de Microarray facility en Lab Hematologie bedanken dat ik gebruik mocht maken van 
hun apparatuur
Een gelukkig privé-leven is tijdens een promotietraject onmisbaar. Ik wil graag al mijn 
vrienden bedanken die op welke wijze dan ook voor afleiding hebben gezorgd (hardlopen, 
muziek maken, spelletjes spelen, sauna-bezoekjes, etentjes). Hierdoor kon ik de batterij 
weer opladen! Pap en Mam, hoewel ik niet altijd zin had om inhoudelijk over mijn onderzoek 
te praten ben ik jullie heel dankbaar voor de kans die jullie me hebben gegeven door te gaan 
studeren. Jullie hebben me altijd gesteund in de keuzes die ik heb gemaakt en zonder jullie 
had ik dit nooit kunnen doen. Pap, bedankt voor de opmaak van mijn proefschrift. Het ziet 
er fantastisch uit en ik hoop dat er nog vele mogen volgen samen met Guus! Hetty en Johan, 
het onderzoekende karakter zit in ons bloed. Hetty, je bent nu mijn paranimf, maar over een 
paar jaar sta jij op mijn plek. Johan, jij ontpopt je als een ware studiebol zolang je maar iets 
doet waar je passie ligt. Wie weet ook nog een promotietraject voor jou? Bedankt voor al 
jullie interesse en gezellige familie-uitjes.
Lieve Pieter, woorden schieten te kort als ik moet omschrijven wat je voor me betekent. Ons 
avontuur begon tegelijk met mijn promotietraject. Wanneer het nodig was heb jij bij mij 
de rem erop gezet, maar je hebt me zeker in de laatste fase ook de ruimte gegeven om me 
volledig te concentreren op de afronding van mijn proefschrift. Dank je voor je luisterend 
oor en je vertrouwen in mij. Als je een promotietraject met mij kunt doorstaan dan weet ik 
zeker dat we samen nog veel avonturen gaan beleven!
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Annemarie Boleij was born in Boxtel on September 13, 1983. She followed secondary 
education at the "Jacob-Roelands Lyceum" in Boxtel and graduated in 2001 with a profile 
Nature and Health (including Physics, Chemistry, Mathematics and Biology). From 2001 to 
2006 she studied Biomedical Sciences at the Radboud University in Nijmegen. During her 
bachelor internship at the department of Pharmacology and Toxicology of the Nijmegen 
Center for Molecular Life Sciences (NCMLS) in 2004 she discovered her interest in research. 
This made her decide to follow a minor in Pharmaceutical Research and a major in Toxicology. 
For her minor she followed an internship at the Netherlands Vaccin Institute (NVI) in 
Bilthoven in 2005 that focused on the immunogenicity of Bordetella pertussis, the causative 
agent of whooping cough. Annemarie's graduation internship for her major in Toxicology 
was executed at the German Cancer Research Center(DKFZ) in Heidelberg, Germany in 
2006. The goal of this research project was to investigate the effectiveness of chemotherapy 
administered by drug-eluting beads in a rat model for colon cancer metastasis.
After obtaining her MSc. degree, Annemarie was appointed as PhD student on a project 
at the interface of infection and colon cancer at the Radboud University Nijmegen 
Medical Center (RUNMC). The research described in this thesis focused on elucidating the 
association between infections with the opportunistic pathogen Streptococcus gallolyticus 
and colorectal cancer (CRC) by investigating the clinical relation of this infection with 
CRC and by exploring the molecular interactions between this bacterium and CRC cells. 
Annemarie's work resulted in several publications in well-established journals within the 
field of infectious diseases. Since November 2012, Annemarie is working as a post-doctoral 
researcher at the department of Immunopathology (Sanquin) and Center for Experimental 
and Molecular Medicine (Academic Medical Center (AMC)) in Amsterdam on a project 
investigating the effect of C1-inhibitor in infectious and allergic lung inflammation.
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